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ABSTRACT I 
ABSTRACT 
Neuroblastoma is the most common extracranial solid tumor in childhood, and characteristically 
displays a wide variety of clinical outcomes. While prognosis is generally favorable in low-risk and 
intermediate-risk tumors, outcome remains poor in high-risk neuroblastoma, and infaust in case of 
relapse. Multidrug resistance is frequent in high-risk neuroblastoma and remains to be one of the 
major factors limiting treatment success despite intensive multimodal therapy regimens, highlighting 
the need for novel treatment approaches capable of reducing neuroblastoma drug resistance. 
Histone deacetylases (HDACs) are involved in numerous cancer-relevant pathways and have become 
attractive anti-tumor targets due to their excellent druggability. Broadband inhibition of HDACs is, 
however, associated with dose-limiting side effects, which can be possibly circumvented by the 
inhibition of individual tumor-relevant isozymes. Previous work of our group has shown that high 
expression of class IIb histone deacetylase HDAC10 supports chemoresistance of neuroblastoma cells 
by promoting macroautophagy. Data suggested that HDAC10 was critical for lysosomal function, but 
the precise lysosomal role of HDAC10 and its cellular substrates remained unknown.  
The data presented in this study indicate that HDAC10 is crucial for lysosomal homeostasis in a 
number of highly drug-resistant neuroblastoma cell lines (SK-N-BE(2)-C, IMR-32, SK-N-AS) while being 
dispensable in others (Kelly, NB-1) and in non-transformed fibroblasts. In HDAC10-dependent cells, 
interference with HDAC10 function causes accumulation of lysosomes, a phenotype that is not 
observed in case of functional interference with the highly homologous class IIb member HDAC6. 
Depletion or inhibition of HDAC10 further interferes with downstream lysosomal processes such as 
lysosomal exocytosis, indicating that accumulating lysosomes are dysfunctional. Lysosomal 
accumulation and the inhibition of lysosomal exocytosis in turn promote intracellular accumulation 
of weakly basic chemotherapeutics such as doxorubicin, which does not remain sequestered in 
lysosomes but is also highly enriched in nuclei. Consequently, co-treatment with doxorubicin and 
HDAC10 inhibitors efficiently promotes cell death in treatment resistant neuroblastoma cell lines 
while sparing non-malignant cells.  
Lysosomal exocytosis is an important pro-survival mechanism under cytotoxic treatment. Inhibition 
of HDAC10, and thus lysosomal exocytosis, sensitizes cells not only by promoting doxorubicin 
accumulation, but also by inhibiting the process of lysosomal exocytosis itself. Moreover, 
interference with HDAC10 function promotes accumulation of DNA double-strand breaks (DSBs) both 
in absence and presence of doxorubicin, suggesting an additional role for HDAC10 in DSB repair. 
Preliminary data of mass spectrometric analyses of protein lysine acetylation after HDAC10 inhibition 
suggest that HDAC10 modulates acetylation of the V-ATPase subunit A and the Ku70/Ku80 complex 
member Ku80. It is thus conceivable that HDAC10 modulates lysosomal function at the level of 
 
II ABSTRACT 
lysosomal acidification, as well as DNA repair at the level of non-homologous end joining of DSBs. 
The recently published function of HDAC10 as N8-acetylspermidine deacetylase remains to be 
confirmed. Follow-up studies on the mechanistic role of HDAC10 could be greatly facilitated by a 
highly specific HDAC10 antibody. In this context, several promising HDAC10-reactive mouse 
hybridoma clones were generated, but recurring instability of the promising hybridoma clones 
delayed stable production of the antibody. 
In summary, in this thesis, a novel function of HDAC10 in regulation of lysosomal downstream 
mechanisms was identified and a previously published role of HDAC10 in DNA repair was confirmed. 
These mechanisms possess the translational potential to overcome drug resistance in combination 
with chemotherapies. 
 
 
 
ZUSAMMENFASSUNG III 
ZUSAMMENFASSUNG 
Das Neuroblastom ist der häufigste solide extrakranielle Tumor im Kindesalter und zeichnet sich 
durch sein variables klinisches Erscheinungsbild aus. Während die Heilungschancen bei Patienten der 
niederen und mittleren Risikogruppen in der Regel günstig sind, weisen insbesondere sogenannte 
Hochrisiko-Neuroblastome und rezidivierende Tumore eine schlechte bzw. infauste Prognose auf. 
Hochrisiko-Neuroblastome sind dabei häufig durch eine gesteigerte Resistenz gegenüber einer 
Vielzahl von Zytostatika gekennzeichnet, was trotz intensiver multimodaler Therapien zu einem 
Therapieversagen führt und die Notwendigkeit neuer resistenzbrechender Behandlungsansätze im 
Neuroblastom unterstreicht. Histondeacetylasen (HDACs) sind entscheidend an der Steuerung vieler 
krebsrelevanter Prozesse beteilig, was sie, zusammen mit ihrer exzellenten Wirkstoff-
Bindungsfähigkeit, interessant für die Tumortherapie macht. Dabei geht die Breitbandinhibition der 
HDACs jedoch mit dosislimitierenden Nebenwirkungen einher, was mit der gezielten Hemmung der 
tumorrelevanten Enzyme umgangen werden könnte. Eine vorangegangene Studie unserer 
Arbeitsgruppe hat gezeigt, dass eine hohe Expression der Klasse IIb Histondeacetylase HDAC10 die 
Chemoresistenz von Neuroblastomzellen durch Antreiben der Makroautophagie fördert. Auch wenn 
die Daten dieser Studie darauf hindeuteten, dass HDAC10 bedeutend für die Lysosomenfunktion ist, 
blieben die genaue lysosomal Rolle der HDAC10 und deren nachgeschaltete zelluläre Substrate 
unbekannt. 
Die in dieser Arbeit präsentierten Daten zeigen, dass HDAC10 in einigen der untersuchten 
Neuroblastommodelle (SK-N-BE(2)-C, IMR-32, SK-N-AS) eine entscheidende Rolle in der Homöostase 
sogenannter Lysosomen zukommt, während die Lysosomen anderer Neuroblastomzelllinien (Kelly, 
NB-1) und proliferierender Fibroblasten nicht durch HDAC10 beeinflusst sind. Bei einer 
Beeinträchtigung der HDAC10 Funktion kommt es in HDAC10-abhängigen Zellen zu einer 
Ansammlung von Lysosomen, was bei Hemmung der nahe verwandten HDAC6 nicht der Fall ist. 
Depletion und Inhibition von HDAC10 führen dabei weiterhin zu einer Störung nachgeschalteter 
lysosomaler Prozesse wie der lysosomalen Exozytose, was auf eine Dysfunktion der akkumulierenden 
Lysosomen hindeutet. In Folge der Ansammlung von Lysosomen und der Hemmung der lysosomalen 
Exozytose kommt es in den betreffenden Zelllinien zu einer Ansammlung schwach basischer 
Chemotherapeutika wie Doxorubicin, welche sich sowohl in Lysosomen und Zellkernen anreichern. 
Folglich führt die Kombinationsbehandlung mit Doxorubicin und HDAC10 Inhibitoren in 
Neuroblastomzellen, nicht aber in nicht-malignen Zellen, zu einer erhöhten Zelltodrate. 
Die lysosomale Exozytose selbst wird zu einem wichtigen Überlebensmechanismen unter 
Zytostatikabehandlung. Die Hemmung von HDAC10, und damit der lysosomalen Exozytose, 
sensitiviert Neuroblastomzellen dabei nicht nur durch vermehrte intrazelluläre 
 
IV ZUSAMMENFASSUNG 
Doxorubicinansammlung, sondern auch durch die Inhibition der lysosomalen Exozytose selbst. Des 
Weiteren erhöht die Hemmung der HDAC10 Funktion die Anzahl sogenannter DNA 
Doppelstrangbrüche sowohl in An- als auch in Abwesenheit von Doxorubicin, was auf eine Funktion 
von HDAC10 in der Reparatur von DNA Doppelstrangbrüchen hindeutet. 
Vorläufige massenspektrometrische Analysen der Lysin-Acetylierung in Proteinen nach HDAC10-
Hemmung weisen darauf hin, dass HDAC10 die Acetylierung von Untereinheiten der V-ATPase bzw. 
des Ku70/Ku80-Komplexes beeinflusst. Es ist also denkbar, dass HDAC10 die Lysosomenfunktion auf 
Ebene der lysosomalen Ansäuerung, und DNA Reparatur auf Ebene der nicht-homologen 
Endverknüpfnung (non-homologous end joining) reguliert. Die kürzlich publizierte Funktion von 
HDAC10 als N8-Acetylspermidindeacetylase konnte in dem hier verwendeten Zellmodell noch nicht 
bestätigt werden. Zukünftige mechanistischen Studien würden durch einen hochspezifischen, bisher 
jedoch nicht verfügbaren, HDAC10 Antikörper vereinfacht. Im Rahmen dieses Projekts wurden 
mehrere vielversprechende HDAC10-reaktive Hybridomklone generiert, eine zuverlässige Produktion 
des HDAC10 Antikörpers verzögert sich jedoch bisher auf Grund wiederkehrender Instabilität dieser 
Hybridome.  
Zusammenfassend konnte in dieser Arbeit eine neue Funktion von HDAC10 in der Regulation der 
Lysosomenfunktion gezeigt und eine bereits publizierte Rolle von HDAC10 in der DNA Reparatur 
bestätigt werden. Diese können als Angriffspunkte zur Minderung von Chemoresistenzen dienen. 
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INTRODUCTION 1 
A INTRODUCTION 
1 Neuroblastoma - a childhood tumor of the neural crest 
Neuroblastoma is a solid embryonal neuroendocrine tumor and the most common extracranial solid 
tumor in childhood, accounting for approximately 7% of total cancer cases diagnosed in children 
(Ward et al. 2014). It is by far the most common cancer in infancy with a median onset age of 18 
months, and over 90 % of cases are diagnosed before the age of 10 (Ward et al. 2014; Matthay et al. 
2016). Neuroblastoma is about 1.3-fold more common in males, although the reasons for this 
preference remain unknown (Ward et al. 2014; Kaatsch et al. 2018). In total, it is the second most 
frequent malignant tumor in children below the age of 14, but with an incidence of one child in 
100,000 per year in Germany, neuroblastoma is a rare disease (Kaatsch et al. 2018). Nonetheless, 
neuroblastoma alone is responsible for about 15% of cancer-related deaths in children in the United 
States and thus ranks among the most devastating childhood tumors (Mueller and Matthay 2009). 
Neuroblastomas originate from migrating cells of the neural crest, a temporary embryonal tissue that 
arises between the neural tube and the non-neuronal ectoderm during neural tube closure and gives 
rise to various cells and tissues such as the cells of the peripheral nervous system, the adrenal 
medulla, glia, craniofacial bone and cartilage and melanocytes (Crane and Trainor 2006). Initiation of 
the neural crest takes place at the border of the neural plate and the adjacent ectoderm, and is 
coordinated by a gradient of signaling factors that are secreted from the non-neuronal ectoderm and 
the underlying mesoderm, such as BMPs, Wnt and FGFs, Notch and retinoic acid (Prasad et al. 2012; 
Mayor and Theveneau 2013). In order to migrate, neural crest cells must then undergo a process 
called epithelial to mesenchymal transition, during which epithelial cells adapt a mesenchymal 
phenotype, leading to a loss of cellular polarity and adhesion that allows them to delaminate from 
the closing neural tube (Duband 2010; Mayor and Theveneau 2013). Delamination from the neural 
tube is followed by migration of neural crest cells along dorso- or ventrolateral routes, which, along 
with their site of origin along the anterior-posterior axis, determines neural crest cell fate (Krispin et 
al. 2010; Nitzan and Kalcheim 2013). Functionally, the neural crest can be divided into four partly 
overlapping domains or regions: The cranial, the cardiac, the vagal/sacral, as well as the trunk neural 
crest, all giving rise to different tissues and structures (Mayor and Theveneau 2013; Matthay et al. 
2016). The trunk neural crest itself harbors two cell populations, one of which travels along the 
dorsolateral route and differentiates into melanocytes. The other, migrating ventrolaterally, gives 
rise to the dorsal root ganglia, as well as to sympathoadrenal progenitor cells, which differentiate 
into cells of the sympathetic nervous system, including chromaffin cells of the adrenal medulla and 
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sympathetic ganglia (Anderson 1993; Jiang et al. 2011; Matthay et al. 2016). Neuroblastomas arise in 
structures derived from the sympathoadrenal lineage and are therefore thought to originate from 
incompletely differentiated sympathoadrenal progenitor cells. They are found in the neuronal ganglia 
along the entire sympathetic nervous system, with the most common sites being the adrenal medulla 
and lumbar sympathetic ganglia (65 %), and more rarely the sympathetic ganglia of the chest (20 %), 
neck and pelvis (5 %) (Cheung and Dyer 2013). Given their close connection to neural crest cell fate, it 
is hardly surprising that neuroblastoma cells harbor alterations in genes that are relevant for 
neuronal development, such as MYCN and ALK, as well as in genes that are important for the 
differentiation of sympathoadrenal progenitor cells such as PHOX2B (Dubreuil et al. 2000; Goridis 
and Rohrer 2002; Raabe et al. 2008).  
1.1  Genetic and genomic alterations in neuroblastoma 
Due to its rareness and the paucity of recurrent mutations at disease diagnosis, the understanding of 
neuroblastoma carcinogenesis remains incomplete (Pugh et al. 2013). Given its early onset, 
environmental factors seem unlikely, and to date no environmental factor has been identified that 
significantly increases the risk for neuroblastoma, although maternal exposure to drugs and 
chemicals during pregnancy cannot be fully ruled out (McCall et al. 2005; Bluhm et al. 2006; Matthay 
et al. 2016). In contrast, a number of genetic and structural chromosomal aberrations have been 
identified and linked to both neuroblastoma pathogenesis and prognosis, the most important of 
which will be discussed below.  
1.1.1 Mutations in the ALK and PHOX2B genes predispose for familial 
neuroblastoma 
Intriguingly, and despite its early onset, cases of familial neuroblastoma that originate from germline 
mutations are exceedingly rare and only account for only 1-2 % of total neuroblastoma cases (Ward 
et al. 2014; Matthay et al. 2016). To date, mutations in only two genes, namely ALK and PHOX2B, 
have been identified as high penetrance predisposing factors of hereditary neuroblastoma, even 
though recent genome wide association studies suggest that common polymorphisms in other 
genetic loci such as BARD1, LMO1 or LIN28B may contribute to neuroblastoma susceptibility (Cheung 
and Dyer 2013; Pugh et al. 2013; Matthay et al. 2016). 
In 2008, activating mutations in the ALK gene were identified as the most common cause for familial 
neuroblastoma (Janoueix-Lerosey et al. 2008; Mosse et al. 2008; Matthay et al. 2016). ALK mutations, 
which are present in almost all cases of familial neuroblastoma as well as in 6-10% of sporadic 
neuroblastomas, are found within the kinase domain of the ALK gene, mainly affecting the amino 
acids R1275, F1174 and F1245, thereby triggering constitutive activation of ALK kinase activity 
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independent of ligand binding (Janoueix-Lerosey et al. 2008; Ogawa et al. 2011). The ALK gene 
encodes for a receptor tyrosine kinase, which is highly expressed in the developing nervous system 
along with its ligands Midkine and pleiotrophin (Wellstein 2012). It is essential for sympathetic 
neuronal development, promoting proliferation of sympathetic neurons via interaction with its 
ligands (Reiff et al. 2011). Tightly controlled expression of ALK is essential for balancing neuronal 
progenitor proliferation, differentiation and survival during embryogenesis (Yao et al. 2013). Notably, 
ALK is amplified in 3-4 % of sporadic neuroblastoma cases (Mosse et al. 2008; Reiff et al. 2011; 
Cheung and Dyer 2013), in some instances co-amplified with the MYCN oncogene, likely due to the 
proximity of the two genes on the short arm of chromosome 2 (2p) (Mosse et al. 2008; Matthay et al. 
2016). Both ALK overexpression and aberrant activity have been found to promote proliferation and 
suppress cell death in neuroblastoma cell lines (Chen et al. 2008; George et al. 2008; Janoueix-
Lerosey et al. 2008). Elevated ALK expression is associated with poor outcome (Schulte et al. 2011), 
and ALK and MYCN cooperatively drive neuroblastoma tumorigenesis (Schulte et al. 2013).  
Germline mutations in the gene encoding for the paired homeodomain transcription factor PHOX2B 
were the first predisposing genetic aberrations discovered in familial neuroblastoma, although they 
occur at much lower frequency than ALK mutations (Mosse et al. 2004; Trochet et al. 2004). 
Mutations in PHOX2B are found in roughly 6 % of familial, as well as 4 % of sporadic neuroblastoma 
cases (Mosse et al. 2004; Trochet et al. 2004; Raabe et al. 2008; Louis and Shohet 2015). PHOX2B is 
an important regulator of neural crest development and it is mainly thought to promote sympathetic 
neuronal differentiation, as well as cell cycle exit (Pattyn et al. 1999; Trochet et al. 2005; Raabe et al. 
2008; Cheung and Dyer 2013; Pei et al. 2013; Wang et al. 2014). On the other hand, PHOX2B has also 
been shown to have oncogenic potential, since high PHOX2B expression was found to directly 
promote expression of ALK (Bachetti et al. 2010). 
1.1.2 MYCN amplification 
A frequent, albeit not the most common, genetic alteration found in roughly 20-25 % of sporadic 
neuroblastomas is the amplification of the MYCN oncogene on chromosome 2p24 (Schwab et al. 
1983; Huang and Weiss 2013; Matthay et al. 2016). Of all genetic and chromosomal aberrations 
known to occur in neuroblastoma, MYCN amplification possesses the highest predictive value for 
disease outcome and defines an aggressive tumor subtype with poor overall prognosis (Brodeur et al. 
1984; Louis and Shohet 2015). Amplification of the MYCN gene leads to overexpression of the 
transcription factor MYCN, a basic helix-loop-helix (bHLH) transcription factor of the MYC family of 
transcription factors (Kohl et al. 1984; Dang 2012). Like other members of the MYC family, MYCN is 
considered as a master regulator of transcription that can both activate and repress gene 
transcription, mainly via heterodimerization with its interaction partners MAX and MIZ1, respectively 
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(Blackwood and Eisenman 1991; Peukert et al. 1997; Huang and Weiss 2013). Evidence shows that 
the MYC family member C-Myc (hereafter referred to as MYC) alone may regulate up to 10-15 % of 
all genes in human cells (Fernandez et al. 2003). High expression of MYCN drives neuroblastoma 
tumorigenesis in multiple ways. MYCN has been shown to affect a grand number of cancer hallmarks, 
including the promotion of uncontrolled proliferation, enhanced cell survival and self-renewal, 
angiogenesis, migration and metastasis formation (Tweddle et al. 2001; Ribatti et al. 2002; van Golen 
et al. 2003; Kang et al. 2008; Izumi and Kaneko 2012; Huang and Weiss 2013; Matthay et al. 2016). At 
the same time MYCN is able to block cell cycle exit and repress differentiation (Lasorella et al. 1996; 
Lasorella et al. 2002). 
Physiologically, MYCN is highly, but not exclusively, expressed in the developing neural tissues of 
embryonic and newborn mice (Zimmerman et al. 1986; Laurenti et al. 2008). MycN knockout is lethal 
in mouse embryos (E10.5-E11.5) and MycN and Myc functions have been shown to be highly 
overlapping, although studies clearly suggest a non-redundant function of MycN in neuronal 
development (Charron et al. 1992; Sawai et al. 1993; Kenney et al. 2003; Hatton et al. 2006; Huang 
and Weiss 2013). Notably, the Myc family member C-Myc is known to be required for the 
maintenance of multipotency in neural crest cells (Bellmeyer et al. 2003; Sauka-Spengler and 
Bronner-Fraser 2008). Given the partly redundant functions of Myc family members, a similar role of 
aberrantly expressed MYCN in developing neuroblastomas is conceivable, possibly reflected by the 
finding that MYCN amplified tumors commonly display a lower grade of differentiation (Malynn et al. 
2000; Cotterman and Knoepfler 2009; Loven et al. 2010; Huang and Weiss 2013). At the same time, 
earlier studies suggest that MYCN expression is required for ventral migration and neuronal 
differentiation of neural crest cells (Wakamatsu et al. 1997). Yet, mouse models with ectopic 
expression of MYCN in sympathetic precursor cells under the control of the tyrosine hydroxylase (TH) 
promoter clearly underline the oncogenic potential of MYCN, as mice developed neuroblastoma with 
high penetrance, although tumors occurred with significant latency and commonly displayed 
additional chromosomal alterations (Weiss et al. 1997; Olsen et al. 2017). More recently, the 
oncogenic potential of ectopic MYCN expression was also directly shown in murine neural crest cells 
(Olsen et al. 2017). 
1.1.3 The role of segmental chromosomal copy number alterations and 
chromosomal translocations 
A large number of neuroblastomas are characterized by the occurrence of genomic, as well as 
recurring segmental chromosomal alterations (Matthay et al. 2016), some of which are strongly 
associated with disease outcome (see section A1.2). Karyotype analyses, for instance, show that DNA 
content in aneuploid neuroblastoma tumors can range from near-diploidy to near-tetraploidy, with 
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near-triploidy and near-diploidy occurring most frequently (Bourhis et al. 1991; Cohn et al. 2009). 
The most common chromosomal alteration, however, is the gain of the long arm of chromosome 17 
(17q) via unbalanced translocation to other chromosomes. Gain of 17q occurs in over 50 % of 
neuroblastoma cases (Bown et al. 1999; Schleiermacher et al. 2004; Matthay et al. 2016), making it 
the single most common genetic event in neuroblastoma. Sectional loss of chromosome 1p occurs in 
up to 35 % of neuroblastoma cases and strongly correlates with MYCN amplification in that a high 
number of MYCN amplified tumors also show loss of 1p (Caron et al. 1996; Maris et al. 2001; Brodeur 
2003). Another common deletion, which is observed in 35-45 % of neuroblastoma cases, occurs at 
the long arm of chromosome 11 (11q) (Attiyeh et al. 2005; Mlakar et al. 2017). As with the above 
described segmental alterations, deletions on 11q correlate with unfavorable disease outcome. In 
contrast to 17q gain or 1p loss however, 11q deletion displays a strong negative correlation with 
MYCN amplification (Caren et al. 2010) and is considered as an important predictor of poor outcome 
in MYCN non-amplified tumors (Caren et al. 2010; Schleiermacher et al. 2012; Mlakar et al. 2017). 
Finally, other recurring segmental alterations include gain of 1q, 2p and 14q, as well as loss of 3p and 
4p, but they are of lower prognostic impact than the above-described alterations at 17q, 11q or 1p 
(Schleiermacher et al. 2012; Matthay et al. 2016). 
Recurring losses and gains of the above described chromosomal sections suggest the presence of 
tumor suppressor genes and oncogenes at the respective genetic loci, but as of yet solely responsible 
gene has been found in the respective chromosomal segments. In case of chromosome 1p, however, 
evidence suggests the presence of multiple genes with tumor suppressive function, such as CDH5 
(Bagchi et al. 2007), KIF1B (Munirajan et al. 2008), CAMTA1 (Henrich et al. 2011), CASZ1 (Liu et al. 
2011), as well as the micro RNA mir-34A (Welch et al. 2007; Wei et al. 2008; Henrich et al. 2012; 
Matthay et al. 2016). 
1.1.4 TERT rearrangements and maintenance of telomeres 
Recent evidence suggests that telomere maintenance plays a crucial role in the aggressiveness of 
high-risk neuroblastomas. Two independent studies have demonstrated that the TERT gene locus, 
which encodes for the reverse transcriptase subunit of the telomerase complex, is frequently 
translocated to genomic regions that contain strong enhancer elements, causing strong 
transcriptional activation of the TERT gene (enhancer hijacking) (Peifer et al. 2015; Valentijn et al. 
2015). TERT rearrangements, which were observed in 23 and 31% of high-risk neuroblastomas, 
respectively, occurred mutually exclusive of MYCN amplification and identified a subgroup of 
aggressive tumors (Valentijn et al. 2015). Notably, TERT expression was high in MYCN amplified 
tumors despite the absence of TERT translocations, suggesting that telomere maintenance was as 
well crucial in this subset of high-risk tumors (Peifer et al. 2015).  
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Intriguingly, a number of high-risk tumors with neither MYCN amplification nor TERT rearrangement 
display alterations in the ATRX gene. The RNA helicase ATRX is required for the incorporation of 
histone variant H3.3 at genomic repeat sequences such as telomeres, leading to their epigenetic 
silencing (Wong et al. 2010; Udugama et al. 2015), and ATRX mutations are known to occur especially 
in neuroblastoma patients above 18 months of age (Cheung et al. 2012; Cheung and Dyer 2013). 
ATRX represses a homologous-recombination mediated mode of telomere elongation, known as 
alternative lengthening of telomeres, in a variety of cancers (Napier et al. 2015). Accordingly, 
neuroblastomas with ATRX mutations display an abundant number of telomeric repeats (Cheung et 
al. 2012; Peifer et al. 2015; Valentijn et al. 2015). Taken together, the above described studies 
suggest that telomere lengthening and maintenance are important features of high-risk 
neuroblastoma (Nicolai et al. 2015).  
1.2 Disease staging and classification 
Neuroblastomas rank among the most heterogeneous tumors with regards to course of disease. 
Observed clinical outcomes range from spontaneous regression, to differentiation to more benign 
ganglioneuroblastoma or ganglioneuromas, as well as to highly aggressive and metastatic disease 
with often fatal progression. Despite the unusually high rate of spontaneous regression - up to half of 
all neuroblastomas arising in the first year of life regress spontaneously -, about 36 % of 
neuroblastomas present with high-risk features at diagnosis, and survival rates in high-risk patients 
remain below 50 % despite intensive multimodal therapy (Woods et al. 1996; Schilling et al. 2002; 
Hero et al. 2008). 
The clinical course of neuroblastoma can be partly estimated from tumor size, the extent of surgical 
resection, as well as metastatic burden at disease diagnosis. This provides the basis for the 
International Neuroblastoma Staging System (INSS), one of the two most widely used neuroblastoma 
staging systems (Brodeur et al. 1993; Matthay et al. 2016). Briefly, tumors are categorized into six 
stages, whereat patients with localized disease (stages 1-3) usually have a better prognosis than dose 
with metastatic disease (stage 4), with the exception of patients categorized as 4s (Berthold and Hero 
2000; Cohn et al. 2009) (Figure 1). The International Neuroblastoma Risk Group Staging System 
(INRGSS) differs from the INSS in that stage is determined from tumor imaging, allowing for staging 
prior to treatment or surgery, as well as in that anatomical risk factors (so called image-defined risk 
factors/IDRFs) are included into the staging process. Moreover, children up to 18 months of age are 
grouped into stage MS, corresponding to stage 4s in the INSS (Monclair et al. 2009) (Figure 1). 
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Finally, INRG classification describes the assignment of patients into pre-treatment risk groups (very 
low, low, intermediate and high risk) depending on INRGSS stage, as well as the presence or absence 
of risk factors with proven prognostic impact on clinical outcome, the most important of which will 
be summarized below (Cohn et al. 2009). 
Age at diagnosis is of high prognostic impact in neuroblastoma, as overall survival rates decrease 
with increasing age of onset. Patients below 18 months of age display better 5-year event-free (82 %) 
and overall (88 %) survival rates than patients above that age (49 % EFS and 55 % OS) (Cohn et al. 
2009; Matthay et al. 2016).  
Neuroblastomas can have favorable or unfavorable histopathologic features, depending on the 
degree of neuroblast maturation, the amount of Schwannian stroma, as well as the mitosis-
karyorrhexis index. These parameters, as well as patient age, are basis of the Shimada, or more 
recently, the International Neuroblastoma Pathology (INPC) classification system, in which stroma-
Stage 1
Localized tumor with complete gross surgical 
excision and no metastasis to the representative 
ipsilateral lymph nodes  that were not attached 
to tumor
Stage 2a
Localized tumor with incomplete gross surgical  
excision and no metastasis to lymph nodes
Stage 3
Unresectable, unilateral tumor infiltrating 
across the midline, with or without regional 
lymph node metastasis
OR:  localized unilateral tumor with 
contralateral regional lymph node metastasis
OR: midline tumor with bilateral infiltration or 
lymph node involvement
Stage 4
Any primary tumor with metastasis to distant 
lymph nodes and/or other organs, except as 
defined fro stage 4s
Stage 4s
Localized primary tumor (stages 1, 2A, 2B) in 
patients < 1 year of age, with metastasis limited 
to skin, liver or bone marrow (< 10% tumor 
involvement)
Stage 2b
Localized tumor with or without complete gross 
surgical excision, with tumor metastasis to the 
ipsilateral lymph nodes but no metastasis in any 
enlarged contralateral lymph node
INSS
Stage L2
Locoregional tumor 
with presence of 
one or more image-
defined risk factors 
(e.g. compression of 
vital organs or 
ipsilateral tumor 
extension within 
two body 
compartments)
Stage MS
Metastatic disease in children < 18 months with 
metastases confined to skin, liver, and/or bone 
marrow (< 10% tumor involvement)
Stage M
Distant metastatic disease except as defined for 
MS. Distant lymph node involvement is 
metastatic disease.
Stage L1
Localized tumor not 
involving vital 
structures as 
defined by the list 
of image-defined 
risk factors and 
confined to one 
body compartment
INRGSS
Figure 1: Staging of neuroblastoma according to the International Neuroblastoma Staging System (INSS) 
and the International Neuroblastoma Risk Group Staging System (INRGSS). Figure adapted from (Matthay 
et al. 2016) and (Cohn et al. 2009). 
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rich and more differentiated tumors are associated with favorable outcome (Shimada et al. 1984; 
Shimada et al. 1999; Cohn et al. 2009). 
Furthermore, neuroblastomas can have favorable or unfavorable genetic and genomic features. 
Near-diploidy or tetraploidy, as well as structural chromosomal aberrations like deletions at 11q, 1p 
or gain of 17q and especially MYCN amplification, are associated with unfavorable prognosis (Cohn et 
al. 2009).  
With the increasing availability of high-throughput profiling techniques in recent years, gene 
expression signatures have proven to be of significant prognostic value in neuroblastoma in various 
studies (De Preter et al. 2010; Oberthuer et al. 2010; Henrich et al. 2016; van Groningen et al. 2017). 
Thus, these methods, which enable tumor characterization with unprecedented precision, could 
become an important tool for neuroblastoma risk stratification in the near future. 
1.3 Neuroblastoma prognosis and therapy  
Neuroblastoma treatment regimens are dictated by the above described INRG pre-treatment risk 
stratification strategies and can include observation, surgery, radio- and chemotherapy, autologous 
hematopoietic stem cell transplantation, as well as immunotherapy and differentiation therapy 
(Matthay et al. 2016). In case of very low-risk tumors in infants, it is often sufficient to observe 
tumors without biopsy or surgery, unless tumors show signs of progression (Nuchtern et al. 2012; 
Matthay et al. 2016). Further standard treatment of low-risk tumors includes surgical removal of the 
bulk tumor mass, as well as limited chemotherapy in case of symptomatic tumors or tumors that 
have unfavorable features. Overall, survival rates in this group are excellent, with 99-100% overall 
survival and > 90 % event-free survival (Strother et al. 2012; Iehara et al. 2013; Matthay et al. 2016). 
Intermediate risk tumors are standardly treated with limited cycles of chemotherapy and surgery if 
possible (Baker et al. 2010; Kohler et al. 2013; Defferrari et al. 2015; Matthay et al. 2016). Radiation 
therapy can be warranted in case of unresectable, progressing or refractory tumors (Matthay et al. 
1998; Baker et al. 2010; Kohler et al. 2013; Defferrari et al. 2015). Overall five-year survival in the 
intermediate risk group is very good (> 90%), but can be as low as 70 % in children over 18 months of 
age with unresectable tumors (Matthay et al. 2016). 
In contrast, prognosis in high-risk patients remains poor with five-year overall survival rates below 
50 %, despite intensive multimodal treatment regimens that include myeloablative chemotherapy 
and autologous hematopoietic stem cell transplantation (AHSCT), external or 131I-
metaiodobenzylguanidine (MIBG)-based radiotherapy, as well as differentiating agents such as 13-cis 
retinoic acid (Pinto et al. 2015; Matthay et al. 2016). Treatment success of high-risk neuroblastomas 
is further limited by the occurrence of relapsed tumors in up to 50 % of high-risk patients (Pinto et al. 
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2015), and survival in relapsed high-risk patients remains exceedingly poor (London et al. 2011; Basta 
et al. 2016). These poor survival rates, along with the occurrence of often irreversible, therapy-
induced, side effects such as hearing loss, impaired growth, infertility and secondary neoplasms 
clearly highlight the necessity of innovative and more targeted therapy approaches (Matthay et al. 
2016). 
2 Histone deacetylases (HDACs) 
Histone deacetylases (HDACs) are a class of highly conserved enzymes that catalyze the removal of 
acetyl groups from lysine residues of proteins. Initially named after their first discovered substrate 
proteins, i.e. histones, it is now clear that histone deacetylases should be more precisely referred to 
as lysine deacetylases (KDACs), since they have a plethora of non-histone targets and thus affect a 
multitude of cellular processes apart from gene transcription and chromatin organization (Seto and 
Yoshida 2014; Scholz et al. 2015)(described in more detail in section A2.4). 
2.1 Molecular functions of lysine acetylation  
Lysine acetylases and deacetylases are evolutionary highly conserved enzymes. They are found in 
both prokaryotes and eukaryotes (Kleff et al. 1995; Taunton et al. 1996; Starai et al. 2002; Gardner et 
al. 2006; Drazic et al. 2016), underlining the importance of lysine acetylation as an essential post-
translational protein modification (Zhang et al. 2009a; Drazic et al. 2016). Lysine acetylation occurs 
on the -amino group of lysine residues of proteins and the transfer of the acetyl groups from acetyl-
CoA to lysine residues is catalyzed by the family of lysine acetyl transferases (KATS, originally referred 
to as histone acetyl transferase (HATs)). It is thus a reversible and highly dynamic process, the 
equilibrium of which is tightly governed by two families of enzymes with opposing enzymatic activity 
(reviewed in (Yang and Seto 2008a; Witt et al. 2009)). 
The best understood consequence of lysine acetylation both in yeast and higher eukaryotes is the 
modulation of higher genomic structure by reversible acetylation of histone proteins. The genome of 
eukaryotic cells is condensed into a highly dynamic polymeric structure called chromatin, the 
conformation and compactness of which depends on the organization of its fundamental repeating 
unit, the nucleosome (Jenuwein and Allis 2001). Nuleosomes themselves consist of roughly 150 base 
pairs of DNA that are wrapped around an octamer of four core histone proteins: two histone H2A/ 
H2B dimers, and a H3/H4 tetramer (Kornberg 1974; McGinty and Tan 2015). The flexible, N-terminal 
histone tails carry an extensive and reversible set of posttranslational modifications, including 
acetylation, methylation, ubiquitinylation and sumoylation, which together govern DNA accessibility 
and transcriptional activity and are often referred to as the "histone code" (Strahl and Allis 2000; 
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Jenuwein and Allis 2001; Kouzarides 2007). The acetylation state of histones strongly influences the 
compactness of the chromatin fiber and enables switching between a transcriptionally permissive or 
a repressive chromatin state, termed euchromatin and heterochromatin, respectively (Shogren-
Knaak et al. 2006). Hyperacetylation of histones favors the formation of loosely packed, 
transcriptionally active euchromatin both by neutralizing positively charged lysine residues, thereby 
weakening histone interactions with the negatively charged DNA backbone, as well as by weakening 
intra- and inter-nucleosome interactions (Dorigo et al. 2003; Ye et al. 2005; Tessarz and Kouzarides 
2014; Zhang et al. 2017a). Additionally, hyperacetylated histones are known to promote transcription 
by recruiting bromodomain-containing proteins and transcription factors (Dhalluin et al. 1999; 
Agalioti et al. 2002; Filippakopoulos and Knapp 2014). In contrast, hypoacetylation of histones is 
associated with tightly packed heterochromatin that is less accessible to transcription factors and 
transcriptionally silent.  
Acetylation also occurs on proteins other than histones, but the function of non-histone protein 
acetylation is less well understood (Choudhary et al. 2014; Scholz et al. 2015). Various modes of 
action have been described, including the blockage of other lysine-specific modifications such as 
sumoylation or ubiquitinylation, which in turn can affect protein-protein interactions, protein 
localization or protein stability (Li et al. 2002; Zheng and Yang 2005; Yang and Seto 2008a). 
Moreover, it can directly alter the affinity of proteins to interacting molecules, including other 
proteins and DNA (Mujtaba et al. 2004; Friedler et al. 2005), or change the activity of enzymes in case 
of acetylation of an active site lysine residue (Starai et al. 2002), suggesting that acetylation is a way 
of fine-tuning the activity of the respective target protein. 
2.2 Classification of the human HDAC family 
The human HDAC family consists of 18 members. Depending on the co-factor required for their 
enzymatic function and the catalytic mechanism involved, they are divided into two families: The 
Zn2+-dependent so called classical HDACs (Figure 2) and the NAD+-dependent sirtuins (reviewed in 
(Seto and Yoshida 2014)). According to sequence homology to their yeast orthologues Rpd3 and 
Hda1, classical HDACs can be further subdivided into HDAC classes I (HDACs 1, 2, 3 and 8), IIa (HDACs 
4, 5, 7, 9), IIb (HDACs 6, 10) and class IV (HDAC11), while the Sir2-related sirtuins are also referred to 
as class III HDACs (reviewed in (Gregoretti et al. 2004; Yang and Seto 2008b)). In total, the human 
genome encodes for 11 classical HDACs and seven sirtuins. 
Class I is comprised of HDACs 1, 2, 3 and 8, which share a high homology to the yeast histone 
deacetylase Rpd3 (Figure 2). Structurally, they are characterized by an N-terminal deacetylase 
domain and a C-terminal tail. The latter harbors one or more CK2 phosphorylation sites in case of 
HDACs 1-3, the phosphorylation of which promotes enzymatic activity and is further important for 
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complex formation (Pflum et al. 2001; Tsai and Seto 2002; Yang and Seto 2008b). HDACs 1-3 are 
found in nuclear multiprotein complexes, also termed corepressor complexes due to their repressive 
impact on transcription. While HDACs 1 and 2 associate with at least three such complexes (Sin3, 
NuRD and CoREST), HDAC3 seems to be more specifically located in a complex with N-CoR (Nagy et 
al. 1997; Ayer 1999; Wen et al. 2000; Hakimi et al. 2002; Denslow and Wade 2007; Seto and Yoshida 
2014). Collective evidence shows that association with these complexes is required for full enzymatic 
activity of HDACs 1-3 (Wen et al. 2000; Alland et al. 2002; Boyer et al. 2004; Seto and Yoshida 2014). 
In contrast, HDAC8 has not been shown to be present in multiprotein complexes, suggesting that it 
can be enzymatically active in the absence of protein cofactors (Buggy et al. 2000; Wolfson et al. 
2013). It lacks C-terminal CK2 phosphorylation sites and is instead negatively regulated by 
phosphorylation of a PKA phosphorylation site near its N-terminus (Figure 2) (Lee et al. 2004). HDAC8 
is present in both nucleus and cytoplasm, but deacetylating activity on histones has only been shown 
in cell-free biochemical assays (Olson et al. 2014; Chakrabarti et al. 2015). Thus, in cells HDAC8 is 
thought to primarily deacetylate other substrates, such as the cohesin component SMC3 (Deardorff 
et al. 2012) and the estrogen receptor ERR(Wilson et al. 2010). 
Class II shares a catalytic domain homologous to the deacetylase domain of yeast Hda1, and is 
subdivided into two subclasses (Figure 2). Class IIa members are characterized by a C-terminal 
deacetylase domain and a long N-terminal section with further protein binding motifs that are not 
found in yeast Hda1 (Yang and Gregoire 2005; Yang and Seto 2008b). Class IIa members also harbor 
both nuclear localization (NLS) and export signals (NES) and are thus found both in the nucleus and 
cytoplasm. Their subcellular localization is governed by MEF2 and 14-3-3 protein binding sites in their 
N-terminal domain. Like HDACs 1-3, they are primarily thought to act as transcriptional repressors, 
although their expression seems to be tissue-specific (Parra and Verdin 2010). Moreover, it is still 
debated whether they require other HDAC members for substrate deacetylation as they have been 
repeatedly shown to possess low deacetylase activity (Lahm et al. 2007; Jones et al. 2008).  
Class IIb members HDAC6 and HDAC10 do not possess an extended N-terminal domain, and are 
further unique within the HDAC family because they contain two putative enzymatic sites, the 
second of which is active only in case of HDAC6 (Guardiola and Yao 2002; Kao et al. 2002; Yang and 
Seto 2008b) (Figure 2). They are mainly localized in the cytoplasm and are thus thought to have 
largely cytoplasmic functions, although context-dependent nuclear localization has been shown for 
both proteins (Guardiola and Yao 2002; Seto and Yoshida 2014; Yang et al. 2015). While little is 
known about the function of HDAC10, HDAC6 is primarily known for its function as a deacetylase of 
-tubulin (Hubbert et al. 2002). Moreover, HDAC6 is involved in cellular stress responses by 
modulating HSP90 chaperone function and by promoting aggresome formation and resistance to 
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proteotoxic stress via its C-terminal, ubiquitin-binding zinc finger domain (Hook et al. 2002; 
Kawaguchi et al. 2003; Bali et al. 2005). 
The sole class IV HDAC member, HDAC11, is unique in that its catalytic domain is homologous to both 
class I and class II HDACs. Although it is highly conserved (Gao et al. 2002; Seto and Yoshida 2014), 
little is known about its physiological function apart from its role as a negative regulator of 
interleukin 10 expression in antigen-presenting cells, suggesting a role for HDAC11 in immune 
tolerance (Villagra et al. 2009). 
Seven members - named SIRT1-7 according to their homology to the yeast deacetylase Sir2 - make up 
the HDAC class III. They are not classified as classical HDACs due to their dependency on NAD+ rather 
than Zn2+ as co-factor. Furthermore, they show a diverse pattern of subcellular localization, with 
SIRT1 and SIRT2 shuttling between nucleus and cytoplasm, SIRT3 being present in nucleus and 
mitochondria, SIRT4 and SIRT5 being exclusively localized in mitochondria, and SIRT6 and 7 being 
localized to nucleus and nucleolus, respectively (Seto and Yoshida 2014). 
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2.3 Classical HDACs and their cancer relevant functions 
It is becoming increasingly clear that cancer is not only a genetic, but to some degree also an 
epigenetic disease characterized by widespread epigenetic changes that cause large-scale changes in 
gene expression (Sharma et al. 2010; Sturm et al. 2014; Yu et al. 2014; Hashizume 2017). Given their 
Figure 2: Classification and domain organization of the classical (Zn2+-dependent) human HDACs.HDACs are 
grouped into different classes according to their homology to yeast deacetylases Rpd3 (class I) and Hda1 (class 
II). Class IV member HDAC11 shares homology with both class I and II HDACs. HDACs can have various domains 
and sites of phosphorylation in their N- and C-terminal domains which regulate their function and localization, 
or can have additional functions (e.g. in case of the ubiquitin-binding domain of HDAC6). Numbers on the right 
indicate length in amino acids of the respective HDAC (full-length isoform). Figure was adapted and modified 
from (Yang and Seto 2008b) and (Seidel et al. 2015). 
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role as important epigenetic modifiers, it is hardly surprising that HDACs have been found to be 
critically involved in a number of cancer-relevant processes such as proliferation, apoptosis 
avoidance, angiogenesis, migration and metastasis formation (reviewed in (Witt et al. 2009; Hanahan 
and Weinberg 2011; Li and Seto 2016)). The activity of histone acetylating and deacetylating enzymes 
is tightly controlled in non-neoplastic cells, and often becomes deregulated upon malignant 
transformation. A shift towards aberrant activity of HDACs and the loss of certain histone acetylation 
marks has been observed in a number of cancers, often caused by deregulated HDAC expression, 
which is observed more frequently than mutations in HDACs (Yasui et al. 2003; Fraga et al. 2005; 
Ropero et al. 2006; Witt et al. 2009; Fullgrabe et al. 2011; Ceccacci and Minucci 2016). Increased 
HDAC activity is associated with increased heterochromatin formation and reduced gene expression. 
The latter often affects genes that govern cell cycle control, differentiation and apoptosis (Ropero 
and Esteller 2007; Witt et al. 2009). Nonetheless, the function of HDACs in cancer cannot be reduced 
to their role as epigenetic modifiers, as they are also known to target non-histone proteins with 
cancer-relevant functions (discussed below). 
The class I HDAC members HDAC1, 2 or 3 have been observed to be overexpressed in a number of 
cancer entities, including gastric cancer (Choi et al. 2001; Weichert et al. 2008a), colorectal cancer 
(Weichert et al. 2008b) and prostate cancer (Halkidou et al. 2004). Overexpression in these tumors 
regularly correlated with poor prognosis, advanced disease stage, apoptosis resistance, increased 
proliferation, although elevated HDAC1 or HDAC3 expression also have been found to predict better 
disease-free survival in some tumor entities (Krusche et al. 2005; Zhang et al. 2005; Witt et al. 2009). 
HDAC2 specifically has been described to contribute to tumor cell survival in both medulloblastoma 
and neuroblastoma (Lodrini et al. 2013; Ecker et al. 2015). HDAC8, the class I member mainly 
targeting non-histone proteins, has been demonstrated to be upregulated in advanced stage (INSS 
stage 4) neuroblastomas, where it correlated with poor survival (Oehme et al. 2009a; Oehme et al. 
2009b; Rettig et al. 2015). Mechanistically, class I have been repeatedly linked to cell cycle 
progression due to their ability to promote the expression of cyclins, while repressing expression of 
Cyclin-dependent kinase inhibitors such as p21 and p27 in various cancer cell lines (Wilson et al. 
2006; Senese et al. 2007; Jung et al. 2012; Xie et al. 2012). HDAC1 has also been associated with 
increased chemoresistance in neuroblastoma, although a precise mechanism was not described 
(Buurman et al. 2012). To make matters more complex, tumorsuppressive functions have been 
reported for HDACs 1 and 2 in pre-tumor stages, which can switch to a tumor promoting function in 
the same model once tumors have established (Heideman et al. 2013; Santoro et al. 2013). 
Interference with HDAC8 function in particular has been reported to promote differentiation and cell 
cycle arrest in neuroblastoma cell lines by inducing p21 and NTRK expression suggesting that some 
HDACs are specifically involved in the regulation of genes that are required for neuronal or neural 
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crest cell differentiation (Oehme et al. 2009a; Oehme et al. 2009b; Rettig et al. 2015). This is possibly 
underlined by the fact that HDAC8 knockout mice show aberrant gene expression patterns in cranial 
neural crest cells, leading to perinatal mortality due to skull instability and frontocranial dysplasia 
(Haberland et al. 2009). 
Class IIa HDACs 4, 5, 7 and 9 have been reported to be deregulated in a number of cancers, although 
the mode of action by which they exert their oncogenic function is often unknown. HDAC5 and 
HDAC9 levels have been shown to be elevated in medulloblastoma subgroups with poor prognosis 
and interference with HDAC5 or HDAC9 function impaired proliferation and viability of 
medulloblastoma cell lines (Milde et al. 2010). HDAC5 was also found in other studies to promote 
tumor cell proliferation and resistance to cell death (Fan et al. 2014; Feng et al. 2014). HDAC7, along 
with class I member HDAC1, has been reported to be necessary for the maintenance of cancer stem 
cells in breast cancer (Witt et al. 2017). Notably, HDAC7 was also reported have pro-angiogenic 
potential by blocking expression of the angiogenesis suppressor AKAP12 in endothelial cells, 
suggesting that HDAC7 might promote angiogenesis in a tumor setting (Mottet et al. 2007; Turtoi et 
al. 2012). Another recent study demonstrated that HDAC9 possesses pro-proliferative potential in 
breast cancer by positively regulating of Sox9 expression (Lapierre et al. 2016). 
The role of class IIb HDACs in cancer is not well understood and high expression of these HDACs has 
been associated with both poor and good prognosis depending on study (Zhang et al. 2004; Sakuma 
et al. 2006; Oehme et al. 2013a; Jin et al. 2014; Tao et al. 2017; Zhang et al. 2017b). Whether these 
HDACs possess oncogenic or tumorsuppressive potential might therefore ultimately depend on 
tumor tissue and tumor environment. Mechanistically, HDAC6 has been described to promote cell 
motility and epithelial-mesenchymal transition, both of which have been linked to its ability to alter 
cytoskeletal dynamics via deacetylation of-tubulin and the F-actin binding protein cortactin, the 
latter of which is also a direct target of class III HDAC Sirt1 (Hubbert et al. 2002; Shan et al. 2008; 
Zhang et al. 2009b). Moreover, HDAC6 is known to promote stress response in various disease 
models. It has been, for instance, described as a master regulator of protein aggregate formation and 
clearance under proteotoxic stress conditions (Kawaguchi et al. 2003; Boyault et al. 2007; Tran et al. 
2007). Here, HDAC6 was shown to bind to unanchored ubiquitin C-termini within protein aggregates 
via its ubiquitin-binding zinc finger (ZnF) domain, and to promote their retrograde transport along 
microtubules to the microtubule-organizing center (MTOC), where they are incorporated into 
aggregate-containing compartments (aggresomes) (Kawaguchi et al. 2003; Ouyang et al. 2012). These 
aggresomes can then be degraded via autophagy (see section A3.2.2). HDAC6 was also described as a 
promoter of productive autophagy by enabling autophagosome-lysosome fusion under basal and 
aggregation-induced autophagy (aggrephagy) conditions, while being dispensable for this process in 
case of starvation-induced autophagy (Lee et al. 2010b). To add to the complexity, HDAC6 has also 
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been proposed as a negative regulator of autophagy in one study (Yang et al. 2013). Finally, HDAC6 
has emerged as a modulator of cell signaling and as a sensor of cell stress by deacetylating the 
cellular chaperone HSP90 (Bali et al. 2005; Kovacs et al. 2005). HSP90 chaperone function is known to 
be required for the function of various oncoproteins, including Bcr-Abl or ERBB2, that act as HSP90 
client proteins (Bali et al. 2005; Neckers and Workman 2012). With regards to the fact that tumor 
cells often display proteotoxic stress due to their exposure to environmental or treatment stress, the 
above described studies suggest that HDAC6 could be involved in tumor stress resistance. However, a 
clear anti-tumor effect of HDAC6 inhibition remains to be shown.  
The function of the other class IIb member, HDAC10, remains even more enigmatic, since no cellular 
bona-fide substrate has been described for this enzyme. Moreover, little is known about its 
interaction partners or the regulation of its function. A study in neuroblastoma suggests, however, 
that HDAC10 is critically involved in productive autophagy in neuroblastoma cells, where its absence 
leads to autophagosome accumulation and autophagic flux stop (Oehme et al. 2013a; Oehme et al. 
2013b). This study also suggested that the inducible heat shock protein HSP70 could be a target of 
HDAC10 and that HDAC10 is a mediator of chemoresistance in neuroblastoma. 
Only little is known about the cancer-related roles of the only class IV member HDAC11. A few 
studies, however, show that HDAC11 possesses tumor-promoting potential in neuroblastoma 
(Deubzer et al. 2013; Thole et al. 2017) and Hodgkin's lymphoma (Buglio et al. 2011). 
2.4 Non-histone targets of HDACs 
Histone deacetylases have a high number of non-histone targets and should be thus more precisely 
referred to as lysine deacetylases (KDACs). Examples of HDAC non-histone targets include-tubulin 
at lysine 40, which is a target of HDAC6, as well p53, which has been shown to be a substrate of 
HDAC 1 and SIRT1 (Luo et al. 2000; Vaziri et al. 2001). Moreover, transcription factors like the NF-B 
subunit RelA or STAT3 have been described as HDAC targets, suggesting that HDACs alter 
transcription not only on the level of histone acetylation (Greene and Chen 2004; Gupta et al. 2012). 
In fact, proteomics approaches suggest that lysine acetylation is abundant on non-histone proteins 
and that inhibition of classical HDACs increases acetylation at as many as 10 % of identified 
acetylation (Choudhary et al. 2009). 
More recently, HDACs have also emerged as important regulators of cellular stress, which is partly 
mediated by their ability to reverse acetylation on heat shock proteins HSP70 and HSP90 (see 
following section).  
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2.4.1 Heat shock proteins (HSPs) as HDAC targets 
A number of recent studies have identified heat shock proteins as potential HDAC targets. Heat shock 
proteins  are highly conserved proteins that are found in all living organisms (Ashburner and Bonner 
1979; Ingolia et al. 1982; Hunt and Morimoto 1985; Lindquist 1986; Li and Srivastava 2004). Their 
expression is induced by various stress stimuli including hypoxia, UV light, toxins, inflammation, and 
high temperature (reviewed in (Lindquist and Craig 1988; Ritossa 1996; Santoro 2000)). Heat shock 
proteins that help other proteins to achieve and stabilize their functional three-dimensional 
conformation are also called chaperones (Ellis 1987). Chaperones and their cofactors are organized in 
large cooperative networks and are essential in the processes of nascent protein folding, as well as in 
the refolding of denatured proteins, the prevention of protein aggregation, the maintenance of 
folded proteins in their functionally active conformation and the assembly of oligomeric complexes. 
Furthermore, they assist in protein trafficking and degradation (reviewed in (Hartl et al. 2011)). 
Chaperones are broadly grouped into six conserved families according to their molecular weight in 
kilodaltons: small HSPs (12-43 kDa), HSP40, HSP60 (chaperonins) HSP70, HSP90 and HSP110 
(reviewed in (Schlesinger 1990; Hartl et al. 2011; Bakthisaran et al. 2015)). Of these, especially 
members of the HSP70, the HSP90 and the HSP60 family play a major role in protein folding (Langer 
et al. 1992; Frydman et al. 1994; Hartl et al. 2011). Although the mode of protein folding differs 
between these chaperones, they commonly recognize and bind to hydrophobic residues exposed to 
the surface of unfolded or misfolded proteins and promote protein folding by repeating substrate 
binding and release cycles that are driven by cycles of ATP binding and hydrolysis (Flynn et al. 1989; 
McCarty et al. 1995; Theyssen et al. 1996; Prodromou et al. 2000; Meyer et al. 2003a; Hartl et al. 
2011; Mayer 2013). Given their central importance in numerous cellular stress responses, it is hardly 
surprising that aberrant chaperone expression and function have been associated with a variety of 
diseases, including cancer (reviewed in (Ciocca and Calderwood 2005; Rappa et al. 2012; Lindberg et 
al. 2015)). Apart from their transcriptional regulation, chaperone function is highly controlled at the 
posttranslational level, e.g. by binding of various cofactors and by posttranslational modifications 
such as phosphorylation, sumoylation, ubiquitination, glycosylation and acetylation (reviewed in 
(Scroggins and Neckers 2007; Cloutier and Coulombe 2013)). In this context, especially members of 
the chaperone classes HSP90 and HSP70 have been repeatedly reported to be modified by lysine 
acetylation and to be targeted by HDACs.  
HSP90s are a very prominent example of regulation of chaperone activity by acetylation. They consist 
of three well-defined structural domains: a highly conserved N-terminal nucleotide binding domain 
responsible for ATP-binding and hydrolysis, a middle domain which binds client proteins and is also 
required for ATP hydrolysis, and a highly conserved C-terminal dimerization domain that also recruits 
cochaperones (Minami et al. 1994; Prodromou et al. 1997; Meyer et al. 2003b; Ali et al. 2006; Hartl 
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et al. 2011). HSP90s commonly work as dimers downstream of HSP70 and promote folding, refolding, 
as well as structural maturation and maintenance of client proteins, many of which are critically 
involved in cellular signal transduction (reviewed in (Taipale et al. 2010; Hartl et al. 2011)). Collective 
evidence suggests that HDAC6 acts as the main HSP90 deacetylating enzyme (Bali et al. 2005; Kovacs 
et al. 2005; Murphy et al. 2005; Scroggins et al. 2007; Yang et al. 2008; Kekatpure et al. 2009), 
although class I HDACs have been also proposed to deacetylate HSP90 (Nishioka et al. 2008; Zhou et 
al. 2008). Reversible acetylation of HSP90 modulates major HSP90 functions including its chaperone 
activity and binding to cochaperone p23 (Kovacs et al. 2005), activation of HSP90-dependent proteins 
(Bali et al. 2005; Scroggins et al. 2007; Yang et al. 2008; Kekatpure et al. 2009), as well as stability of 
such client proteins (Rao et al. 2008). 
HSP70 possesses two major functional domains: an N-terminal ATPase domain and a C-terminal 
substrate binding domain, which can be sub-divided into a -sandwich subdomain and an -helical 
lid segment (Flaherty et al. 1990; Zhu et al. 1996; Hartl et al. 2011). In its ATP bound open 
conformation, HSP70, with the help of its cochaperone HSP40, binds to stretches of exposed 
hydrophobic amino acids of incorrectly folded proteins and helps to prevent their aggregation (Flynn 
et al. 1991; Cyr et al. 1992; Rudiger et al. 1997). ATP hydrolysis, which is assisted by HSP40, closes the 
-helical lid of the substrate binding domain and stabilizes the substrate-chaperone interaction, 
while ADP dissociation and subsequent binding of a new ATP molecule result in substrate release and 
recycling (Ha and McKay 1995; McCarty et al. 1995; Theyssen et al. 1996; Mayer 2010; Hartl et al. 
2011). Notably, HSP70 is known to work in a complex with or transfer partially folded substrates to 
other chaperones such as HSP90 for final maturation or to chaperonins (TRiC/CCT in eukaryotes) in 
case of unsuccessful folding (Langer et al. 1992).The human HSP70 family consists of thirteen 
members, which mainly differ in subcellular localization and stress inducibility. The constitutively 
expressed HSC70 (HSPA8) acts as housekeeping chaperone in the nucleus and cytoplasm (Ingolia and 
Craig 1982; Chappell et al. 1986; Beckmann et al. 1990; Daugaard et al. 2007b), while HSP70 family 
members HSPA1A and HSPA1B (below referred to as HSP70) are expressed when cells are exposed to 
stress stimuli such as hyperthermia or upon malignant transformation (Wu et al. 1985; Tavaria et al. 
1996; Murphy 2013). HSPA5 (GRP78/BiP) is restricted to the ER lumen where it is responsible for 
protein translocation and quality control and acts as a critical sensor of ER stress and response 
regulator of the unfolded protein response (Haas and Wabl 1983; Munro and Pelham 1986; Ting and 
Lee 1988; Hamman et al. 1998; Bertolotti et al. 2000; Harding et al. 2002). Another member, called 
GRP75 or mtHSP70, is located in the mitochondrial matrix (Domanico et al. 1993; Bhattacharyya et al. 
1995; Daugaard et al. 2007b). Expression of HSP70 is induced by application of HDAC inhibitors via 
epigenetic mechanisms, although the main heat shock response mediating transcription factor HSF1 
requires deacetylation of lysine 80 by class III HDAC SIRT1 in order to promote expression of HSPs 
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(Zhao et al. 2006; Westerheide et al. 2009). At the same time, a small number of studies suggest that 
HSP70 function is also directly modulated by HDACs. HSP70 was hyperacetylated after treatment of 
human leukemia cells with pan-HDAC inhibitors (Rao et al. 2008). In a follow-up study, it was shown 
that six lysine residues (K88, K126, K159, K523, K558 and K560) were differentially acetylated after 
panobinostat treatment. Based on previous studies, the authors suggested HDAC6 as the major 
deacetylase of HSP70 (Rao et al. 2008; Yang et al. 2008; Yang et al. 2013). Functionally, acetylation of 
HSP70 lysine 159 was crucial for induction of autophagy (see section A3.2.2) in breast cancer cells, 
where it facilitated formation of the autophagosome-inducing Beclin-1-Vps34 complex. The same 
group also proposed the ER-resident GRP78 as a target of HDAC6 (Rao et al. 2010). Here, the authors 
showed that acetylation of GRP78 on lysine 11 leads the dissociation partner of GRP78 from its ER 
interaction partner PERK, thereby triggering a lethal unfolded protein response (UPR) in human 
breast cancer cell lines. At the same time, another study suggests that HDAC10 potentially 
deacetylates HSP70 and that hyperacetylated HSP70 might impair lysosomal function (Oehme et al. 
2013a). Acetylation of HSP70 at lysine 11 has also been reported and acetylation at this site switched 
HSP70 function from promoting protein folding to promoting their degradation. HSP70 was 
acetylated by the acetyl transferase ARD1 early during stress response, while being deacetylated by 
HDAC4 at later stages. Differential acetylation was associated with changes in cochaperone binding. 
The cochaperone HOP, which promotes the protein folding function of HSP70, was found to bind to 
acetylated HSP70, while deacetylated HSP70 bound to the co-chaperone CHIP that mediates 
ubiquitinylation and elimination of HSP70 targets (Seo et al. 2016). 
Other HSP family members have been reported to be modulated by lysine acetylation including 
HSP10 (Lu et al. 2015) and HSP20 (Karolczak-Bayatti et al. 2011). Moreover, DNAJB8, a member of 
the HSP40 family that act as HSP70 cochaperones, interacts with HDACs 4, 6, and SIRT2, which 
deacetylate two C-terminal lysine residues. This was shown to be critical for the prevention of toxic 
polyglutamine protein aggregation and the accumulation of other misfolded proteins (Hageman et al. 
2010).  
2.4.2 Polyamines as potential targets of HDAC10 
The recently published crystal structure of zebrafish HDAC10 suggests that HDAC10, due to its 
sterically constricted active site, is a polyamine rather than a lysine deacetylase (Hai et al. 2017). 
Polyamines are small, polycationic alkylamines, three of which - spermidine, spermine and putrescine 
- occur naturally in all living organisms with cellular concentrations in the millimolar range (Tabor and 
Tabor 1984; Casero and Marton 2007). Polyamines are essential in both prokaryotic and eukaryotic 
cells and their biosynthesis, transport and catabolism are tightly regulated (Figure 3a) (Casero and 
Marton 2007). Due to their cationic nature, they bind to anionic cellular macromolecules, and they 
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have been implicated in a number of physiological processes such as the structural maintenance of 
DNA and chromatin, protein synthesis, autophagy, the regulation of ion channels, as well as the 
scavenging of free radicals (Williams 1997; Das and Misra 2004; Casero and Marton 2007; Eisenberg 
et al. 2009; Park et al. 2010; Mandal et al. 2013; Baronas and Kurata 2014; Pasini et al. 2014). At the 
same time, their biosynthesis and metabolism have frequently been shown to be deregulated in a 
number of diseases including cancer (Casero and Marton 2007). 
Polyamine synthesis critically depends on the activity of two rate-limiting enzymes, namely ornithine 
decarboxylase (ODC-1), which generates putrescine from ornithine, and S-adenosylmethionine 
decarboxylase (AdoMetDC), which converts S-adenosylmethionine to S-adenosylmethioninamine 
(Stanley et al. 1989; Pegg 2006). The latter intermediate provides the aminopropyl residue for the 
sequential synthesis of spermidine and spermine from putrescine by spermidine synthase and 
spermine synthase, respectively (Wahlfors et al. 1990; Korhonen et al. 1995). In the catabolic 
process, spermine and spermidine are degraded by the sequential action of two enzymes to 
spermidine and putrescine, respectively. First, they are acetylated at their respective N1 position by 
spermidine/spermine N1-acetyltransferase (SSAT) that transfers an acetyl group from acetyl-CoA to 
the respective polyamine (Casero and Pegg 1993). In a second step, N1-acetylated spermine or 
spermidine are cleaved to spermidine and putrescine, respectively, by the peroxisomal enzyme N1-
acetylpolyamine oxidase (APAO) under the generation of 3-aceto-aminopropanal and H2O2 (Vujcic et 
al. 2003). Notably, spermine can also be directly cleaved to spermidine by the enzyme spermine 
oxidase (SMO) (Vujcic et al. 2002; Wang et al. 2003). Polyamines are both taken up and secreted by 
cells via a specific polyamine transport system, but this system remains incompletely characterized 
(Palmer and Wallace 2010; Uemura and Gerner 2011). However, one identified polyamine 
transporter, SLC3A2, was shown to specifically export N1-acetylated polyamines (Uemura et al. 
2008). In eukaryotic cells, spermidine can be also acetylated at its N8 position by a nuclear enzyme, 
yielding N8-acetyl spermidine (Figure 3b) (Libby 1980). N8-acetyl spermidine can be processed back to 
spermidine by a cytoplasmic polyamine deacetylase (PDAC), and HDAC10 has been recently 
suggested as that PDAC (Blankenship 1978; Libby 1980; Hai et al. 2017). Based on the crystal 
structure from zebrafish HDAC10, the study demonstrated that HDAC10 harbors a conserved 
glutamate residue near its active site, which is not present in other HDACs and acts as a gatekeeper. 
Along with the sterically constricted active site of HDAC10, this gatekeeper was suspected to confer 
high specificity for positively charged acetylpolyamine substrates, or more specifically N8-
acetylspermidine. Subsequent biochemical analyses with recombinant human and zebrafish HDAC10 
demonstrated that HDAC10 had high PDAC and low lysine deacetylase activity. However, the cellular 
function of N8-acetylspermidine or the extent to which this spermidine derivative is present in cells 
remains unknown. 
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Importantly, the rate-limiting enzyme of polyamine synthesis, ODC-1, has been shown to be a direct 
transcriptional target of MYC transcription factors, including MYCN in neuroblastoma (Hogarty et al. 
2008). Subsequent studies have shown that polyamine metabolism is often severely deregulated in 
high-risk neuroblastoma cases, and high ODC-1 expression was shown to be associated with poor 
outcome independently of MYCN amplification (Hogarty et al. 2008; Gamble et al. 2012). In various 
models, polyamines contribute to tumorigenicity by suppressing apoptosis (Singh et al. 2000; Babbar 
et al. 2003), increasing cell proliferation (Singh et al. 2000), as well as by promoting protein 
translation (Mandal et al. 2013), angiogenesis (Takigawa et al. 1990) and possibly autophagy 
(Eisenberg et al. 2009). Consequently, inhibitors that target polyamine metabolism and transport are 
attractive for anti-cancer therapy (Samal et al. 2013; Evageliou et al. 2016). Polyamine synthesis 
inhibitors, such as the ODC-1 inhibitor difluoromethylornithine (DMFO) have been repeatedly tested 
in clinical trials (NCT02139397; NCT03536728) in a variety of cancers including neuroblastoma, most 
recently also in combination with polyamine import inhibitors such as AMXT-1501 (Abeloff et al. 
1984; Abeloff et al. 1986; Meyskens et al. 1986; Saulnier Sholler et al. 2015). 
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Figure 3: Synthesis and metabolism of polyamines. (a) Ornithine decarboxylase (ODC-1) is the rate limiting 
enzyme of putrescine synthesis, while S-adenosylmethionine decarboxylase (AdoMetDC) provides the 
aminopropyl residue for the sequential synthesis of spermidine and spermine by converting the S-
adenosylmethionine to S-adenosylmethioninamine. Spermidine/spermine N1-acetyltransferase (SSAT) acetylates 
polyamines at their N1 position and N1-acetylated polyamines are then converted by the peroxisomal enzyme 
N1-acetylpolyamine oxidase (APAO) under the generation of 3-aceto-aminopropanal and H2O2). Spermine can 
also be directly cleaved to spermidine by the enzyme spermine oxidase (SMO). (b) In eukaryotic cells, spermidine 
can be also acetylated at its N8 position by a nuclear acetyltransferase, yielding N8-acetylspermidine. N8-
acetylspermidine can be processed back to spermidine by a cytoplasmic polyamine deacetylase (PDAC), and 
HDAC10 has been recently suggested as that PDAC. Figure (a) was adapted from (Casero and Marton 2007), 
figure (b) (Hai et al. 2017). 
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2.5 HDAC inhibitors 
Given their excellent druggability and critical importance in pathways that are relevant to the 
development of cancers and other diseases, HDACs have become an attractive target for clinical 
intervention and pre-clinical drug research (Witt et al. 2009). The initial discovery that trichostatin A 
(TSA) - a compound later found to be a broad-spectrum HDAC inhibitor - had anti-proliferative effects 
in transformed rat fibroblasts, triggered an enormous amount of follow-up research, ultimately 
leading to the discovery of numerous other substances with HDAC inhibitory capacity (Yoshida and 
Beppu 1988; Yoshida et al. 1990; Finnin et al. 1999; Sternson et al. 2001; Khan et al. 2008). Although 
these inhibitors share a common mode of action - namely the chelation of Zn2+ at the HDAC active 
site -, they are nevertheless chemically diverse and can be grouped into five classes according to the 
chemical structure of their zinc-binding group: Hydroxamic acids, cyclic tetrapeptides, ortho-
aminoanilides (such as benzamides), aliphatic carboxylic acids and electrophilic ketones (Figure 4) 
(Wagner et al. 2013). Most HDAC inhibitors commonly have three structural features: The 
aforementioned zinc-binding group, a hydrophobic cap group which interacts with the surface of the 
target enzyme, and a non-mandatory hydrocarbon linker group (Wagner et al. 2013). Many of these 
substances inhibit HDACs rather unselectively and are therefore referred to as broad-spectrum 
(SAHA/vorinostat, trichostatin A) or pan-HDAC (panobinostat, abexinostat (PCI-24781)) inhibitors 
(Balasubramanian et al. 2008; Witt et al. 2009; Wagner et al. 2013). However, some inhibitors display 
a marked preference for a certain HDAC class, or even individual HDAC enzymes. These include for 
example class I HDAC inhibitors (e.g. entinostat (MS-275), valproic acid), as well as class IIb HDACs 
inhibitors, such as tubastatin A (Butler et al. 2010; Oehme et al. 2013a), bufexamac (Bantscheff et al. 
2011) and tubacin (Haggarty et al. 2003; Bantscheff et al. 2011), the latter displaying a very high 
preference for HDAC6. Another example of a highly selective HDAC inhibitor is PCI-34051 which 
inhibits HDAC8 but not HDACs 1, 2, 3, 6 and 10 (Balasubramanian et al. 2008). 
Five HDAC inhibitors have been approved to date for the treatment of hematological malignancies, 
four of which are FDA-approved (vorinostat, romidepsin, belinostat and panobinostat). Vorinostat 
and romidepsin are used for the treatment of cutaneous T-cell lymphoma, chidamide and belinostat 
for peripheral T-cell lymphoma and panobinostat for multiple myeloma (Mann et al. 2007; Piekarz et 
al. 2009; Whittaker et al. 2010; Poole 2014; Cheng et al. 2015; Laubach et al. 2015; Shi et al. 2015). 
Moreover, more than 20 HDAC inhibitors are currently tested in clinical trials, but all approved and 
most of the tested HDAC inhibitors are either broad-spectrum, pan- or class I selective HDAC 
inhibitors (Mottamal et al. 2015; Eckschlager et al. 2017). Clinical application of these inhibitors is 
commonly associated with severe dose-limiting side effects including gastrointestinal symptoms 
(anorexia, nausea, vomiting and diarrhea), myelosuppression (e.g. thrombocytopenia) and fatigue 
(Lane and Chabner 2009), possibly related to the fact that HDACs 1, 2, 3 epigenetically control the 
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expression of thousands of genes due to their presence in co-repressor complexes. This raises the 
question whether inhibition of individual HDACs by more selective compounds could be favorable in 
a clinical setting (Witt et al. 2009). 
 
3 Mechanisms of cancer drug resistance 
Resistance to both cytotoxic and targeted treatment is still a major factor that limits therapy success 
in cancer. Many cancers are responsive to initial treatment but develop resistance through a variety 
of mechanisms. Such resistance mechanisms can be either intrinsic, i.e. resistance-mediating factors 
that are inherent to the bulk tumor cells before treatment, or acquired, meaning that resistance 
develops during treatment for instance by the acquisition of mutations or other adoptive responses 
(reviewed in (Longley and Johnston 2005; Holohan et al. 2013)). Moreover, resistance can be induced 
by the selection of therapy-resistant cell clones that pre-exist in the highly heterogeneous tumor 
microenvironment (Holohan et al. 2013). At the cellular level, such resistance mechanisms include 
the deregulation of apoptotic pathways (Miyashita and Reed 1992; Debatin and Krammer 2004; 
Figure 4: HDAC inhibitor classes and their molecular structure.Figure adapted from (Wagner et al. 2013) 
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Wilson et al. 2009; Ni Chonghaile et al. 2011), the presence of cancer stem cells (Singh and Settleman 
2010), alterations in drug metabolism or mutations in drug targets (Kobayashi et al. 2005; Housman 
et al. 2014), increased DNA repair capacity (Bouwman and Jonkers 2012), activation of alternative or 
bypass signaling pathways (Engelman et al. 2007; Sergina et al. 2007), upregulation of resistance 
promoting stress responses such as autophagy (White 2012), as well as decreased drug uptake and 
increased drug efflux (Gottesman et al. 2002). Many of these resistance mechanisms have also been 
shown to be important in neuroblastoma treatment resistance (Keshelava et al. 2000; Michaelis et al. 
2009; Khalil et al. 2012; Bresler et al. 2014; Murakami-Tonami et al. 2016; Bingel et al. 2017). 
3.1 Drug efflux as a mechanism of cancer drug resistance 
Cancer cells can reduce accumulation of cytotoxic drugs by increasing their efflux. Drug efflux is one 
of the most widely studied resistance mechanisms in cancer and has been largely attributed to the 
presence of ATP-dependent drug efflux pumps that belong to the ATP-binding cassette (ABC) 
transporter family (Gottesman et al. 2002). In humans, this family comprises 49 members, 
characterized by a highly conserved nucleotide binding domain and the presence of a more variable 
transmembrane domain in almost all of its members, which is also responsible for substrate 
recognition (reviewed in (Vasiliou et al. 2009; Housman et al. 2014)). Hydrolysis of ATP in the NBD 
induces a conformational change which allows for the transport of substrate across membranes 
against a concentration gradient (Sauna and Ambudkar 2001). ABC transporter substrates include a 
variety of different molecules including peptides, amino acids, sugars, as well as metal ions and a 
large number of hydrophobic compounds (Vasiliou et al. 2009). Apart from their physiological role, 
transporters, especially when present at high levels, have been associated with drug resistance in 
cancer, and three ABC transporters have been particularly well studied with respect to cancer drug 
resistance: multidrug resistance protein 1/ P-glycoprotein (MDR1/P-gp), multidrug resistance-
associated protein (MRP1) and breast cancer resistance protein (BCRP/ABCG2) (reviewed in (Vasiliou 
et al. 2009; Robey et al. 2018)). These transporters recognize and drive efflux of a broad and partly 
overlapping set of substrates that include many first line cancer therapeutics including vinca 
alkaloids, anthracyclines, taxanes but also kinase inhibitors and thus promote to a plethora of anti-
cancer drugs (Gros et al. 1986; Ueda et al. 1987; Szakacs et al. 2006; Dohse et al. 2010; Holohan et al. 
2013; Housman et al. 2014). This phenomenon is also referred to as multidrug resistance (MDR). Not 
surprisingly, high expression of either of these transporters has been repeatedly linked to poor 
prognosis in various cancer entities including neuroblastoma (Filipits et al. 1999; Baekelandt et al. 
2000; Steinbach et al. 2002; Haber et al. 2006; Vasiliou et al. 2009). 
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3.2 Lysosomes as mediators of drug resistance 
Lysosomes are membrane-bound cytoplasmic organelles with an acidic lumen. Originally described 
by Belgian scientist Christian de Duve in 1955 (De Duve et al. 1955; De Duve and Beaufay 1959; de 
Duve 2005), they exist in all eukaryotic cells, although size and numbers vary between cell types 
(Perera and Zoncu 2016). Although lysosomes are the primary catabolic compartment in eukaryotic 
cells, an ever increasing body of evidence suggests that they are also critical regulators of cell 
homeostasis. They act as central cellular signaling hubs, controlling essential processes like cell 
proliferation(Stoscheck and Carpenter 1984), nutrient sensing, cell metabolism, stress response, 
organelle turnover and even cell death (Stoscheck and Carpenter 1984; Boya et al. 2003; Sancak et al. 
2008; Zoncu et al. 2011; Kallunki et al. 2013). Not surprisingly, mutations in key lysosomal genes that 
impair lysosomal function are the cause of hereditary metabolic syndromes commonly referred to as 
lysosomal storage disorders (reviewed in (Platt et al. 2012)). In contrast to impaired lysosomal 
degradation capacity, efficient lysosomal function is reported to be important for the maintenance of 
multiple cancer hallmarks, such as evasion of cell death, deregulated cellular metabolism and even 
invasion and metastasis (Hanahan and Weinberg 2011; Appelqvist et al. 2013; Machado et al. 2015). 
3.2.1 Lysosomal biogenesis and homeostasis 
Lysosomes are highly dynamic organelles of heterogeneous size and cellular distribution, which can 
be identified by a set of hallmark features: They are electron-dense organelles surrounded by a single 
7-10 nm phospholipid bilayer membrane that contains heavily glycosylated membrane proteins. 
Lysosomes are further characterized by their acidic luminal pH between 4.5 and 5.0 and their lack of 
mannose-6-phosphate receptors, the latter of which distinguishes them from the late endosomal 
compartment (reviewed in (Mullins and Bonifacino 2001; Mindell 2012)). In metazoan cells, the 
lysosomal diameter ranges from 0.1 µm to 1 µm under physiological conditions, but enlarged 
lysosomes are common under disease settings such as LSDs (Durchfort et al. 2012; Perera and Zoncu 
2016). Lysosomes are usually found close to the nucleus in proximity to microtubule-organizing 
center (MTOC) (Matteoni and Kreis 1987) but changes in lysosomal position have been described 
upon cell stimulation, maturation, as well as malignant transformation (Nishimura et al. 2003; 
Stinchcombe et al. 2006; Korolchuk et al. 2011; Mrakovic et al. 2012; Willett et al. 2017). 
The biogenesis of lysosomes is not fully understood, but it is commonly thought that lysosomes arise 
from fusion and maturation events of at least two pools of vesicles or vesicular compartments, 
namely trans-Golgi network derived vesicles and cargo-filled vesicular compartments such as late 
endosomes or autophagosomes (Figure 5) (Mullins and Bonifacino 2001; Luzio et al. 2003; Saftig and 
Klumperman 2009; Perera and Zoncu 2016). Thereby, at least three routes can be distinguished by 
which membranes and macromolecules are delivered to the lysosomal compartment, namely the 
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biosynthetic route, the endocytic route (including phagocytosis) and the auto-catabolic route of 
(macro-)autophagy, the latter of which will be discussed in more detail in section A3.2.2 (Luzio et al. 
2003). The biosynthetic route starts with the de novo synthesis of lysosomal proteins into the 
endoplasmic reticulum (ER), where they are processed and undergo N-glycosylation. After export to 
the Golgi apparatus and trimming of glycosylation, many but not all soluble lysosomal proteins, carry 
an exposed mannose-6-phosphate sugar which is recognized by so called Mannose-6-phosphate 
receptors (MPRs) at the trans-Golgi that promote packing of lysosomal enzymes into trans-Golgi 
network vesicles (Kaplan et al. 1977; Ullrich et al. 1978; Fedde and Sly 1985). Upon fusion of these 
vesicles with the slightly acidic late endosome, the enzymes dissociate from their receptors and the 
receptors are recycled to the Golgi, whereas the enzymes continue their way to the lysosome 
(Griffiths et al. 1988).  
At the same time extracellular, as well as plasma membrane bound cargo, is delivered to lysosomes 
through various modes of endocytosis (Luzio et al. 2003). In the endocytic route, cargo passes 
through a continuum of intermediate organelles that undergo a maturation process associated with 
changes in morphology, lipid and protein composition, as well as gradual acidification of the involved 
organelles. Both early and late endosomes act as sorting stations that separate cargo receptors and 
cargo destined for recycling or degradation (Mayor et al. 1993; Jovic et al. 2010). While early 
endosomes are tubular in shape and located near the cell periphery, late endosomes are more 
spherical in shape and are located closer to the nucleus (reviewed in (Gruenberg and Stenmark 2004; 
Klumperman and Raposo 2014)). During the maturation to late endosomes, cargo destined for 
degradation is also, with the help of so called ESCRT complexes that recognize mono-ubiquitinated 
proteins, sorted into so called intra-luminal vesicles (ILVs), that give late endosomes their 
characteristic multivesicular appearance (Estable et al. 1957; Katzmann et al. 2001; Gruenberg and 
Stenmark 2004; Takahashi et al. 2015). The latter is the reason why late endosomes are often 
referred to as multivesicular bodies (MVBs) (Estable et al. 1957). While maturation of endosomes is 
the most likely mode of cargo trafficking through the endosomal system, exchange of cargo between 
endosomes and lysosomes is mainly achieved by transient fusion and fission processes, termed "kiss 
and run" (Storrie and Desjardins 1996), and, in some instances, complete fusion processes between 
endosomes and lysosomes (Mullock et al. 1998; Gan et al. 2009). Complete fusion events of 
lysosomes and late endosomes lead to the formation of hybrid organelles called endolysosomes, 
which likely are the primary compartment of macromolecule degradation (Mullock et al. 1998; Luzio 
et al. 2003; Luzio et al. 2014; Bright et al. 2016). Lysosomes are constantly regenerated from these 
hybrid organelles by tubulation, maturation and condensation processes in which endosomal 
membrane proteins are removed (Pryor et al. 2000; Yu et al. 2010; Bright et al. 2016). Lysosomes are 
thus considered as storage organelles for hydrolytic enzymes that can fuse with endosomes to 
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generate transient endolysosomal organelles (Bright et al. 2005; Luzio et al. 2007; Jahreiss et al. 
2008; Bright et al. 2016). The biosynthetic intersects the endocytic route at various stages, 
highlighted by the delivery of membrane proteins, which can be trafficked to lysosomes directly and 
indirectly. On the indirect route, these proteins first enter the secretory route, leading to their 
presence at the plasma membrane, from where they are delivered to lysosomes via the endocytic 
route (Luzio et al. 2014). 
 
Figure 5: Lysosomal biogenesis and delivery of material to the lysosomal compartment involves 
biosynthetic, endocytic and autocatabolic routes. On the biosynthetic route, lysosomal proteins (e.g. acid 
hydrolases) are synthesized into the ER where they are processed and undergo posttranslational modification. 
After export to the Golgi and trimming of N-glycosylation, they arrive at the trans-Golgi network, from where 
they are sorted to the endolysosomal compartment either directly (intracellular route, black arrows) or 
indirectly via the secretory pathway (secretion and re-internalization via endocytosis, not shown). Cargo and 
membrane material is deliverd to lysosomes either via the endocytic pathway (blue arrows) or 
macroautophagy (green arrows). On the endocytic route, endocytic vesicles deliver their material to early 
endosomes (EE), from where material can recycle to the plasma membrane either directly or via recycling 
endosomes (RE). EEs gradually convert to late endosomes (LE) in complex maturation process, during which 
they move centripetally to perinuclear areas while gradually becoming more acidic and accumulating 
intraluminal vesicles, that contain cargo destined for degradation. Both transient ("kiss and run") and 
complete fusion processes with lysosomes form a transient organelle, the endolysosome, where cargo is 
degraded, and from which lysosomes are constantly regenerated by fission processes. Additionally, 
intracellular materials including membranes, aged organelles and aggregates can be delivered to the 
lysosomal compartment via macroautophagy (see section A3.2.2). Here, intracellular cargo is first sequestered 
in a double membrane organelle termed the autophagosome. Fusion with lysosomes generates transient 
autophagolysosomes, from which lysosomes are constantly regenerated in a process called autophagic 
lysosome reformation. Figure modified from (Saftig and Klumperman 2009; Huotari and Helenius 2011; Luzio 
et al. 2014) and created in collaboration with Julia Zaman (Clinical Cooperation Unit Neuropathology, DKFZ). 
Organelle sizes are schematic and not representative of cellular organelle sizes. 
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Lysosomal proteins and their functions 
The proteins that govern lysosomal function can be coarsely divided into two categories: soluble 
hydrolases that are located within the lysosomal lumen, and integral lysosomal membrane proteins. 
Lysosomes are equipped with over 50 hydrolytic enzymes including proteases, peptidases, 
phosphatases, sulfatases, nucleases and glycosidases, which are referred to as acid hydrolases due to 
their functional optimum at low pH (Czupalla et al. 2006; Schroder et al. 2010; Sleat et al. 2013; 
Perera and Zoncu 2016). These enzymes are capable of degrading a large set of macromolecules, 
including proteins, lipids, nucleic acids and carbohydrates, the catabolic products of which can be 
transported across the lysosomal membrane into the cytosol where they are re-used for the 
synthesis of new macromolecules. One class of well-characterized lysosomal peptidases is the family 
of cathepsins, which are synthesized as inactive pro-enzymes and only become active after cleavage 
upon their packaging into lysosomes (reviewed in (Turk et al. 2012)). These small proteases are 
heavily involved in lysosomal bulk protein degradation as well as in the induction of cell death after 
lysosomal membrane permeabilization (LMP), also referred to as lysosomal cell death. LMP leads to 
the release of cathepsins to the cytosol and this release has been shown to trigger both apoptotic 
and necrotic modes of cell death depending on the extent of lysosomal permeabilization (Boya et al. 
2003; Repnik et al. 2012; Aits and Jaattela 2013).  
The limiting lysosomal membrane contains a high number of often heavily glycosylated proteins, also 
referred to as lysosome associated membrane proteins (LAMPs), lysosome associated integral 
membrane proteins (LIMPs) or lysosome glycoproteins (LGPs) (Luzio et al. 2003; Schroder et al. 
2010). The high degree of glycosylation on their luminal domain allows them to form a glycoprotein 
layer called the glycocalyx, that prevents autodigestion of the lysosomal membrane by lysosomal 
hydrolases (Kornfeld and Mellman 1989; Peters and von Figura 1994; Perera and Zoncu 2016). 
Lysosomal membrane proteins like LAMP-1 and LAMP-2, which alone constitute up to 50 % of total 
lysosomal membrane protein, are therefore regarded as safeguards of lysosomal membrane integrity 
(Schwake et al. 2013). LAMP-1 and LAMP-2 are also involved in lysosomal positioning and fusion 
processes (Huynh et al. 2007), as well as in the import of cytosolic proteins during chaperone 
mediated autophagy, which is mediated by the LAMP-2 splice variant LAMP-2A (Bandyopadhyay et 
al. 2008). In addition, the lysosomal membrane contains various transporters, carriers, ion channels 
and pumps, as well as SNARE proteins such as VAMP7, which mediate fusion of lysosomes with other 
organelles or the plasma membrane (Pryor et al. 2004; Rao et al. 2004; Schwake et al. 2013). Via 
their cytosolic domain, lysosomal membrane proteins also recruit protein complexes involved in cell 
signaling and nutrient sensing (Sancak et al. 2008; Yonehara et al. 2017). Lysosomal membrane 
proteins thus govern all lysosome-related functions and are essential for lysosomal motility, 
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positioning, acidification, import of proteins, lipid homeostasis and export of degradation products 
(reviewed in (Saftig and Klumperman 2009)).  
Among lysosomal membrane proteins are also members of the V0/V1-ATPase complex. This multi-
subunit ATP-dependent proton pump uses energy from ATP hydrolysis to pump protons against their 
electrochemical gradient into the lysosome and is thus responsible for the acidification of the 
lysosomal lumen (Ohkuma et al. 1982; Forgac 1999). The V0/V1-ATPase complex consists of a 
cytoplasmic V1 domain, which consists of subunits A-H and drives ATP hydrolysis, and the membrane-
embedded V0 domain made from six subunits (a, d, e, c, c'/Ac45, c''), which uses energy generated 
from ATP for proton translocation (Forgac 1999; Forgac 2007). The two subcomplexes are connected 
by central and peripheral stalks made from subunit D, F and subunits E and G respectively. This 
allows coupling of ATP hydrolysis to a rotary movement in V0 subunit that is thought to 
mechanistically drive proton pumping (Mindell 2012). The activity of V-ATPases is tightly controlled 
and various mechanisms have been proposed how regulation is accomplished. One of those 
mechanisms is the reversible assembly and disassembly of the V-ATPase complex into the V1 and V0 
subunits (Sautin et al. 2005). At least in yeast, disassembly in vivo seems to be at least partly 
controlled by a non-homologous region of the catalytic subunit A in the V1 subcomplex (Shao et al. 
2003). Evidence further suggests that V-ATPase activity can be controlled at the level of coupling 
efficiency, i.e. the amount of protons pumped per hydrolyzed ATP molecule. Mutations in various V-
ATPase subunits have been shown to affect coupling efficiency. Interestingly, a subset of mutations 
in subunits A and d can increase the coupling efficiency of the V-ATPase complex, suggesting that the 
native or wild type ATPase is not optimally coupled (Shao et al. 2003; Owegi et al. 2006; Forgac 
2007). 
Functions and regulation of the lysosomal compartment 
The best characterized function of the lysosome is the degradation and recycling of aged 
macromolecules and organelles, as well as the degradation of extracellular or cell-foreign materials 
including pathogens (Wei et al. 2005; Pryor and Raines 2010; Platt et al. 2012). Extracellular material 
is transported to the lysosome by various modes of endocytosis or phagocytosis while aged 
organelles, macromolecules or non-degradable aggregates typically reach the lysosome by various 
modes of autophagy (see section A3.2.2). These molecules are then degraded with the help of 
lysosomal hydrolases and their monomers cross the lysosomal membrane either passively or by 
means of various lysosomal transporters. However, the function of the lysosome cannot be simply 
reduced that of a cellular waste bag. In fact, lysosomes have pivotal roles in other cell physiological 
processes such as lipid metabolism, cholesterol homeostasis, plasma membrane repair, cell signaling 
and control of cell metabolism (reviewed in (Settembre et al. 2013)). Lysosomes and so called 
lysosome-related organelles additionally have cell-specific functions unrelated to degradation. These 
 
INTRODUCTION 31 
include pigment-carrying melanosomes in melanocytes or lytic granules in cytotoxic T-lymhpocytes 
(Mullins and Bonifacino 2001; Marks et al. 2013). In a process that is not fully understood, lysosomes 
fuse with the plasma membrane and release their content to the extracellular space. This process, 
which will be discussed in more detail in section A3.2.3, is called lysosomal exocytosis and has been 
shown to be important for several physiological processes such as osteoclast differentiation, bone 
resorption or plasma membrane repair (Andrews 2000; Reddy et al. 2001; Zhao et al. 2008; Yang et 
al. 2012; Ferron et al. 2013). It is also becoming increasingly clear that lysosomes act as a central 
control hub of cellular signaling pathways, with a special role in cellular nutrient sensing and thus 
metabolic control (Sancak et al. 2008; Zoncu et al. 2011; Perera and Zoncu 2016). One of the first 
insights into how lysosomes control cellular signaling came from the observation that the EGF 
receptor, upon ligand binding, is internalized into endosomes and later degraded in the lysosome 
(Gorden et al. 1978; Stoscheck and Carpenter 1984; Felder et al. 1990). This ligand induced 
degradation is required for negative feedback regulation and has been also described for other cell 
surface receptors (Sorkin and von Zastrow 2009). More recently, the lysosome has emerged as a 
central nutrient sensor that regulates the mammalian target of rapamycin (mTOR) signaling pathway, 
which is essential for cell growth and metabolic homeostasis (Laplante and Sabatini 2012). One of the 
two mTOR signaling complexes, mTORC1, is recruited to lysosomes via Rag GTPases, which become 
activated upon accumulation of amino acids in the lysosome (Sancak et al. 2008; Sancak et al. 2010; 
Zoncu et al. 2011). Recruitment to lysosomes is required for mTORC1 kinase activity and thus 
activation of downstream pro-growth signaling pathways (Sancak et al. 2008; Groenewoud and 
Zwartkruis 2013). In contrast, amino acid starvation leads to the dissociation of mTORC1 from the 
lysosomal membrane, its inactivation, and therefore the activation of the self-degradative program 
of autophagy, underlining the importance of the lysosome in balancing biosynthetic and catabolic 
programs (Settembre et al. 2013; Demetriades et al. 2014). 
Intriguingly, lysosomes are also involved in regulating their own biogenesis by modulating the activity 
of the transcription factor TFEB, the master regulator of a lysosomal gene network called the 
coordinated lysosomal expression and regulation (CLEAR) network (Sardiello et al. 2009). 
Analogous to mTORC1, TFEB is recruited to the lysosomal membrane by Rag GTPases under nutrient 
supplied conditions and becomes phosphorylated by mTORC1 and/or ERK2 (Pena-Llopis et al. 2011; 
Settembre et al. 2011; Martina et al. 2012; Roczniak-Ferguson et al. 2012; Settembre et al. 2012; 
Martina and Puertollano 2013). Phosphorylation of TFEB at Ser142 and Ser211 leads to its retention 
in the cytoplasm by binding of 14-3-3 proteins, thereby inhibiting its transcriptional activity 
(Settembre et al. 2011; Roczniak-Ferguson et al. 2012). Under starvation, TFEB becomes 
dephosphorylated and translocates to the nucleus where it promotes the expression of genes with 
key roles in lysosomal biogenesis and lysosome related pathways including autophagy, endocytosis, 
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exocytosis and lipid catabolism (Medina et al. 2015). This suggests that TFEB is involved in the global 
control of lysosomal biogenesis and lysosome-related catabolic processes (Palmieri et al. 2011; 
Settembre et al. 2013). 
3.2.2 Autophagy - an auto-catabolic process involving lysosomes 
The term autophagy describes a cellular "self-eating" process, in which cellular components such as 
aged or damaged organelles, as well as damaged or aggregated proteins, are degraded and recycled 
with the help of lysosomes in order to generate energy, nutrients and monomeric building blocks for 
macromolecules under stress conditions. Such stress conditions are for example starvation, hypoxia, 
oxidative stress, protein aggregation, ER stress and treatment with cytotoxic drugs (Katayama et al. 
2007; Dikic and Elazar 2018). 
Depending on how cytoplasmic material is delivered to lysosomes, at least three modes of autophagy 
can be distinguished: Chaperone-mediated autophagy, which involves direct delivery of cytosolic 
proteins that carry a KFERQ-like motif to lysosomes with the help of heat shock protein HSC70 and 
cochaperones. HSC70 binds, unfolds, and delivers target proteins to a complex of the lysosomal 
membrane protein LAMP-2A, which in turn translocates the unfolded protein directly into the 
lysosomal lumen (Cuervo and Dice 1996; Salvador et al. 2000; Kaushik and Cuervo 2018). 
Microautophagy describes the direct engulfment of cytoplasmic material by lysosomes via 
invagination of the lysosomal membrane itself (Arstila and Trump 1968; Li et al. 2012). In contrast, 
macroautophagy, by far the most common mode of autophagy and hereon referred to as autophagy, 
involves an extra organelle. Here, cytoplasmic material is sequestered within double-membrane 
organelles, termed autophagosomes, which deliver their material to lysosomes for degradation, 
either by complete fusion with lysosomes or by a kiss-and-run mechanism (see section A3.2.1) 
(Arstila and Trump 1968; Ohsumi 2014; Dikic and Elazar 2018). Although especially macroautophagy 
was regarded as a bulk degradation process for a long time, evidence suggests that it can be a highly 
selective process, and organelle-specific modes of autophagy including mitophagy, lysophagy, 
pexophagy, nucleophagy have been described (reviewed in (Okamoto 2014)). 
The process of autophagy involves a number of highly conserved proteins, termed autophagy-
related, which are encoded by ATG genes (Tsukada and Ohsumi 1993; Mizushima et al. 1998; 
Nakatogawa et al. 2009). They mostly govern three very critical events in the early phase of 
autophagy, namely the nucleation, elongation and maturation of the autophagosome (Mizushima et 
al. 2010; Ohsumi 2014).  
Formation of the autophagosome is commonly thought to occur at the ER, although membranes 
derived from other organelles including Golgi, mitochondria, endosomes and the plasma membrane 
have been shown to contribute to this process (reviewed in (Martens et al. 2016)), and at least four 
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major protein complexes control formation of the autophagosome. In its best characterized mode, 
autophagy initiation under starvation conditions is controlled positively by the AMP-activated protein 
kinase (AMPK) or negatively by the mTORC1 complex, which sense ATP:AMP ratio and lysosomal 
amino acids, respectively (Sancak et al. 2008; Oakhill et al. 2011). These modulate function of the 
Unc-51-like kinase 1 complex made of ULK1/ATG1, ATG13, FIP200 and ATG101, by activating (AMPK) 
or inactivating (mTORC1) phosphorylation of the ULK1 kinase (Kim et al. 2011; Dikic and Elazar 2018). 
The ULK1 complex is recruited to the phagophore assembly site (PAS) by a ternary complex of 
ATG17-ATG31-ATG29, where ULK1 activates the class III PI3K complex I, consisting of the class III PI3K 
VPS34, Beclin-1, ATG14, AMBRA1 and p15, by phosphorylating Beclin-1 (Suzuki et al. 2007; Russell et 
al. 2013; Dikic and Elazar 2018). The latter complex generates phosphatidylinositol-3-phosphate 
(PI3P) at the PAS, which recruits PI3P binding proteins like WIPI2. WIPI2, in turn, recruits the ATG12-
ATG5-ATG16L1 complex (Dooley et al. 2014). This complex, together with ATG4B, ATG7 and ATG3 
mediates the processing and conjugation of ATG8 family members (including LC3) to membrane-
resident phosphatidylethanolamine, thereby generating the lipidated, membrane-bound form LC3-II, 
the main autophagosome marker (Mizushima et al. 1998; Ichimura et al. 2000; Kabeya et al. 2000; 
Hemelaar et al. 2003; Tanida et al. 2004; Fujita et al. 2008; Walczak and Martens 2013). Membrane-
bound LC3-II then recruits factors required for cargo binding and elongation of the autophagosome 
membrane, thereby promoting the elongation process and autophagosome closure (Olsvik et al. 
2015; Dikic and Elazar 2018). Autophagosome closure is then followed by a maturation process in 
which ATG proteins are cleared from the outer autophagosomal membrane, while proteins required 
for fusion with lysosomes are recruited (Dikic and Elazar 2018). The regulation of delivery of 
autophagosomal cargo to lysosomes is poorly characterized, but known to require the SNAREs 
syntaxin 17 (STX17) and SNAP29 on autophagosomes, as well as the lysosomal SNARE VAMP8 and 
the HOPS complex as tethering factor (Itakura et al. 2012; Jiang et al. 2014; Diao et al. 2015). 
Acidification of lysosomes is required for efficient turnover of autophagic substrates, but not 
necessary for autophagosome-lysosome fusion itself (Mauvezin et al. 2015; Mauvezin and Neufeld 
2015). 
Autophagy is transcriptionally regulated. One family of transcription factors with transcriptional 
activity on autophagy genes is the FoxO family, especially its members FoxO1 and FoxO3 (Zhao et al. 
2007; Zhao et al. 2010; van der Vos et al. 2012). Similar to the lysosomal transcription factor TFEB, 
FoxO transcription factors are negatively regulated by phosphorylation, in this case mediated by AKT, 
which leads to their 14-3-3 protein dependent retention in the cytoplasm (Brunet et al. 1999). In 
addition, FoxO transcription factors are regulated via reversible acetylation mediated by the histone 
acetyltransferase CBP and the HDAC member SIRT1, respectively (Brunet et al. 2004; Daitoku et al. 
2004; Zhao et al. 2010; Daitoku et al. 2011). Notably, lysosomal and autophagosome biogenesis are 
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also linked on a transcriptional levels via the lysosomal master regulator transcription factor TFEB 
that promotes the expression of both lysosomal and autophagy genes (see section A3.2.1). 
In the context of tumor formation, autophagy has been described to act as a "double-edged sword", 
meaning that it can have both tumor-promoting and tumor suppressive functions (White and DiPaola 
2009). In early or even pre-malignant tumor stages, autophagy has tumor-suppressive capacity by 
clearing aged or damaged organelles such as mitochondria, which can produce reactive oxygen 
species (ROS) and thus promote tumor relevant processes such as the acquisition of mutations or 
inflammatory processes (Karantza-Wadsworth et al. 2007; Mathew et al. 2007). However, 
established tumors have been repeatedly shown to use or even depend on autophagy for the 
generation of amino acids and nucleotides, which in turn enables them to cope with a number of 
stress factors such as hypoxia, starvation, oxidative stress or cytotoxic treatment (Guo et al. 2013). 
3.2.3 Lysosomal drug resistance mechanisms independent of autophagy 
Lysosomes are involved in cancer drug resistance and progression independently of their role in 
autophagy. Cancer cells are known to be highly dependent on the efficient function of the lysosomal 
compartment. The lysosomal compartment undergoes striking changes during malignant 
transformation and cancer progression, including changes in volume of the lysosomal compartment, 
changes in lysosomal composition and positioning, as well as changes in enzymatic activity 
(Appelqvist et al. 2013; Piao and Amaravadi 2016). With regards to the latter, especially enhanced 
expression and secretion of lysosomal hydrolases has been repeatedly associated with cancer 
progression and metastasis formation (Gocheva et al. 2006; Vasiljeva and Turk 2008; Ramessur et al. 
2010). Lysosomes have been also implicated in cancer multidrug resistance (MDR) and at least two 
distinct but partly interdependent mechanisms of lysosomal-mediated MDR have been described 
(Figure 6) (Zhitomirsky and Assaraf 2016). 
Various substances are trapped in lysosomes by a mechanism called lysosomal sequestration or 
trapping (Zhitomirsky and Assaraf 2016) due to their hydrophobic and weakly-basic chemical 
properties. These include widely used first-line anti-cancer drugs such as daunorubicin, doxorubicin, 
vincristine, sunitinib and imatinib, which, after passively entering cells and lysosomes, become 
protonated in the lysosomal lumen, leading to the addition of extra charge that results in their 
trapping and accumulation within lysosomes (Hurwitz et al. 1997; Groth-Pedersen et al. 2007; 
Herlevsen et al. 2007; Chapuy et al. 2008; Zhitomirsky and Assaraf 2015; Zhitomirsky and Assaraf 
2016). This compartmentalization phenomenon prevents them from reaching their cellular target 
and from exerting their cytotoxic activity (Figure 6). The ability of cells to trap chemotherapeutic 
drugs in lysosomes might be acquired during first-line treatment (Hurwitz et al. 1997; Altan et al. 
1998), possibly as a consequence of drug-induced expansion of the lysosomal compartment (Gotink 
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et al. 2015; Zhitomirsky and Assaraf 2015). Lysosomal accumulation of weakly basic anti-cancer drugs 
critically depends on lysosomal acidification, which creates a pH gradient between lysosomes and 
cytoplasm (Zhitomirsky and Assaraf 2016). In this context, several studies have demonstrated that 
drug resistant cell lines adapt to cytotoxic treatment not only by promoting de novo biogenesis of 
lysosomes, but also by increasing the pH gradient between the cytoplasm and lysosomes, endosomes 
as well as trans-Golgi network vesicles, which is achieved by enhanced acidification of the 
aforementioned compartments (Schindler et al. 1996; Altan et al. 1998; Larsen et al. 2000; Gong et 
al. 2003; Hrabeta et al. 2015). As lysosomal trapping is not a single drug-specific mechanism, 
expansion of the lysosomal compartment also induces significant cross-resistance (Gotink et al. 
2015). Intriguingly, drugs do not only passively enter lysosomes by diffusion, but are also actively 
pumped into lysosomes by various ABC transporters including P-glycoprotein, which can be present 
on intracellular membranes as well as vesicles (Molinari et al. 2002; Rajagopal and Simon 2003). This 
indicates that lysosomal sequestration is at least in parts an active process (Ferrao et al. 2001; 
Chapuy et al. 2008; Yamagishi et al. 2013). 
Lysosomes do not only sequester weakly basic chemotherapeutic drugs but also cause their secretion 
in a process termed lysosomal exocytosis, i.e. the fusion of lysosomes with the plasma membrane 
whereby lysosomal cargo is released to the extracellular space (Figure 6) (Andrews 2000; Yanes et al. 
2013; Machado et al. 2015; Zhitomirsky and Assaraf 2017). Even before the description of lysosomal 
exocytosis, it was known that lysosome related organelles of various cell types can act as secretory 
granules. It is now known that lysosomal exocytosis can occur in all cell types from the pool of 
conventional lysosomes (Rodriguez et al. 1997; Page et al. 1998; Blott and Griffiths 2002). Lysosomal 
secretion has been implicated in various important physiological mechanisms, including plasma 
membrane repair, bone resorption in osteoclasts, as well as various pathogen defense mechanisms. 
(Reddy et al. 2001; Zhao et al. 2008; Appelqvist et al. 2013; Luzio et al. 2014). 
 36 INTRODUCTION 
 
Despite its identification more than 20 years ago, the regulation of lysosomal exocytosis and its 
underlying molecular machinery are still poorly understood (Rodriguez et al. 1997). It is a two-step 
processes, where lysosomes are first recruited to the plasma membrane in a Ca2+-independent 
fashion, while fusion with the plasma membrane occurs in a second step after elevation of 
cytoplasmic Ca2+ levels, leading to the presence of lysosomal transmembrane proteins like LAMP-1 at 
the plasma membrane (Jaiswal et al. 2002; Tucker et al. 2004). Key proteins involved in lysosomal 
exocytosis include the v-SNARE VAMP7 and the calcium sensor synaptotagmin VII on lysosomes, the 
t-SNAREs SNAP23 and syntaxin 4 on the plasma membrane, as well as Rab proteins (Rao et al. 2004; 
Laulagnier et al. 2011). After formation of the trans-SNARE complex, lysosomal exocytosis further 
requires an increase in intracellular Ca2+ levels to trigger membrane fusion, which is most likely 
released from lysosomes themselves via the lysosomal transporter MCOLN1 (LaPlante et al. 2006; 
Medina et al. 2011). 
Lysosomal exocytosis is not only involved in the clearing of lysosome-sequestered drugs, but it might 
even be triggered by lysosomal drug accumulation. A recent report suggests that lysosomal 
accumulation of weakly basic chemotherapeutics induces nuclear translocation of the lysosomal 
master regulator TFEB, which in turn activates a transcriptional program that promotes lysosomal 
Figure 6: Lysosomal drug resistance mechanisms independent of autophagy. Lysosomes promote resistance to 
weakly basic hydrophobic drugs independently of autophagy by at least two distinct mechanisms. Firstly, 
weakly basic drugs can become trapped in lysosomes in a process termed lysosomal sequestration, where the 
drug becomes protonated due to the low lysosomal pH, reducing its ability to diffuse out of the lysosome. 
Secondly, lysosomes can fuse with the plasma membrane in a process called lysosomal exocytosis, leading to 
the secretion of lysosomal content to the extracellular space. 
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exocytosis (Medina et al. 2011; Zhitomirsky and Assaraf 2017). Finally, lysosomal exocytosis also 
promotes cancer progression via the release of lysosomal hydrolases including cathepsins that 
degrade extracellular matrix proteins and enhance cancer cell invasiveness (Fonovic and Turk 2014; 
Machado et al. 2015). 
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B MATERIALS 
1 Cell culture 
1.1 Cell lines 
Cell line Tissue of origin Tumor type Genetic alterations/ 
Characteristics 
Supplier 
SK-N-BE(2)-C/ 
BE(2)-C (I-type) 
Bone marrow 
(metastasis) 
Neuroblastoma MYCN ampl., TP53 mut.  ECACC, Salisbury, 
UK 
IMR-32 (N-type) Abdominal 
primary tumor 
Neuroblastoma MYCN ampl.  DSMZ, 
Darmstadt, 
Germany 
IMR-32 e.v. see above Neuroblastoma MYCN ampl.,  
stably transfected with 
pCMV / hygro-Negative 
Control Vector 
see above 
IMR-32 HDAC10 see above Neuroblastoma MYCN ampl., 
pCMV/hygro-FLAG 
HDAC10 
see above 
Kelly (N-type) Primary tumor Neuroblastoma MYCN ampl., TP53 mut. 
ALK mut. (F1174L) 
DSMZ, 
Darmstadt, 
Germany 
SK-N-AS (S-type) Bone marrow 
(metastasis) 
Neuroblastoma TP53 mut. M. Schwab, DKFZ, 
Heidelberg, 
Germany 
HAP1 wild type Bone marrow 
(parental KBM-7 
cell line) 
Chronic 
Myelogenous 
Leukemia (CML) 
Near haploid Horizon 
Discovery, 
Cambridge, UK 
HAP1 HDAC10 
knockout 
See above See above Near haploid, 
HDAC10 knockout 
Horizon 
Discovery, 
Cambridge, UK 
HAP1 HDAC8 
knockout 
See above See above Near haploid, 
HDAC8 knockout 
Horizon 
Discovery, 
Cambridge, UK 
Hybridoma  
cell lines 
B-lymphocytes 
from popliteal 
lymph nodes 
(BALB/c mouse) 
fused with 
murine 
myeloma cell 
line Sp2/0-Ag-
14 
Murine myeloma/ 
hybridoma 
Sp2/0-Ag-14: HGPRT 
deficient; eliminated 
endogenous antibody 
expression (Shulman et 
al. 1978), expresses 
aberrant non-productive 
 light chain (abV) 
(Carroll et al. 1988) 
ATCC, Manassas, 
Virginia, United 
States 
VH7/ human 
fibroblasts 
Skin Non-
transformed/ 
healthy donor 
unknown P. Boukamp, 
DKFZ, Heidelberg, 
Germany 
Table 1: Cell lines. 
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1.2 Culture media 
Medium Additives Cell lines 
DMEM 10% FCS, 1% NEAA SK-N-BE(2)-C, IMR-32, SK-N-AS, 
HEK293T, VH7 human 
fibroblasts 
DMEM IMR-32 selection 
medium 
10% FCS, 1% NEAA 
170-225 µg/ml hygromycin B 
IMR-32 e.v. and IMR-32 
HDAC10 overexpressing cells 
RPMI-1640 10% FCS Kelly, NB-1 
RPMI-1640 hybridoma medium 5% FCS, 2 mM Glutamine, 1 % 
Penicillin/Streptomycin, 1% 
NEAA, 0.5 mM sodium 
pyruvate 
Hybridoma lines 
IMDM 10% FCS HAP1 wild type, HAP1 HDAC10 
knockout, HAP1 HDAC8 
knockout 
Table 2: Cell culture media. 
1.3 Solutions for cell culture 
1.3.1 Versene (PBS/EDTA) 
1 x PBS 495 ml 
0.5 M EDTA pH 8.0 (filtered) 5 ml 
Table 3: Versene (PBS/EDTA). 
1.4 Inhibitors 
1.4.1 Characterized histone deacetylase inhibitors 
Compound Supplier Molecular 
weight 
Stock 
concentration 
Solvent Storage 
abexinostat (PCI-
24781) 
Selleckchem 397.42 g/mol 10 mM DMSO -20°C 
bufexamac Sigma 223.27 g/mol 100 mM DMSO -20°C 
panobinostat Cayman 349.43 g/mol 0.5 mM DMSO -20°C 
PCI-34051 Selleckchem 296.32 g/mol 20 mM DMSO -80°C 
entinostat (MS-275) Biomol/USBio 376.416 g/mol 10 mM DMSO -80°C 
tubacin Santa Cruz 721.86 g/mol 1 mM DMSO -20°C 
tubastatin A BIOZOL 335.40 g/mol 10 mM DMSO -20°C 
trichostatin A (TSA) Calbiochem 302.374 g/mol 1 mM DMSO -20°C 
valproic acid (VPA) Sigma 144.211 g/mol 1 M DMSO -20°C 
vorinostat Selleckchem 264.30 g/mol 100 mM DMSO -20°C 
Table 4: Characterized histone deacetylase inhibitors. 
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1.4.2 Investigational Compounds 
Compound Stock 
concentration 
Solvent Storage Source 
DKFZ-00477 10 mM DMSO -20°C Dr. Aubry Miller, DKFZ 
DKFZ-00494 10 mM DMSO -20°C Dr. Aubry Miller, DKFZ 
DKFZ-00495 50 mM DMSO -20 °C Dr. Aubry Miller, DKFZ 
DKFZ-00546 10 mM/50mM DMSO -20°C Dr. Aubry Miller, DKFZ 
DKFZ-00565 50 mM DMSO -20°C Dr. Aubry Miller, DKFZ 
DKFZ-00574 50 mM DMSO -20°C Dr. Aubry Miller, DKFZ 
DKFZ-00580 50 mM DMSO -20°C Dr. Aubry Miller, DKFZ 
Marbostat-100 
(MARB1) 
50 mM DMSO -20°C Prof. Dr. Siavosh Mahboobi, Institute of 
Pharmacy, University of Regensburg, 
Germany 
Table 5: Investigational compounds. 
1.4.3 Other substances and inhibitors 
Compound Category Supplier Stock 
concentration 
Solvent Storage 
bafilomycin A1 lysosomal V-ATPase 
inhibitor 
Santa Cruz 
Biotechnology 
10 µM DMSO -20°C 
chloroquine lysosomal inhibitor Sigma-Aldrich 100 mM water -20°C 
doxorubicin chemotherapeutic 
agent 
Calbiochem 10 mM 
(5.8 mg/ml) 
water -80°C 
vacuolin-1 lysosomal 
exocytosis inhibitor 
Calbiochem 10 mM DMSO -20°C 
verapamil P-glycoprotein 
inhibitor 
Sigma 20 mM DMSO -20°C 
Table 6: Other substances and inhibitors. 
1.5 Nucleic acids 
1.5.1 Small interfering RNAs (siRNAs) 
Gene siRNA ID/ 
product number 
Catalog number Company 
Amb #1 (siCtrl #1) n.a. AM4611 Ambion, Huntingdon, UK 
Amb #5 (siCtrl #5) n.a. AM4642 Ambion, Huntingdon, UK 
ATG5 #6 SI02655310/ 
1027415 
GS9474 QIAGEN, Hilden, Germany 
ATG5 #3 SI00069258/ 
1027415 
GS9474 QIAGEN, Hilden, Germany 
BECN1 #5 SI05126534/ 
n.a. 
SI05126534 QIAGEN, Hilden, Germany 
FOXO3 #1 s5260 4392420 Ambion, Huntingdon, UK 
FOXO3 #2 s5262 4392420 Ambion, Huntingdon, UK 
FOXO3 #3 s5261 4392420 Ambion, Huntingdon, UK 
HDAC1 #1 120418 AM51331 Ambion, Huntingdon, UK 
HDAC1 #2 120419 AM16708 Ambion, Huntingdon, UK 
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HDAC1 #6 SI02663472/ 
1027416 
GS3065 QIAGEN, Hilden, Germany 
HDAC2 #1 120208 AM51331 Ambion, Huntingdon, UK 
HDAC2 #3 120210 AM51331 Ambion, Huntingdon, UK 
HDAC3 #1 120349 AM51331 Ambion, Huntingdon, UK 
HDAC3 #2 120350 AM16708 Ambion, Huntingdon, UK 
HDAC6 #1 120451 AM16708 Ambion, Huntingdon, UK 
HDAC6 #3 120450 AM51331 Ambion, Huntingdon, UK 
HDAC10 #1 33581 AM16708 Ambion, Huntingdon, UK 
HDAC10 #2 120681 AM16708 Ambion, Huntingdon, UK 
HDAC11 #1 130749 AM16708 Ambion, Huntingdon, UK 
HDAC11 #2 130750 AM16708 Ambion, Huntingdon, UK 
siLAMP1 #1 s8080 4427037 Ambion, Huntingdon, UK 
P-glycoprotein/ 
ABCB1 (pooled 
siRNA) 
not available L-003868-00-0005 GE Dharmacon, Lafayette, CO, 
USA 
Table 7: Small interfering RNAs. 
additional siRNAs (self-designed) 
Gene Sequence (sense) Sequence (antisense) Company 
BECN1  5′-CAG UUU GGC ACA 
AUC AAU Att-3′ 
5′-UAU UGA UUG UGC CAA 
ACU Gtt-3′ 
Ambion, Huntingdon, UK 
Table 8: additional siRNAs. 
1.5.2 Primers for real-time RT-PCR 
Gene Sequence (forward) Sequence (reverse) Supplier 
HDAC1 5'-TGA CGA GTC CTA TGA 
GGC CAT T-3' 
5'-CCG CAC TAG GCT GGA 
ACA TC-3' 
ThermoFisher Scientific, 
Braunschweig, Germany 
HDAC2 5'-TGT GAG ATT CCC AAT 
GAG TTG C-3' 
5'-GGT AAC ATG CGC AAA 
TTT TCA A-3' 
ThermoFisher Scientific, 
Braunschweig, Germany 
HDAC3 5'-CCT CAC TGA CCG GGT 
CAT G-3' 
5'-ACC TGT GCC AGG GAA 
GAA GTA A-3' 
ThermoFisher Scientific, 
Braunschweig, Germany 
HDAC10 5'-CTC ACT GGA GCT GTG 
CAA AA-3' 
5'-GAT CCT GTG TAG CCC 
GTG TT-3' 
Sigma-Aldrich, Munich, 
Germany 
HDAC10 
alternative 
5′-ATC TCT TTG AGG ATG 
ACC CCA-3' 
5′-ACT GCG TCT GCA TCT 
GAC TCT C-3′ 
ThermoFisher Scientific, 
Braunschweig, Germany 
HDAC11 5'-CAA TGG GCA TGA GCG 
AGA C-3' 
5'-TGT GGC GGT TGT AGA 
CAT CC-3' 
ThermoFisher Scientific, 
Braunschweig, Germany 
HPRT 5′-TGA CAC TGG CAA AAC 
AAT GCA-3′ 
5′-GGT CCT TTT CAC CAG 
CAA GCT-3′ 
ThermoFisher Scientific, 
Braunschweig, Germany 
LAMP2A not provided by supplier not provided by supplier QIAGEN, Hilden, Germany  
assay #: QT00077063 
P-gp/ ABCB1 5'-GGG ATG GTC AGT GTT 
GAT GGA-3' 
5'-GCT ATC GTG GTG GCA 
AAC AAT A-3' 
Sigma-Aldrich, Munich, 
Germany 
SDHA 5′-TGG GAA CAA GAG 
GGC ATC TG-3 
5′-CCA CCA CTG CAT CAA 
ATT CAT G-3′ 
ThermoFisher Scientific, 
Braunschweig, Germany 
Table 9: Primers for real-time RT-PCR. 
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1.5.3 Primers for PCR amplification of HDAC10 fragments for antibody 
production 
Name Sequence (forward) Sequence (reverse) Supplier 
HDAC10T1 5'- CGG GGA TCC ATG 
GAT GTG ACC GCT GTG 
CC -3' 
5'- GCC AAG CTT GGA 
CAG GCC TCT CCG AA -3' 
Sigma-Aldrich, Munich, 
Germany 
HDAC10T2 5′- GCC GGA TCC ATG CAC 
GGA GCC CAG AGG C -3' 
5′- GCC AAG CTT TAG CTG 
GGG TGT GGA GTT -3′ 
Sigma-Aldrich, Munich, 
Germany 
Table 10: Primers for PCR amplification of HDAC10 fragments for antibody production. BamHI and HindIII 
restriction sites are highlighted in green and orange, respectively. 
1.5.4 Plasmids 
Plasmid name Backbone Insert Resistance 
(bacteria/human) 
Catalog number / 
reference 
pCMV/hygro-FLAG 
HDAC10 
pCMV/hygro
-FLAG 
human HDAC10  
(NM_032019.5) 
ampicillin/ 
hygromycin B 
HG11507-M-F 
(Sino Biological) 
pCMV / hygro-Negative 
Control Vector (FLAG-
tagged) 
pCMV/hygro
-FLAG 
none ampicillin/ 
hygromycin B 
CV005 (Sino 
Biological) 
pEGFP-N1-TFEB pEGFP-N1 human TFEB 
(NM_00116782
7.2) 
kanamycin/ 
neomycin 
#38119 
(Addgene) 
Table 11: Plasmids. 
2 Buffers and solutions 
2.1 Flow cytometry (FACS) 
2.1.1 RPMI w/o Phenol Red 
Medium Additives 
RPMI w/o Phenol Red 10 % FCS 
Table 12: RPMI without Phenol Red. 
2.1.2 FACS buffer (5 % FCS/PBS) 
ingredient volume 
1x PBS 45 ml 
FCS 2.5 ml 
Table 13: FACS buffer. 
2.1.3 Acridine orange staining solution 
ingredient concentration 
Acridine orange solution (10 mg/ml) 0.01% (v/v) in RPMI w/o phenol red + 10 % FCS 
Table 14: Acridine orange staining solution. 
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2.1.4 1x Fixation and permeabilization solutions for staining of nuclear 
antigens 
Solution Stock solution Diluent 
1x Fixation solution 4x Fixation/Permeabilization 
Concentrate (eBioscience) 
Fixation/Permeabilization 
Diluent (eBioscience) 
1x Permeabilization Solution 10x Permeabilization buffer 
(eBioscience) 
De-ionized water 
Table 15: Solutions for FACS staining of nuclear antigens. 
2.2 Fluorescence microscopy and immunofluorescence 
2.2.1 4% Paraformaldehyde (PFA) fixation solution 
1x PBS 40 ml 
16% PFA stock solution 10 ml 
Table 16: 4% PFA fixation solution.  The solution was distributed to black 1.5 ml reaction tubes and stored at 
20°C. Solution was thawed 1h before use. 
2.2.2 Blocking and permeabilization solutions for cytoplasmic and nuclear 
antigens 
OT/microscopy slide blocking solution 10 % NGS, 0.25 % BSA, 0.1 % Triton-X 100 in PBS 
Blocking solution (nuclear staining) 3 % BSA, 0.05% Triton-X 100 in 1x PBS  
Permeabilization solution (cytoplasmic) 0.1 % Triton-X 100 in 1x PBS 
Permeabilization solution (nuclear) 0.2 % Triton-X 100 in 1x PBS 
Table 17: Blocking and permeabilization solutions for immunofluorescence 
2.3 Immunoprecipitation 
2.3.1 PBS-T (0.02 %) 
ingredient volume 
1x PBS 200 ml 
Tween 20 40 µl 
Table 18: PBS-T for immunoprecipitation. PBS-T was stored at 4°C. 
2.3.2 Triethanolamine buffer 
ingredient volume final concentration 
Triethanolamine 2.64 ml 0.2 M 
PBS 100 ml ---- 
pH adjusted to 8.2 with concentrated HCl   
Table 19: Triethanolamine buffer. Triethanolamine buffer was stored at 4°C. 
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2.3.3 Dimethyl pimelimidate (DMP) solution for crosslinking 
DMP stock solution 
ingredient amount/volume 
DMP dihydro chloride 13 mg 
Triethanolamine buffer 1 ml 
Table 20: DMP stock solution. DMP stock solution was freshly prepared directly before use. 
DMP working solution  
ingredient volume final concentration 
DMP stock solution 0.5 ml 20 mM 
Triethanolamine buffer 0.7 ml  
Table 21: DMP working solution. DMP working solution was freshly prepared directly before use. 
2.3.4 Quenching solution (50 mM Tris pH 7.5) 
ingredient amount/volume final concentration 
Trizma Base  1.22 g 50 mM 
ddH2O 200 ml ---- 
pH adjusted to 7.5 with concentrated HCl   
Table 22: Quenching solution. Quenching solution was stored at 4°C. 
2.4 Colony formation assay 
2.4.1 Crystal violet staining solution 
Ingredient Final concentration 
Crystal violet 1 % (w/v) 
ethanol 70 % (v/v) 
de-ionized water 30 % (v/v) 
Table 23: Crystal violet staining solution. 
2.5 Quantification of polyamines  
2.5.1 10x SSAT breaking buffer 
ingredient amount/volume final concentration 
HEPES  1.2 g 50 mM 
LiChroSolv water 100 ml ---- 
pH adjusted to 7.2 with NaOH   
Table 24: 10x SSAT breaking buffer. SSAT breaking buffer was stored at -20°C and diluted in LiChroSolv water to 
yield 1x SSAT breaking buffer. 
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2.6 Cathepsin Release Assay 
2.6.1 Extraction buffer 
Ingredient Final concentration 
Sucrose 250 mM 
HEPES 20 mM 
KCl 10 mM 
MgCl2 1.5 mM 
EGTA 1 mM 
EDTA 1mM 
pH adjusted to 7.5 with NaOH  
Table 25: Extraction buffer for cathepsin release assay. Buffer was stored at 4°C. DTT (8 mM), PMSF (1 mM) 
and digitonin (15 or 200 µg/ml) were added directly prior to use. 
2.6.2 Reaction buffer (2x) 
Ingredient Final concentration 
Sodium acetate 50 mM 
EDTA 8 mM 
pH adjusted to 5.0 with HCl  
Table 26: Reaction buffer (2x) for cathepsin release assay. Buffer was stored at 4°C. DTT (8 mM), PMSF (1 mM) 
were added directly prior to use. 
3 Western Blot 
3.1 Buffers and solutions 
Buffers and solutions for Western Blot were stored at room temperature unless otherwise indicated 
below. 
3.1.1 Running gel buffer for SDS PAGE (1.5 M Tris pH 8.8) 
Ingredient Final concentration 
Trizma Base 1.5 M 
HCl (12.1 M) Added dropwise to set pH to 8.8 
Table 27: Running gel buffer for SDS PAGE. 
3.1.2 Stacking gel buffer for SDS PAGE (0.5M Tris pH 6.8) 
Ingredient Final concentration 
Trizma Base 0.5 M 
HCl (12.1 M) Added dropwise to set pH to 6.8 
Table 28: Stacking gel buffer for SDS PAGE. 
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3.1.3 10x Running buffer for SDS PAGE 
Ingredient Final concentration 
Trizma Base 25 mM 
Glycine 1,9 M 
SDS 1 % (w/v) 
HCl (12.1 M) Added dropwise to set pH to 8.3 
Table 29: 10x Running buffer for SDS PAGE. 10x Running buffer was diluted in de-ionized water before use. 
Transfer buffer. 
3.1.4 Transfer buffer for western blot 
Ingredient Final concentration 
Trizma Base 480 mM 
Glycine 390 mM 
Table 30: 10x Transfer buffer for western blot. 
1x Transfer buffer 
Ingredient Volume 
10x Transfer buffer 100 ml 
Methanol 200 ml 
ddH2O ad 1000 ml 
Table 31: 1x Transfer buffer for western blot. 
3.1.5 TBS and TBS-Tween (TBS-T) for western blot 
Ingredient Final concentration 
Trizma Base 200 mM 
NaCl 1.37 M 
HCl (12.1 M) added to set pH to 7.6 
Table 32: 10x TBS for western blot. 
1x TBS 
Ingredient Volume 
10x TBS 100 ml 
ddH2O 900 ml 
Table 33: 1x TBS for western blot. 
1x TBS-T 
Ingredient Volume (final concentration) 
10x TBS 100 ml (1x) 
ddH2O 900 ml 
Tween 20 2 ml (0.2 % v/v) 
Table 34: 1x TBS-T for western blot. 
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3.1.6 Blocking buffers for western blot 
All blot membranes were blocked standard blocking buffer for Western Blot unless otherwise 
specified below 
Standard blocking buffer for western blot membranes 
Ingredient Final concentration 
Nonfat dry milk 20 % (w/v) 
FCS (non-inactivated) 20 % (v/v) 
BSA 3 % (w/v) 
NGS 1 % (v/v) 
Tween 20 0.2 % (v/v) 
1x TBS ad 1l 
Table 35: Standard blocking buffer for western blot. Blocking solution was stored in 50 ml aliquots at -20°C. 
BSA blocking solution 
Ingredient Final concentration Antibodies used for 
BSA 3 % (w/v) in TBS-T FOXO3a, ATG5, ATG7 
Table 36: BSA blocking solution for western blot. BSA blocking solution for Western Blot was stored at 4°C. 
3.1.7 Antibody dilution buffers for western blot 
Primary and secondary antibodies for Western blot were diluted in 2 % (w/v) nonfat dry milk in 1x 
TBS-T with the exception of antibodies listed in Table 36, where primary and secondary antibodies 
were diluted in BSA blocking solution. 
3.1.8 Lysis buffers for protein biochemistry 
SDS lysis buffer for whole cell lysates 
Ingredient Volume/amount (final concentration) 
Stacking gel buffer 12.4 ml (62.5 mM TRIS pH 6.8) 
SDS 2 g (2 % w/v) 
Glycerol  10 ml (10 % v/v) 
ddH2O ad 100 ml 
Table 37: SDS lysis buffer for whole cell lysates. 1mM DTT was added directly before use. 
Triton-X based lysis buffer for postnuclear lysates 
Ingredient Final concentration 
Trizma Base 20 mM 
NaCl 137 mM 
Glycerol  10 % (v/v) 
0.5 M EDTA pH 8.0 2 mM 
Triton-X 100 0.2 - 1 % 
HCl (12.1 M) added dropwise to adjust pH to 8.0 
ddH2O ad 100 ml 
Table 38: Lysis buffer for postnuclear lysates. Buffer was stored at -20°C. One cOmplete™ Mini EDTA-free 
Protease Inhibitor Cocktail Tablet was added per 10 ml of lysis buffer directly prior to use. 
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1x RIPA buffer 
Ingredient Volume 
Cell Signaling Technology (CST) RIPA buffer (10x) 2 ml 
ddH2O ad 20 ml 
Table 39: 1x RIPA buffer. RIPA buffer was stored at -20°C. One cOmplete™ Mini EDTA-free Protease Inhibitor 
Cocktail Tablet was added per 20 ml of lysis buffer directly prior to use. 
3.1.9 4x Laemmli sample buffer 
Ingredient Volume Final concentration 
Stacking gel buffer pH 6.8 10 ml 62.5 mM Tris 
Glycerol  8 ml 20 % (v/v) 
SDS 1.6 g 4 % 
Bromophenol blue 2 mg 0.005% 
ddH2O ad 40 ml ----- 
Table 40: 4x Laemmli sample buffer. In case of reducing sample buffer 5% (v/v) -Mercaptoethanol (14.3 M) 
were added. 4x Laemmli buffer was diluted in equal volume of ddH2O to yield 2x Laemmli buffer. 
3.1.10 Coomassie Brilliant Blue staining solution 
Ingredient Final concentration 
Brilliant Blue G 0.05 % (w/v) 
Isopropanol 25 % (v/v) 
Acetic acid 10 % (v/v) 
Table 41: Coomassie Brilliant Blue staining solution. Coomassie Brilliant Blue solution was filtered before use 
and stored protected from light. 
3.1.11 Ponceau S staining solution 
Ponceau S solution (AppliChem) 5 ml 
ddH2O 45 ml 
Table 42: Ponceau S staining solution. 
3.1.12 further solutions for SDS PAGE and western blot 
EDTA pH 8.0 stock solution 
0.5 M EDTA (conjugate base) in ddH2O, pH 
adjusted to 8.0 with HCl 
10 % Ammoniumpersulfate (APS) 10% (w/v) in ddH2O 
1M Dithiothreitol (DTT) (1000x) stock solution 1M in ddH2O 
Table 43: Further solutions for SDS PAGE and western blot. 10% APS and 1 mM DTT were stored as aliquots at 
-20°C. 
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3.2 Gels for SDS-PAGE 
3.2.1 Running gels 
 8 % gel 10 % gel 15 % gel 
H2O 4.05 ml 3.67 ml 2.67 ml 
Running gel buffer 1.88 ml 1.88 ml 1.88 ml 
Acrylamide/Bis 
solution (40% w/v) 
1.5 ml 1.88 ml 2.88 ml 
20 % SDS in H2O 37.5 µl 37.5 µl 37.5 µl 
10% APS 37.5 µl 37.5 µl 37.5 µl 
TEMED 5 µl 5 µl 5 µl 
Total volume (1 gel) 7.5 ml 7.5 ml 7.5 ml 
Table 44: Running gels. 
3.2.2 Stacking gel 
H2O 3.15 ml 
Stacking gel buffer 1.25 ml 
Acrylamide/Bis solution (40% w/v) 0.5 ml 
20 % SDS in H2O 25 µl 
10% APS 25 µl 
TEMED 5 µl 
Total volume (2 gels) 5 ml 
Table 45: Stacking gels. 
3.3 Protein size standards 
BenchMark Pre-stained Protein Ladder ThermoFisher Scientific 
Precision Plus Protein™ Kaleidoscope™ 
Prestained Protein Standards 
Bio-Rad 
Table 46: Protein size standards. 
4 Antibodies 
4.1 Primary antibodies for western blot analysis 
Target/name Source species, 
type 
Immunogenic 
peptide/epitope 
supplier Dilution for 
Western Blot 
acetylated H3 rabbit, 
polyclonal 
Histone H3 amino acids 
7-17, K14-ac 
EMD Millipore 1:1000 
acetylated SMC3 
(Nishiyama et al. 
2010) 
mouse, 
monoclonal  
amino acids 97-115, 
K105-ac, K106-ac 
K. Shirahige, 
Institute for 
Molecular and 
Cellular 
Biosciences, 
University of 
Tokyo, Japan 
1:5000 
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acetylated tubulin mouse, 
monoclonal (6-
11B-1) 
acetylated sea urchin 
tubulin/epitope 
located within four 
residues of -tubulin 
K40-ac 
Sigma-Aldrich 1:1000 
ATG5 rabbit, 
polyclonal 
near C-terminal 
peptide of ATG5 
Cell Signaling 
Technology 
1:500 - 1:1000 
ATG7 Rabbit, 
polyclonal 
N-terminal peptide of 
ATG7 
Cell Signaling 
Technology 
1:500 
-actin mouse, 
monoclonal (AC-
15) 
-actin N-terminal 
peptide coupled to KLH 
 1:20,000 - 
1:40,000 
Beclin-1 goat, polyclonal near N-terminal 
peptide of Beclin-1 
Santa Cruz 
Biotechnology 
1:1000 
FoxO3a rabbit, 
monoclonal 
(75D8) 
peptide surrounding 
D50 of human FOXO3a 
Cell Signaling 
Technology 
1:500 - 1:1000 
HDAC6 rabbit, 
polyclonal 
amino acids 916-1215 
of human HDAC6 
Santa Cruz 
Biotechnology 
1:1000 
HDAC8 rabbit, 
polyclonal 
amino acids 1-145 
against human HDAC8 
Santa Cruz 
Biotechnology 
1:2000 
HDAC10 rabbit, 
polyclonal 
amino acids 2-16 of 
human HDAC10 
Sigma-Aldrich 1:500 
HSC70 rat, monoclonal 
(1B5) 
full length hamster 
HSC70 
Abcam 1:10,000 
HSP70 mouse, 
monoclonal 
(C92F3A-5) 
amino acids 436-503 of 
human HSP70  
Santa Cruz 
Technology 
1:1000 
LAMP-1 mouse, 
monoclonal 
(H3A4) 
NIH/3T3 mouse 
embryo fibroblast 
tissue culture cell 
membranes/recognizes 
LAMP1 luminal region 
Developmental 
Studies 
Hybridoma Bank 
1:1000 
LAMP-2 mouse, 
monoclonal 
(H4B4) 
full-length LAMP2 Santa Cruz 
Technology 
1:1000 
LC3B rabbit, 
polyclonal 
LC3B amino acids 2-15 Sigma-Aldrich 1:5000 
p62/SQTM1 mouse, 
monoclonal 
(5F2) 
recombinant human 
p62 amino acids 120-
440 
Biozol 1:1000 
p62/SQTM1 rabbit, 
polyclonal 
amino acids 256-269 of 
human p62 coupled to 
KLH 
Sigma-Aldrich 1:1000 
P-Glycoprotein for 
western blot 
rabbit, 
monoclonal 
(E1Y7S) 
recombinant protein 
surrounding Alanin 650 
of human P-gp 
Cell Signaling 
Technology 
1:1000 
Tubulin (/) rabbit, 
polyclonal 
full-length /tubulin Cell Signaling 
Technology 
1:1000 
Table 47: Primary antibodies for western blot analysis. 
 
52 
4.2 Primary antibodies for flow cytometry and 
immunofluorescence 
Target/name Source 
species, 
type 
Immunogenic 
peptide/epitope 
supplier Dilution/concentration 
H2A.X rabbit, 
monoclonal 
(20E3) 
synthetic peptide 
surrounding 
phosphorylated S139 of 
human H2A.X 
Cell Signaling 
Technology 
1:200 
LAMP-1 mouse, 
monoclonal 
(H3A4) 
NIH/3T3 mouse embryo 
fibroblast tissue culture 
cell 
membranes/recognizes 
LAMP1 luminal region 
Developmental 
Studies 
Hybridoma 
Bank 
1-2.5 µg/ml 
P-
glycoprotein 
mouse, 
monoclonal 
(MRK16) 
Adriamycin resistant 
human K-562 
cells/discontinuous 
extracellular epitope 
Biozol 1:100 
mouse IgG1 
isotype 
control 
mouse 
IgG1, 
monoclonal 
(NCG01) 
not available Dianova final concentration 
equal to target 
antibody 
Table 48: Primary antibodies for flow cytometry and immunofluorescence. 
4.3 Secondary antibodies for western blot analysis 
Target 
species 
Source 
species 
Type Conjugation supplier Dilution 
mouse goat IgG horseradish 
peroxidase 
Dianova, Hamburg, 
Germany 
1:70,000 
rabbit donkey IgG horseradish 
peroxidase 
Dianova, Hamburg, 
Germany 
1:60,000 (1:10,000 in case 
of ATG5, ATG7, FOXO3a) 
rat goat IgG horseradish 
peroxidase 
Santa Cruz, 
Heidelberg, 
Germany 
1:20,000 
Table 49: Secondary antibodies for western blot analysis. 
4.4 Secondary antibodies for flow cytometry and 
immunofluorescence 
Name Target 
species 
Source 
species 
Conjugation supplier Dilution Application 
anti-
mouse-
Alexa 
488 
mouse goat Alexa Fluor® 
488 
Cell Signaling 
Technology, Leiden, 
Netherlands 
1:500 Fluorescence 
microscopy 
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anti-
mouse-
APC 
mouse goat Allophycocyanin 
(APC) 
Dianova, Hamburg, 
Germany 
1:200 Flow 
cytometry 
anti-
mouse-
Cy3 
mouse goat Cy3 Cedarlane Laboratories, 
Burlington, Canada 
1:200 Fluorescence 
microscopy 
anti-
rabbit-
Alexa 
488 
rabbit goat Alexa Fluor® 
488 
Life 
Technologies/Thermo 
Fisher Scientific, 
Braunschweig, 
Germany 
1:500/ 
1:1000 
Flow 
cytometry/ 
Fluorescence 
microscopy 
anti-
rabbit-
Alexa 
568 
rabbit donkey Alexa Fluor® 
568 
Life 
Technologies/Thermo 
Fisher Scientific, 
Braunschweig, 
Germany 
1:500/ 
1:1000 
Fluorescence 
microscopy 
anti-
rabbit-
Cy3 
rabbit goat Cy3 Cedarlane Laboratories, 
Burlington, Canada 
1:200 Fluorescence 
microscopy 
Table 50: Secondary antibodies for flow cytometry and immunofluorescence. 
5 Peptides for monoclonal antibody production 
Peptide 
name 
Amino acid sequence 
HDAC10T1 NH2-MRGSHHHHHHGSMDVTAVPMSPSSHSPEGRPPPLLPGGPVCKAAASAPSSLLDQPCLC
PAPSVRTAVALTTPDITLVLPPDVIQQEASALREETEAWARPHESLAREEALTALGKLLYLLDGML
DGQVNSGIAATPASAAAATLDVAVRRGLSKLN-COOH 
HDAC10T2 NH2-MRGSHHHHHHGSMHGAQRLLCVALGQLDRPPDLAHDGRSLWLNIRGKEAAALSMFHV
STPLPVMTGGFLSCILGLVLPLAYGFQPDLVLVALGPGHGLQGPHAALLAAMLRGLAGGRVLAL
LEENSTPQLKLN-COOH 
Table 51: Peptides for the production of monoclonal HDAC10 antibodies. Amino acid sequence of peptides 
HDAC10T1 and HDAC10T2. HDAC10 amino acids are highlighted in green, the 6x histidine tag in orange.  
6 Chemicals, consumables and kits 
6.1 Chemicals 
Substance Supplier 
Acetic acid Carl Roth, Karlsruhe, Germany 
Acridine orange solution (10 mg/ml) Sigma-Aldrich, Munich, Germany 
Acrylamide/Bis solution, 40 % (w/v) Serva Electrophoresis, Heidelberg, Germany 
APS (Ammonium persulfate) Sigma-Aldrich, Munich, Germany 
Bromophenol blue AppliChem, Darmstadt, Germany 
BSA Type H1 Sigma-Aldrich, Munich, Germany 
Cell Dissociation Buffer, enzyme-free, PBS-based Thermo Fisher Scientific, Braunschweig, 
Germany 
Collagen Type I (#C3867) Sigma-Aldrich, Munich, Germany 
cOmplete Mini™ Sigma-Aldrich, Munich, Germany 
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Brilliant Blue G Sigma-Aldrich, Munich, Germany 
DAPI (4',6-Diamidino-2-phenylindol) AppliChem, Darmstadt, Germany 
Digitonin Sigma-Aldrich, Munich, Germany 
DMEM Lonza Group, Basel, Switzerland 
DMP (Dimethyl pimelimidate dihydro chloride) Sigma-Aldrich, Munich, Germany 
DMSO (Dimethyl sulfoxide) Sigma-Aldrich, Munich, Germany 
DPBS Lonza Group, Basel, Switzerland 
DTT (Dithiothreitol) AppliChem, Darmstadt, Germany 
ECL Prime GE Healthcare, Munich, Germany 
EDTA (ethylene diamine tetraacetate) GERBU Biotechnik GmbH, Heidelberg, Germany 
EGTA (ethylene glycol-bis(β-aminoethyl ether)-
N,N,N′,N′-tetraacetic acid/egtazic acid) 
Sigma-Aldrich, Munich, Germany 
Ethanol Sigma-Aldrich, Munich, Germany 
FCS (fetal calf serum) Sigma-Aldrich, Munich, Germany 
Glycine Sigma-Aldrich, Munich, Germany 
Glycerol for molecular biology Honeywell Riedel-de-Haën, Seelze, Germany 
HCl (hydrochlorid acid 12.1 M) Sigma-Aldrich, Munich, Germany 
HEPES Carl Roth, Karlsruhe, Germany 
Hygromycin B solution Sigma-Aldrich, Munich, Germany 
IMDM ThermoFisher Scientific, Braunschweig, Germany 
Isopropanol Sigma-Aldrich, Munich, Germany 
KCl (potassium chloride) Carl Roth, Karlsruhe, Germany 
LiChrosolv® water LC-MS Grade Merck Millipore, Darmstadt, Germany 
Low melting agarose Biozym Scientific, Hessisch Oldendorf, Germany 
LysoTracker™ Red DND-99 ThermoFisher Scientific, Braunschweig, Germany 
Methanol Sigma-Aldrich, Munich, Germany 
MgCl2( Magnesium chloride)  Merck, Darmstadt, Germany 
Milk powder Carl Roth, Karlsruhe, Germany 
NaCl (sodium chloride) Sigma-Aldrich, Munich, Germany 
NaOH (sodium hydroxide) 1M solution Sigma-Aldrich, Munich, Germany 
NaOH pellets Sigma-Aldrich, Munich, Germany 
NEAA (non-essential amino acids) 100x Lonza Group, Basel, Switzerland 
NGS (normal goat serum) Dianova, Hamburg, Germany 
Opti-MEM I ThermoFisher Scientific, Braunschweig, Germany 
Paraformaldehyde (PFA) 16% MeOH free Alfa Aesar, Karlsruhe, Germany 
Ponceau S solution AppliChem, Darmstadt, Germany 
PMSF (phenylmethane sulfonyl fluoride) Sigma-Aldrich, Munich, Germany 
RIPA buffer (10x) Cell Signaling Technology, Leiden, Netherlands 
RPMI 1640 ThermoFisher Scientific, Braunschweig, Germany 
RPMI 1640, no Phenol Red ThermoFisher Scientific, Braunschweig, Germany 
Sodium acetate Sigma-Aldrich, Munich, Germany 
SDS (Sodium dodecyl sulfate) Carl Roth, Karlsruhe, Germany 
sodium pyruvate 100x ThermoFisher Scientific, Braunschweig, Germany 
Sucrose Carl Roth, Karlsruhe, Germany 
SYTOX Green Nucleic Acid Stain ThermoFisher Scientific, Braunschweig, Germany 
TEMED (N, N, N, N-Tetramethyl-
Ethylenediamine) 
Carl Roth, Karlsruhe, Germany 
Triethanolamine  Sigma-Aldrich, Munich, Germany 
Tris/HCl Sigma-Aldrich, Munich, Germany 
Triton-X 100 AppliChem, Darmstadt, Germany 
Trizma Base Sigma-Aldrich, Munich, Germany 
trypsin-EDTA, 0.05 % (w/v) ThermoFisher Scientific, Braunschweig, Germany 
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Tween 20 (polyoxyethylene sorbitan 
monolaureate) 
GERBU Biotechnik GmbH, Heidelberg, Germany 
Vi-Cell XR Cell Viability Analyzer™ solutions  Beckmann Coulter, Krefeld, Germany 
Z-FR-AFC cathepsin L substrate (ALX-260-129) Enzo Life Sciences, Lörrach, Germany 
Table 52: Chemicals. 
6.2 Consumables 
Name Supplier 
Cell scraper Sarstedt, Nürnbrecht, Germany 
Chromatography Paper "Whatman CHR 3mm" GE Healthcare, Munich, Germany 
CometSlide™ 2 Well Trevigen, Gaithersburg, United States 
Conical tubes, 15 ml ThermoFisher Scientific, Braunschweig, Germany 
Conical tubes, 50 ml ThermoFisher Scientific, Braunschweig, Germany 
Dynabeads™ Protein G for Immunoprecipitation ThermoFisher Scientific, Braunschweig, Germany 
Falcon® 5mL Round Bottom Polystyrene Test 
Tube (FACS Tubes) 
ThermoFisher Scientific, Braunschweig, Germany 
Glassware SCHOTT AG, Mainz, Germany 
Ibidi 8-well µ-Slides Ibidi GmbH, Martinsried, Germany 
Microplates, 96 well, clear Greiner Bio-One, Frickenhausen, Germany 
Microplates, 96 well, white Greiner Bio-One, Frickenhausen, Germany 
Parafilm® M Benis, Braine-l'Alleud, Belgium 
PCR tube strips and domed caps Thermo Fisher Scientific, Braunschweig, Germany 
Pipette filter tips, 10 µl nerbe plus, Winsen/Luhe, Germany 
Pipette filter tips, 20 µl nerbe plus, Winsen/Luhe, Germany 
Pipette filter tips, 100 µl nerbe plus, Winsen/Luhe, Germany 
Pipette filter tips, 200 µl nerbe plus, Winsen/Luhe, Germany 
Pipette filter tips, 1000 µl nerbe plus, Winsen/Luhe, Germany 
Pipette tips, 2-10 µl Steinbrenner Laborsysteme, Wiesenbach, 
Germany 
Pipette tips, 20-200 µl Steinbrenner Laborsysteme, Wiesenbach, 
Germany 
Pipette tips, 1000 µl Steinbrenner Laborsysteme, Wiesenbach, 
Germany 
Polystyrene Round-Bottom Tube with Cell-
Strainer Cap 
Corning, Kaiserslautern, Germany 
PVDF membrane Bio-Rad Laboratories, Munich, Germany 
Reaction tubes "Safe-Lock Tubes", 0.5 ml Eppendorf, Hamburg, Germany 
Reaction tubes "Safe-Lock Tubes", 1.5 ml Eppendorf, Hamburg, Germany 
Reaction tubes "Safe-Lock Tubes", 2.0 ml Eppendorf, Hamburg, Germany 
Serological pipettes, 5 ml Sigma-Aldrich, Munich, Germany 
Serological pipettes, 10 ml Sigma-Aldrich, Munich, Germany 
Serological pipettes, 25 ml Sigma-Aldrich, Munich, Germany 
Tissue culture dishes, 100x20 mm Thermo Fisher Scientific, Braunschweig, Germany 
Tissue culture flasks "Cellstar" 25 cm2, 75 cm2, 
175 cm2 
Greiner Bio-One, Frickenhausen, Germany 
Tissue culture plates, 6 well, 12 well, 96 well Corning, Kaiserslautern, Germany 
Tissue culture plates 96 well round bottom (U-
base) TPP® 
Sigma-Aldrich, Munich, Germany 
Table 53: Consumables. 
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6.3 Commercial kits 
Kit Supplier 
Amersham ECL Prime Western Blotting Detection 
Reagent 
GE Healthcare, Munich, Germany 
Cyto-ID® Autophagy Detection Kit 2.0 Enzo Life Sciences, Lörrach, Germany 
eBioscience™ Foxp3 / Transcription Factor Staining 
Buffer Set 
ThermoFisher Scientific, Braunschweig, 
Germany 
Venor® GenM Classic Mycoplasma Detection Kit Minerva Biolabs, Berlin, Germany 
Pierce BCA Protein Assay Kit ThermoFisher Scientific, Braunschweig, 
Germany 
Pierce NE-PER Nuclear and cytoplasmic extraction 
reagents 
ThermoFisher Scientific, Braunschweig, 
Germany 
PlasmoTest™ Mycoplasma Detection Kit InvivoGen, San Diego, CA, United States 
QIAGEN RNeasy Mini Kit QIAGEN, Hilden, Germany 
qPCR Mastermix for SYBR® Green I Eurogentec, Liège, Belgium 
RevertAid First Strand cDNA Synthesis Kit ThermoFisher Scientific, Braunschweig, 
Germany 
Table 54: Commercial kits. 
7 Equipment and instruments 
Instrument Supplier 
ABI 7500 Real-Time PCR System with Dell™ 
Notebook 
Applied Biosystems, Foster City, United States 
Analytical Balance "BP 121S" Sartorius, Göttingen, Germany 
Barnstead™ GenPure™ xCAD Plus Ultrapure 
Water Purification System 
ThermoFisher Scientific, Braunschweig, Germany 
Benchtop centrifuge "Allegra X-12R" Beckmann Coulter, Krefeld, Germany 
Biometra T3000 Thermocycler LabRepCo, Horsham, PA, United States 
Blotting chamber "TransBlot® SD Semi-Dry 
Transfer Cell" 
Bio-Rad Laboratories, Munich, Germany 
Butane/Propane cartridge Campingaz/Newell Brands, Hoboken, United 
States 
Canon EOS 500D SLR digital camera Canon, Krefeld, Germany 
"CellMate® II Serological Pipette" Matrix Technologies Corporation/ThermoFisher 
Scientific 
Chemiluminescence imaging system "Chemi-
Smart 5000" 
Vilber Lourmat, Eberhardzell, Germany 
Cell culture incubator "C200" Labotect, Rosdorf, Germany 
Cell culture sterile bench "Safe 2020" ThermoFisher Scientific, Braunschweig, Germany 
Cell culture sterile bench "Gelaire BSB4A" ICN/MP Biomedicals, Illkirch Cedex, France 
Cell counter "Vi-Cell XR Cell Viability Analyzer" Beckman Coulter, Krefeld, Germany 
Dark hood DH-10 Biostep, Burkhardtsdorf, Germany 
DynaMag™-2 Magnet ThermoFisher Scientific, Braunschweig, Germany 
Electrophoresis chamber "Mini-Protean® Tetra 
System" 
Bio-Rad Laboratories, Munich, Germany 
Flow cytometer "FACSCalibur" Becton, Dickinson and Company, Heidelberg, 
Germany 
Flow cytometer "FACS Canto II" Becton, Dickinson and Company, Heidelberg, 
Germany 
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Heating block "Thermomixer® comfort" Eppendorf, Hamburg, Germany 
Heat sealer "Folio" Severin Elektro, Sundern, Germany 
Heraeus Minifuge 4400 GL Heraeus, Leverkusen, Germany 
Incubator Heraeus B6420 Heraeus, Leverkusen, Germany 
Innova 4230 refrigerated benchtop incubator New Brunswick Scientific, Nürtingen, Germany 
Light microscope "CKX31" Olympus, Hamburg, Germany 
Light microscope "CKX41" with reflected 
fluorescence system 
Olympus, Hamburg, Germany 
Light microscope "Zeiss LSM710" confocal 
microscope for fluorescence imaging 
Carl Zeiss, Oberkochen, Germany 
Magnetic stirrer with heating "MR-3001" Heidolph Instruments, Schwabach, Germany 
MatriGrid ridged scaffolds for 3D culture TU Ilmenau, Ilmenau, Germany 
Metafer4 automated cell scanning system MetaSystems Hard & Software, Altlußheim, 
Germany 
Microcentrifuge "5417 R"; rotor: "F 45-24-11" Eppendorf, Hamburg, Germany 
Micropipette “PIPETMAN Neo® P2N”  Gilson, Limburg-Offheim, Germany 
Micropipette “PIPETMAN Neo® P10N”  Gilson, Limburg-Offheim, Germany 
Micropipette “PIPETMAN Neo® P20N”  Gilson, Limburg-Offheim, Germany 
Micropipette “PIPETMAN Neo® P200N”  Gilson, Limburg-Offheim, Germany 
Micropipette “PIPETMAN Neo® P1000N” Gilson, Limburg-Offheim, Germany 
Micropipette "Eppendorf Research® 10-100 µl" Eppendorf, Hamburg, Germany 
Micropipette "Eppendorf Research® 0.5-10 µl" Eppendorf, Hamburg, Germany 
Microplate fluorescence reader "FLUOstar 
OPTIMA" 
BMG Labtech, Ortenberg, Germany 
Microwave oven "Severin MW 7869" Severin Elektro, Sundern, Germany 
Multi-axle rotating mixer "TRM 56" IDL GmbH, Nidderau, Germany 
Multichannel pipette "Finnipipette® Digital 40-
200 µl" 
ThermoFisher Scientific, Braunschweig, Germany 
Multi Gel Unit FU300 Biostep, Burkhardtsdorf, Germany 
NanoAcquity UPLC system Waters GmbH, Eschborn, Germany 
Nano Drop ND-1000 Spectrophotometer PEQLab, Erlangen, Germany 
pH meter "SevenEasy" Mettler-Toledo, Gießen, Germany 
Pipette controller "accu-jet® pro" BRAND, Wertheim, Germany 
Power supply "EV231"  PEQLab, Erlangen, Germany 
Power supply "PowerPac™ Basic Power Supply" Bio-Rad, Munich, Germany 
Precision balance "440-47N" KERN & SOHN, Balingen, Germany 
Q Exactive™ HF hybrid quadrupole-Orbitrap 
Mass Spectrometer 
ThermoFisher Scientific, Braunschweig, Germany 
Refrigerator with freezer Liebherr, Biberach an der Riß, Germany 
Rocking platform "WT 16" Biometra, Göttingen, Germany 
Scanner "Perfection V700 photo" Epson, Meerbusch, Germany 
Test tube shaker "Reax top" Heidolph Instruments, Schwabach, Germany 
TQ Orbitrap XL Mass Spectrometer ThermoFisher Scientific, Braunschweig, Germany 
UltiMate 3000 RSLCnano UPLC system ThermoFisher Scientific, Braunschweig, Germany 
Ultra-low temperature freezer ThermoFisher Scientific, Braunschweig, Germany 
Universal 320R tabletop centrifuge (for plates) Hettich Lab Technology, Tuttlingen, Germany 
UV transilluminator "UST-15M-8K" Biostep, Burkhardtsdorf, Germany 
Vortexer "IKA VF2" IKA Janke & Kunkel, Staufen im Breisgau, 
Germany 
Waterbath Memmert, Schwabach, Germany 
Table 55: Equipment and instruments. 
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8 Software 
Software Supplier 
Adobe Illustrator CS3 Adobe 
Adobe Photoshop CS3 and CS6 Adobe 
Argus® X1 Version 7  Biostep 
EndNote X5 Thomson Reuters/Clarivate Analytics 
FlowJo v10 FlowJo, LLC 
GraphPad Prism Version 5.0 GraphPad Software Inc. 
ImageJ 1.48v National Institutes of Health 
Microsoft Office 2007/2010 Microsoft 
OPTIMA Microplate Reader Software Version 2.20R2 BMG Labtech 
Scaffold 4.03 Proteome Software 
Zen 2012 lite Carl Zeiss 
Table 56: Software. 
9 Databases 
Database Website 
Ensembl Genome Browser www.ensembl.org 
NCBI www.ncbi.nlm.nih.gov 
UniProt www.uniprot.org 
Table 57: Databases. 
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C METHODS 
1 Cell Biological Methods 
1.1 Cell culture and propagation of cells 
Unless otherwise specified, all cell culture media, DPBS and trypsin-EDTA were pre-warmed to room 
temperature before use. All cell lines and short-term cultures were kept under standard cell culture 
conditions (37°C, 5 % CO2, 95 % relative humidity) Adherent commercial cell lines (SK-N-BE(2)-C / 
BE(2)-C, IMR-32, Kelly, SK-N-AS, HAP1) were subcultured every 3-4 days when reaching 70-80% 
confluency. To that end, cells were briefly washed in DPBS and incubated in trypsin-EDTA for 3-4 
minutes at 37°C. After addition of 5 ml of the respective culture medium (Table 2), cells were 
resuspended and either transferred to a new culture flask in an appropriate split ratio or transferred 
to a 50 ml centrifuge tube for cell counting and seeding. 
For subculturing of semi-adherent cell lines (e.g. hybridomas), supernatant was transferred to a 50 
ml centrifuge tube. Cells were detached by thorough pipetting, transferred to the respective 
centrifuge tube and centrifuged for 5 minutes at 230 x g. Cells were resuspended in 5 ml culture 
medium and transferred to a new culture flask in an appropriate split ratio. 
Cell lines were checked weekly for mycoplasm contamination with the PlasmoTest™ Mycoplasma 
Detection Kit (InvivoGen), and mothly via PCR using the Venor® GenM Classic Mycoplasma Detection 
Kit (Minerva Biolabs). Cell lines were further checked for viral contamination by Multiplexion 
(Heidelberg, Germany) and cell identity was verified via DNA fingerprinting authentication (DMSZ, 
Germany). 
1.2 Cryoconservation and defrosting of cells 
Adherent cells were detached at 70-80 % confluency as described above and centrifuged for 5 
minutes at 230 x g. The supernatant was removed and cells were resuspended in cryoconservation 
medium (respective cell medium supplemented with 10 % DMSO). Typically, cells from one 75 cm² 
flask were resuspended in 3-5 ml cryoconservation medium and quickly distributed to sterile 
cryoconservation vials at 1 ml per vial. The sample vials were immediately frozen at -20°C over night 
and transferred to -80°C the following morning for long-term storage. 
To defrost cells, cryoconservation vials were thawed rapidly at room temperature and the cell 
suspension was immediately transferred to a 15 ml tube containing 9 ml of the respective culture 
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medium. For the removal of DMSO remnants, the supernatant was aspirated after centrifugation for 
5 minutes at 230 x g. Depending on pellet size, cells were resuspended in 2 ml or 5 ml cell culture 
media and transferred to a 6-well plate or a 25 cm² flask. The culture medium was replaced on the 
following day. In case of stably transfected or transduced cells, antibiotic selection was started as 
soon as cells had been transferred to 75 cm² flasks. 
1.3 Cell counting and seeding 
For seeding, cell concentration and viability were assessed using a Vi-Cell XR automatic cell counter 
(Beckmann Coulter). Cell suspensions were then diluted in order to achieve the required cell density 
and cells were distributed to the respective cell culture vessel (cell numbers given in the sections for 
individual assays). 
Seeding of cells on MatriGrid ridged scaffolds for 3D culture 
Threedimensional cultures of BE(2)-C cells were cultivated on microcavity-containing, ridged 
scaffolds (MatriGrid structures with a diameter of 300 µm, depth of 207 µm and a total active area of 
5 x 5 mm2). MatriGrid scaffolds were coated with substratum (10 µg/cm2 collagen type I), which 
allowed cells to adhere to the scaffold and dried for 2h. Cell suspension was added (2.5*105 cells per 
chip in 6-well plate) and allowed to adhere for at least 24h under standard cell culture conditions 
before beginning of treatment. Cells were allowed to grow on scaffolds for 3-7 days depending on 
assay. For retrieval of cells from scaffolds, cells were incubated in trypsin-EDTA for 4 minutes at 37°C. 
1.4 Treatment of cells 
For treatment of cells with antibiotics, chemotherapeutics or inhibitors, substances were diluted in 
the respective culture medium. If necessary, substances were pre-diluted in order to avoid pipetting 
of substance volumes below 1 µl. In case of adherent cells, the cell medium was aspirated completely 
before addition of treatment solutions. In case of semi-adherent cells, substances were directly 
added to the cell culture supernatant in order to avoid loss of floating cells.  
1.5 Transient and stable transfections 
Cells were transfected with plasmids using the QIAGEN Effectene Transfection Reagent. For transient 
transfections with pEGFP-N1-TFEB (Table 11), 1*106 BE(2)-C cells were seeded on sterile 10 cm 
dishes 24h before the transfection procedure. The following day, 1 µg of plasmid was added to 100 µl 
of EC buffer. Next, 2 µl of Enhancer were added, samples were briefly vortexed and incubated at 
room temperature for 5 minutes. After addition of 7.5 µl Effectene, the transfection mix was again 
vortexed and incubated at room temperature for 30 minutes. After addition of 1 ml medium, the 
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transfection mix was added dropwise to cells on 10 cm dishes containing 3 ml of cell culture 
supernatant and incubated over night under standard cell culture conditions. Medium was changed 
the following day (10 ml per plate), and cells were transferred to 6-well dishes for treatment with 
HDAC inhibitors. Microscopic images were taken 72h-96h after transfection. 
For stable transfections of IMR-32 cells with pCMV/hygro-FLAG HDAC10 or pCMV / hygro-Negative 
Control Vector (Table 11), 2*105 cells were seeded in 6-well plates and transfected the following day 
as described above with the following modifications: Transfection mixes were filled up with 500 µl of 
medium before dropwise addition of the transfection mix to 6-wells containing cells and 1.5 ml 
culture supernatant. Medium was replaced the following day (3 ml per well). Antibiotic selection with 
hygromycin B was started 24h after transfection and selection medium was replaced every 3 days. 
Cells were propagated to larger culture vessels when reaching a confluency of 70%. 
1.6 Transfection of cells with siRNAs 
Cells were transfected with siRNA using the QIAGEN HiPerFect transfection reagent. To that end, 
4*105 cells were seeded on 10 cm dishes. The next day, 50 µl of pre-diluted siRNAs (2 µM) (Table 7 
and Table 8) were added to sterile 1.5 ml reaction tubes containing 20 µl HiPerFect transfection 
reagent and diluted to a final concentration of 100 nM using 930 µl Opti-MEM medium. The 
transfection reaction was mixed by flicking and brief centrifugation, followed by incubation at room 
temperature for 10 minutes. The transfection mix was then added dropwise to the 10 cm dishes 
containing 3 ml of cell culture supernatant and incubated over night under standard cell culture 
conditions. The following morning, the supernatant was aspirated and replaced by 10 ml fresh 
culture medium per plate. Cells transfected with siRNA were typically analyzed three to six days after 
transfection. 
1.7 Flow cytometry (Fluorescence activated cell sorting - FACS) 
Flow cytometry allows for the counting and the analysis of the physical and biochemical properties of 
particles (cells or beads) in fluids. Cellular properties like size, shape and granularity can be 
determined by means of forward and sideward light scattering (FSC = forward scatter, SSC = side 
scatter) and reflection. Flow cytometry is furthermore used to characterize single cells in suspension 
by their specific cell surface proteins, receptors or antigens. The use of fluorescently-labeled 
antibodies allows for the quantification of these cell-surface proteins on a single-cell scale. Finally, 
flow cytometry also allows for the quantitative detection of the cellular uptake and/or the retention 
of fluorescent dyes. 
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1.7.1 Flow cytometric analysis of cell surface protein expression 
For flow cytometric analysis of cell surface protein expression, adherent cells were dissociated from 
dishes or flasks using non-enzymatic cell dissociation reagent for 5 minutes at 37°C. Detaching cells 
were resuspended in Phenol red free RPMI medium supplemented with 10 % FCS and counted using 
a Vi-Cell XR automatic cell counter (Beckmann Coulter). After centrifugation at 230 x g for 5 minutes 
at 4°C, 2.5-3*105 cells were resuspended in FACS buffer (Table 13) and transferred into a pre-cooled 
96-well round bottom plate, followed by centrifugation at 180 x g for 3 minutes at 4°C. After each 
centrifugation step, the supernatant was discarded by careful tapping of the 96-well plate on paper 
tissue. Cells were stained with primary antibodies against P-gp, LAMP-1 or control antibody of 
identical isotype (Table 48) diluted in FACS buffer for 1.5 - 2 hours on ice. Cells were washed three 
times in 200 µl/well FACS buffer, followed by centrifugation as described above and incubated with 
either Alexa 488 or APC-labeled secondary antibody (Table 50) for 1h on ice. After three final 
washing steps, cells were resuspended in 130 µl/well FACS buffer and transferred to pre-chilled FACS 
tubes. Cells were analyzed on a BD FACSCanto II platform. Data from 10,000 cells per sample were 
acquired and analyzed using FlowJo® analysis software (version 10). 
1.7.2 Flow cytometric analysis of DNA double strand breaks 
Flow cytometry is not only suitable for the analysis of cell surface markers, but also allows for the 
quantification of intracellular and even nuclear proteins after fixation and permeabilization of cells 
with suitable buffers. Serine 139 phosphorylation of histone variant H2A.X (H2A.X) is known to 
occur after the formation of DNA double strand breaks and the occurrence of nuclear H2A.X foci is 
used as a reliable and quantitative marker for DNA double strand breaks (Rogakou et al. 1998; Kuo 
and Yang 2008). In order to assess DNA double strand breaks after treatment of cells with 
chemotherapeutics and/or HDAC inhibitors, cells were detached from dishes using trypsin-EDTA for 3 
minutes at 37°C. Detaching cells were resuspended, counted and transferred to 96-well round 
bottom plates at 4*105 cells per well as described in section C1.7.1 Cell pellets were fixed and 
permeabilized using the eBioscienceTM Foxp3/Transcription Factor Staining Buffer Set (Thermo Fisher 
Scientific, see Table 15). For fixation, cells were resuspended in 200 µl per well fixation solution 
(Table 15), followed by incubation on ice for 30 minutes. Cells were centrifuged at 180 x g and 4°C for 
3 minutes. For nuclear permeabilization, cells were first resuspended in 50 µl per well 1x 
permeabilization buffer (Table 15), centrifuged as described above, and again resuspended in 200 µl 
per well 1x permeabilization buffer. Following centrifugation, cells were incubated for 1.5h at 4°C 
with primary antibody (Table 48) diluted in 1x permeabilization buffer (100 µl per well), followed by 
two to three washing steps in 200 µl per well 1x permeabilization buffer. After staining with Alexa 
488 labeled secondary antibody for 1h at 4°C (Table 50), cells were washed as described above and 
 
METHODS 63 
transferred to pre-chilled FACS tubes for analysis. FACS analysis was performed as described in 
section C1.7.1. 
1.7.3 Flow cytometric analysis of intracellular doxorubicin accumulation 
Doxorubicin, also known as adriamycin, is a widely used chemotherapeutic agent that belongs to the 
class of anthracyclines, and is a commonly used drug in neuroblastoma therapy. It possesses a 
marked autofluorescence (excitation max 427/501 nm; emission max 552/585 nm), which can be 
used for the quantification of cellular doxorubicin concentrations.  
Doxorubicin accumulation in 2D-cultured cells 
Flow cytometric quantification of intracellular doxorubicin was performed as described in (Ridinger 
et al. 2018). Briefly, cells were seeded in 6-well dishes at densities of 1.5*105 cells/well (BE(2)-C and 
SK-N-AS, HAP1, human fibroblasts) and 3*105 cells/well (IMR-32, Kelly, NB-1). Cells were treated with 
doxorubicin for 24 - 48h at the following concentrations: 25 ng/ml, 50 ng/ml, 100 ng/ml (indicated in 
figure legends). Where indicated, cells were co-treated with HDAC6/10 inhibitors or lysosomal 
inhibitors. Where indicated, vacuolin-1 was directly added to doxorubicin-treated cells 1h or 24h 
before flow cytometric analysis.  
In case of knockdown of HDAC6, HDAC10, ATG5 or P-glycoprotein in BE(2)-C cells, measurement was 
performed three days (ATG5), five days (P-glycoprotein) or six days (HDAC6/10) after transfection 
with siRNA (indicated in the respective figure legend). Cells were transferred to 6-well dishes 
(1.5*105 cells per well) 1-4 days after transfection and treated with 100 ng/ml doxorubicin. Where 
indicated, HDAC6/10i and lysosomal inhibitors were added for the last 24h.  
After doxorubicin treatment, cells were washed with 1 ml per well ice-cold Phenol red free RPMI 
containing 10% FCS and detached using 500 µl per well trypsin-EDTA for 3 minutes at 37°C. Cells 
were resuspended by the addition of 500 µl per well RPMI, transferred to 1.5 ml reaction tubes, 
centrifuged for 3 minutes at 8600 x g and 4°C, resuspended in Phenol red free RPMI and transferred 
to pre-chilled FACS tubes. Doxorubicin fluorescence of 10,000 cells was quantified on a BD 
FACSCanto II platform using the PE filter setting. 
Doxorubicin accumulation in 3D-cultured neuroblastoma cells 
BE(2)-C cells were seeded in MatriGrid scaffold as described in section C1.3. 24h prior to beginning of 
treatment. 3D cultures were treated with 500 ng/ml doxorubicin and co-treated with HDAC6/10 or 
lysosomal inhibitors where indicated. In case of ATG5, FoxO3a or Beclin-1 knockdown, BE(2)-C cells 
were seeded in MatriGrid scaffold 72h after transfection with siRNAs, grown for an additional 48 h 
and treated for the last 24h with 500 ng/ml doxorubicin. Cells were detached from MatriGrid 
scaffolds after one washing step with Phenol red free medium by trypsinization for 4 minutes at 
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37 °C, centrifuged and washed again in Phenol red free medium. Doxorubicin fluorescence was 
analyzed via flow cytometry as described in the previous section. 
Doxorubicin washout experiments 
BE(2)-C cells were seeded in 6-well dishes (one 6-well plate per timepoint) at a density of 1.5*105 
cells/well. One day post seeding, cells were pre-treated with HDAC6/10 inhibitors over night (12h) 
and labeled with high doxorubicin concentrations (1 µg/ml) the next day for 3h under standard cell 
culture conditions. After labeling with doxorubicin, cells were washed twice with pre-warmed 
medium and either directly analyzed for doxorubicin fluorescence after detachment (t0 timepoint 
plate) or re-incubated for 3-6h with medium containing HDAC6/10, lysosomal inhibitors or solvent. 
Detachment of cells and analysis of doxorubicin fluorescence was performed as described in the 
sections above. Doxorubicin fluorescence at 3h and 6h after washout was normalized to fluorescence 
at t0. 
1.7.4 Flow cytometric analysis of staining with LysoTracker® Red DND-99 
The LysoTracker® dyes are weakly basic organic compounds suitable to track acidic organelles. At a 
neutral pH, they are only partially protonated and therefore able to freely permeate across 
membranes. At low pH however, the LysoTracker dye becomes protonated and will therefore 
accumulate preferably in acidic organelles such as lysosomes. LysoTracker staining was performed as 
described in (Ridinger et al. 2018). Six days after siRNA transfection or 24 h after treatment with 
inhibitors, cells were stained with LysoTracker for 1h under standard cell culture conditions by direct 
addition of the LysoTracker dye to the cell supernatant (final concentration 50 nM). Post incubation, 
cells were washed with ice-cold Phenol red free RPMI and detached using 500 µl per well trypsin-
EDTA for 3 minutes at 37°C. Cells were resuspended by addition of 500 µl ice-cold RPMI and the cell 
suspension was transferred to a pre-chilled 1.5 ml reaction tube. Cells were centrifuged for 3 minutes 
at 8600 x g and 4°C. After aspiration of the supernatant, cell pellets were resuspended in ice-cold 
RPMI and LysoTracker® Red fluorescence of at least 10,000 cells was quantified on a BD FACSCanto II 
platform using the PE filter setting. 
1.7.5 Flow cytometric quantification of Cyto-ID® staining 
For Cyto-ID staining of 2D- grown BE(2)-C cells, cells were seeded at a density of 1.5*105 cells/well in 
6-well plates. Where indicated, cells were treated over night with lysosomal inhibitors before 
staining with 0.5 ml of Cyto-ID staining solution (1 × assay buffer, 5% FCS, 1 μl Cyto-ID) for 30 min 
under standard cell culture conditions. Cells were detached as described in the section above.  
In case of 3D cultures, BE(2)-C cells were seeded in MatriGrid scaffolds 72h after siRNA transfection, 
followed by growth for three more days under standard cell culture conditions. Where indicated, 
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cells were treated for the last 24h with lysosomal inhibitors. For staining (6d after-siRNA 
transfection), MatriGrid scaffolds were washed in Phenol red free medium, transferred to a fresh 6-
well plate and stained with 0.5 ml of Cyto-ID staining solution (see above) for 30 min at 37 °C. Cells 
were washed in Phenol red free medium, trypsinized for 4 minutes at 37 °C, centrifuged and washed 
again. Cyto-ID fluorescence of at least 10,000 cells was quantified on a BD FACSCanto II platform 
using the Alexa 488 filter setting. 
1.7.6 Flow cytometric quantification of acridine orange staining 
Acridine orange is a weak base fluorophor that freely diffuses across cellular membranes. 
Protonation at low pH leads to trapping of the dye in the respective compartments (e.g. acidic 
vesicles, lysosomes or autophagolysosomes). Trapping and accumulation in lysosomes, in turn, 
causes the metachromatic shift from green to red fluorescence (Thome et al. 2016). 
For staining of cells with acridine orange, BE(2)-C cells were seeded at 1.5*105 cells/well into 6-well 
plate one or two days before staining. Cells were stained with acridine orange staining solution (1 
µg/ml acridine orange in Phenol Red free RPMI (Table 12 and Table 14) for 30 minutes at 37°C. Cells 
were detached for flow cytometric analysis as described in section C1.7.3. Red acridine orange 
fluorescence of 2*104 cells was quantified on a "FACSCalibur" flow cytometer.  
1.8 Fluorescence microscopy 
1.8.1 Fluorescence microscopic analysis of doxorubicin and LysoTracker® 
Red DND-99 and Cyto-ID® staining 
For doxorubicin staining, BE(2)-C cells were seeded into ibidi 8-well µ-slides (2*104 cells per well) and 
allowed to attach to the slide surface for 24h. Cells were treated with 250 ng/ml doxorubicin in 
absence or presence of HDAC6/10i or lysosomal inhibitors for 24h. On the following day, cells were 
washed twice in PBS and fixed for 20 minutes using 4% PFA at room temperature. Fixed cells were 
again washed twice with PBS and counterstained with DAPI (0.25 µg/ml in PBS) or SYTOX Green (100 
nM in PBS) for 10-15 minutes. For LysoTracker staining or Cyto-ID, cells were seeded into ibidi slides 
as described above, treated for 24h with HDAC6/10 inhibitors where indicated, and stained for 1h 
with 50 nM LysoTracker or for 30 minutes with 200 µl/well Cyto-ID staining solution (1 × assay buffer, 
5% FCS, 1 μl Cyto-ID, 1 µg/ml Hoechst 33342) under standard cell culture conditions. Cells were 
washed as described above, fixed for 15 minutes (4% PFA at room temperature) and, in case of 
LysoTracker staining, counterstained as described above. Slides were imaged on a Zeiss LSM710 
confocal microscope. 
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Cyto-ID imaging of 3D-grown BE(2)-C cells on 3D MatriGrid scaffolds 
Cyto-ID imaging of 3D-grown BE(2)-C cells was performed as described according to (Bingel et al. 
2017). Briefly, BE(2)-C cells were seeded at a density of 2.5*105 cells per scaffold and grown for two 
days under standard cell culture conditions. One day prior to treatment, scaffolds were carefully 
transferred into 8-well μ-Slides (Ibidi) and treated in sterile Phenol Red free medium (Table 12) 
where indicated. For staining, slides were washed twice in 1x assay buffer supplemented with 5% FCS 
and stained with 200 μl/well CYTO-ID staining solution (1 × assay buffer, 5% FCS, 2 μl CYTO-ID, 1 
µg/ml Hoechst 33342) for 30 min at 37 °C. Scaffolds were carefully washed with and finally 
completely submerged in Phenol Red free medium. Z-Stack imaging was performed on a Zeiss 
LSM710 confocal microscope. 
1.8.2 Immunofluorescence 
Staining of cytoplasmic antigens 
BE(2)-C and IMR-32 cells were seeded into ibidi 8-well µ-slides at a density of 2-4*104, and allowed to 
adhere to the slide surface for at least 24h (48h or longer in case of treatment). Cells were washed 
once in PBS, fixed in 4% PFA for 15 minutes (BE(2)-C) and 25 minutes (IMR-32), respectively, and 
washed again. Cells were permeabilized for 10 minutes with permeabilization solution for 
cytoplasmic antigens and blocked for 1h at room temperature with blocking solution for cytoplasmic 
antigens (Table 17). Cells were stained with respective antibodies at concentrations given in the 
respective figure legend in blocking solution over night (4°C) followed by 2x washing in PBS and 
incubation with the respective secondary antibody at room temperature for 2h on the following day. 
Slides were washed twice with PBS and nuclei were counterstained with DAPI (0.25 µg/ml in PBS) for 
10 minutes at room temperature. Images were acquired on a Zeiss LSM710 confocal microscope. 
Staining of chromatin-located antigens (H2A.X staining) 
BE(2)-C cells were seeded and fixed as described above. Cells were permeabilized for 30 minutes 
with permeabilization solution for nuclear antigens and blocked for 1h at room temperature with 
blocking solution for nuclear antigens (Table 17). Cells were stained with anti Phospho-Histone H2A.X 
(S139) primary antibody diluted in blocking solution over night (4°C), followed by 2x washing in PBS 
and incubation with Alexa-488-labeled secondary antibody at room temperature for 2h on the 
following day. Counterstaining of nuclei and imaging was performed as described above. 
1.9 Trypan Blue Cell viability assay 
The diazo dye Trypan Blue is routinely used to discriminate dead from viable cells, as it is effectively 
excluded from cells with an intact plasma membrane and therefore only stains dead cells with 
compromised membrane integrity. For 48 h and 96 h treatments, BE(2)-C cells and non-transformed 
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VH7 fibroblasts were seeded at a density of 1.5*105 (24h, 48 h) and 7.5*104 (96 h) cells per well, and 
treatment was started on the following day. After completion of treatment, cell supernatants were 
collected in 15 ml centrifuge tubes and cells were detached applying 500 µl per well trypsin-EDTA for 
3 minutes at 37°C. Cells were resuspended by addition of 1 ml respective culture medium and the 
cell suspension was transferred to the 15 ml centrifuge tube containing the respective cell culture 
supernatant. Cells were centrifuged for 5 minutes at 335 x g and the supernatant was decanted. Cell 
pellets were resuspended in 800 µl culture medium and cell number, as well as cell viability were 
analyzed by automated trypan blue staining on a Vi-Cell XR Cell Viability Analyzer. 
1.10 Colony formation assay 
BE(2)-C cells were seeded into 6-well plates (800 cells per well) and treated the following day. After 
treatment for 24h, drugs were removed by washing with pre-warmed medium once and cells were 
allowed to grow for 11 more days. Colonies were stained with crystal violet staining solution (Table 
23) for 10 minutes and carefully washed with ddH2O. Plates were scanned (Perfection V700 photo, 
Epson), and colony growth was quantified on 16-bit binary pictures using the ITCN plugin in ImageJ 
(U. S. National Institutes of Health, Bethesda, MD, USA; http://imagej.nih.gov/ij/). 
1.11 Cathepsin Release Assay 
BE(2)-C cells were seeded at 1*106 cells per dish on 10 cm plates and allowed to adhere overnight. 
Cells were treated for 24h with HDAC inhibitors as indicated in the respective figure legend. On the 
following day, cells were washed with PBS, harvested with enzyme-free cell dissociation buffer (5 
minutes 37°C) and counted. For triplicate measurement, 1.875*104 cells were transferred into a pre-
chilled 1.5 ml reaction tube, pelleted for 4 minutes at 200 x g, washed once in ice-cold PBS and 
pelleted again for 3 minutes at 18,000 x g. Cell pellets were lysed in 75 µl ice-cold extraction buffer 
(containing either 15 µg/ml or 200 µg/ml digitonin) and incubated for 12 minutes on ice before 
addition of the same volume of freshly prepared 2 x cathepsin reaction buffer. After addition of 7.5 
µl cathepsin substrate (Z-FR-AFC), each 50 µl of the reaction mix were distributed to three wells of a 
clear bottom 96-well plate. AFC fluorescence was quantified on a FLUOstar OPTIMA microplate 
reader (excitation 380 nm, emission 520 nm) every 10 minutes (1 kinetic cycle) for at least 17 cycles. 
1.12  NanoBRET assay 
NanoBRET is a BRET-based in-cell tracer displacement assay which measures the competitive 
displacement of a fluorescently labeled tracer (e.g. the pan HDAC inhibitor SAHA) from NanoLuc® 
luciferase coupled enzymes. Tracer displacement reduces the transfer of donor/NanoLuc® 
fluorescence to the acceptor fluorophor (Non-Chloro-TOM/NCT dye) on the tracer. Therefore, a high 
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ratio of acceptor to donor signal directly reflects high target engagement by the tracer, while a low 
ratio reflects displacement of the tracer and therefore binding of a competitive inhibitor (Marks et al. 
2011; Robers et al. 2015). 
NanoBRET assays were performed in the group of Cancer Drug Discovery (Dr. Aubry Miller, DKFZ) as 
described in (Kolbinger et al. 2018; Ridinger et al. 2018). Briefly, HeLa cells stably expressing 
NanoBRET plasmids NanoLuc®-HDAC6 FL Fusion Vector or NanoLuc®-HDAC10 FL Fusion Vector 
(Promega, Madison, WI, USA) were seeded at a density of 20.000 cells per well into white 96 well 
plates. Tracer (0.3µM) and respective inhibitors were added in separate pipetting steps, followed by 
incubation for 2h under standard cell culture conditions. For NanoBRET measurement, plates were 
equilibrated to room temperature for 10 minutes. Nanoglow substrate was diluted in Phenol Red 
free Opti-MEM and added to the cells. Measurement was performed within 10 minutes of substrate 
addition in a BMG Labtech CLARIOstar plate reader (donor emission: 460 nm, acceptor: 610 nm low 
pass filter). Data were normalized to negative controls (50 µM SAHA) and positive controls (no 
inhibitor), respectively, and BRET signal is given as ratio of acceptor to donor signal. IC50 values were 
calculated from normalized BRET ratios using nonlinear regression curve fit in GraphPad Prism 
version 5.0. 
2 Biochemical Methods 
2.1 Preparation of whole cell lysates and postnuclear 
supernatants 
For whole cell lysates, cells were washed with DPBS and then collected in ice-cold DPBS using a cell 
scraper. Cell suspensions were transferred to pre-chilled 1.5 ml reaction tubes and centrifuged for 3 
minutes at 8600 x g and 4°C. DPBS was aspirated and cell pellets were lysed in 100-300 µl SDS-lysis 
buffer + 1 µM DTT (Table 37) depending on pellet size. Whole cell lysates were immediately 
incubated at 95°C for 10 minutes and rigorously vortexed before centrifugation for 10 minutes at 
11,000 x g and 15°C. The supernatant was then transferred to a fresh, pre-chilled 1.5 ml reaction 
tube and stored at -80°C. 
For the generation of postnuclear lysates, cells were washed and collected as described above. Cell 
pellets were lysed in either Triton-X (1 % TX-100) or RIPA buffer (Table 38 and Table 39) with freshly 
added cOmplete ™, Mini, EDTA-free Protease Inhibitor Cocktail (1 tablet per 10 ml lysis buffer). 
Lysates were vigorously vortexed and incubated for 20-30 minutes on ice, vortexing every 5-10 
minutes to ensure efficient cell lysis. Cell debris and intact nuclei were precipitated by 15 minute 
centrifugation at 12,000 x g for 15 minutes. Supernatants were transferred to fresh, pre-chilled 1.5 
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ml reaction tubes and a 20 µl of each lysate was set aside for protein quantification. The remaining 
lysate was immediately mixed in a one in four ratio with 4 x SDS sample buffer + 5 % (v/v) -
mercaptoethanol and incubated for 10 minutes at 95°C. Boiled lysates were either directly used for 
SDS-PAGE or stored at -80°C. 
2.2 Nuclear and cytoplasmic fractionation 
The Pierce NE-PER Nuclear and cytoplasmic extraction reagents kit was used according to 
manufacturer's instructions for nuclear and cytoplasmic fractionation with slight modifications to cell 
number. Briefly, 7.5*106 BE(2)-C cells were harvested by trypsinization and washed in ice-cold PBS. 
Cells were lysed in 200 µl CER I buffer, vigorously vortexed and incubated on ice for 10 minutes. Next, 
11 µl of CER II buffer were added, followed by vortexing and incubation on ice for 1 minute. Lysates 
were centrifuged for 5 minutes at maximum speed and 4°C. The supernatant was transferred to a 
fresh, pre-chilled 1.5 ml reaction tube and the nuclear pellet was resuspended in 60 µl NER buffer, 
followed by rigorous vortexing for 15 seconds. The nuclear lysate was placed on ice for 40 minutes, 
with vigorous vortexing every 10 minutes. Finally, insoluble nuclear debris was removed by 
centrifugation at maximum speed and 4°C for 10 minutes and the nuclear lysate supernatant was 
transferred to a fresh, pre-chilled 1.5 ml reaction tube. Nuclear fractionation lysates were stored at -
80°C. 
2.3 Preparation of lysates for polyamine quantification 
Whole cell lysates for Dansyl Chloride labeling of cellular polyamines (performed in the lab of Dr. Bob 
Casero, Baltimore, Maryland, United States) were prepared from 1.5*106 BE(2)-C cells. Cells were 
detached from 10 cm dishes with trypsin-EDTA for 3 minutes at 37°C , counted and washed twice in 
ice-cold PBS. Cell pellets in 1.5 ml reaction tubes were resuspended in 75 µl ice-cold 1x SSAT breaking 
buffer (Table 24) and immediately quick frozen in a ethanol/dry-ice mixture. Polyamines lysates were 
stored at -80°C and shipped on dry ice. In case of nuclear polyamine lysates, nuclei were enriched 
and lysed as described in section C2.2. 
2.4 Immunoprecipitation 
2.4.1 Covalent coupling of antibodies to Protein-G Dynabeads™ 
Protein G coupled Dynabeads™ were vortexed, transferred to a 2 ml microcentrifuge tube, washed 
once with 100 µl PBS-T (Table 18) and coupled to HSC70 and HSP70 antibody as indicated in Table 58 
by incubation for 1h at room temperature on an Eppendorf Thermomixer under agitation (700-750 
rpm). Beads were washed once in 200 µl PBS-T and two times in 1ml triethanolamine buffer (Table 
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19). Crosslinking of antibodies to Protein G Dynabeads was performed by adding 1ml of 20 mM DMP 
working solution (Table 21) and 30 minute overhead rotation at room temperature. DMP was 
removed and remaining DMP was quenched by addition of 1ml quenching solution (Table 22) for 20 
minutes at room temperature. Beads were washed two times in 1 ml PBS-T and directly used for IP or 
stored over night in 2x bead volume PBS-T at 4°C. Beads stored over night were re-equilibrated in 
100 µl PBS-T directly prior to addition of lysates (see following section). 
 coupling of HSC70 antibody 
(Abcam 1B5) 1x reaction 
coupling of HSP70 antibody 
(sc-66048) 1x reaction 
Dynabeads 22 µl 22 µl 
Amount of antibody 3.3 µg 3.3 µg 
Volume of antibody  3.3 µl batch-dependent (roughly 
65 µl) 
Total coupling 
reaction volume 
75 µl (72 µl PBS-T added) 75 µl (10 µl PBS-T added) 
Table 58: Coupling of HSC70 and HSP70 antibodies to Dynabeads. 
2.4.2 Cell lysis and immunoprecipitation 
BE(2)-C cells were seeded at a density of 2*106 cells per dish on multiple 10 cm dishes and grown for 
24h before treatment with HDAC inhibitors for 24h. Plates were washed once with PBS and cells 
were detached using non-enzymatic cell dissociation reagent or versene for five minutes at 37°C. 
Detaching cells were resuspended in non-sterile cell culture medium and counted using a Vi-Cell XR 
automatic cell counter (Beckmann Coulter). Cell lysis was performed as indicated in Table 59 and was 
allowed to continue for 20 minutes on ice with repeated vortexing before centrifugation for 10-15 
minutes at 15,000 x g and 4°C. Five percent of postnuclear supernatant was drawn off as input 
control and the remaining supernatant was transferred to the respective antibody-coupled 
Dynabeads (see previous section), followed by careful resuspension and incubation on an Eppendorf 
Thermomixer for 5-6h under gentle agitation (700 rpm) in the cold room. After IP, 5% of supernatant 
was drawn off as flowthrough control. Beads were washed thrice in PBS-T (HSC70 IP) or RIPA buffer 
(HSP70 IP) and transferred into a fresh 2 ml microcentrifuge tube during each washing step. Bound 
proteins were eluted by 10 minute incubation in 30 µl (or 1.5 x original bead volume) 2x Laemmli 
buffer + 5 % -mercaptoethanol at 95°C. 
IP cell number (1x IP) lysis buffer lysis volume (1x IP) 
HSC70 7.875*105 (7.5*105 + 5 %) Triton-X lysis buffer (0.2 % TX-100) 
(Table 38) 
160 µl 
HSP70 5.25*106 (5*106 + 5 %) RIPA lysis buffer (Table 39) 160 µl 
Table 59: Lysis conditions for HSC70 and HSP70 immunoprecipitation. 
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2.5 Protein quantification via the BCA assay 
The Bicinchoninic acid (BCA) assay is a sensitive method to determine protein concentrations in 
solution. It is based on the Biuret reaction, i.e. the reduction of Cu2+ to Cu+ ions by proteins in alkaline 
solution. Under alkaline conditions, proteins - via peptide bonds, cysteine, tyrosine and tryptophan 
residues - reduce Cu2+  to Cu+, which forms a purple complex with bicinchoninic acid (BCA) (Smith et 
al. 1985). Absorbance of this complex can be detected with a spectrophotometer at 562 nm. For the 
assay, BCA reagent A and B of the "Pierce BCA Protein Assay Kit" are mixed in a 50:1 ratio to obtain 
the BCA working solution. Protein lysates were typically diluted in a 1:5 or 1:10 ratio in their 
respective lysis buffer. Five µl of each dilution were added into a 96-well microplate as duplicates or 
triplicates and filled up with 200 µl BCA working solution. In order to determine protein 
concentration, 5 µl of albumin (BSA) standards of known concentrations ranging from 0-2 mg/ml, as 
well as a blank containing only the respective lysis buffer, were used to generate a blank corrected 
BSA standard curve. After 30-45 minutes of incubation at 37°C, absorbance at 570 nm was measured 
on a FLUOstar OPTIMA microplate reader.  
2.6 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE describes a method in which proteins are separated via electrophoresis in a 2D gel-matrix. 
This method is useful for the analysis of protein mixtures, enabling for instance the crude 
determination of a protein's molecular weight or the subsequent transfer and immobilization of 
proteins on a synthetic membrane for further analysis. In order to ensure that the electrophoretic 
separation is independent of the protein's own net charge and thus almost exclusively dependent on 
the protein's molecular weight, protein lysates, gels and gel buffers are supplemented with the 
denaturing detergent sodium dodecyl sulphate (SDS). SDS interacts with proteins, forming 
negatively-charged SDS protein complexes that are characterized by a constant charge-to-mass ratio. 
SDS, along with heat denaturation at 95°C, further promotes the unfolding of proteins, rendering the 
separation also largely independent of the protein's secondary and tertiary structure. Reducing 
agents like DTT or -Mercaptoethanol are commonly added to lysates in order to reduce inter- and 
intramolecular disulfide bonds and to destroy protein-protein interactions (quaternary structure). 
Running and stacking gels were prepared according to Table 44 and Table 45 and whole cell- , as well 
as postnuclear protein lysates were denatured as described in section C2.1. Between 20 and 60 µg of 
protein were loaded per lane depending on the detected antigen. In case of preparative gels for 
hybridoma supernatant testing, between 370 µg and 450 µg of postnuclear lysate were loaded per 
gel. The PAGE chamber was filled with 1x running buffer (Table 29) and gels were initially run at 80 V 
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until the bromophenol blue leading front entered the running gel, where voltage was increased to 
120V until the desired separation was reached. 
2.7 Western blotting 
The term blotting describes a procedure during which nucleic acids or proteins are transferred from a 
gel onto a synthetic membrane. In case of western blotting, proteins are separated via SDS-PAGE 
according to their molecular weight and then transferred to a membrane via the application of an 
electric field. Proteins immobilized on the membrane can then be detected and identified with the 
help of specific antibodies. 
2.7.1 Transfer of proteins onto a PVDF membrane (semi-dry blotting) 
After completion of electrophoresis, running gels were carefully retrieved from the running chamber, 
briefly rinsed in de-ionized water and equilibrated in 1 x transfer buffer (Table 31). For the transfer of 
proteins to PVDF membranes, five Whatman chromatography papers (9 x 6.5 cm) were soaked in 1 x 
transfer buffer and placed on the anode (positive pole) of the blotting chamber. The PVDF membrane 
(8.5 x 6 cm) was activated in pure methanol, briefly washed in de-ionized water, equilibrated in 1 x 
transfer buffer for at least 1 minutes and placed on top of the lower Whatman stack. The gel was 
carefully placed on top of the membrane, followed by five more Whatman chromatography papers. 
Proteins were blotted at a constant current of 0.67 mA/cm2 of membrane. Blotting times were 
adapted according to protein size and gel percentage (1h 30 minutes for small proteins < 25 kDa, 2h 
30 minutes for proteins of 25 - 150 kDa and 2h 45 minutes up to 3h for proteins > 150 kDa). After 
transfer, membranes were put in pure methanol for 1 minute and stained for 2-3 minutes in Ponceau 
S staining solution in order to check for uniform protein transfer. Residual protein in gels was 
detected with Coomassie Brilliant Blue staining solution (30 minutes), followed by rinsing in de-
ionized water until gels were sufficiently destained.  
In case of preparative gels for hybridoma supernatant testing, membranes were carefully labeled 
with serial numbers at the top of the membrane when stained with Ponceau S solution. This later 
allowed for the identification of blot strips and corresponding hybridoma supernatants.  
2.7.2 Immunodetection 
In order to avoid non-specific binding of antibodies to the PVDF membrane, membranes were 
blocked in either blocking solution (Table 35) or in 3 % BSA/TBS-T (Table 36) for 1h, depending on 
antibody (Table 36). Before application of primary antibody, antibodies were washed for 10 minutes 
in TBS-T and for 10 minutes in TBS. When membranes were used for testing of hybridoma 
supernatants, membranes were cut into small strips after washing with TBS-T. Membranes were 
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incubated with primary antibody (diluted in 2.5 % milk/TBS-T or 3% BSA/TBS-T) or hybridoma 
supernatants over night at 4°C. Unbound primary antibody was removed by 2 x washing in TBS-T and 
2 x washing in TBS (10 minutes each), followed by incubation in peroxidase-conjugated secondary 
antibody for 1 h at room temperature. Again, unbound antibody was removed by washing as 
described above. A chemoluminescence substrate (ECL Prime), which releases light upon oxidation of 
luminol by peroxidases, was used for the detection of bound antibodies. To that end, membranes or 
fixed membrane strips were incubated with 1 ml of a freshly prepared 1:1 mixture of detection 
reagents 1 and 2 for 2-5 minutes at room temperature. Emitted light was detected using a Vilber 
Chemi-Smart 5000 chemoluminescence imaging system.  
2.8 Liquid chromatography tandem-mass spectrometry (LC-
MS/MS) 
LC-MS/MS analyses in section E2.2.2 were performed by the Core Facility for Mass Spectrometry and 
Proteomics (ZMBH, Heidelberg, Germany). Briefly, immunoprecipitated HSP70/HSC70 proteins were 
separated by 1D SDS-PAGE (NuPAGE Novex 4-12% Bis-Tris, Invitrogen), and the gel area including the 
mass range of the target proteins, was excised and digested by trypsin. Peptides were separated on 
an UltiMate 3000 RSLCnano (Thermo Scientific) using an in-house (ZMBH) packed C18 reversed-
phase column of 35 cm length (140 min gradient from 3% to 40% acetonitril). Peptides were then 
directly injected into a Q Exactive HF Orbitrap LC-MS/MS. Analysis of peptides was performed using 
an untargeted data-dependent approach, in which precursors had been selected according to their 
intensity for MS/MS analysis. In addition, a targeted approach was applied, which allows for the 
detection of specific peptides with higher sensitivity. An inclusion list of masses, calculated from 
theoretical ion masses of possible acetylated tryptic peptides of the target proteins (see above), has 
been added to the analysis to ensure MS/MS acquisition of these targets. MS/MS spectra from all 
samples were using Mascot search engine (version 2.1.0.81) against a manually compiled database 
that contained the sequence of the target proteins. Fragment ion tolerance was set to 20 ppm and 
parent ion tolerance to 10 ppm. Carbamidomethylation of cysteine residues was set as fixed 
modification. Variable modifications were: Deamidation of asparagine, oxidation of methionine and 
acetylation of lysine. MS/MS based peptide and protein identifications were evaluated using Scaffold, 
whereby peptide identifications were accepted if determined at greater than 95.0% probability by 
the Peptide Prophet algorithm with Scaffold delta-mass correction (Keller et al. 2002). Protein 
probabilities were assigned by the Protein Prophet algorithm (Nesvizhskii et al. 2003), and protein 
identifications were accepted if established at greater than 95.0% probability, containing at least one 
identified peptide. Proteins with similar peptides that could not be differentiated via MS/MS analysis 
alone were grouped to meet the principles of parsimony. 
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LC-MS/MS analysis in section E2.3 were performed in the group of Dr. Martina Schnölzer (DKFZ, 
Heidelberg) as follows. 25 µg of protein lysates were separated by 1D SDS-PAGE (NuPAGE Novex 4-
12% Bis-Tris, Invitrogen). Commassie staining was performed according to (Dyballa and Metzger 
2009), and each lane was cut into 21 slices in the molecular weight region between 39 and 97 kDa. 
Tryptic digestion and extraction were performed as previously described (Shevchenko et al. 2006) 
with adaption to the volume of the gel slices. Peptide separation was performed on a nanoAcquity 
UPLC system (Waters GmbH) using a C18 trap column (180 μm ×20 mm, particle size 5 µm; Waters 
GmbH) (Aretz et al. 2013). Liquid chromatography separation was performed on a BEH130 C18 main-
column (100 μ m × 100 mm, particle size 1.7 µm; Waters GmbH) at a flow rate of 0.4 μl/min. Peptides 
from each gel slice were separated by a 1 h gradient consisting of 95.9% water, 4% DMSO, 0.1% 
formic acid (A) and 0.1% formic acid, 99.9% acetonitrile (B) set as follows: from 0 to 4% B in 1 min, 
from 4 to 40% B in 39 min, from 40 to 60% B in 5 min, from 60 to 85% B in 0.1 min, 6 min at 85% B, 
from 85 to 0% B in 0.1 min, and 9 min at 0% B. Separated peptides were injected into a LTQ Orbitrap 
XL mass spectrometer.Data were acquired with XCalibur (version 2.0.7; Thermo Scientific), using scan 
cycles of one FTMS scan with a resolution of 60000 at m/z 400 and a range from 300 to 2000 m/z in 
parallel with six MS/MS scans in the ion trap of the most abundant precursor ions (Michalak et al. 
2016). Peak lists were extracted from raw files using Mascot Daemon and subsequently searched 
against the SwissProt database (SwissProt 2017_04 (554241 sequences; 198410167 residues)) using 
Mascot (v2.4.0) with the following parameters: cysteine carbamidomethylation was used as fixed 
modification; methionine oxidation, deamidation of asparagine and glutamine and acetylation at 
lysine were set as variable modifications. Precursor tolerance was set to 7 ppm and 0.4 Da for 
fragment ions. Enzyme specificity was set to trypsin with an allowed maximum of five missed 
cleavages. 
2.9 HDAC8 activity assay (HDAC-Glo assay) 
All of the following steps were performed in the research group Cancer Drug Development (Dr. Aubry 
Miller, DKFZ Heidelberg). HDAC8 activity was measured in a 384-well format with the HDAC‐Glo™ I/II 
Assay and Screening System, using recombinant HDAC8 enzyme (BPS Bioscience, 50008). Briefly, 250 
ng/ml enzyme were used and inhibitors were used at concentrations ranging from 0.0188 nM to 10 
µM. Enzyme and inhibitors were incubated for 30 minutes at room temperature, followed by 
addition of HDAC‐Glo™ I/II reagent, shaking (800 rpm 30 s), centrifugation (300 x g for 1 min) and 
further incubation for 40 minutes at room temperature. Luminescence was quantified using a BMG 
Labtech CLARIOStar plate reader. Data were normalized to negative controls (30 µM PCI-34051) and 
positive controls (no inhibitor), respectively. IC50 values were calculated using nonlinear regression 
curve fit in GraphPad Prism version 7.04. 
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3 Molecular biological methods 
3.1 RNA extraction from tumor cells 
RNA from neuroblastoma cells was isolated with the QIAGEN RNeasy® Mini Kit according to the 
manufacturer’s instructions. Briefly, cells grown 6-well plates (70 % confluency) were lysed in 350 μl 
RLT buffer supplemented with 1 % -and mixed with an equal volume of 70 % ethanol before 
transfer to the RNeasy Mini Spin column and centrifugation at 10,000 x g for 1 minute. Columns were 
washed once in 350 μl RW1 buffer before on-column DNase digestion for 20 minutes at room 
temperature. Columns were washed again in RW1 buffer and twice in 500 μl RPE buffer, each step 
being followed by a centrifugation step (1-2 minutes 10,000 x g, according to manufacturer's 
instructions). Residual RPE buffer was removed by transfer to a fresh collection tube and high-speed 
centrifugation step at 13,000 x g for 1 minute. After transfer of the RNeasy column to a 1.5 ml 
microcentrifuge tube, RNA was eluted by addition of 40 μl of nuclease-free, followed by 1 minute 
incubation at room temperature and collection of the eluate by centrifugation (13,000 x g for 1 
minute). RNA was stored at -80°C. 
3.2 Determination of RNA concentration 
RNA concentration was determined on a NanoDrop UV spectrophotometer, which measures 
absorbance of light by nucleic acids at 260 nm (OD260/A260) and calculates DNA or RNA concentrations 
via the Beer-Lambert law. An OD260 of 1.0 corresponds to 40 ng/μl RNA. Protein contaminations were 
controlled by measuring absorbance at 280 nm and an OD260/OD280 ratio of 1.8 to 2.0 was considered 
as optimal. Degradation of nucleic acids and contaminations with aromatic solvents was checked for 
by measuring OD260/OD230 ratio, where a ratio between 2.0 and 2.2 was considered as good. 
3.3 Reverse transcription (cDNA synthesis) 
Between 0.5 and 1 µg of RNA were reverse transcribed to cDNA using the ThermoFisher RevertAid 
First Strand cDNA Synthesis Kit. Briefly, the desired amount of RNA was transferred to a PCR tube 
and filled up to 12 µl with 1 µl of oligo (dT) primer and nuclease-free water. After 5 minute 
incubation at 65°C and cooling on ice, the reaction was filled up to 20 µl with reaction mastermix 
containing each 4 µl of 5 x Reaction Buffer, 1 µl RiboLock RNase Inhibitor, 2 µl of 10 mM dNTP Mix 
and 1 µl of M-MuLV reverse transcriptase. The reaction was incubated for 60 minutes at 42°C. For 
longterm storage, samples were kept at -80°C. 
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3.4 Real-time quantitative PCR (RT-qPCR) 
Real-time quantitative PCR allows for both absolute and relative quantification of PCR-amplified DNA 
with the help of fluorescent reporter molecule (e.g. SYBR®-Green I), which upon binding of double-
stranded DNA and excitation with blue light, emits green fluorescence light. Fluorescence of the dye 
increases proportionally with the amount of amplified DNA and the number of PCR cycles required 
until the fluorescence meets a pre-defined fluorescence threshold (Cycle of Threshold/CT value) can 
be used for relative or, with the help of a standard, absolute quantification of the original amount of 
template in the PCR mix. 
Real-time quantitative PCR was performed using the qPCR Mastermix for SYBR® Green I from 
Eurogentec. For each gene of interest, a mastermix was prepared according to Table 60or Table 61, 
25 µl of which were transferred into a 96-well plate per reaction. Each reaction was filled up with 5 µl 
of the respective pre-diluted cDNA (5 ng/µl). The PCR was run on an ABI 7500 Real-Time PCR System 
using the PCR program given in Table 62. Expression of genes was normalized to the averaged 
expression of SDHA and HPRT1, which are constitutively expressed in stage 4 and 4S neuroblastoma 
(Fischer et al. 2005). Relative quantification of gene expression was performed using the 2-CT 
method (Winer et al. 1999; Livak and Schmittgen 2001). 
Reagent Volume [µl] 
2x Reaction Buffer 12.5 
Diluted SYBR® 0.75 
Forward Primer (100 µM) 0.08 
Reverse Primer (100 µM) 0.08 
nuclease-free water 6.59 
cDNA (added in well) 5 
total volume in well 25 
Table 60: 1x RT-qPCR reaction for ThermoFisher primers.  Mastermixes for multiple reactions were prepared 
accordingly without addition of cDNA. 
Reagent Volume [µl] 
2x Reaction Buffer 12.5 
Diluted SYBR® 0.75 
QIAGEN QuantiTect Primers (10x) 2.5  
nuclease-free water 4.25 
cDNA (added in well) 5 
total volume in well 25 
Table 61: 1x RT-qPCR reaction for QIAGEN QuantiTect primers.  Mastermixes for multiple reactions were 
prepared accordingly without addition of cDNA. 
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Stage Step name temperature  time  number of cycles 
Holding stage Uracil N-Gycosylase 
activation 
50°C 2 min 1 
HotGoldStar DNA 
polymerase activation 
95°C 10 min 
Cycling stage denaturation 95°C  15 sec 40 
annealing and elongation 60°C 1 min 
Dissociation 
stage 
complete dissociation 95°C 15 sec 1 
complete annealing 60°C 1 min 
gradual dissociation 95°C 30 sec 
annealing 60°C ----- 
Table 62: RT-qPCR parameters and program.  
3.5 Comet assay (alkaline single cell electrophoresis) 
BE(2)-C cells were seeded at a density of 1.5*106 cells per 10 cm dish and treated with tubastatin A 
+/- doxorubicin for 18h as indicated in the respective figure legend. Untreated and -irradiated cells 
(5 Gy from a 137Cs radiation source, at a dose rate of 1 Gy/min) were used as negative and positive 
control, respectively. Cells were subjected to alkaline single cell electrophoresis as described in 
(Mayer et al. 2002; Greve et al. 2012) with the following modifications: Cells were mixed with 0.7% 
low-melting temperature agarose before plating on two-well CometSlides™ and overnight lysis. 
Single cell electrophoresis was performed on the following day at 4°C. DNA damage was analyzed via 
automated fluorescence microscopy using the Metafer4 cell scanning and imaging platform as 
described in (Schunck et al. 2004). ‘‘Tail DNA in %” was used as parameter to assess DNA damage. 
Statistical evaluation was performed using Mann Whitney test in GraphPad Prism version 5.04. 
4 Generation of HDAC10 antibodies 
4.1 Production of HDAC10 peptides 
All of the following steps were performed in the monoclonal antibody facility (MAF) of the DKFZ. 
Briefly, two fragments corresponding to amino acids 361 to 500 (HDAC10T1) and 501 to 617 
(HDAC10T2) of full-length HDAC10 were PCR amplified from cDNA generated from RNA of BE(2)-C 
cells using the primers indicated in Table 10. The respective fragments were cloned into pQE-8 vector 
using BamHI and HindIII restriction sites for the expression of N-terminally 6x histidine-tagged 
HDAC10T1 and HDAC10T2 protein. Vectors were transformed into chemically competent M15 E. coli 
cells and protein expression was induced by addition of IPTG (60 µM for 3.5h). His-tagged proteins 
were purified using Ni-NTA agarose (QIAGEN) under denaturing conditions (8M Urea). 
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4.2 Immunization of mice and production of murine monoclonal 
HDAC10 antibodies 
Unless otherwise indicated., all of the following steps for the production of HDAC10-reactive 
hybridoma clones were performed in the monoclonal antibody facility (MAF) of the DKFZ. BALB/c 
wild type mice were injected on day zero with 20 µg of Ni-NTA purified HDAC10T2 peptide including 
Freund's complete adjuvant. Immune reactions were boosted by re-injection of antigen on day three 
(including Freund's incomplete adjuvant) and day six (without adjuvant). Mice were sacrificed on day 
8, followed by fusion of B-lymphocytes from popliteal lymph nodes with Sp2/0 myeloma cells using 
polytheylene glycol 1500. Hybridomas were raised as described by (Köhler and Milstein 1975), and 
supernatants were checked for the production of IgG via ELISA starting seven days after fusion. 
HDAC10 reactivity of hybridoma supernatants was analyzed via immunoblot (performed by me as 
described in section C2.7). Antibodies were purified from hybridoma supernatants using Protein G 
sepharose (GE Healthcare). Antibodies were eluted using glycine buffer (pH 10) and dialyzed against 
PBS. 
4.3 Generation of monoclonal HDAC10 antibodies by antibody 
phage display  
Antibody phage display screening allows for the generation of monoclonal antibodies without the 
immunization of animals. To that end, the genetic information of the antigen-binding regions of 
antibodies (variable heavy (VH) and variable light (VL) chains) are PCR-amplified (e.g. from naive 
human B cells) to generate an antibody gene phage display library, and fused to the gene encoding 
for the pIII surface protein of the M13 bacteriophage. Depending on the mode of PCR amplification, 
antibodies are then presented on the surface of the M13 phage either as Fab or scFV fragments. 
Fusing the genetic information of antibody variable regions to the pIII surface protein gene enables 
the generation of a whole library of phage particles, in which the antigen-binding function is 
physically linked to the genetic information that encodes the respective antibody within. The phage 
library allows for biochemical high-throughput affinity screening of antibody binding to any epitope 
in a cell-free assay (so called panning) and, in succession, for the quick production of recombinant 
monoclonal antibodies (reviewed in (Frenzel et al. 2017)). 
The following steps were performed by Saskia Helmsing in the lab of Prof. Dr. Michael Hust 
(Department of Biotechnology, TU Braunschweig, Germany). Antibodies were selected from the 
human naive antibody gene phage display libraries HAL9/10 (Kugler et al. 2015) using microtiter plate 
immobilized antigen (HDAC10T1 and HDAC10T2, see Table 51) as described in (Russo et al. 2018). 
Monoclonal scFvs were produced in microtiter plates and binder antibodies were screened by ELISA 
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as described in (Russo et al. 2018). Subsequently, binding scFvs were recloned into the vector 
pCSE2.6-mIgG2a-Fc-XP, produced as scFv-Fc in Expi293F™ cells (ThermoFisher Scientific) and purified 
by protein A (Jager et al. 2013). 
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D AIMS OF THE STUDY 
Members of the HDAC family are aberrantly expressed in various cancer entities where they support 
numerous cancer relevant cellular processes. Consequently, HDAC inhibitors are of great interest for 
novel anti-tumor treatment regimens. Pan- and broad-spectrum HDAC inhibitors have shown 
promise in the treatment of hematological malignancies such as CTCL and multiple myeloma, and are 
currently being tested in numerous other clinical trials. Their success, however, is ultimately 
restricted by dose-limiting side effects, which are thought to arise from unspecific simultaneous 
inhibition of class I HDACs 1, 2 and 3. Such unspecific side effects can likely be circumvented by the 
inhibition of single HDAC isozymes that have a critical function in the respective tumor entity or 
subtype. HDAC10 is of high relevance in advanced stage neuroblastoma (stage 4), where its inhibition 
promoted sensitization of high-risk neuroblastoma cell lines to chemotherapeutic treatment in a 
previous study. This suggested HDAC10 inhibition as a strategy to reduce chemoresistance, a 
common problem in advanced stages of neuroblastoma. HDAC10 inhibition blocked late autophagic 
flux, i.e. the turnover of autophagic material in lysosomes, and increased intracellular acidic vesicles, 
which led to the hypothesis that HDAC10 governs lysosomal function or biogenesis in neuroblastoma 
cells. As of yet, protein downstream targets of HDAC10 have not been conclusively identified, but 
several studies suggest that class IIb HDACs 6 and 10 bind to and modulate lysine acetylation of 
HSP70 family members. Conversely, a recent study demonstrating poylamine deacetylase activity of 
HDAC10 in biochemical assays raised the question whether polyamines are the primary cellular 
HDAC10 substrates. Finally, while HDAC10 showed promise as a drug target in advanced-stage 
neuroblastoma and as improved HDAC10 inhibitors are currently being developed, mechanistic 
studies and validation of HDAC10 expression on patient tissue are currently hampered by the lack of 
suitable HDAC10 antibodies. The key items of this study thus were to: 
 dissect how class IIb HDAC members HDAC6 and HDAC10 affect lysosomal composition of 
neuroblastoma cells.  
 investigate lysosomal downstream processes upon interference with HDAC6/10 function. 
 analyze lysosomal effector mechanisms and their link to increased chemosensitivity of 
neuroblastoma cells.  
 verify downstream protein or non-protein targets of HDAC10 with a special focus on HSP70 
family members and polyamines in neuroblastoma. 
 generate a novel highly specific HDAC10 antibody suitable for immunofluorescence and 
immunohistochemistry approaches. 
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E RESULTS 
1 HDAC10 and its role in lysosomal homeostasis, 
exocytosis and drug resistance 
Ongoing research focuses on specific functions of single HDAC family members, which can be very 
diverse and often in opposing directions. For example HDAC inhibitors have differential effects on 
autophagy, with some inducing and others blocking autophagy (reviewed in (Koeneke et al. 2015)). In 
this context, a previous report of our research group suggests that HDAC10 is important for 
lysosomal homeostasis and trafficking to lysosomes (Oehme et al. 2013a; Oehme et al. 2013b). The 
latter function has also been associated with the other class IIb HDAC member HDAC6 (Gao et al. 
2010; Lee et al. 2010b). Thus, given the high sequence homology of class IIb HDACs, a function of 
both HDAC6 and HDAC10 in lysosomal homeostasis is conceivable. Nevertheless, non-overlapping 
functions of the two HDACs exist, highlighted by their differential ability to deacetylate tubulin at 
lysine 40 (K40) (Hubbert et al. 2002). The role of class IIb HDACs HDAC6 and HDAC10 in lysosomal 
homeostasis in neuroblastoma was thus investigated in more detail in the following sections.  
1.1 Depletion of HDAC10 but not HDAC6 causes the 
accumulation of lysosomes in neuroblastoma cells 
1.1.1 Knockdown of class IIb HDACs 6 and 10 leads to the accumulation of the 
lysosomal membrane protein LAMP-2 in neuroblastoma cells 
Changes in the lysosomal composition of cells, i.e. an expansion or a shrinkage of the lysosomal 
compartment, can be roughly estimated by analyzing levels of lysosomal markers, such as LAMP-2, 
on western blot. To investigate whether interference with class IIb HDAC function affected lysosomal 
numbers in neuroblastoma cells, HDAC6 and HDAC10 were individually depleted in SK-N-BE(2)-C 
cells, a highly chemoresistant neuroblastoma cell line (hereafter referred to as BE(2)-C) (Gogolin et al. 
2013), using a pool of two siRNAs against either HDAC. Western blot analysis on whole cell lysates 
generated 72h (Figure 7a) and six days (Figure 7b) after siRNA transfection revealed elevated LAMP-
2 levels in case of both HDAC6 and HDAC10 depletion at both time points. Densitometric 
quantification of n=4 experiments in case of six day knockdown revealed that the increase in LAMP-2 
levels was statistically significant in case of either HDAC knockdown. LAMP-2 levels were significantly 
more elevated in case of HDAC10 knockdown compared to HDAC6 knockdown (Figure 7c). 
Substantial cross-reactivity of the used siRNA pools against the respective other HDAC transcript was 
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not observed, ruling out that increased LAMP-2 levels in case of HDAC6 knockdown were due to an 
off-target effect on HDAC10 and vice versa (Figure 7a, b, d). Rather, increased HDAC6 levels were 
repeatedly observed in case of HDAC10 depletion, suggesting that HDAC6 compensates for some of 
the HDAC10 functions. At the same, knockdown of HDAC6 but not HDAC10 increased tubulin 
acetylation, confirming that HDAC6 and HDAC10 have non-redundant functions in spite of their close 
structural relation (Figure 7d). 
As increased LAMP-2 levels were especially striking in case of HDAC10 knockdown, it was 
investigated whether LAMP-2 was upregulated on a transcriptional level via real-time RT-PCR, using 
primers against the LAMP2A transcript (Figure 7e). LAMP2A transcript levels were not reproducibly 
elevated upon HDAC10 knockdown, suggesting that the robustly elevated levels of LAMP-2 protein 
were not caused by de novo expression of the LAMP2 gene but rather by accumulation of lysosomes. 
Taken together, depletion of HDAC6 and especially HDAC10 increased the level of the lysosomal 
marker LAMP-2, pointing towards an enlargement of the lysosomal compartment in neuroblastoma 
cells.  
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1.1.2 Knockdown of HDAC10 but not HDAC6 results in the accumulation of 
acidic lysosomes  
The analysis of LAMP-2 levels after knockdown of HDAC6 and HDAC10 suggested that both class IIb 
HDACs might cause lysosomal accumulation. However, expression of LAMP-2 alone is not sufficient 
for the identification of lysosomes, as it is also expressed on endosomes. Furthermore, lysosomes 
can be highly divergent with regards to their luminal pH (Johnson et al. 2016). Thus, the lysosomal 
phenotype after depletion of HDAC6 and HDAC10 was characterized more closely with the 
acidotropic LysoTracker DND-99 probe. This dye consists of a fluorophor coupled to a weak base, 
which can freely cross membranes at neutral pH but gets trapped when protonated and thus stains 
lysosomes and lysosome-related structures such as endolysosomes or autophagolysosomes 
(Pierzynska-Mach et al. 2014). To demonstrate lysosomal specificity of the dye in BE(2)-C cells, cells 
Figure 7: Knockdown of HDAC6 or HDAC10 promote accumulation of the lysosomal marker LAMP-2 in 
neuroblastoma cells.(a, b) Western blot analysis of LAMP-2 expression72h (a) and 6d (b) after transfection with 
siRNAs against HDAC6 and HDAC10 or control siRNAs. (c) Densitometric quantification of LAMP-2 expression on 
western blot 6d after siRNA transfection (n=4 experiments) .(d) Western blot analysis of tubulin acetylation 72h 
after transfection with siRNAs against HDAC6 and HDAC10. Numbers below the blot indicate expression of the 
respective protein normalized to E-actin (HDAC6/10) and relative to siCtrl, or normalized to total tubulin 
(acetylated tubulin) and relative to siCtrl. (e) Real-time RT-PCR analysis of HDAC10 and LAMP2A transcript 
expression knockdown of HDAC10. Bar graph depicts fold regulation versus cells transfected with control siRNA 
of n=3 experiments. Statistical analyses were performed on non-normalized data using unpaired (c) or paired (e) 
two-tailed t-test (***p < 0.001; **0.001 ≤p <0.01; *0.01 ≤ p < 0.05). Error bars represent standard error of the 
mean (SEM). Parts of figure published in (Ridinger et al. 2018). 
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were treated for 24h with lysosomal inhibitors. Confocal fluorescence microscopy analysis confirmed 
that LysoTracker was localized in perinuclear vesicles under basal conditions. These very likely 
represented lysosomes, which are preferentially located in perinuclear regions due to their 
association with microtubules and the retrograde transport towards the microtubule-organizing 
center (MTOC) (Figure 8a). Treatment for 24h with the lysosomal V-ATPase inhibitor bafilomycin A1, 
which hindered acidification, almost completely abrogated LysoTracker accumulation, while low 
concentrations of chloroquine, a lysosomotropic agent that sequesters lysosomal protons, increased 
vesicular LysoTracker staining. This effect is probably caused by an expansion of the lysosomal 
compartment (Figure 8a), which has been reported for lower doses or short exposures to 
chloroquine (Boya et al. 2003). In contrast, prolonged exposure to higher concentrations of 
chloroquine is known to cause both alkalinization of lysosomes as well as lysosomal membrane 
permeabilization (Boya et al. 2003; Enzenmuller et al. 2013). Accordingly, treatment with 25 µM 
chloroquine reduced lysosomal staining and caused a shift of LysoTracker fluorescence from vesicles 
to cytoplasm and nuclei due to strong alkalinization of lysosomes under this condition (Figure 8a).  
To test if the LysoTracker probe was applicable for medium throughput methods such as flow 
cytometry, mean cellular LysoTracker fluorescence after treatment with lysosomal inhibitors was 
quantified via flow cytometry and compared to microscopy data (Figure 8b-d). Living cells were 
discriminated from cellular debris via forward and side scatter according to Figure 8b. Analogous to 
the microscopic analysis, 24h application of bafilomycin A1 caused a strong reduction in cellular 
LysoTracker fluorescence, while low concentrations of chloroquine (5 µM) increased LysoTracker 
fluorescence (Figure 8c, d). Thus, although lacking the spatial information of fluorescence 
microscopy, flow cytometric quantification of LysoTracker staining served as an estimation of cellular 
lysosomal content. 
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BE(2)-C cells transfected with HDAC10 siRNA pools reproducibly and significantly displayed increased 
LysoTracker accumulation compared to cells transfected with control siRNA. This was not observed in 
case of HDAC6 knockdown. These results were confirmed by the use of another acidotropic dye, 
acridine orange. Similar to LysoTracker dyes, acridine orange is a weak base fluorophor that 
accumulates in acidic vesicles, where protonation leads to trapping of the dye. Trapping and 
accumulation in lysosomes, in turn, causes the metachromatic shift from green to red fluorescence 
(Moriyama et al. 1982; Thome et al. 2016). Analogous to the LysoTracker staining, acridine orange 
accumulated in BE(2)-C cells upon HDAC10 but not HDAC6 knockdown (Figure 9c). Taken together 
with the results described in section E1.1.1, these data indicate that acidic lysosomal vesicles 
accumulate upon HDAC10 but not upon HDAC6 depletion. Thus, HDAC6 and HDAC10 have non-
overlapping functions in lysosomal homeostasis in BE(2)-C neuroblastoma cells. 
Figure 8: Characterization of LysoTracker staining in BE(2)-C cells. (a) Fluorescence microscopic analysis 
LysoTracker DND-99 staining 24h after treatment with lysosomal inhibitor chloroquine (CQ) or vacuolar ATPase 
inhibitor bafilomycin (100 nM). Nuclei were counterstained with DAPI. (b) Flow cytometric gating of BE(2)-C 
neuroblastoma cells according to forward (FSC-A) and side (SSC-A) scatter. (c) Histogram showing flow 
cytometric analysis of LysoTracker staining 24h after treatment with indicated substances. (d) Normalized mean 
LysoTracker fluorescence from flow cytometric analysis (n=2 experiments) 24h after treatment with indicated 
substances. Error bars represent standard deviation (SD).  
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1.1.3 HDAC10 knockdown causes accumulation of acidic lysosomes 
throughout the cytoplasm 
Although LysoTracker dyes are known to accumulate in acidic cellular compartments, the flow 
cytometric data given in section E1.1.2 did not provide spatial information on the subcellular 
LysoTracker distribution after HDAC6 and HDAC10 knockdown and thus could not fully rule out the 
possibility of unspecific LysoTracker accumulation in the cytoplasm under these conditions. Hence, 
HDAC6 and HDAC10 depleted, LysoTracker stained, BE(2)-C cells were also analyzed via confocal 
fluorescence microscopy. LysoTracker accumulated in perinuclear lysosomes in cells transfected with 
control or HDAC6 siRNAs (Figure 10). While no increase in lysosomal number was observed in case of 
HDAC6 knockdown, cells with HDAC10 knockdown contained higher amounts of lysosomal vesicles, 
confirming flow cytometric data from section E1.1.2. In case of HDAC10 knockdown, an increased 
number of lysosomes appeared not only in the perinuclear cloud but also throughout the cytoplasm 
and close to the cell periphery. Taken together, the above described data indicate that depletion of 
class IIb HDAC10 but not HDAC6 causes a substantial enlargement of the lysosomal compartment in 
neuroblastoma cells.  
Figure 9: Knockdown of HDAC10 increases LysoTracker staining in BE(2)-C neuroblastoma cells. (a) Histogram 
showing flow cytometric analysis of LysoTracker staining in BE(2)-C cells 6d after transfection with siRNAs 
against HDAC6 and HDAC10 or with control siRNAs. (b) Mean LysoTracker fluorescence of n=4 experiments 
quantified via flow cytometry. Fluorescence was normalized to fluorescence in siCtrl transfected cells. (c) Flow 
cytometric analysis of acridine orange staining 6d after transfection with siRNAs. Fluorescence of n=3 
experiments was quantified and normalized to cells transfected with control siRNAs. Statistical analyses were 
performed on non-normalized data using paired two-tailed t-test (***p < 0.001; **0.001 ≤p <0.01; *0.01 ≤ p < 
0.05). Error bars represent standard error of the mean (SEM). Parts of figure published in (Ridinger et al. 2018). 
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1.2 Inhibition of class IIb member HDAC10 causes accumulation 
of acidic lysosomes in neuroblastoma cells 
1.2.1 HDAC10 inhibition causes accumulation of acidic lysosomes throughout 
the cytoplasm 
The experiments described in section E1.1 show that depletion of HDAC10 but not HDAC6 increases 
the lysosomal compartment in BE(2)-C cells. This raised the question, if lysosomal accumulation after 
HDAC10 depletion was due to the reduction of enzymatic function of HDAC10. To date, no inhibitor is 
available that selectively blocks HDAC10 function, but various studies suggest that tubastatin A 
(Butler et al. 2010; Oehme et al. 2013a) and bufexamac (Bantscheff et al. 2011) are dual specific 
HDAC6/10 inhibitors while tubacin has a strong preference for HDAC6 (Butler et al. 2010). As no 
deacetylation substrate protein solely specific for HDAC10 has been described, activity of class IIb 
inhibitors tubastatin A and tubacin against HDAC10 could not be investigated on western blot level. 
The affinity of tubastatin A and tubacin towards HDAC10 was therefore assessed in NanoBRET assays 
(performed in the group of Cancer Drug Development (Dr. Aubry Miller) at the DKFZ) (Figure 11a). 
This BRET-based in-cell tracer displacement assay measures the competitive displacement of a 
fluorescently labeled tracer (in this case the pan HDAC inhibitor SAHA) from NanoLuc® luciferase 
coupled HDAC10 enzyme. Tracer displacement reduces the transfer of donor/NanoLuc® fluorescence 
to the acceptor fluorophor (Non-Chloro-TOM/NCT dye) on the tracer. Therefore, a high ratio of 
acceptor to donor signal directly reflects high target engagement by the tracer, while a low ratio 
reflects displacement of the tracer and therefore binding of a competitive inhibitor (Marks et al. 
2011; Robers et al. 2015). NanoBRET analysis of tubastatin A and tubacin binding to HDAC10 in HeLa 
cells confirmed that the suspected dual HDAC6/10 inhibitor tubastatin A had a high affinity towards 
HDAC10 in the low nanomolar range (IC50 approx. 8 nM). In contrast, the suspected HDAC6 specific 
but HDAC10 non-reactive inhibitor tubacin displayed a roughly 200 fold lower affinity towards 
HDAC10 than tubastatin A (IC50 approx. 1600 nM) (Figure 11b). 
SYTOX Green, LysoTracker DND-99
siCtrl siHDAC10
35 µm
siHDAC6
Figure 10: Knockdown of HDAC10 but not HDAC6 causes expansion of the lysosomal compartment in BE(2)-C 
neuroblastoma cells. BE(2)-C cells were stained with LysoTracker DND-99 6d after transfection with siRNAs 
against HDAC6, HDAC10 or control siRNA and analyzed via confocal fluorescence microscopy. Nuclei were 
counterstained with SYTOX Green. Figure published in (Ridinger et al. 2018). 
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In flow cytometric LysoTracker assays performed after 24h treatment of BE(2)-C cells with HDAC6 or 
HDAC6/10 inhibitors, cells treated with dual specific inhibitor tubastatin A displayed significantly 
higher levels of LysoTracker fluorescence than vehicle-treated cells, while 24h application of HDAC6 
inhibitor tubacin had no effect (Figure 12a, b). Treatment with the previously published HDAC6/10 
inhibitor bufexamac (Bantscheff et al. 2011) also substantially increased lysosomal staining in BE(2)-C 
cells. Inhibition of HDAC6 as the cause for lysosomal accumulation under the experimental conditions 
above was further excluded by western blot analysis of tubulin K40 acetylation. Here, 24h treatment 
of BE(2)-C cells with bufexamac, tubastatin A and tubacin collectively induced strong acetylation of 
tubulin, confirming that all three class IIb inhibitors were excellent HDAC6 inhibitors at the 
concentrations used in the LysoTracker experiments (Figure 12c). The HDAC6 inhibitor tubacin even 
induced stronger tubulin acetylation than the HDAC6/10 inhibitor bufexamac while not inducing 
lysosomal accumulation. Thus, lysosomal accumulation was not caused by HDAC6 inhibition. 
Figure 11: In cell target engagement (NanoBRET) assay reveals differential HDAC10 binding capability of 
HDAC6/10 inhibitor tubastatin A and HDAC6 inhibitor tubacin. (a) Principle of the NanoBRET assay. The assay 
measures displacement of a fluorescently (Non-Chloro-TOM/NCT dye) labeled tracer (SAHA) from NanoLuc® 
luciferase coupled HDAC10 enzyme. Tracer displacement reduces the transfer of donor/NanoLuc® fluorescence 
to the acceptor fluorophor on the tracer. (b) Tracer displacement from HDAC10 by tubastatin A and tubacin in 
HeLa cells. Graph depicts tracer signal relative to total NanoLuc signal (% fractional occupancy, y-axis) versus 
logarithmic drug concentration in nM (x-axis). Curves were generated via non-linear curve fitting (variable 
slope) using GraphPad Prism version 5.0. NanoBRET assays were performed by Lars Hellweg in the group of 
Cancer Drug Development (Dr. Aubry Miller) at the DKFZ. Parts of figure published in (Ridinger et al. 2018).  
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Fluorescence microscopic analysis of LysoTracker staining after 24h inhibition of HDAC6 and HDAC10 
further revealed that treatment with HDAC6/10 inhibitors tubastatin A and bufexamac increased the 
number of LysoTracker positive vesicles compared to solvent-treated cells (Figure 13). Analogous to 
the data obtained after HDAC10 knockdown (Figure 10), lysosomal vesicles after HDAC6/10 
inhibition were not restricted to the perinuclear cloud or preferentially localized at the cell periphery, 
but rather spread throughout the cytoplasm. In contrast, specific HDAC6 inhibition caused neither 
accumulation nor re-localization of lysosomes (Figure 13a). 
In line with real-time RT-PCR data, which indicate that interference with HDAC10 function did not 
cause de novo transcription of lysosomal genes, HDAC10 inhibition did not cause translocation of the 
lysosomal master regulator TFEB (see section A3.2.1) to the nucleus (Figure 13b), suggesting that 
HDAC10 inhibition did not cause de novo lysosomal biogenesis via the CLEAR network.  
Taken together with knockdown data described in section E1.1, these data suggest that inhibition of 
HDAC10 but not HDAC6 enzymatic function causes expansion of the lysosomal compartment in 
neuroblastoma cells, likely via the accumulation of lysosomes.  
Figure 12: Inhibition of HDAC10 but not HDAC6 promotes lysosomal accumulation in BE(2)-C neuroblastoma 
cells. (a) Analysis of LysoTracker staining via flow cytometry 24h after treatment with HDAC6/10 inhibitors 
tubastatin A (7.5 μM), bufexamac (30 μM) or HDAC6 inhibitor tubacin (7.5 μM). Fluorescence histogram shows 
percentage of cells (y-axis) versus fluorescence (x-axis). (b) Quantification of mean LysoTracker fluorescence via 
flow cytometry of n=4 experiments. LysoTracker fluorescence was normalized to mean fluorescence in DMSO 
treated cells. (c) Western blot analysis of tubulin K40 acetylation 24h after treatment with HDAC6/10 inhibitors 
(concentrations as described in (a)).Numbers below blot indicate densitometric quantification of acetylated 
tubulin signal versus total tubulin normalized to the DMSO control. Statistical analyses were performed on non-
normalized data using paired two-tailed t-test (***p < 0.001; **0.001 ≤p <0.01; *0.01 ≤ p < 0.05). Error bars 
represent standard error of the mean (SEM). Figure published in (Ridinger et al. 2018).  
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1.2.2 HDAC10 binding and inhibitory capability of tubastatin A derivatives are 
determined by the presence of a nitrogen atom in the inhibitor's cap 
group 
The results described in the previous sections show that HDAC10 but not HDAC6 inhibition causes 
the accumulation of lysosomes in neuroblastoma cells. Previous studies from our lab have further 
identified HDAC10 inhibition as a potential strategy to sensitize neuroblastoma cells to 
chemotherapy, making HDAC10 an attractive target for neuroblastoma therapy. In this context, 
inhibitors with high specificity for HDAC10 over HDAC6 are of great interest, as they allow for the 
precise disentanglement of HDAC6 and HDAC10 specific effects in preclinical studies. As such 
inhibitors are currently not available (see section E1.2.1 Figure 12c and (Bantscheff et al. 2011)), the 
collaborating group of Drug Development (Dr. Aubry Miller) at the DKFZ synthesized a number of 
tubastatin A derivatives with a modified cap group structure in order to perform structure-activity 
Figure 13: Inhibition of HDAC10 but not HDAC6 is followed by an expansion of the lysosomal compartment 
in BE(2)-C neuroblastoma cells. (a) BE(2)-C cells were stained with LysoTracker DND-99 24h after treatment 
with HDAC6/10 inhibitors tubastatin A (7.5 μM), bufexamac (30 μM), HDAC6 inhibitor tubacin (7.5 μM) or 
lysosomal inhibitors chloroquine (5 μM) and bafilomycin (100 nM). (b) BE(2)-C cells were transfected with 
TFEB-EGFP and treated 48h post plasmid transfection with HDAC6/10 inhibitors tubastatin A (7.5 μM), 
bufexamac (30 μM), HDAC6 inhibitor tubacin (7.5 μM) or lysosomal inhibitor chloroquine (25 μM) for 24h. 
Cells in (a, b) were analyzed via confocal fluorescence microscopy. Nuclei were counterstained with DAPI. 
Representative images for each treatment are shown. Parts of figure published in (Ridinger et al. 2018). 
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relationship studies (shown in Figure 14a). NanoBRET testing of HDAC6 and HDAC10 binding capacity 
in HeLa cells (assays performed in the group of Aubry Miller) yielded tubastatin A related compounds 
with significantly altered HDAC10 activity (summarized in Figure 14b). A subset of these derivatives 
was tested for lysosomal accumulation via the LysoTracker assay, as data in section E1.2.1 suggested 
lysosomal accumulation regarded as a functional readout for HDAC10 inhibition in BE(2)-C cells. Their 
ability to induce lysosomal accumulation after overnight treatment was compared to tubastatin A 
using a concentration series that ranged from 0.1 µM to 10 µM. Of note, tubastatin A concentrations 
above 10 µM were highly cytotoxic and reduced lysosomal staining likely due to induction of cell 
death and were thus excluded from further analysis, as they occasionally caused a paradoxical 
decrease in LysoTracker staining (Figure 14c). 
Compounds where a basic nitrogen atom within the tricyclic tetrahydro--carboline cap structure of 
tubastatin A was replaced or removed showed markedly decreased HDAC10 binding capacity in 
NanoBRET assays (Figure 14b). Accordingly, the respective compounds did not induce lysosomal 
accumulation in BE(2)-C cells (Figure 14d). Of these compounds, DKFZ-00494 had reduced HDAC10 
activity but retained full HDAC6 inhibitory capacity, while DKFZ-00495 additionally displayed reduced 
affinity towards HDAC6 in both NanoBRET assays and accordingly on the level of tubulin acetylation 
(Figure 14b, e). The absence of lysosomal accumulation in case of treatment with the DKFZ-00494 
compound despite its full HDAC6 inhibitory capacity again confirmed that lysosomal accumulation 
phenotype described in section E1.2.1 occurred independently of HDAC6 inhibition and was thus a 
good readout for HDAC10 inhibition. Structurally, the DKFZ-00494 compound was characterized by 
the replacement of the basic nitrogen in the tetrahydro--carboline cap structure by a sulphur atom. 
The reduced HDAC10 affinity of the DKFZ-00494 compound suggested that HDAC10 binding capacity 
was likely not due to the nucleophilic nature of the basic nitrogen atom, as replacement with a highly 
nucleophilic sulphur atom strongly reduced HDAC10 binding capacity. Instead, it is possible that the 
nitrogen atom mediates interaction with HDAC10 by other mechanisms, e.g. by forming hydrogen 
bonds with amino acid residues near the HDAC10 catalytic site (discussed in section F1.5 and F2). 
Notably, HDAC10 binding capability did not strictly require the localization of the basic nitrogen atom 
within a tetrahydro--carboline structure, as for example modification of the nitrogen-containing 
heterocyclic structure (DKFZ-00546) did not reduce but rather slightly increased HDAC10 binding 
capability in NanoBRET assays while leaving HDAC6 activity unchanged (Figure 14b). In fact, 
NanoBRET data for DKFZ-00574, a ring-opened tubastatin A analog containing an indazole structure 
in the cap group, also displayed slightly increased HDAC10 activity over tubastatin A. Thus, the 
tetrahydro--carboline itself was not required for HDAC10 activity. Rather, the data suggest that the 
basic amine nitrogen mediates tight binding to HDAC10 via its chemical properties (discussed in 
section F1.5). (Figure 14b). Enhanced HDAC10 and unchanged HDAC6 inhibitory capacity of the 
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DKFZ-00546 and DKFZ-00574 compounds were confirmed in BE(2)-C cells, where both compounds 
induced lysosomal accumulation at lower concentrations than tubastatin A and also caused a higher 
maximal LysoTracker staining, while not displaying substantially changed ability to induce tubulin 
acetylation (Figure 14d, e). 
In summary, these data indicate that the HDAC10 binding capability of tubastatin A and its 
derivatives critically depends on the presence of a basic nitrogen atom within the inhibitor's cap 
group. 
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Figure 14: HDAC10 binding capacity of HDAC6/10 inhibitors is determined by the presence of a basic nitrogen 
atom in the inhibitor's cap group. (a) Structural formula of tubastatin A derivatives, where the basic nitrogen in 
the cap group was ablated (central panel) or modified (right panel). (b) HDAC10 and HDAC6 binding activities 
determined by NanoBRET assays. Tubastatin A derivatives were synthesized and NanoBRET assays were 
performed in HeLa cells in the group of Cancer Drug Development (Dr. Aubry Miller) at the DKFZ. (c, d) Flow 
cytometric analysis of LysoTracker staining in BE(2)-C neuroblastoma cells 24h after treatment with tubastatin 
A (c) and tubastatin A derivatives (d). Graphs depict mean LysoTracker fluorescence normalized to DMSO 
control (y-axis) versus logarithmic concentration (x-axis). Curves were generated using non-linear curve 
fitting(variable slope) in GraphPad Prism version 5.0. (e) Western blot of tubulin acetylation in BE(2)-C cells 24h 
after treatment with tubastatin A and tubastatin A derivatives. Error bars in this figure represent standard error 
of the mean (SEM). 
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1.2.3 Triple HDAC6/8/10 inhibiting tubastatin A derivatives lose their inhibitory 
activity on HDAC6/8/10 in BE(2)-C cells 
Both HDAC8 and HDAC10 have been described as potential drug targets in neuroblastoma and their 
inhibition can promote neuroblastoma cell differentiation and sensitization to chemotherapy, 
respectively (Oehme et al. 2009b; Oehme et al. 2013a; Rettig et al. 2015). Unpublished data show 
that co-inhibition of HDAC8 and 10 in combination with chemotherapy is very efficient in inducing 
cell death in neuroblastoma cell lines (Koeneke, unpublished data), making dual HDAC8/10 inhibition 
an interesting option for neuroblastoma treatment. However, simultaneous application of multiple 
small molecule inhibitors in patients is challenging due to drug interactions and differential drug 
metabolism. The close structural relation of the HDAC6/10 inhibitor tubastatin A and the HDAC8 
specific inhibitor PCI-34051 (Balasubramanian et al. 2008), which mainly differ in the position of the 
Zn2+ binding hydroxamic acid residue (Figure 15a), prompted the idea that synthesis of a chimeric 
molecule carrying two hydroxamic acid moieties and thus resembling both PCI-34051 and tubastatin 
A could circumvent this problem by creating a combined HDAC8/10 inhibitor. Due to its structural 
resemblance to tubastatin A, such an inhibitor would also inhibit HDAC6, thus creating a triple 
HDAC6/8/10 inhibitor. As HDAC6 inhibitors were well tolerated in multiple preclinical and clinical 
studies (Santo et al. 2012; Yee et al. 2016; Vogl et al. 2017), this was not regarded as an exclusion 
criterion for the synthesis of tubastatin A related HDAC8/10 inhibitors (below referred to as triple 
HDAC6/8/10 inhibitors). 
The prototype compound, DKFZ-00477, carried an extra hydroxamic acid at its cap group and thus 
resembled the structure of both tubastatin A and PCI-34051 (Figure 15a). Surprisingly however, 
DKFZ-00477 displayed a 50-fold reduction in HDAC10 binding capacity compared to tubastatin A in 
HeLa cells (NanoBRET assay), as well as a slightly decreased HDAC8 binding capacity (8-fold) 
compared to PCI-34051 in biochemical assays (HDAC-Glo I/II assay) (Figure 15b). Accordingly, no 
lysosomal accumulation was observed when BE(2)-C cells were treated with DKFZ-00477 up to a 
concentration of 30 µM, confirming that it was an ineffective HDAC10 inhibitor in neuroblastoma 
cells (Figure 15c). 
Addition of an extra hydroxamic acid to the cap group of the above described tubastatin A derivative 
DKFZ-00574 (section E1.2.2) yielded the chimeric compound DKFZ-00580, another potential triple 
HDAC6/8/10 inhibitor, while shift of the DKFZ-00574 hydroxamic acid to the cap group yielded the 
PCI-34051 analogous, and thus expectedly HDAC8 specific, DKFZ-00565 (Figure 15a). HDAC-Glo I/II 
(HDAC8) and NanoBRET (HDAC10) data confirmed that the DKFZ-00574 derivative DKFZ-00565 was a 
potent HDAC8 selective inhibitor with low HDAC10 activity (Figure 15b). This was confirmed by 
analysis of the acetylation status of the SMC3 protein in BE(2)-C cells on western blot, a known 
HDAC8 downstream target (Deardorff et al. 2012), where the DKFZ-00565 compound was even 
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slightly more potent than the HDAC8 inhibitor PCI-34051 at concentrations lower than 8 µM (Figure 
15e). As for the DKFZ-00477 compound, biochemical HDAC-Glo assays (HDAC8), as well as NanoBRET 
assays in HeLa cells (HDAC10) again revealed that the chimeric inhibitor had reduced potency on 
HDAC8 (4-fold) and HDAC10 (6.3 fold), respectively, although the loss of potency was not as drastic 
as for the DKFZ-00477 compound (Figure 15b). In marked contrast to NanoBRET data in HeLa cells, 
however, the DKFZ-00580 compound possessed no substantial HDAC10 activity in the LysoTracker 
assay in BE(2)-C cells, where no lysosomal accumulation was observed even at increased 
concentrations up to 30 µM (Figure 15d). Furthermore, DKFZ-00580 did not induce substantial SMC3 
acetylation when used at concentrations up to 64 µM, suggesting that it further did not possess 
HDAC8 activity in BE(2)-C cells (Figure 15e). Analysis of tubulin acetylation revealed a significant drop 
in HDAC6 inhibitory capacity of DKFZ-00580 compared to the DKFZ-00574 compound (Figure 15e). 
Lacking or weak activity against either of the tested HDACs in BE(2)-C cells suggested that addition of 
a second hydroxamic acid residue possibly not only interfered with binding to the respective enzyme 
but also with efficient drug uptake, potentially by increasing polarity and thus reducing diffusion of 
the compound across the plasma membrane. It also appears that the above described chemical 
modifications differentially affected drug uptake between different cell lines, which would explain 
the discrepancies between NanoBRET assays (HeLa cells) and functional HDAC assays (BE(2)-C cells) 
(discussed in section F1.5).  
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Figure 15: Triple HDAC6/8/10 inhibiting tubastatin A derivatives lose their HDAC6/8/10 inhibitory activity. (a) 
Structural formulas showing tubastatin A derivatives with differential placement of the Zn2+ binding hydroxamic 
acid moiety, as well as chimeric, supposed HDAC6/8/10-active inhibitors with two hydroxamic acid groups 
(lower panel). (b) Summary of HDAC10 and HDAC8 binding activities determined by NanoBRET assays (HDAC10) 
and in vitro enzymatic assays (HDAC8). Compounds were synthesized and enzymatic assays were performed in 
the group of Cancer Drug Development (Dr. Aubry Miller) at the DKFZ. (c) Flow cytometric analysis of 
LysoTracker staining after 24h treatment of BE(2)-C cells with tubastatin A or the derivative DKFZ-00477 (n=2 
experiments). Data were normalized to DMSO control. (d) Flow cytometric analysis of LysoTracker staining after 
24h treatment of BE(2)-C cells with indicated compounds (n=2 experiments). Data were normalized to DMSO 
control. Graph depicts normalized mean LysoTracker fluorescence (y-axis) versus concentration (x-axis) Curves 
were generated using non-linear curve fitting (variable slope) in GraphPad Prism version 5.0. (e)  Western blot 
analysis SMC3 (HDAC8 target) and tubulin acetylation in BE(2)-C cells after 24h treatment with indicated 
compounds. PCI-34051 treatment was used as positive control for HDAC8 inhibition. Error bars in this figure 
represent standard error of the mean (SEM). 
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1.2.4 The HDAC6 specific inhibitor MARBOSTAT 100 (MARB1) inhibits 
HDAC10 at higher concentrations 
MARBOSTAT 100 (hereafter referred to as MARB1) is a novel HDAC6 specific inhibitor that is 
structurally closely related to tubastatin A (Figure 16a), but has stronger selectivity for HDAC6 than 
previous HDAC6 inhibitors, as suggested in a recent report (Sellmer et al. 2018). NanoBRET assays in 
HeLa cells confirmed that MARB1 displays high affinity towards HDAC6 (IC50 2.2 nM), with reduced 
affinity towards HDAC10 (IC50 564 nM) compared to tubastatin A (IC50 8 nM) (Figure 16b). Analysis of 
tubulin K40 acetylation via western blot further demonstrated strong HDAC6 inhibitory capacity of 
MARB1 in BE(2)-C cells, inducing robust tubulin acetylation above concentrations of 10 nM after 
overnight treatment (Figure 16c). The results in the previous sections (E1.2.1 and E1.2.2) have shown 
that HDAC10 but not HDAC6 inhibition in BE(2)-C cells causes accumulation of lysosomes. Thus, the 
HDAC10 inhibitory capacity of MARB1 in BE(2)-C cells was analyzed by flow cytometric quantification 
of LysoTracker staining. MARB1 caused lysosomal accumulation at concentrations above 1 µM (EC50 
6.6 µM), suggesting that MARB1 also had HDAC10 inhibitory capacity at high concentrations in BE(2)-
C cells (Figure 16d). Notably, while NanoBRET assays in HeLa cells showed a roughly 70-fold reduced 
affinity of MARB1 to HDAC10 over tubastatin A, LysoTracker analysis revealed a mere 2.3 fold shift in 
EC50, possibly reflecting differential uptake of the two drugs in different cell systems. In this context, 
the data in the previous section (E1.2.3) suggest that even small modifications like the addition of a 
second hydroxamic acid moiety can cause significant discrepancies in drug uptake between different 
cell models. In this case, the chemical modification introduced in MARB1 might have affected drug 
uptake more drastically in HeLa than in BE(2)-C cells. 
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1.2.5 The pan HDACi abexinostat has a high affinity towards HDAC10 and 
causes lysosomal accumulation at clinically relevant concentrations 
Collective evidence suggests that lysosomes are important mediators of chemoresistance in cancer 
making lysosomes an attractive target for clinical intervention (Kirkegaard and Jaattela 2009; 
Zhitomirsky and Assaraf 2016). The data described in section E1.1 and E1.2 show that interference 
with HDAC10 function alters lysosomal composition of neuroblastoma cells. Moreover, a previous 
publication from our lab shows that interference with HDAC10 function can reduce chemoresistance 
of neuroblastoma cells, making HDAC10 an interesting target for neuroblastoma therapy (Oehme et 
al. 2013a). However, none of the above tested HDAC10 inhibitors is currently used in clinical trials, 
and future clinical trials are for example hampered by their unfavorable pharmacokinetic profile 
(discussed in section F1.5.). Thus, either FDA approved or Phase I/II tested pan and broad-spectrum 
Figure 16: The tubastatin A derivative MARB1 binds HDAC10 at high concentrations and causes lysosomal 
expansion in BE(2)-C cells. (a) Structural formula of HDAC6/10 inhibitor tubastatin A and supposed HDAC6-
specific inhibitor MARBOSTAT 100 (MARB1). MARB1 was synthesized in the lab of Siavosh Mahboobi (Institute 
of Pharmacy, University of Regensburg). (b) NanoBRET analysis of MARB1 binding activity against HDAC6 and 
HDAC10 in HeLa cells. Graph depicts tracer signal relative to total NanoLuc signal (% fractional occupancy, y-
axis) versus logarithmic drug concentration in nM (x-axis). NanoBRET assays were performed in the group of 
Cancer Drug Development (Dr. Aubry Miller) at the DKFZ. (c) Western blot analysis of tubulin acetylation after 
24h treatment of BE(2)-C cells with tubastatin A and MARB1, respectively. Experiment was performed in 
collaboration with Fiona Kolbinger (Clinical Cooperation Unit, DKFZ). (d) Analysis of LysoTracker fluorescence via 
flow cytometry 24h after treatment with MARB1. Graph depicts mean LysoTracker fluorescence normalized to 
DMSO treated cells (y-axis) versus logarithmic drug concentration (x-axis). Curves in figures (b) and (d) were 
fitted via non-linear curve fitting (variable slope) using GraphPad Prism version 5.0. Statistical analysis in (d) 
was performed on non-normalized data using paired two-tailed t-test (***p < 0.001; **0.001 ≤p <0.01; *0.01 ≤ 
p < 0.05). Error bars represent standard error of the mean (SEM). Parts of figure published in (Ridinger et al. 
2018). 
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HDAC inhibitors were tested for their activity on HDAC10 in NanoBRET assays. Here, the pan inhibitor 
abexinostat (PCI-24781) (Figure 17a) displayed high HDAC10 activity in the nanomolar range (IC50 
0.74 nM) (Figure 17b). Analogous to other compounds with HDAC10 inhibiting activity (sections 
E1.2.1 and E1.2.4), abexinostat induced expansion of the lysosomal compartment in BE(2)-C cells 
(Figure 17d). Here, abexinostat was especially efficient, inducing lysosomal expansion at nanomolar 
concentrations with an EC50 of 183 nM. Importantly, the concentration at which abexinostat 
interfered with lysosomal homeostasis was well within the range of clinically achievable 
concentrations in patients, which can reach up to 500 nM (Morschhauser et al. 2015). Thus, the pan 
HDAC inhibitor abexinostat is capable of inhibiting HDAC10 and causing lysosomal accumulation at 
concentrations that are achievable in patient plasma, making it a promising compound for HDAC10 
inhibition in future pre-clinical and clinical trials. 
 
Figure 17: The pan HDAC inhibitor abexinostat (PCI-24781) shows strong activity on HDAC10 in NanoBRET 
and LysoTracker assays. (a) Structural formula of abexinostat. (b) NanoBRET analysis of abexinostat binding 
activity against HDAC6 and HDAC10 in HeLa cells. Graph depicts tracer signal relative to total NanoLuc signal (% 
fractional occupancy, y-axis) versus logarithmic drug concentration in nM (x-axis). NanoBRET assays were 
performed in the group of Cancer Drug Development (Dr. Aubry Miller) at the DKFZ. (c) Analysis of LysoTracker 
fluorescence via flow cytometry after 24h treatment of BE(2)-C neuroblastoma cells with abexinostat. Graph 
depicts mean LysoTracker fluorescence normalized to DMSO treated cells (y-axis) versus logarithmic drug 
concentration (x-axis). Curves in figures (b) and (c) were generated via non-linear curve fitting (variable slope) 
using GraphPad Prism version 5.0. Statistical analysis in (c) was performed on non-normalized data using paired 
two-tailed t-test (***p < 0.001; **0.001 ≤p <0.01; *0.01 ≤ p < 0.05). Error bars represent standard error of the 
mean (SEM). Parts of figure published in (Ridinger et al. 2018). 
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1.3 Non class IIb HDACs and their role in lysosomal homeostasis 
1.3.1 Knockdown of class I, class IIb and class IV HDACs reveal that HDACs 
10 and 11 most strongly influence lysosomal composition in BE(2)-C cells 
Data in section E1.2.2 have shown that treatment of BE(2)-C neuroblastoma cells with tubastatin A 
causes lysosomal accumulation at concentrations above 1 µM and that the lysosome-expanding 
property of tubastatin A could be attributed to its HDAC10 rather than HDAC6 inhibitory activity. 
Although tubastatin A is considered as a specific class IIb inhibitor in the literature, a binding to class I 
HDACS (especially HDAC1 (reported IC50 16.4 µM)) at high concentrations cannot be fully ruled out 
(Butler et al. 2010). In fact, western blot analysis confirmed that 24h treatment of BE(2)-C cells with 
high concentrations of tubastatin A (10 µM) increased histone H3 acetylation, a target of HDACS 1, 2 
and 3, suggesting that it interfered with functions class I HDACs at high concentrations (Figure 18a). 
Thus, in order to investigate how interference with the function of individual class I HDACs affected 
the lysosomal compartment, HDACs 1, 2, 3 were knocked down in BE(2)-C cells using pooled siRNAs 
against the respective HDAC. Knockdown of class IV member HDAC11 was included due to the 
relationship of its catalytic domain to both class I and class II HDACS (Gao et al. 2002; Seto and 
Yoshida 2014). Lysosomal content was analyzed via flow cytometric quantification of LysoTracker 
staining six days after siRNA transfection. Here, knockdown of all individual HDACs slightly induced 
lysosomal accumulation in BE(2)-C cells (Figure 18b). However, when averaged over three 
experimental replicates, only HDAC10 knockdown increased lysosomal numbers on a statistically 
significant level. Apart from HDAC10, knockdown HDACs 1 and 11 caused the most substantial 
increase in lysosomal staining, almost reaching statistical significance (p = 0.09 and p = 0.07, 
respectively). This suggested that, apart from HDAC10, HDACs 1 and 11 potentially contributed to 
lysosomal homeostasis in BE(2)-C cells. Nevertheless, interference with HDAC10 function most clearly 
caused lysosomal accumulation. 
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1.3.2 The class I inhibitor MS-275 causes lysosomal accumulation while 
valproic acid does not 
The data provided in section E1.3.1 show that HDAC6/10 inhibitor tubastatin A induces histone H3 
acetylation and thus likely inhibited class I HDACs at high concentrations. Moreover, knockdown of 
individual class I HDACs slightly, but not statistically significantly, induces lysosomal accumulation. 
This raised the question whether simultaneous inhibition of class I HDACs 1, 2, 3 could cause 
significant expansion of the lysosomal compartment in neuroblastoma cells. In order to investigate 
this, BE(2)-C cells were treated with valproic acid, a class I HDAC inhibitor (Wagner et al. 2013), or 
HDAC6/10 inhibitor tubastatin A for 24h and analyzed for lysosomal content via the LysoTracker 
assay. Here, valproic acid did not induce substantial lysosomal accumulation, while treatment with 
the HDAC6/10 inhibitor tubastatin A did (Figure 19a). At the same time, western blot analysis 
revealed that VPA treatment induced a much stronger increase in histone H3 acetylation (5.3 fold) 
than treatment with tubastatin A (1.3 fold) (Figure 19b). This again confirmed that lysosomal 
accumulation in case of tubastatin A treatment was most likely due to its HDAC10 inhibitory activity 
and not because of off-target activity on class I HDACs. Surprisingly, 24h treatment with MS-275, 
another class I HDAC inhibitor (Wagner et al. 2013), caused strong accumulation of lysosomes in 
preliminary experiments and it was thus suspected that MS-275 could have HDAC10 inhibitory 
activity (Figure 19c). NanoBRET analyses, however, did not show any binding activity of MS-275 
against class IIb HDAC members HDAC6 or HDAC10 even at micromolar concentrations, excluding 
that its effects on the lysosomal compartment were due to an HDAC10 inhibitory activity (Figure 
19d). Although expansion of the lysosomal compartment after MS-275 treatment cannot be fully 
Figure 18: Analysis of lysosomal accumulation after RNAi-mediated knockdown of class I HDACs, as well as 
HDAC10 and HDAC11. (a) Western blot analysis of tubulin acetylation after 24h treatment of BE(2)-C cells with 
various tubastatin A doses. (b) Flow cytometric analysis of LysoTracker staining 6d after knockdown of indicated 
HDACs. Bar graph depicts mean LysoTracker fluorescence normalized to siCtrl transfected cells of n=3 
experimental replicates. Statistical analysis in (b) was performed on non-normalized data using paired two-
tailed t-test (***p < 0.001; **0.001 ≤p <0.01; *0.01 ≤ p < 0.05). Error bars represent standard error of the mean 
(SEM). Parts of figure published in (Ridinger et al. 2018). 
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explained, knockdown data in section E1.3.1 and data from class I inhibitor valproic acid (Figure 19a) 
make it unlikely that lysosomal accumulation after MS-275 treatment was due to its inhibitory effect 
on class I HDACs. Notably, MS-275 treatment was highly cytotoxic even at low concentrations, 
suggesting that an off-target effect could be responsible for lysosomal accumulation. In addition, the 
inhibitory activity of MS-275 on HDAC11 has not been characterized, and data in section E1.3.1 
suggest that interference with HDAC11 function can also cause lysosomal accumulation (discussed in 
section F1.1). 
 
Figure 19: Analysis of lysosomal accumulation after treatment of BE(2)-C neuroblastoma cells with class I 
HDAC inhibitors valproic acid (VPA) and MS-275. (a) Normalized fluorescence of LysoTracker staining 24h after 
treatment of BE(2)-C cells with VPA and tubastatin A (n=4 flow cytometry experiments). (b) Western blot 
analysis of histone H3 acetylation after 24h treatment of BE(2)-C cells with VPA and tubastatin A. Numbers 
below the blot indicate densitometric analysis of acetylated histone H3 signal normalized to total histone H3. (c) 
Flow cytometric analysis of LysoTracker staining 24h after treatment of BE(2)-C cells with MS-275 and 
tubastatin A (n=2 experiments). (d) NanoBRET analysis of MS-275 binding activity against HDAC6 and HDAC10 
in HeLa cells. Graph depicts tracer signal relative to total NanoLuc signal (% fractional occupancy, y-axis) versus 
logarithmic drug concentration in nM (x-axis). NanoBRET assays were performed in the group of Cancer Drug 
Development (Dr. Aubry Miller) at the DKFZ. Statistical analysis in (a) was performed on non-normalized data 
using paired two-tailed t-test (***p < 0.001; **0.001 ≤p <0.01; *0.01 ≤ p < 0.05). Error bars represent standard 
error of the mean (SEM). Parts of figure published in (Ridinger et al. 2018). 
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1.4 Interference with HDAC10 function causes doxorubicin 
accumulation in neuroblastoma cells  
Altered lysosomal function has been repeatedly associated with cancer progression and therapy 
resistance. With regards to the latter, collective evidence suggests that enlargement of the lysosomal 
compartment can reduce the efficacy of many clinically chemotherapeutic drugs, including 
doxorubicin. Drugs with weakly basic chemical properties can, after passively entering lysosomes, 
become protonated and sequestered within lysosomes, preventing them from reaching their cellular 
drug target (see section A3.2.3). Moreover, lysosomes can promote the secretion of sequestered 
drugs when they undergo lysosomal exocytosis (Machado et al. 2015). Given the observation that 
interference with HDAC10 function caused an enlargement of the lysosomal compartment (see 
section E1), it was hypothesized that enlargement of the lysosomal compartment could be 
accompanied by increased intracellular accumulation or lysosomal sequestration of doxorubicin, one 
of the most important chemotherapeutic agents used in high-risk neuroblastoma therapy. 
1.4.1 HDAC10 but not HDAC6 depletion causes intracellular doxorubicin 
accumulation  
To investigate if lysosomal accumulation after interference with HDAC10 function altered cellular 
doxorubicin levels, BE(2)-C neuroblastoma cells were transfected with siRNAs against HDAC10, 
HDAC6 and control siRNAs, respectively. Cells were treated with doxorubicin for the last 24h and 
cellular doxorubicin fluorescence was quantified via flow cytometry. Knockdown of HDAC10 
increased cellular doxorubicin fluorescence roughly 1.5-fold when compared to cells transfected with 
control siRNAs (Figure 20a, b). In contrast, depletion of HDAC6 caused a significant, albeit, small 
reduction of intracellular doxorubicin levels (Figure 20a, b). Thus, expansion of the lysosomal 
compartment after HDAC10 depletion in BE(2)-C cells described in section E1.1.2 correlated with 
increased intracellular accumulation of doxorubicin. 
The effects of HDAC10 depletion on doxorubicin accumulation was confirmed in a commercially 
generated near-haploid chronic myeloid leukemia (CML) cell line with an HDAC10 knockout (HAP1 
HDAC10 KO). HDAC10 knockout cells accumulated slightly, but significantly, higher levels of 
doxorubicin than HAP1 wild type cells (HAP1 wt) (Figure 20c-e). 
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1.4.2 HDAC10 but not HDAC6 inhibition causes accumulation of doxorubicin in 
a panel of highly aggressive neuroblastoma cell lines 
The results described in section E1.1 show that enlargement of the lysosomal compartment was not 
only observed in case of HDAC10 depletion but also when HDAC10 enzymatic function was inhibited. 
Given that lysosomal accumulation correlated with increased intracellular doxorubicin levels upon 
HDAC10 depletion, it was hypothesized that HDAC10 inhibition should cause a similar intracellular 
doxorubicin accumulation. The influence of HDAC6 and HDAC6/10 inhibitors on cellular doxorubicin 
accumulation was investigated by 48h co-treatment of BE(2)-C cells with doxorubicin and HDAC6 or 
HDAC6/10 inhibitors. Both HDAC6/10 inhibitors bufexamac and tubastatin A increased intracellular 
doxorubicin levels significantly compared to cells treated with doxorubicin and solvent only (Figure 
21a, b). In contrast, specific inhibition of HDAC6 with tubacin did not alter intracellular doxorubicin 
levels, suggesting that increased doxorubicin accumulation after co-treatment with HDAC6/10 
inhibitors was due to HDAC10 rather than HDAC6 inhibition (Figure 21a, b). In line with this, co-
treatment with doxorubicin and MARB1 elevated doxorubicin levels only at concentrations, at which 
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Figure 20: Depletion of HDAC10 but not HDAC6 causes intracellular accumulation of doxorubicin. (a, b) Flow 
cytometric analysis of cellular doxorubicin fluorescence in BE(2)-C cells 6d after siRNA transfection. Cells were 
treated with doxorubicin for the last 24h. Histogram (a) depicts percentage of cells (y-axis) versus logarithmic 
fluorescence (x-axis). Mean doxorubicin fluorescence normalized to siCtrl transfected cells of n=5 experiments 
was quantified (b). (c, d) Flow cytometric analysis of cellular doxorubicin fluorescence in HAP1 wild type versus 
HDAC10 knockout cells. Figures show representative histogram (c) and mean doxorubicin fluorescence 
normalized to wild type cells of n=6 experiments (d). (e) Western blot analysis of HDAC10 expression in HAP1 
cells. Statistical analyses were performed on non-normalized data using paired two-tailed t-test (***p < 0.001; 
**0.001 ≤p <0.01; *0.01 ≤ p < 0.05). Error bars represent standard error of the mean (SEM). Figure published in 
(Ridinger et al. 2018). 
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MARB1 had strong inhibitory activity on HDAC10 and at which robust lysosomal induction was 
observed (Figure 21c) (5 μM and higher, also see Figure 16). MARB1 had no effect on doxorubicin 
accumulation at lower concentrations which still clearly inhibited HDAC6 (Figure 21c and Figure 16c). 
Thus, in line with the effects described for HDAC10 knockdown in section E1.4.1, doxorubicin 
accumulation after HDAC10 inhibition correlated with the before observed enlargement of the 
lysosomal compartment (also see section E1.2.1). Elevated doxorubicin levels were also observed 
when BE(2)-C cells were co-treated with the pan-HDAC inhibitor abexinostat (Yang et al. 2011; Choy 
et al. 2015; Morschhauser et al. 2015). Data in section E1.2.5 show that abexinostat had strong 
HDAC10 inhibitory activity and caused lysosomal accumulation at concentrations greater than or 
equal to 100 nM (Figure 17c). Increased doxorubicin accumulation was observed, when abexinostat 
was used at concentrations that caused strong lysosomal accumulation (equal to or greater than 
500 nM). 
 
Figure 21: HDAC10 but not HDAC6 inhibition promotes intracellular 
accumulation of doxorubicin. (a, b) Quantification of cellular 
doxorubicin fluorescence via flow cytometry after 48h treatment of 
BE(2)-C cells with 100 ng/ml doxorubicin +/- HDAC6/10 inhibitors 
tubastatin A (7.5 μM), bufexamac (30 μM) and HDAC6 inhibitor tubacin 
(7.5 μM). Representative histogram displaying percentage of cells (y-
axis) versus logarithmic doxorubicin fluorescence (x-axis) (a), as well as 
mean doxorubicin fluorescence of n=4 experiments normalized to cells 
treated with doxorubicin and solvent only (b) are shown. (c, d) Cellular 
doxorubicin fluorescence after 24h treatment of BE(2)-C cells with 100 
ng/ml doxorubicin +/- MARB1 (n=4 experiments) (c) or +/- abexinostat 
(n=5 experiments) (d). Statistical analyses were performed on non-
normalized data using paired two-tailed t-test (***p < 0.001; **0.001 
≤p <0.01; *0.01 ≤ p < 0.05). Error bars represent standard error of the 
mean (SEM). Parts of figure published in (Ridinger et al. 2018). 
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Co-treatment with tubastatin A also increased doxorubicin levels in other high-risk neuroblastoma 
cell lines, including IMR-32 and SK-N-AS cells (Figure 22a, b), albeit the effect in IMR-32 cells was 
small (1.2-fold increase), possibly due to low endogenous HDAC10 expression in this cell line 
(investigated in section E1.4.3).  
Taken together, these data show that interference with HDAC10 function, either by depletion or 
inhibition, increases intracellular accumulation of doxorubicin, which is likely connected to the 
before observed enlargement of the lysosomal compartment after interference with HDAC10 
function. 
 
1.4.3 HDAC10 protein levels in neuroblastoma cell lines are not predictive of 
doxorubicin accumulation 
HDAC10 inhibition in the IMR-32 neuroblastoma cell line only caused a comparably small increase in 
intracellular doxorubicin when compared to BE(2)-C or SK-N-AS cells (section E1.4.2). As IMR-32 cells 
are known to express low endogenous levels of HDAC10, it was hypothesized that HDAC10 protein 
levels might serve as a predictive marker of doxorubicin accumulation after HDAC10 inhibition. 
The analysis of HDAC10 expression in a panel of neuroblastoma cell lines showed that BE(2)-C and 
SK-N-AS cells expressed relatively high amounts of HDAC10 protein, while expression in IMR-32 was 
low (Figure 23a). Notably, the two MYCN amplified high-risk neuroblastoma cell lines (Kelly, NB-1) 
showed intermediate levels of HDAC10 protein expression and it was hypothesized that co-treatment 
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Figure 22: HDAC6/10 inhibitor tubastatin A also promotes doxorubicin accumulation in high-risk 
neuroblastoma cell lines other than BE(2)-C. (a) Quantification of cellular doxorubicin fluorescence in IMR-32 
cells via flow cytometry after co-treatment with 50 ng/ml doxorubicin +/- HDAC6/10 inhibitor tubastatin A 
(7.5 µM) for 18h (n=5 experiments). (b) Quantification of cellular doxorubicin fluorescence in SK-N-AS cells 
after via flow cytometry after co-treatment with 100 ng/ml doxorubicin +/- tubastatin A (7.5 µM) for 48h (n=4 
experiments). Bar graphs depict doxorubicin fluorescence normalized. Statistical analyses were performed on 
non-normalized data using paired two-tailed t-test (***p < 0.001; **0.001 ≤p <0.01; *0.01 ≤ p < 0.05). Error 
bars represent standard error of the mean (SEM). Figure published in (Ridinger et al. 2018). 
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of these cell lines with doxorubicin and tubastatin A should cause an intermediate increase in 
intracellular doxorubicin levels. However, co-treatment of neither Kelly nor NB-1 cells with tubastatin 
A reproducibly increased intracellular doxorubicin levels compared to cells treated with doxorubicin 
and solvent only (Figure 23b). Thus, HDAC10 protein levels did not predict doxorubicin accumulation 
after HDAC10 inhibition.  
Intriguingly, HDAC10 inhibition with tubastatin A and bufexamac did not induce lysosomal 
accumulation in NB-1 and Kelly cells, the latter being known to react only to high concentrations of 
bufexamac (Oehme et al. 2013a) (Figure 23c). Accordingly, lysosomal accumulation in Kelly and NB-1 
was also absent upon treatment with the pan HDAC inhibitor abexinostat (Figure 23d) The lack of 
lysosomal compartment expansion after HDAC10 inhibition possibly explains the lack of doxorubicin 
accumulation under these conditions, as above described data suggest that expansion of the 
lysosomal compartment was a prerequisite to doxorubicin accumulation. Although it remained 
unclear why interference with HDAC10 function caused lysosomal accumulation in some but not 
other neuroblastoma cell lines, it is conceivable that HDAC10 is not equally required for lysosomal 
homeostasis in all of the used cell lines (discussed in sections F1.1, F1.2 and F1.3). Furthermore, the 
question remains whether such a bottleneck behavior can be predicted by the activation of certain 
pathways or by gene expression patterns (prospective biomarker, discussed in section F1.3 and F1.5). 
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1.4.4 Both vesicular and nuclear levels of doxorubicin are increased after 
HDAC10 inhibition in BE(2)-C cells 
Lysosomes can trap weakly basic chemotherapeutics such as doxorubicin and thereby reduce their 
efficacy (Zhitomirsky and Assaraf 2015; Zhitomirsky and Assaraf 2017). The data described in section 
E1.2.1 show that HDAC10 inhibition increased lysosomal numbers in a set of neuroblastoma cells, 
which was accompanied by increased levels of intracellular doxorubicin. Therefore, HDAC10 
inhibition might promote doxorubicin resistance by promoting its sequestration in lysosomes, which 
would stand in marked contrast to our previous study that demonstrated sensitization of 
Figure 23: HDAC10 protein expression does not predict increased doxorubicin accumulation after addition of 
HDAC6/10 inhibitor tubastatin A. (a) Western blot analysis of HDAC6 and HDAC10 expression in various high-
risk neuroblastoma cell lines. (b) Flow cytometric analysis of doxorubicin accumulation in Kelly (n=6 
experiments) and NB-1 (n=4 experiments) neuroblastoma cell lines after 48h co-treatment with 100 ng/ml 
doxorubicin and 7.5 μM tubastatin A. Mean doxorubicin fluorescence was normalized to cells treated with 
doxorubicin and solvent only. (c) Flow cytometric analysis of LysoTracker staining after 24h treatment with 
HDAC6/10 inhibitors tubastatin A (7.5 μM), bufexamac (30 μM), HDAC6 inhibitor tubacin (7.5 μM) and 
lysosomal inhibitor chloroquine (5 μM). Mean fluorescence of n=3 experiments was normalized to DMSO 
treated cells. (d) Flow cytometric analysis of LysoTracker staining in various neuroblastoma cell lines after 24h 
treatment with pan HDAC inhibitor abexinostat (n=1 experiment). Graph depicts mean Lysotracker fluorescence 
normalized to DMSO treated cells (y-axis) versus abexinostat concentration (x-axis). Curves were generated via 
non-linear curve fitting (variable slope) using GraphPad Prism version 5.0. Statistical analyses were performed 
on non-normalized data using paired two-tailed t-test (***p < 0.001; **0.001 ≤p <0.01; *0.01 ≤ p < 0.05). Error 
bars represent standard error of the mean (SEM).  
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neuroblastoma cell lines to chemotherapy by HDAC10 inhibition (Oehme et al. 2013a). Subcellular 
doxorubicin localization in BE(2)-C cells was thus analyzed via confocal microscopy in presence or 
absence of tubastatin A. In cells treated with doxorubicin and solvent only, doxorubicin was mainly 
localized in the nucleus and, to a lesser extent, in perinuclear vesicles, which were presumably 
lysosomes (Figure 24a). Co-treatment with doxorubicin and HDAC6/10 inhibitor tubastatin A 
increased localization of doxorubicin in vesicles, and, as seen with lysosomal vesicles in section 
E1.2.1, doxorubicin positive vesicles were not restricted to perinuclear areas. The acquisition of z-
stack images, showed that cells co-treated with doxorubicin and tubastatin A also displayed a high 
number of strongly condensed and highly doxorubicin positive nuclei in a higher z-stage, likely 
representing nuclei of cells that are on the brink of cell death (Figure 24b). These highly doxorubicin 
positive nuclei were only rarely observed in case of treatment with doxorubicin and solvent only 
(Figure 24c). This suggested that HDAC10 inhibition blocked doxorubicin secretion rather than 
promoting its lysosomal sequestration, in turn increasing doxorubicin levels both in lysosomal 
vesicles and nuclei. Moreover, the data indicate that doxorubicin was leaking from lysosomes either 
by lysosomal permeabilization or passively by diffusion over time. Finally, the increased amounts of 
highly condensed nuclei after combination treatment reflected the onset of cell death, thereby 
confirming previously published data that combination of doxorubicin with HDAC6/10 inhibitors 
sensitizes neuroblastoma cells to doxorubicin treatment (also see section E1.9). 
 
Figure 24: HDAC10 inhibition promotes doxorubicin accumulation in
vesicles and nuclei of BE(2)-C cells. (a, b) Analysis of doxorubicin 
localization in BE(2)-C cells after 24h treatment with 250 ng/ml 
doxorubicin +/- tubastatin A (7.5 μM). Images in (a) and (b) represent
different position of z-stack image series, with (a) depicting cells with 
intact nuclei in the lower z-plane and (b) depicting damaged nuclei 
(presumably from dying cells) in the higher z-plane that were only 
present upon co-treatment with tubastatin A. Nuclei were 
counterstained with DAPI. (c) Manual quantification of nuclei of dying 
cells normalized to total nuclei (including lower z-plane). Bar graph 
depicts % of damaged nuclei versus total nuclei of n=3 experiments. 
Figure published in (Ridinger et al. 2018). 
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1.4.5 HDAC10 inhibition does not promote lysosomal membrane 
permeabilization (LMP) 
The finding that HDAC10 inhibition not only increased lysosomal but also nuclear doxorubicin levels 
(section E1.4.4) raised the question whether HDAC10 inhibition caused the permeabilization of 
lysosomes, leading to the release of doxorubicin into the cytosol. To address this point, BE(2)-C cells 
were treated for 24h with HDAC6/10 inhibitors tubastatin A and bufexamac and release of cathepsin 
proteases from lysosomes into the cytosol was quantified in a cathepsin release assay. Here, the 
plasma membrane was permeabilized with low doses of digitonin (15 μg/ml), a concentration at 
which cytosolic extraction is achieved without permeabilization of lysosomes (Appelqvist et al. 2012); 
Koeneke unpublished). High doses of digitonin inducing permeabilization of both plasma- and 
lysosomal membranes (200 μg/ml) served as positive control. Cathepsin activity was then quantified 
by the turnover of a cathepsin substrate, which upon cleavage releases fluorescent AFC (amino-4-
trifluoromethyl coumarin). HDAC6/10 inhibition occasionally caused cathepsin release into the 
cytosol in some but not all experiments. Thus, the increase of cathepsin release was not statistically 
significant (Figure 25). Although these results demonstrate that HDAC10 inhibition was unlikely to 
induce massive LMP, it cannot be excluded that incomplete LMP occurred (discussed in section F1.2). 
In this context, recent studies show that, depending on the extent of LMP, cathepsins are not 
necessarily released from lysosomes, whereas other molecules, such as reactive oxygen species or 
smaller proteins, are (Ellegaard et al. 2015; Repnik et al. 2017). Further, a partial permeabilization of 
a small subset of lysosomes cannot be ruled out. 
 
Figure 25: Inhibition of HDAC10 does not reproducibly induce cathepsin release from lysosomes. 
Quantification of cathepsin substrate turnover (AFC release) over 17 kinetic cycles after 24h treatment of BE(2)-
C cells with HDAC6/10 inhibitors tubastatin A (7.5 μM) and bufexamac (30 μM). Cathepsin release was 
quantified after addition of 15 μg/ml digitonin in order to selectively permeabilize the plasma membrane. 
Addition of 200 μg/ml digitonin was used as a positive control.  
 
RESULTS 113 
1.5 HDAC10 inhibition does not promote cellular doxorubicin 
accumulation via P-glycoprotein inhibition 
Cancer cells can acquire chemoresistance through the upregulation of various drug efflux pumps that 
are members of the ATP-binding cassette (ABC) transporter family (Gottesman et al. 2002). These 
ATP-driven pumps recognize and drive efflux of a broad and partly overlapping set of substrates that 
include many first line cancer therapeutics including vinca alkaloids, anthracyclines and taxanes, a 
phenomenon often referred to as multidrug resistance (MDR). Not surprisingly, high expression of 
either of these transporters has been repeatedly linked to poor prognosis in various cancer entities 
including neuroblastoma (Michaelis et al. 2009). 
1.5.1 P-glycoprotein is expressed on the surface of neuroblastoma cells and 
promotes the secretion of doxorubicin  
The finding that HDAC10 inhibition caused intracellular accumulation of doxorubicin in 
neuroblastoma cells raised the question whether HDAC6/10 inhibitors interfered with P-glycoprotein 
function/expression. BE(2)-C cells showed substantial expression of P-glycoprotein on their cell 
surface in flow cytometric measurements. (Figure 26a). In order to test if P-glycoprotein was 
involved in doxorubicin efflux from BE(2)-C cells, cells were transfected with pool of siRNAs against P-
glycoprotein four days before addition of doxorubicin for the last 24h. P-glycoprotein knockdown 
efficiently reduced cell surface P-glycoprotein protein levels (Figure 26b), as well as total protein 
(Figure 26c) and transcript levels (Figure 26d) compared to cells transfected with control siRNAs. 
Flow cytometric quantification of cellular doxorubicin showed that BE(2)-C cells with P-glycoprotein 
knockdown accumulated roughly 1.3-fold higher levels of doxorubicin (Figure 26e). The effect of P-
glycoprotein knockdown was confirmed by the P-glycoprotein inhibitor verapamil. Here, verapamil 
treated BE(2)-C cells displayed roughly 2.5-fold higher levels of doxorubicin when compared to DMSO 
treated cells (Figure 26f). These data indicate that P-glycoprotein participates in the disposal of 
doxorubicin from BE(2)-C cells. 
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1.5.2 Increased doxorubicin accumulation in BE(2)-C cells after HDAC10 
inhibition is not caused by interference with P-glycoprotein transport or 
function  
To test whether HDAC10 inhibition interfered with P-glycoprotein transport to the plasma 
membrane, the effect of HDAC6/10 inhibitors tubastatin A and bufexamac on cell surface P-
glycoprotein levels was analyzed via flow cytometry in BE(2)-C cells. Treatment of BE(2)-C cells with 
tubastatin A did not decrease surface levels of P-glycoprotein, nor did treatment with bufexamac 
(Figure 27a). Rather, a significant increase of surface P-glycoprotein levels was detected in case of 
treatment with tubastatin A, P-glycoprotein inhibitor verapamil or lysosomal exocytosis inhibitor 
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Figure 26: The ABC transporter P-glycoprotein promotes doxorubicin secretion from BE(2)-C neuroblastoma 
cells. (a, b) Flow cytometric analysis of surface P-glycoprotein expression on BE(2)-cells 5d after siRNA 
transfection. Representative histogram depicting percentage of cells (y-axis) versus logarithmic antibody 
fluorescence (x-axis) (a) and surface P-glycoprotein expression normalized to siCtrl transfected cells of n=5 
experiments (b) are shown. (c) Western blot analysis of total P-glycoprotein expression in BE(2)-C cells 5d after 
siRNA transfection. (d) Real-time RT-PCR analysis of P-glycoprotein transcript (ABCB1/P-GP) expression in BE(2)-
C cells 5d after transfection of siRNA normalized to cells transfected with control siRNAs (n=1 experiment). (e) 
Flow cytometric analysis of intracellular doxorubicin in BE(2)-C cells transfected with P-glycoprotein and control 
siRNAs. Data were normalized to doxorubicin fluorescence in siCtrl cells. (f) Flow cytometric analysis of 
doxorubicin fluorescence in BE(2)-C cells after 24h treatment with 100 ng/ml doxorubicin +/- P-glycoprotein 
inhibitor (10 µM verapamil) normalized to cells treated with doxorubicin and solvent only. Statistical analysis 
was performed on non-normalized data using paired two-tailed t-test (***p < 0.001; **0.001 ≤p <0.01; *0.01 ≤ 
p < 0.05). Error bars represent standard error of the mean (SEM). Parts of figure published in (Ridinger et al. 
2018). 
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vacuolin-1, although the increase in surface expression was small and thus likely not substantial 
(Figure 27a). Thus, increased doxorubicin accumulation was not caused by impaired transport of P-
glycoprotein to the plasma membrane.  
Flow cytometric quantification of cellular doxorubicin levels in BE(2)-C cells transfected with P-
glycoprotein and control siRNAs, respectively, showed that tubastatin A increased doxorubicin levels 
in both P-glycoprotein knockdown and control cells relative to treatment with doxorubicin and 
solvent only (Figure 27b). Notably, P-glycoprotein knockdown cells accumulated significantly higher 
levels of doxorubicin after HDAC10 inhibition than cells transfected with control siRNAs (Figure 27b). 
However, as shown in section E1.5.1, P-glycoprotein knockdown cells accumulated higher 
doxorubicin levels already in their basal state. Thus, doxorubicin levels after HDAC10 inhibition were 
normalized to the respective basal doxorubicin levels of P-glycoprotein knockdown and control cells. 
Normalization revealed that tubastatin A equally promoted doxorubicin accumulation in P-
glycoprotein knockdown and control cells (Figure 27c). In contrast, P-glycoprotein inhibitor verapamil 
displayed reduced efficacy on doxorubicin accumulation in cells with reduced levels of its substrate 
P-glycoprotein (Figure 27a). Taken together, these data indicate that intracellular doxorubicin 
accumulation after HDAC10 inhibition was not caused by interference with P-glycoprotein function.  
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Figure 27: HDAC10 inhibition promotes doxorubicin accumulation in BE(2)-C cells independent of P-
glycoprotein (P-gp). Cell surface P-glycoprotein levels in BE(2)-C cells were analyzed via flow cytometry 24h 
after treatment with HDAC6/10 inhibitors tubastatin A (7.5 µM), bufexamac (30 µM), HDAC6 inhibitor tubacin 
(7.5 µM), P-glycoprotein inhibitor verapamil (10 µM) and lysosomal exocytosis inhibitor vacuolin-1 (10 µM). 
Mean fluorescence was normalized to cells treated with DMSO. (b) Flow cytometric analysis of intracellular 
doxorubicin accumulation 5d after siRNA transfection. Cells were treated for the last 24h with doxorubicin (100 
ng/ml) +/- tubastatin A (7.5 µM) or verapamil (10 µM). Mean fluorescence normalized to doxorubicin 
fluorescence in DMSO treated siCtrl transfected cells is depicted (n=5 experiments). (c) Graph depicts data from 
graph (b) normalized to siCtrl transfected and siP-gp transfected cells, respectively. Statistical analysis was 
performed on non-normalized data using paired two-tailed t-test (***p < 0.001; **0.001 ≤p <0.01; *0.01 ≤ p < 
0.05). Error bars represent standard error of the mean (SEM). Figure published in (Ridinger et al. 2018). 
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1.6 HDAC10 promotes lysosomal exocytosis 
1.6.1 Lysosomal exocytosis inhibition increases doxorubicin accumulation in 
neuroblastoma cells but not in fibroblasts 
The results described in the previous section show that doxorubicin accumulation after HDAC10 
inhibition is likely independent of P-glycoprotein function. Given the observation that interference 
with HDAC10 function leads to an expansion of the lysosomal compartment (section E1) and in light 
of the fact that recent publications suggest lysosomal exocytosis as a mechanism of lysosome-
mediated drug resistance, it was hypothesized that HDAC10 promoted doxorubicin secretion via this 
mechanism. Cells that undergo lysosomal exocytosis characteristically have high levels of the 
lysosomal marker LAMP-1 at their plasma membrane (Rodriguez et al. 1997), and flow cytometric 
quantification of plasma membrane LAMP-1 levels allows for the quantification of lysosomal 
exocytosis rates (Chakrabarti et al. 2003).  
BE(2)-C cells had substantial amounts of LAMP-1 at their cell surface, suggesting that lysosomal 
exocytosis was occurring in this cell line (Figure 28a). Moreover, treatment of BE(2)-C cells with the 
lysosomal exocytosis inhibitor vacuolin-1 for 1h significantly reduced cell surface LAMP-1 levels, 
while total cellular LAMP-1 levels remained unchanged (Figure 28a, b). The specificity of the FACS 
staining for LAMP-1 was verified using siRNAs directed against LAMP-1, which was expectedly 
followed by a drop of plasma membrane and total LAMP-1 levels (Figure 28c, also see Figure 29b). 
Addition of vacuolin-1 to doxorubicin treated cells for 1h or 24h caused a significant increase in 
cellular doxorubicin levels, indicating that BE(2)-C cells very likely used lysosomal exocytosis as a 
mechanism to dispose of doxorubicin (Figure 28d). In contrast, addition of vacuolin-1 did not raise 
intracellular doxorubicin levels in proliferating human fibroblasts from juvenile donors (Figure 28e), 
even though literature data show that lysosomal exocytosis occurs in fibroblasts (Rodriguez et al. 
1997). Preliminary data from two experiments confirmed that the fibroblasts used in this study also 
exhibited basal levels of lysosomal exocytosis, as substantial cell surface LAMP-1 levels were 
detected and surface LAMP-1 levels were reduced by addition of vacuolin-1 for 1h (Figure 28f). 
However, the effect was smaller than in BE(2)-C cells (Figure 28f). Therefore, lacking doxorubicin 
accumulation in fibroblasts was not due to the absence of lysosomal exocytosis in these cells and the 
cause for this behavioral difference remained unknown (discussed in section F1.3). Regardless, the 
differential behavior of fibroblasts and neuroblastoma cells with respect to doxorubicin accumulation 
after lysosomal exocytosis inhibition indicates that highly chemoresistant tumor cells might 
preferentially use and depend on lysosomal exocytosis as a way to dispose of chemotherapeutic 
drugs, allowing for a certain degree of tumor specificity when targeting this process. 
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Figure 28: Inhibition of lysosomal exocytosis promotes doxorubicin accumulation in BE(2)-C neuroblastoma 
cells. (a) Analysis of surface LAMP-1 staining in BE(2)-C cells via flow cytometry after 1h treatment with 
lysosomal exocytosis inhibitor vacuolin-1 (10 μM). Representative fluorescence histogram depicting 
percentage of cells (y-axis) versus fluorescence (x-axis) (left panel) and surface LAMP-1 levels normalized to 
DMSO treated cells of n=3 experiments (right panel). (b) Western blot analysis of total LAMP-1 expression in 
BE(2)-C cells after vacuolin-1 treatment. (c) LAMP-1 antibody specificity was tested on BE(2)-C cells transfected 
with LAMP-1 siRNAs six days after transfection. Histogram depicts percentage of cells (y-axis) versus 
logarithmic fluorescence (x-axis). (d) Flow cytometric analysis of doxorubicin fluorescence in BE(2)-C cells. Cells 
were treated with 100 ng/ml doxorubicin for 24h +/- 10 μM vacuolin-1 for 1h and 24h, respectively. Graph 
depicts doxorubicin fluorescence normalized to cells treated with doxorubicin and solvent only. (e) Cellular 
doxorubicin fluorescence in BE(2)-C cells versus fibroblasts was quantified via flow cytometry. Both cell types 
were treated for 24h with 100 ng/ml doxorubicin +/- 10 μM vacuolin-1. Fluorescence was normalized to the 
respective treatment condition with doxorubicin and solvent only. (f) Analysis of cell surface LAMP-1 
expression in fibroblasts via flow cytometry after 1h treatment with 10 μM vacuolin-1. Representative 
fluorescence histogram depicting percentage of cells (y-axis) versus fluorescence (x-axis) (left panel) and 
surface LAMP-1 levels normalized to DMSO treated cells of n=2 experiments (right panel). Statistical analysis 
was performed on non-normalized data using paired two-tailed t-test (***p < 0.001; **0.001 ≤p <0.01; *0.01 
≤ p < 0.05). Error bars represent standard error of the mean (SEM). Parts of figure published in (Ridinger et al. 
2018). 
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1.6.2 Interference with HDAC10 function reduces lysosomal exocytosis rates 
The data provided in the previous section show that interference with lysosomal exocytosis in BE(2)-
C neuroblastoma cells promotes cellular doxorubicin accumulation similar to HDAC10 depletion or 
inhibition, prompting the idea that HDAC10 was involved in lysosomal exocytosis. In order to test this 
hypothesis, BE(2)-C cells were transfected with siRNAs against HDAC10 and HDAC6, respectively, as 
well as with control siRNAs. Six days after transfection, cells were analyzed for presence of LAMP-1 at 
the plasma membrane via flow cytometry. Here, cells with HDAC10 knockdown showed substantially 
decreased surface LAMP-1 levels, while the amount of surface LAMP-1 was slightly but not 
significantly increased upon HDAC6 knockdown (Figure 29a). This correlated with the finding that 
siRNA-mediated depletion of HDAC10 but not HDAC6 promoted doxorubicin accumulation in BE(2)-C 
cells (section E1.4.1), suggesting a link between doxorubicin accumulation and reduced lysosomal 
exocytosis rates. Analysis of total LAMP-1 protein levels via western blot showed that knockdown of 
HDAC10 did not reduce, but rather slightly increased total cellular LAMP-1 levels (Figure 29b). This 
demonstrated that trafficking of LAMP-1 to the cell surface, and thus likely lysosomal exocytosis 
rates rather than LAMP-1 expression, was reduced upon depletion of HDAC10.  
A similar phenotype was observed when HDAC10 enzymatic function was inhibited. Here, 6h 
treatment of BE(2)-C cells with HDAC6/10 inhibitors tubastatin A and bufexamac slightly but 
significantly reduced cell surface LAMP-1 levels, while treatment with HDAC6 specific inhibitor 
tubacin had no significant effect (Figure 29c). This indicated that HDAC10 but not HDAC6 enzymatic 
function promoted lysosomal exocytosis in BE(2)-C cells.  
The data described in section E1.6.1 show that lysosomal exocytosis inhibition did not promote 
doxorubicin accumulation in human fibroblasts. In line with this, fibroblasts did not display increased 
doxorubicin levels upon co-treatment with doxorubicin and HDAC6/10 inhibitors tubastatin A or 
bufexamac (Figure 29d). This, however, could not be attributed to failure of HDAC6/10 inhibitors to 
reduce lysosomal exocytosis in fibroblasts. Preliminary data of LAMP-1 surface staining in fibroblasts 
showed that HDAC6/10 inhibitors tubastatin A and bufexamac were capable of reducing LAMP-1 
surface level and thus of inhibiting lysosomal exocytosis (Figure 29e), even though this effect was 
smaller than in BE(2)-C cells (Figure 29e). Therefore, the mechanistic reason for the discrepancy in 
doxorubicin accumulation between fibroblasts and BE(2)-C neuroblastoma cells after lysosomal 
exocytosis inhibition remained elusive (discussed in section F1.3) 
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1.6.3 Kinetic experiments show that HDAC10 inhibition decreases rates of 
doxorubicin secretion 
Given that HDAC10 inhibition reduced lysosomal exocytosis rates in BE(2)-C cells, it was hypothesized 
that HDAC10 inhibition causes a delay in doxorubicin secretion and thus entails a longer retention of 
doxorubicin within cells. To test this hypothesis, a washout approach was performed, where BE(2)-C 
cells were pre-incubated for 12h with HDAC6/10 inhibitors and subsequently stained with high 
doxorubicin concentrations (1 μg/ml) for 3h. Doxorubicin was removed after 3h, cells were washed in 
Figure 29: Interference with HDAC10 function inhibits lysosomal exocytosis. (a) Quantification of surface 
LAMP-1 levels in BE(2)-C neuroblastoma cells via flow cytometry 6d after transfection with siRNAs. Histogram 
depicts percentage of cells (y-axis) versus logarithmic fluorescence (x-axis) of one representative experiment. 
Bar graph depicts mean surface LAMP-1 expression normalized to siCtrl transfected cells of n=3 experiments. (b) 
Western blot analysis of total LAMP-1 levels in BE(2)-C cells 6d after transfection with respective siRNAs. (c) 
Flow cytometric analysis of surface LAMP-1 levels after 6h treatment of BE(2)-C cells with HDAC6/10 inhibitors 
tubastatin A (7.5 μM), bufexamac (30 μM), HDAC6 inhibitor tubacin (7.5 μM). Lysosomal exocytosis inhibitor 
vacuolin-1 (10 μM) was added for 1h where indicated. Data of n=4 experiments are shown. (d) Flow cytometric 
analysis of doxorubicin accumulation in fibroblasts after 48h treatment with 100 ng/ml doxorubicin +/- 
HDAC6/10 inhibitors tubastatin A (7.5 μM), bufexamac (30 μM), tubacin (7.5 μM) or P-glycoprotein inhibitor 
verapamil (10 μM). Data of n=3 experiments were normalized to cells treated with doxorubicin and DMSO. (e) 
Flow cytometric analysis of surface LAMP-1 expression in fibroblasts treated for 6h with tubastatin A (7.5 μM), 
bufexamac (30 μM), tubacin (7.5 μM) and lysosomal exocytosis inhibitor vacuolin-1 (10 μM). Bar graph depicts 
mean fluorescence of n=2 experiments normalized to DMSO treated cells. Statistical analysis was performed on 
non-normalized data using paired two-tailed t-test (***p < 0.001; **0.001 ≤p <0.01; *0.01 ≤ p < 0.05). Error 
bars represent standard error of the mean (SEM). Parts of figure published in (Ridinger et al. 2018). 
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medium and HDAC6/10 inhibitors were re-added. Cellular doxorubicin levels were quantified via flow 
cytometry at the time of doxorubicin removal (t0), as well as 3h (t3h) and 6h (t6h) after doxorubicin 
removal (Figure 30a). In case of HDAC10 inhibition with bufexamac or tubastatin A, cellular 
doxorubicin levels were already increased at t0, which was not the case when HDAC6 was inhibited 
with tubacin (Figure 30b). These findings are in line with the observations described in section E1.4.2 
where doxorubicin accumulation after HDAC10 inhibition was observed at later timepoints.  
Cells that had undergone pre-incubation with HDAC6/10 inhibitors tubastatin A and bufexamac 
indeed showed higher levels of cellular doxorubicin at t3h and t6h, and this was also observed when 
lysosomal exocytosis inhibitor vacuolin-1 was added after doxorubicin removal (Figure 30c, d). 
However, since doxorubicin levels were already considerably increased at t0 in case of treatment with 
tubastatin A and bufexamac, data were normalized to the cellular doxorubicin fluorescence at t0 of 
the given treatment condition. Thus Figure 30e, f shows the remaining doxorubicin fluorescence as a 
percentage of the fluorescence at t0. Normalization clearly showed that treatment with HDAC6/10 
inhibitors bufexamac and tubastatin A caused a significantly higher retention of doxorubicin at t3h 
and t6h, respectively. In marked contrast, HDAC6 specific inhibitor tubacin had no effect on 
doxorubicin retention. 
Taken together, these data show that inhibition of HDAC10 but not HDAC6 slows down secretion of 
doxorubicin in BE(2)-C cells, most likely by reducing lysosomal exocytosis rates.  
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Figure 30: Doxorubicin secretion is slowed down after inhibition of HDAC10 but not HDAC6. (a) Timeline of the 
washout experiment. BE(2)-C neuroblastoma cells were pre-incubated for 12h with HDAC6/10 inhibitors 
tubastatin A (7.5 μM), bufexamac (30 μM) and HDAC6 inhibitor tubacin (7.5 μM) before addition of high dose 
doxorubicin (1 μg/ml) for 3h. After doxorubicin washout, cellular fluorescence was quantified via flow cytometry 
at 0h (t0h), 3h (t3h) and 6h (t6h) after doxorubicin removal. (b) Doxorubicin fluorescence at t0h. Unnormalized data 
of n=3 experiments are shown. (c, d) Doxorubicin fluorescence at t3h (c) and t6h (d) of n=3 experiments without 
normalization to fluorescence at t0h. (e, f) Doxorubicin fluorescence at t3h (e) and t6h (f) after normalization to the 
respective fluorescence at t0h. Statistical analysis was performed on non-normalized data using unpaired two-
tailed t-test (***p < 0.001; **0.001 ≤p <0.01; *0.01 ≤ p < 0.05). Error bars represent standard error of the mean 
(SEM). Parts of figure published in (Ridinger et al. 2018). 
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1.7 Lysosomal accumulation after HDAC10 inhibition is possibly 
linked to inhibition of lysosomal exocytosis 
The finding that HDAC10 promotes lysosomal exocytosis, led to the hypothesis that the before 
observed accumulation of lysosomes after HDAC10 inhibition is a consequence of lysosomal 
exocytosis inhibition. To test, whether reduced rates of lysosomal exocytosis caused the 
accumulation of lysosomes, BE(2)-C cells were treated with lysosomal exocytosis inhibitor vacuolin-1 
for 1h and 24h, respectively, and analyzed for lysosomal content via flow cytometric evaluation of 
LysoTracker staining. Either treatment period significantly increased LysoTracker staining compared 
to cells treated with DMSO, indicating that lysosomal exocytosis inhibition caused accumulation of 
lysosomes (Figure 31a). To test if lysosomal exocytosis inhibition was upstream of lysosomal 
accumulation, a flux experiment was performed, where lysosomal exocytosis was inhibited via 
treatment with vacuolin-1 and combined with tubastatin A (Figure 31b). Under the assumption that 
lysosomal exocytosis was fully inhibited under the given conditions (10 μM vacuolin-1 for 24h), an 
increase in lysosomes in case of combination treatment versus vacuolin-1 treatment alone would 
speak in favor of de novo biogenesis of lysosomes upon HDAC10 inhibition. Addition of tubastatin A 
to vacuolin-1 did not significantly increase LysoTracker staining when compared to vacuolin-1 
treatment alone (Figure 31b). These results indicated that lysosomal exocytosis inhibition, and not de 
novo biogenesis of lysosomes, is the cause of lysosomal accumulation upon HDAC10 inhibition. 
 
Figure 31: Lysosomal exocytosis inhibition causes the accumulation of lysosomes in BE(2)-C cells. (a) Flow 
cytometric analysis of LysoTracker staining after 1h and 24h treatment with lysosomal exocytosis inhibitor 
vacuolin-1 (10 μM). Bar graph depicts normalized LysoTracker fluorescence normalized to DMSO treated cells. 
(b) Flow cytometric analysis of LysoTracker staining after 24h treatment with HDAC6/10 inhibitor tubastatin A 
(7.5 μM), vacuolin-1 (10 μM) and the respective combination. Statistical analysis was performed on non-
normalized data using paired two-tailed t-test (***p < 0.001; **0.001 ≤p <0.01; *0.01 ≤ p < 0.05). Error bars 
represent standard error of the mean (SEM). Figure published in (Ridinger et al. 2018). 
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1.8 Autophagy contributes to doxorubicin secretion in 
neuroblastoma, but only under three-dimensional culturing 
conditions 
1.8.1 Autophagy does not contribute to doxorubicin secretion in 2D 
neuroblastoma monolayer cultures 
Recent evidence suggests that lysosomal exocytosis is not a purely lysosomal event, but also includes 
other organelle or vesicle pools, such as autophagosomes and autophagolysosomes (Feeney et al. 
2013). This raised the question whether autophagic vesicles contributed to the secretion of 
doxorubicin in neuroblastoma cells. Moreover, a study from our lab suggests a role for HDAC10 in 
late stage autophagic flux, where interference with HDAC10 function caused accumulation of 
autophagosomes (Oehme et al. 2013a). It was therefore conceivable that this pool of 
autophagosomes possibly contributed to doxorubicin secretion. 
In order to test this hypothesis, BE(2)-C cells were transfected with siRNAs against ATG5, a key 
protein in autophagosome formation (see section A3.2.2). Knockdown of ATG5 inhibits the 
autophagic pathway by interfering with autophagosome formation (Singh et al. 2009; Mizushima et 
al. 2010). In the case of autophagosomal contribution to doxorubicin secretion, cells should display 
increased doxorubicin levels in case of ATG5 depletion mediated autophagy disruption. Flow 
cytometric analysis of intracellular doxorubicin fluorescence showed that 2D grown BE(2)-C cells with 
ATG5 knockdown did not display increased doxorubicin levels when compared to cells transfected 
with control siRNAs (Figure 32a, b). Increased doxorubicin accumulation was also not observed in 
case of HDAC10 inhibition with tubastatin A (Figure 32a). Thus, autophagy or autophagosomes did 
not contribute to doxorubicin secretion in 2D cultured neuroblastoma cells, neither under basal nor 
under HDAC10-inhibited conditions. 
 124
RESULTS 
  
1.8.2 Neuroblastoma cells grown in 3D show elevated levels of autophagy and 
partially depend on autophagy for the secretion of doxorubicin 
Most cell culture tumor models are cultivated as flat 2D monolayers. These conditions are clearly 
different from the in vivo situation with regards to cell-cell contacts, cell signaling and cell 
morphology (Levinger et al. 2014). Moreover, blood, oxygen and nutrient supplies to certain tumor 
areas are restricted in vivo due to the three-dimensional growth of tumors. This, in turn, subjects a 
subset of bulk tumor cells to stress such as lack of oxygen or starvation. Activation of autophagy 
under stress conditions has been shown to protect tumor cells from cell death and promote tumor 
growth (Strohecker et al. 2013). In this context, a recent study from our group has demonstrated that 
neuroblastoma cells transcriptionally activate autophagy when grown in three-dimensional cultures 
and that autophagy protects neuroblastoma cells from chemotherapeutic treatment (Bingel et al. 
2017). This raised the question whether autophagy could contribute to doxorubicin secretion under 
these, autophagy-activated, conditions. When cultivated under three-dimensional conditions in 
collagen type I coated ridged scaffolds (MatriGrid) (Weise et al. 2013), BE(2)-C cells form spheroid 
structures (see Figure 1b in Bingel et al., 2017). In the respective study, cells grown in 3D displayed 
slightly higher rates of conversion of the autophagosome marker LC3-I to the autophagosome-bound 
LC3-II under basal conditions, indicating that autophagy was increased under 3D conditions. LC3-II 
accumulation was strongly increased in 3D cells when the lysosomal V-ATPase inhibitor bafilomycin 
A1 was added, which blocks fusion of autophagosomes to lysosomes and stops turnover of 
autophagosomes. Stronger accumulation of autophagosomes in 3D versus 2D grown cells confirmed 
an increased basal autophagic flux in 3D grown BE(2)-C cells (see Figure 5h in Bingel et al., 2017). 
Figure 32: Knockdown of ATG5 does not cause doxorubicin accumulation in two-dimensionally cultured BE(2)-
C cells. (a) Flow cytometric analysis of cellular doxorubicin fluorescence 72h after transfection with siRNAs 
against ATG5 and control siRNAs, respectively. Cells were treated with doxorubicin (100 ng/ml) for the last 24h 
Bar graph shows mean doxorubicin fluorescence normalized to DMSO treated siCtrl transfected cells of n=3 
experiments. (b) Western blot analysis of ATG5 knockdown. Statistical analysis was performed on non-
normalized data using paired two-tailed t-test (***p < 0.001; **0.001 ≤p <0.01; *0.01 ≤ p < 0.05). Error bars 
represent standard error of the mean (SEM).  
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To monitor autophagic flux in the spheroid itself, the green fluorescent cationic amphiphilic tracer 
(CAT) dye Cyto-ID was used, which, according to supplier information and literature data, stains 
autophagosomes while only negligibly staining lysosomes (Chan et al. 2012). To test if the Cyto-ID 
dye indeed stained autophagosomes rather than lysosomes, BE(2)-C cells were treated with low 
doses of lysosomal inhibitor chloroquine (CQ), a lysosomal inhibitor that interferes with the turnover 
of autophagic substrate in autolysosomes and at low concentrations leads to expansion of the 
lysosomal compartment, as well as with saturating concentrations of bafilomycin A1 which de-
acidifies lysosomes (see section E1.1.2). Under bafilomycin treated conditions, an autophagosome 
dye should display increased staining despite the disruption of lysosomal pH, as bafilomycin 
treatment causes the accumulation of autophagosomes, as shown by accumulation of the 
autophagosome marker LC-3II and the autophagosomal cargo receptor SQSTM1/p62 on western blot 
(Figure 33a). Flow cytometric and fluorescence microscopic analysis of Cyto-ID staining, however, 
revealed that, similar to LysoTracker staining described in section E1.1.2, bafilomycin decreased 
Cyto-ID fluorescence, while low doses of CQ caused a fluorescence increase (Figure 33b, c). Thus, 
Cyto-ID was more likely an autophagolysosome or lysosome specific dye than a specific 
autophagosome dye.  
Regardless, analysis of Cyto-ID staining via confocal immunofluorescence microscopy revealed that 
Cyto-ID positive cells were largely located in the inner zone of the tumor spheroid, suggesting that 
(autophago-)lysosomes and thus increased autophagic flux occurred in tumor cells within the 
spheroid (Figure 33d). This was even more apparent when CQ was added for the last 24h in order to 
block turnover of autophagolysosomes. Here, 3D grown BE(2)-C cells were highly positive for Cyto-ID 
in inner areas of the tumor spheroid. Taken together, these data show that BE(2)-C cells display 
elevated levels of autophagy when grown in 3D conditions. 
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Two dimensional and 3D-grown BE(2)-C cells displayed a remarkable difference with regards to Cyto-
ID staining under conditions where ATG5 was depleted and cells were additionally treated with CQ 
(Figure 33e, f). Under 2D conditions, cellular Cyto-ID fluorescence did not differ under CQ treatment 
between ATG5 knockdown and control cells, suggesting there was no difference in 
autophagolysosomal content. In contrast, siATG5 cells displayed lower Cyto-ID staining as control 
cells when they were grown under 3D conditions for the last 72h and CQ was added (Figure 33e). It is 
Figure 33: (Autophago-)lysosomal staining with the Cyto-ID dye shows that 3D-cultured BE(2)-C cells 
accumulate (autophago-)lysosomes in the inner section of the spheroid. (a) Western blot analysis of LC3 
conversion (left) and accumulation of the autophagosomal cargo receptor SQSTM1/p62 after 24h treatment with 
bafilomycin (100 nM). (b, c) Flow cytometric (n=1 experiment) (b) and immunofluorescence (c) analysis of Cyto-ID 
staining in BE(2)-C cells after 24h treatment with lysosomal inhibitor chloroquine and V-ATPase inhibitor 
bafilomycin (100 nM). (d) Confocal microscopy analysis of Cyto-ID staining in 3D-grown BE(2)-C cells. Images 
show maximum intensity projection of z-stack images covering the whole spheroid. (e) Flow cytometric analysis 
of Cyto-ID staining 72h after transfection with ATG5 and control siRNAs in two- and three-dimensionally cultured 
BE(2)-C cells. Where indicated, cells were treated with chloroquine for the last 24h. Bar graphs depict mean Cyto-
ID fluorescence normalized to DMSO treated siCtrl cells of n=4 (2D) and n=5 experiments (3D). (f) Western blot 
analysis of ATG5 knockdown. Statistical analysis was performed on non-normalized data using paired two-tailed 
t-test (***p < 0.001; **0.001 ≤p <0.01; *0.01 ≤ p < 0.05). Error bars represent standard error of the mean (SEM).  
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conceivable that remaining levels of ATG5 after knockdown (Figure 33f) were sufficient to keep up 
basal autophagic flux required under 2D conditions, but insufficient under autophagy-dependent 
conditions in the 3D culture, leading to reduced lysosomal or autophagolysosomal content. This only 
became obvious under conditions where turnover of autophagosomes and autophagolysosomes was 
blocked (CQ treatment), suggesting a stronger contribution of the autophagic route to lysosomal and 
autophagolysosomal content under 3D conditions. 
In contrast to 2D conditions (see section E1.8.1), ATG5 knockdown under 3D conditions significantly 
increased doxorubicin accumulation in BE(2)-C cells compared to cells transfected with control 
siRNAs (Figure 34a). A similar increase in doxorubicin levels was observed when other important 
mediators of autophagy, such as Beclin-1 or the pro-autophagic transcription factor FoxO3a were 
depleted via RNAi (Figure 34b). It is thus conceivable that organelles from the autophagic route also 
contribute to lysosomal exocytosis under 3D conditions.  
 
 
Figure 34: RNAi-mediated blocking of autophagy causes doxorubicin accumulation in three-dimensionally 
cultured BE(2)-C cells. (a, b) Flow cytometric analysis of cellular doxorubicin fluorescence 5d after transfection 
with siRNAs against ATG5 (a) FoxO3a and Beclin-1 (b). Cells were treated with doxorubicin (500 ng/ml) for the 
last 24h. Bar graphs show mean doxorubicin fluorescence normalized to siCtrl transfected cells of n=5 
experiments (ATG5, FoxO3a) and n=2 experiments (Belcin-1), respectively. (b) Western blot analysis of ATG5, 
Beclin-1 and FoxO3a expression after knockdown. Statistical analysis was performed on non-normalized data 
using paired two-tailed t-test (***p < 0.001; **0.001 ≤p <0.01; *0.01 ≤ p < 0.05). Error bars represent standard 
error of the mean (SEM).  
 128
RESULTS 
1.8.3 HDAC10 is also involved in doxorubicin secretion in 3D cultured 
neuroblastoma cells 
Recent data from our lab show that three-dimensionally cultured neuroblastoma cells are highly 
resistant to doxorubicin treatment and that resistance can be reverted by HDAC10 inhibition with 
bufexamac (Bingel et al. 2017). This raised the question whether HDAC10 also promoted doxorubicin 
secretion in 3D cultured neuroblastoma cells. To address this point, 3D grown BE(2)-C cells were 
treated with doxorubicin for 48h and co-treated with HDAC6/10 inhibitors tubastatin A and 
bufexamac, where indicated. Flow cytometric analysis of cellular doxorubicin fluorescence revealed 
that co-treatment with either HDAC6/10 inhibitor significantly increased doxorubicin accumulation in 
3D grown BE(2)-C cells (Figure 35a). RNAi mediated knockdown of HDAC6 and HDAC10, respectively, 
revealed that HDAC10 but not HDAC6 depletion increased intracellular doxorubicin levels in 3D 
cultured cells (Figure 35b, c), analogous to the results obtained in 2D cultures (see section E1.4.1). It 
is thus likely that HDAC6/10 inhibitors contribute to sensitization of 3D grown neuroblastoma cells to 
doxorubicin via inhibition of HDAC10-mediated lysosomal exocytosis. 
 
1.9 HDAC10 inhibition increases doxorubicin sensitivity of 
neuroblastoma cells but not fibroblasts 
The observation that lysosomal exocytosis inhibition by tubastatin A increased doxorubicin 
accumulation in neuroblastoma cells but not in non-transformed fibroblasts (see sections E1.4.2 and 
Figure 35: Inhibition and depletion of HDAC10 increase doxorubicin accumulation in three-dimensionally 
cultured BE(2)-C cells. (a) Cellular doxorubicin fluorescence in 2D and 3D-cultured BE(2)-C cells was analyzed via 
flow cytometry. Cells were treated with 500 ng/ml doxorubicin for 24h and, where indicated, 3D-grown cells 
were treated with HDAC6/10 inhibitors tubastatin A (7.5 μM) and bufexamac (30 μM). Bar graph depicts mean 
doxorubicin fluorescence normalized to 3D-grown cells treated with doxorubicin and DMSO. (b) Flow cytometric 
analysis of cellular doxorubicin fluorescence in 3D-cultured BE(2)-C cells 5d after transfection with siRNAs. Cells 
were treated for the last 24h with 500 ng/ml doxorubicin. Bar graph depicts mean doxorubicin fluorescence 
normalized to siCtrl transfected cells. (c) Western blot analysis of HDAC6 and HDAC10 expression after RNAi-
mediated knockdown. Statistical analysis was performed on non-normalized data using paired two-tailed t-test 
(***p < 0.001; **0.001 ≤p <0.01; *0.01 ≤ p < 0.05). Error bars represent standard error of the mean (SEM).  
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E1.6.1) raised the question whether tubastatin A could be used to selectively sensitize 
neuroblastoma cells to doxorubicin treatment, while sparing non-malignant cells such as fibroblasts. 
Such a selectivity towards malignant cells could, in turn, make HDAC10 an attractive target for clinical 
intervention.  
1.9.1 Combination of doxorubicin with HDAC6/10 inhibitor tubastatin A 
induces cell death in neuroblastoma cells 
To test whether HDAC6/10 inhibitor tubastatin A sensitizes neuroblastoma cells to doxorubicin 
treatment, BE(2)-C cells were treated with 100 ng/ml doxorubicin in the presence or absence of 
7.5 µM tubastatin A. Cell viability and the number of viable cells were quantified via automated 
trypan blue staining, and compared to DMSO treated cells or to cells subjected to single treatment 
after 24h, 48h and 96h, respectively. Here, combination treatment with doxorubicin and tubastatin A 
substantially and significantly reduced cell viability at all investigated timepoints when compared to 
either solvent treated or single treated cells (Figure 36a-c). Treatment with tubastatin A alone 
slightly reduced cell viability after 48h and 96h, but this effect was not statistically significant at 
either timepoint (Figure 36b, c). Also, doxorubicin alone did not substantially affect cell viability 
within the first 48h of treatment, and only caused a prominent loss of cell viability after 96h (Figure 
36b, c). The effect at 96h was not statistically significant, due to big variations in treatment efficiency 
with doxorubicin alone. This variation in doxorubicin efficiency at the 96h timepoint also caused the 
differences of doxorubicin treatment alone and the combination treatment with tubastatin A to be 
non-significant, even though cells that underwent combination treatment displayed substantially 
lower cell viability than cells treated with doxorubicin alone in each individual experiment (Figure 
36c).  
In addition to cell viability, the cell number after treatment was quantified to test for the cytostatic 
properties of the above described treatment combinations. Here, both single treatment with 
tubastatin A and especially doxorubicin were cytostatic after 48h and 96h (Figure 36d-f). 
Combination of doxorubicin with tubastatin A further reduced the amount of viable cells compared 
to single treatment with doxorubicin, but this effect was not statistically significant as single 
treatment with doxorubicin alone also resulted in low cell numbers due to its highly cytostatic 
potential (Figure 36d-f).  
Taken together, combination treatment with tubastatin A and doxorubicin effectively induced cell 
death compared to single treatments, which were rather cytostatic than cytotoxic. 
As the P-glycoprotein inhibitor verapamil was also capable of substantially increasing intracellular 
doxorubicin levels in BE(2)-C cells (see section E1.5.1), it was hypothesized that combination 
treatment with doxorubicin and verapamil should reduce cell viability in a similar fashion as 
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combination of doxorubicin with tubastatin A. However, although combination treatment with 
verapamil was clearly cytostatic at early treatment timepoints (24h and 48h) (Figure 36d, e), effects 
on cell viability were delayed with the latter combination (Figure 36a-c). A substantial reduction in 
cell viability after combined treatment with doxorubicin and verapamil over doxorubicin treatment 
alone was only visible after 96h, although this effect was not statistically significant due to the high 
variance in doxorubicin efficiency (Figure 36c). It was thus hypothesized that sensitization of BE(2)-C 
cells to doxorubicin treatment by addition of HDAC6/10 inhibitor tubastatin A was not only caused by 
increased doxorubicin accumulation, but potentially by secondary and tertiary mechanisms (see 
sections E1.9.4 and E1.10). 
 
Figure 36: HDAC6/10 inhibition sensitizes BE(2)-C neuroblastoma cells to doxorubicin treatment. (a-c) 
Viability of BE(2)-C cells after treatment with 100 ng/ml doxorubicin +/- tubastatin A (7.5 μM) and verapamil 
(10 μM) for 24h (a), 48h (b) and 96h (c), respectively. (d-f) Number of viable BE(2)-C cells after the above 
described treatments. Viability and cell number were analyzed via trypan blue exclusion on an automated cell 
counter. Statistical analysis was performed on non-normalized data using unpaired two-tailed t-test (***p < 
0.001; **0.001 ≤p <0.01; *0.01 ≤ p < 0.05). Error bars represent standard error of the mean (SEM). Parts of 
figure published in (Ridinger et al. 2018). 
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1.9.2 Combination of doxorubicin with HDAC6/10 inhibitor tubastatin A has 
cytostatic but not cytotoxic effects on fibroblasts  
Treatment regimens that increase sensitivity of cancer cells should ideally target tumor cells while 
sparing non-malignant cells. Because of their ability to readily proliferate in culture, which makes 
them potentially sensitive to chemotherapeutic drugs, fibroblasts represent a suitable cell culture 
model to test combinatorial treatments that include cytostatic drugs. Human fibroblasts were 
treated with 100 ng/ml doxorubicin in the absence or presence of 7.5 µM HDAC6/10 inhibitor 
tubastatin A or 10 µM of the P-glycoprotein inhibitor verapamil. As for BE(2)-C cells in the section 
above, cell viability (Figure 37a-c) and the number of viable cells (Figure 37d-f) were measured by 
automated trypan blue staining after treatment for 24h, 48h and 96h, respectively. In marked 
contrast to BE(2)-C cells, double treatment with tubastatin A and doxorubicin did not substantially 
affect cell viability at 24h, 48 or 96h (Figure 37a-c). In fact, the only treatment regimen that slightly 
and significantly reduced cell viability in fibroblasts was the combination of doxorubicin with 
verapamil for 96h (Figure 37c).  
Analogous to BE(2)-C cells, however, single treatment with doxorubicin or tubastatin A caused a 
substantial reduction in the number of viable cells, and viable cell numbers were further decreased 
by combination treatment with either HDAC6/10 inhibitor doxorubicin or P-glycoprotein inhibitor 
verapamil (Figure 37d-f).  
Taken together, the data in sections E1.9.1 and E1.9.2 show that doxorubicin and tubastatin A, as 
well as their combination have cytostatic effects on both fibroblasts and neuroblastoma cells. 
However, in contrast to its mere cytostatic effect on fibroblasts, combination of doxorubicin and 
HDAC6/10 inhibitor tubastatin A clearly had cytotoxic potential in BE(2)-C neuroblastoma cells. 
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1.9.3 Combination of doxorubicin with HDAC6/10 inhibitor tubastatin A 
reduces colony formation of BE(2)-C neuroblastoma cells 
The data presented in section E1.9.1 demonstrate that combination treatment with doxorubicin and 
the HDAC6/10 inhibitor tubastatin A has cytotoxic effects on BE(2)-C neuroblastoma cells, while 
single treatment is rather cytostatic. Colony assays can reveal both cytostatic and cytotoxic drug 
characteristics in a single readout, i.e. the outgrowth of colonies in a recovery phase after a limited 
period of treatment.  
Combination of tubastatin A with 100 ng/ml doxorubicin over a treatment period of 24h with eleven 
days of colony outgrowth substantially reduced colony formation compared to solvent control and 
Figure 37: HDAC6/10 inhibition does not sensitize proliferating human fibroblasts cells to doxorubicin 
treatment. (a-c) Viability of fibroblasts after treatment with 100 ng/ml doxorubicin +/- tubastatin A (7.5 μM) 
and verapamil (10 μM) for 24h (a), 48h (b) and 96h (c), respectively. (d-f) Number of viable fibroblasts after the 
above described treatments. Viability and cell number were analyzed via trypan blue exclusion on an automated 
cell counter. Statistical analysis was performed on non-normalized data using unpaired two-tailed t-test (***p < 
0.001; **0.001 ≤p <0.01; *0.01 ≤ p < 0.05). Unless otherwise indicated by asterisks, differences were not 
statistically significant. Error bars represent standard error of the mean (SEM). Parts of figure published in 
(Ridinger et al. 2018). 
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individual treatments, respectively (Figure 38). This was in line with the data from cell viability assays 
described in section E1.9.1. Colony assays also reflected the cytostatic capacity of tubastatin A and 
doxorubicin, as both drugs were capable of reducing colony formation, although this effect was not 
significant in case of tubastatin A. The combination of doxorubicin and tubastatin A was also capable 
of reducing colony outgrowth at lower doxorubicin concentrations (50 ng/ml) that are potentially 
achievable in patient serum and which only slightly reduced colony formation on its own. Thus, 
tubastatin A sensitized highly chemoresistant BE(2)-C cells to clinically achievable concentrations of 
doxorubicin. 
 
1.9.4 Lysosomal exocytosis inhibition itself contributes to sensitization of 
BE(2)-C cells to doxorubicin 
The data presented in sections E1.6 and E1.9 show that HDAC6/10 inhibitors can promote 
doxorubicin accumulation in neuroblastoma cells by inhibition of HDAC10 mediated lysosomal 
exocytosis and that combination treatment of doxorubicin with HDAC6/10 tubastatin A sensitizes 
neuroblastoma cells to doxorubicin treatment. Surprisingly, however, sensitization to doxorubicin 
was less efficient with the P-glycoprotein inhibitor verapamil, even though the latter promoted 
stronger intracellular accumulation of doxorubicin than tubastatin A (Figure 27b). Thus, increased 
doxorubicin accumulation alone was not solely responsible for cell death induction after co-
treatment with doxorubicin and tubastatin A. 
Data in section E1.4.4 show that HDAC6/10 inhibitor alters the subcellular localization of doxorubicin, 
raising the question whether doxorubicin was unable to reach the nucleus and in case of 
Figure 38: Colony formation of BE(2)-C cells is inhibited by combined treatment with doxorubicin and 
HDAC6/10 inhibitor tubastatin A. BE(2)-C cells were treated for 24h with different doses of doxorubicin, 7.5 μM 
tubastatin A and the respective combination. Colonies were allowed to outgrow for eleven days after washout 
of drugs and colonies were stained with crystal violet. Bar graphs depict mean colony number. Statistical 
analysis was performed on non-normalized data using unpaired, two-tailed t-test (***p < 0.001; **0.001 ≤ p < 
0.01; *0.01 ≤ p < 0.05). Error bars represent standard error of the mean (SEM). Figure published in (Ridinger et 
al. 2018). 
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combination with verapamil. Analysis of subcellular doxorubicin localization upon verapamil 
treatment via confocal immunofluorescence microscopy, however, showed that doxorubicin strongly 
accumulated in nuclei of BE(2)-C cells after verapamil treatment, thus ruling out that the lack of 
sensitization was due to altered subcellular localization of doxorubicin (Figure 39a). This led to the 
hypothesis that inhibition of lysosomal exocytosis itself could have contributed to sensitization of 
neuroblastoma cells to doxorubicin treatment. In order to investigate this, BE(2)-C cells were treated 
with doxorubicin and the lysosomal exocytosis inhibitor vacuolin-1 for 24h and cell viability was 
analyzed by automated trypan blue staining. Here, combination of doxorubicin with vacuolin-1 
reduced cell viability in a similar fashion as combined treatment with doxorubicin and tubastatin A 
did (Figure 39b). Similar to tubastatin A treatment, vacuolin-1 alone did not substantially lower cell 
viability, indicating that inhibition of lysosomal exocytosis increased chemosensitivity of 
neuroblastoma cells only under stress conditions like doxorubicin treatment. Notably, no substantial 
cytotoxicity of the vacuolin-1 doxorubicin combination was observed in fibroblasts, again suggesting 
the inhibition of lysosomal exocytosis as a strategy to selectively target tumor cells (Figure 39b). 
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1.10HDAC6/10 inhibition causes formation of DNA double-strand 
breaks (DSB) and increases doxorubicin induced DSBs 
The results in section E1.9.1 show that combination of the neuroblastoma chemotherapeutic 
doxorubicin with HDAC6/10 inhibitor tubastatin A induces cell death more rapidly than combination 
of doxorubicin with P-glycoprotein inhibitor verapamil, even though verapamil promoted stronger 
intracellular doxorubicin accumulation than tubastatin A (Figure 27b). Thus, enriched intracellular 
doxorubicin per se cannot be the only reason for sensitization of neuroblastoma cells to doxorubicin 
after HDAC10 inhibition, suggesting that additional mechanisms are involved in the induction of cell 
death. Doxorubicin is a DNA-intercalating agent which also induces DNA double strand breaks (DSBs) 
by a process called topoisomerase II poisoning (Nitiss 2009; Yang et al. 2014). In this context, recent 
studies have suggested a role of nuclear HDAC10 in DNA repair, with a special focus on DNA 
mismatch repair and the repair of DSBs (Kotian et al. 2011; Radhakrishnan et al. 2015; Islam et al. 
Figure 39: Lysosomal exocytosis inhibition itself contributes to sensitization of neuroblastoma cells to 
doxorubicin treatment. (a) Confocal immunofluorescence analysis of cellular doxorubicin localization in BE(2)-C 
cells after 24h treatment with 250 ng/ml doxorubicin +/- HDAC6/10 inhibitor tubastatin A (7.5 μM) and P-
glycoprotein inhibitor verapamil (10 μM). Images depict maximum intensity projection of z-stacks. (b) Viability 
of BE(2)-C cells and human fibroblasts after 24h treatment with 100 ng/ml doxorubicin +/- HDAC6/10 inhibitor 
tubastatin A (7.5 μM) or lysosomal exocytosis inhibitor vacuolin-1 (10 μM). Statistical analysis was performed 
on non-normalized data using unpaired two-tailed t-test (***p < 0.001; **0.001 ≤p <0.01; *0.01 ≤ p < 0.05). In 
case of fibroblasts, no statistically significant changes in viability were observed. Error bars represent standard 
error of the mean (SEM). Parts of figure published in (Ridinger et al. 2018). 
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2017). It was thus not only investigated if interference with HDAC10 function increased doxorubicin 
induced DSBs, but also if inhibition of HDAC10 itself enhanced the formation of DNA double strand 
breaks. 
1.10.1 HDAC6/10 inhibition increases the formation of H2A.X positive foci  
Upon the formation of DSBs, cells quickly induce a DNA damage response and recruit DNA repair 
enzymes to DNA lesions. One of the earliest responses to DSBs includes the phosphorylation of 
histone variant H2A.X at serine 134 (so called H2A.X), which is in turn incorporated into chromatin 
at the DSB site. This is followed by the formation of so called H2A.X foci, which can be used as a 
readout for the amount of DSBs in a cell (Rogakou et al. 1998; Kuo and Yang 2008). 
To investigate if HDAC6/10 inhibition enhanced the formation of DSBs, BE(2)-C neuroblastoma cells 
were, in an initial experiment, analyzed for the presence of chromatin foci that contained via 
confocal immunofluorescence microscopy (Figure 40a). Treatment with tubastatin A for 24h 
moderately increased DSBs while P-glycoprotein inhibitor verapamil did not. Moderate doses of 
doxorubicin (25 ng/ml) also induced low levels of DSBs, and these were substantially increased when 
combined with tubastatin A. This effect was not as pronounced when doxorubicin was combined 
with P-glycoprotein inhibitor verapamil at concentrations where verapamil induced stronger 
intracellular doxorubicin accumulation than tubastatin A (Figure 40a, Figure 27b). These data suggest 
that tubastatin A can increase DSB formation on its own and promote enhanced DSB formation 
under genotoxic treatment.  
To establish an approach capable of quantifying DSBs, H2A.X positive foci were measured by flow 
cytometric analysis on PFA fixed cells. Treatment of BE(2)-C cells with doxorubicin caused a dose-
dependent increase in the percentage of H2A.X highly positive cells, demonstrating that the 
fluorescent signal measured by flow cytometry correlated with the amount of H2A.X positive lesions 
and thus likely DSBs (Figure 40b).  
Confirming the results of immunofluorescence microscopy, addition of tubastatin A to doxorubicin 
significantly increased the amount of H2A.X positive cells compared to doxorubicin treatment alone 
(Figure 40c, d). The increase in H2A.X positive cells was significantly greater than when verapamil 
was combined with doxorubicin (Figure 40d). Single treatment of BE(2)-C cells confirmed a slight 
increase in H2A.X positive cells in case of tubastatin A but not verapamil treatment and the DSB 
inducing capability of tubastatin A was also observed in IMR-32 cells (Figure 40e). Notably, single 
treatment with lysosomal exocytosis inhibitor vacuolin-1 did not cause elevated H2A.X levels, and 
combination of vacuolin-1 with doxorubicin raised the percentage of H2A.X highly positive cells in 
about the same magnitude as co-treatment with verapamil did, which was below the combination of 
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doxorubicin and tubastatin A (Figure 40d, f). Taken together with the data presented in sections 
E1.4.4, E1.6.2, E1.9.1 and E1.9.4, this indicate that HDAC6/10 inhibitor tubastatin A promoted 
sensitization of neuroblastoma cells to doxorubicin by at least three mechanisms: increased 
doxorubicin accumulation by lysosomal exocytosis inhibition, decreased stress resistance by 
lysosomal exocytosis inhibition, as well as induction of DNA double strand breaks. 
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Figure 40: HDAC6/10 inhibition induces the formation of JH2A.X positive foci in neuroblastoma cells. (a) 
immunofluorescence analysis of JH2A.X staining in BE(2)-C cells after 24h treatment with tubastatin A (7.5 μM), 
verapamil (10 μM) +/- 25 ng/ml doxorubicin. Red arrows indicated JH2A.X highly positive cells (b) Flow 
cytometric analysis of JH2A.X staining in BE(2)-C cells after 24h treatment with indicated doxorubicin 
concentrations. Number of highly JH2A.X positive cells was quantified in 2 experiments (2 technical replicates 
per experiment, one experiment shown). (c) Flow cytometric analysis of JH2A.X staining in BE(2)-C cells after 
24h treatment with tubastatin A (7.5 μM), verapamil (10 μM) +/- 100 ng/ml doxorubicin. Fluorescence 
histograms depict percentage of cells (y-axis) and logarithmic JH2A.X fluorescence (x-axis). Ranged gates 
represent cells gated as highly JH2A.X positive. (d) Flow cytometric analysis JH2A.X positive BE(2)-C cells (n=6 
experiments). (e) Flow cytometric quantification of JH2A.X positive cells in IMR-32 cells after 24h treatment 
with 7.5 μM tubastatin A. (f) Flow cytometric quantification of JH2A.X positive BE(2)-C cells after 24h treatment 
with 10 μM vacuolin-1 +/- 100 ng/ml doxorubicin (n= 4 experiments). Statistical analysis was performed on non-
normalized data using paired two-tailed t-test (***p < 0.001; **0.001 ≤p <0.01; *0.01 ≤ p < 0.05). Parts of 
figure published in (Ridinger et al. 2018). 
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1.10.2 HDAC6/10 inhibition increases the formation of doxorubicin induced 
DNA double strand breaks 
H2A.X positive foci are a very commonly used readout for the induction of DSBs. However, they can 
also occur upon replication fork stalling (Ewald et al. 2007). The physical presence of DNA damage 
can be quantified by a single cell electrophoresis approach called comet assay, in which agarose 
enclosed single cells are lysed under alkaline conditions and then subjected to an electric field. Here, 
damaged DNA leaves a tell-tale pattern of DNA migration that resembles a comet and quantification 
of percentage of tail DNA versus total DNA can be used as a readout to assess the amount of DNA 
damage.  
Two independent comet assays (performed in the group of Dr. Peter Schmezer, Division of 
Epigenomics and Cancer Risk Factors, DKFZ, Germany) confirmed that addition of tubastatin A to 
doxorubicin treatment significantly increased the relative amount of tail DNA and thus DSBs 
compared to solvent treated cells or cells treated with 100 ng/ml doxorubicin only (Figure 41). As 
reported for H2A.X positive foci, treatment with tubastatin A alone increased DSBs also in comet 
assays, although this effect was statistically significant in only one of the biological replicates. At the 
same time, however, treatment with 100 ng/ml doxorubicin alone did not significantly increase DNA 
damage in either replicate, suggesting that comet assays had a lower sensitivity for DSBs that the 
flow cytometric analysis of H2A.X staining. Taken together with the previous section, these data 
indicate that HDAC6/10 inhibition with tubastatin A increases the formation DSBs in neuroblastoma 
cells, both as single treatment and much higher in combination with DNA-inducing agents such as 
doxorubicin. 
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2 Approaches to identify HDAC10 downstream targets 
2.1 HDAC10 and its potential role as a polyamine deacetylase 
The recently published crystal structure of zebrafish HDAC10 suggests that HDAC10 is a poor lysine 
deacetylase and rather acts as a polyamine deacetylase, specifically of N8-acetylated spermidine (Hai 
et al. 2017). Polyamine metabolism is often severely deregulated in high-risk neuroblastoma cases, 
and high expression of the rate-limiting polyamine synthesizing enzyme ODC-1 is associated with 
poor outcome independently of MYCN amplification (Hogarty et al. 2008; Gamble et al. 2012). This 
raised the question whether HDAC10 also acts as a polyamine deacetylase in human neuroblastoma 
cells and whether HDAC10 function influences cellular polyamine levels. To investigate this, BE(2)-C 
cells were either treated with HDAC6/10 inhibitors for 24h or transfected with siRNAs against HDAC6 
or HDAC10 for 3d and 6d, respectively. Cells were subjected to whole cell lysis using SSAT lysis buffer 
and then analyzed for the presence of polyamines and their acetylated derivatives via high 
performance liquid chromatography (HPLC) after dansyl chloride labeling in the collaborating group 
of Dr. Robert Casero (Johns Hopkins University, Baltimore, United States). Raw polyamine levels were 
normalized to protein concentration.  
N8-acetylspermidine was detected in none of the samples (data not presented as figure), possibly 
due to low abundance of that polyamine species in BE(2)-C cells. Since N8-acetylatspermidine is 
generated in the nucleus and therefore potentially enriched in this compartment (Libby 1980), 
Figure 41: Analysis of DNA double strand breaks in BE(2)-C cells via comet assay (two biological replicates). 
Cells were treated with HDAC6/10 inhibitor tubastatin A (7.5 μM) in absence or presence of 100ng/ml 
doxorubicin for 18h. Gamma ray irradiated cells (5 Gy, see methods section C3.5) served as positive control for 
DSBs. Bar graphs show median % tail DNA (y-axis) per treatment of each one biological replicate experiment. 
Numbers above bars give % tail DNA, as well as the number of analyzed nuclei in brackets. Statistical was 
performed using one-tailed Mann Whitney test. Parts of figure published in (Ridinger et al. 2018). 
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nuclear fractions were enriched by nuclear-cytoplasmic fractionation prior to the generation of 
polyamine lysates. However, detection of N8-acetylated polyamines also failed on nuclear lysates 
from both tubastatin A and DMSO treated cells (data not presented as figure). Furthermore, neither 
knockdown of HDAC6 or HDAC10 (Figure 42a, b), or inhibition of either enzyme (Figure 42c) 
consistently changed total levels of putrescine, spermidine and spermine.  
Taken together these data suggest that class IIb HDACs do not control total polyamine levels in the 
above named cell model. Moreover, N8-acetylation of spermidine should be investigated in other cell 
lines (currently ongoing), or in cellular supernatants, as preliminary data from our collaborators 
suggest that N8-acetylspermidine is secreted (see discussion section F2). 
 
2.2 Analysis of lysine acetylation in HSP70 family members 
HSC70 and HSP70 after HDAC10 inhibition 
Members of the HSP70 family of heat shock proteins have been repeatedly reported to be important 
for various modes of autophagy, as well as for lysosomal membrane integrity. Most famously, the 
constitutively expressed HSP70 family member HSC70 is a central mediator of chaperone-mediated 
autophagy, where it delivers cytosolic proteins destined for degradation to a lysosomal LAMP-2 
complex, which in turn translocates the proteins into the lysosomes (Cuervo and Dice 1996; Salvador 
et al. 2000). In contrast, the stress-regulated HSP70 family members HSPA1A (HSP70-2, from here on 
referred to as HSP70) is known to act as a guardian of lysosomal membrane integrity in cancer 
(Daugaard et al. 2007a) and has been further shown to be required for the initiation of 
Figure 42: Interference with HDAC10 function does not alter polyamine levels in BE(2)-C neuroblastoma cells. 
(a) HPLC quantification of polyamines per mg protein in BE(2)-C 72h after transfection with siRNAs against 
HDAC6 and HDAC10, respectively. Two replicate experiments were pooled. (b) Western blot analysis of 
knockdowns. (c) HPLC quantification of polyamines per mg protein in BE(2)-C whole cell lysates after 24h 
treatment with HDAC6/10 inhibitors tubastatin A (7.5 μM), bufexamac (30 μM), HDAC6 inhibitor tubacin (7.5 
μM) and pan HDAC inhibitor panobinostat (10 nM). Levels of the respective polyamine were normalized to 
DMSO treated cells. All HPLC analyses were performed by Dr. Tracy Murray-Stewart in the lab of Dr. Bob Casero 
(Johns Hopkins University, Baltimore, United States). 
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autophagosome formation during macroautophagy (Yang et al. 2013). Several studies show that heat 
shock protein function can be heavily modified by lysine acetylation (Kovacs et al. 2005; Yang et al. 
2013) and recent papers also hint at a potential interaction of HDAC10 with HSP70 family members 
HSC70 or HSP70 (Lai et al. 2010; Oehme et al. 2013a), making them a prime candidate downstream 
target of HDAC10. 
2.2.1 Separate enrichment of heat shock proteins HSC70 and HSP70 via 
immunoprecipitation 
Due to their high sequence homology, separate enrichment of HSC70 and HSP70 was prerequisite to 
identifying HDAC10 specific deacetylation sites in HSC70 and HSP70, respectively. To that end, two 
separate immunoprecipitation (IP) protocols were established using non-crossreactive HSC70 and 
HSP70 antibodies (Figure 43a) which allowed for the successful enrichment of HSC70 and HSP70 
from BE(2)-C cells, respectively (Figure 43b). Specificity of the HSP70 and HSC70 pulldowns for either 
protein was confirmed both by using non-specific rat and mouse control IgG antibodies (Figure 43c) 
and by cross-incubating the blot of each pulldown with the antibody of the respective other HSP70 
family member (Figure 43d). Here, no substantial cross contamination with the respective other 
HSP70 family member was detected in the eluate fractions.  
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2.2.2 No HDAC10 specific deacetylation sites in HSP70 or HSC70 could be 
identified via tandem mass spectrometry 
In order to identify HDAC10 specific deacetylation sites in HSP70 and HSC70, both proteins were 
separately enriched via immunoprecipitation (IP) from BE(2)-C lysates after 24h treatment with 
7.5 μM tubastatin A (HDAC6/10 inhibitor) and 7.5 μM tubacin (HDAC6 inhibitor), as well as control 
treatment with solvent only. A pan HDAC inhibitor (500nM TSA) was added to all lysates prior to the 
IP in order to stop unspecific deacetylase activity after cell lysis. IP-enriched HSP70 and HSC70 
proteins were separated on 1D-PAGE, excised at the target mass range, digested with trypsin and 
analyzed via LC-MS/MS (see section C2.8). Peptides with putative acetylation sites on lysines directly 
N-terminal of tryptic cleavage were omitted as false positive. 
Figure 43: Optimization of immunoprecipitation protocols for separate enrichment of HSP70 and HSC70. (a) 
Indicated amounts of recombinant HSP70 and HSC70 protein were separated via PAGE, blotted on a PVDF 
membrane and used for testing cross-reactivity of candidate HSP70 and HSC70 antibodies. Example shows 
identification of two non cross-reactive antibodies. (b) Western blot analysis of an exemplary HSC70 (left) and 
HSP70 (right) pulldown. Proteins were pulled down for 5h-6h at 4°C. (c) Non specific rat (top figure) and mouse 
(bottom figure) IgGs were used as control to exclude unspecific binding of HSP70 family members HSC70 and 
HSP70 to IgG antibodies. (d) Criss-Cross detection of HSC70 on HSP70 pulldown and vice versa in order to control 
pulldown specificity for either HSP family member. Membranes were afterwards re-probed with the respective 
correct HSP antibody. 
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In contrast to western blot analysis of HSP70 IPs (Figure 43), cross-contamination of HSC70 protein 
with HSP70 and vice versa were detected in all analyzed MS experiments (data not shown), probably 
due to the higher sensitivity of MS over western blot. In a first set of experiments, treatment with 
HDAC6/10 inhibitor tubastatin A but not with HDAC6 inhibitor tubacin increased acetylation of 
HSP70 but not HSC70 at lysine 159 (K159) (Figure 44a), a before reported target site of HDAC6, 
acetylation of which promoted autophagy (Yang et al. 2013). The contaminating HSP70 protein in the 
HSC70 pulldown showed a similar pattern of K159 acetylation, namely K159 acetylation only 
occurring after HDAC6/10 but not after HDAC6 inhibition (Figure 44a). None of the follow-up 
experiments, using either IP-enriched HSP70 (experiment 2) or a 70kDa target mass range slice from 
PAGE of postnuclear lysates (experiments 3 and 4) could however confirm that HSP70 was 
differentially acetylated at K159 HDAC6/10 or HDAC6 inhibition (Figure 44c). Common de novo 
acetylation patterns after either HDAC6/10 or HDAC6 inhibition were also not observed, pointing 
towards a poor HSP70 sequence coverage in some of the experiments (Figure 44c). 
No conclusive pattern of additional acetylation sites was observed for HSC70 after treatment with 
HDAC6 or HDAC6/10 inhibitors (Figure 44d). Here, a high number of acetylated peptides could be 
identified when sequence coverage was good, but no de novo acetylation occurred after either 
HDAC6 or HDAC6/10 inhibitor treatment. Regardless, it cannot be ruled out that commonly 
acetylated sites like K128 become hyperacetylated in case of HDAC inhibitor treatment and a 
quantitative SILAC based approach might be more suitable to analyze stoichiometric changes in 
acetylation. In summary, the data do not provide conclusive evidence to confirm or rule out HSP70 or 
HSC70 as HDAC6 or HDAC10 targets and the approach used to answer this question should be 
refined. 
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Figure 44: Analysis of HSP70 and HSC70 acetylation via 
LC-MS/MS. (a) Fragmentation spectrum of HSP70 
peptide after HSP70 IP showing lysine acetylation at 
K159 after 24h tubastatin A treatment. (b) 
Fragmentation spectrum of HSP70, which was detected 
as a contaminant in the HSC70 IP, also showing lysine 
acetylation at K159 after tubastatin A treatment. (c, d) 
Summary of HSP70 (left) and HSC70 (right) lysine 
acetylation of all four experiments. BE(2)-C cells were 
treated for 24h with HDAC6/10 inhibitor tubastatin A 
(7.5 μM), HDAC6 inhibitor tubacin (7.5 μM) or solvent. 
Experiment 1 (and 2 in case of HSP70) include IP-
enrichment of HSP70 or HSC70. In experiments 3 and 4, 
30 μg and 60 μg of postnuclear supernatants were 
separated via 1D PAGE, respectively, and gel slices were 
extracted at the target mass range (70 kDa). 
Abbreviations: n.i. - not investigated. 
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2.3 LC-MS/MS on whole cell lysates reveal potential lysosomal 
and nuclear targets of HDAC10 
In a parallel approach to the IP enrichment of HSP family members described in the previous section, 
whole cell lysates from BE(2)-C cells treated with HDAC6 inhibitor tubacin, HDAC6/10 inhibitor 
tubastatin A or solvent, were separated on 1D PAGE, followed by excision of small gel slices which 
were individually analyzed by LC-MS/MS (outlined in Figure 45a). Although identification of HDAC10 
specific acetylation sites in HSP70 were the primary aim of this screen, the mass range of gel slices 
was expanded to roughly 95 to 50 kDa, which allowed for screening for other potential HDAC10 
downstream candidates (Figure 45a). As in the previous section, peptides with putative acetylation 
sites on lysines directly N-terminal of tryptic cleavage sites were omitted as false positives and 
excluded from further analysis. Moreover, true hits were sorted by peptide score (Mascot) by the 
DKFZ Proteomics Core Facility (Dr. Martina Schnölzer), omitting peptides with a score below 30. Both 
HDAC6 and HDAC6/10 inhibitor treated samples had a higher number of acetylated peptides than 
the DMSO group (Figure 45b). Duplicate peptides, i.e. peptides with identical sequence and 
posttranslational modification, were removed from each treatment group in order to yield lists 
where each specifically modified peptide was only represented once. Here, HDAC6 and HDAC6/10 
inhibitor treated samples showed a similar number of acetylated peptides, which was only slightly 
increased compared to DMSO treated cells (Figure 45b lower row). Analysis of overlapping peptides 
between treatment groups showed that 80 peptides overlapped between tubastatin A and tubacin 
treated samples, as well as 90 peptides that were identified in tubastatin A treated cells only (Figure 
45c). More than half (44) of the 80 peptides shared between tubastatin A and tubacin treated 
samples also overlapped with DMSO control. Considering the fact that both tubastatin A and tubacin 
are excellent HDAC6 inhibitors (see Figure 12c), the fraction of peptides specifically overlapping in 
these treatment groups (36) was comparably small (discussed in section F2). Neither tubastatin A nor 
tubacin treated cells showed a strong increase in HSP70 or HSC70 peptides that were specifically 
acetylated under these conditions. In fact, only two HSP70 peptides were found differentially 
acetylated between treatment groups, namely K561 in DMSO treated cells and K77 in tubastatin A 
treated cells. This again suggested that these HSP70 family members were either no direct targets of 
HDAC6 or HDAC10, or that the approach was not suitable to properly detect acetylation on these 
proteins.  
Treatment with tubastatin A causes lysosomal expansion and DNA double strand breaks (see sections 
E1.2 and E1.10). Thus, in a hypothesis driven approach, peptides that were specifically acetylated in 
the tubastatin A treated group were analyzed - in addition to HSP70 family - for candidate proteins 
that are involved in lysosomal homeostasis and the repair of DNA double strand breaks, respectively 
 
RESULTS 147 
(Figure 45d). Here, two peptides of subunit A of the vacuolar V-ATPase, which is responsible for 
acidification of lysosomes, were de novo acetylated after HDAC6/10 but not HDAC6 inhibitor 
treatment at two sites (K480, K506), and mutations introduced in this V-ATPase subunit in yeast have 
been associated with increased coupling efficiency of the V-ATPase complex (Shao et al. 2003; Owegi 
et al. 2006; Forgac 2007) (further discussed in section F1.1). Moreover, tubastatin A treatment 
caused acetylation of Ku80 (XRCC5) at K443. Ku80 is a critical subunit of Ku70/Ku80 complex that 
initiates the repair of DSBS via NHEJ  (Davis and Chen 2013). Lysine 443 lies within the central Ku core 
region that is important for DNA binding and Ku80 was reported to be differentially acetylated after 
application of pan HDAC inhibitors in a recent study (Robert et al. 2016). Although a specific site of 
lysine acetylation was not determined in the latter study, hyperacetylation of Ku protein was 
reported to impair DSB repair by NHEJ. 
Although the above described data require validation in a biological replicate (see section F2), it is 
conceivable that their function is critically regulated by HDACs. As acetylation at these sites occurred 
specifically after use of HDAC6/10 tubastatin A but not HDAC6 inhibitor tubacin, it is likely that 
deacetylation of these peptides was mediated by HDAC10 rather than HDAC6.  
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3 Generation of an HDAC10 antibody  
Previous publications from our group have identified high HDAC10 expression as a risk factor in a 
sub-group high-risk neuroblastoma. The results collectively shown in previous sections (E1) further 
demonstrate that HDAC10 has a critical function in lysosomal homeostasis in a set of neuroblastoma 
cell lines and that interference with its function can sensitize chemoresistant neuroblastoma cells to 
chemotherapeutic agents such as doxorubicin (Oehme et al. 2013a). This makes HDAC10 an 
attractive target both for further mechanistic studies and clinical intervention, which require a high 
Figure 45: LC-MS/MS on whole protein lysates from BE(2)-C cells after treatment with HDAC6 and HDAC6/10 
inhibitors. (a) Separation of whole cell lysates from BE(2)-C cells treated for 24h with HDAC6/10 inhibitor 
tubastatin A (7.5 μM), HDAC6 inhibitor tubacin (7.5 μM) and solvent (DMSO). Red boxes indicate target mass 
range and individually analyzed gel slices. (b) Number of acetylated peptides found after the respective 
treatment. Lower row gives number of acetylated peptides cleared of peptides with identical sequence and post 
translational modification. (c) Venn diagram depicting number of overlapping, acetylated, peptides between 
treatment groups. (d) A hypothesis driven approach looking for peptides only acetylated after treatment with 
HDAC6/10, which could be connected to enlargement of the lysosomal compartment (VATA) and impaired DNA 
damage repair (XRCC5), respectively. 
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quality antibody that allows for the analysis of subcellular localization, interaction partners and tissue 
expression, respectively. Such analyses are, however, drastically hampered by the poor quality of 
commercially available HDAC10 antibodies. This is highlighted by the fact that the most reliable of 
these antibodies (Sigma H3413) recognizes multiple bands on western blot (Figure 46a). Bands of 
higher molecular weight are unlikely to be HDAC10 isoforms, as the reported isoform2 has a slightly 
smaller molecular weight (69 kDa) than the predominantly expressed isoform 1 (roughly 71 kDa) due 
to the lack of an in-frame coding exons. Bands of smaller molecular weight most likely also did not 
represent isoform 2, as these bands did not fade upon HDAC10 knockdown even though HDAC10 
siRNAs were designed to target both isoforms. Moreover, the commercial H3413 antibody is 
unspecific in immunofluorescence approaches (Figure 46b). Thus, a goal of this study was the 
generation of a highly specific, monoclonal HDAC10 antibody suitable for such purposes. 
 
3.1 Generation of a mouse monoclonal HDAC10 antibody 
3.1.1 Selection of the HDAC10 immunization peptide and pipeline for testing of 
hybridoma supernatants 
To generate HDAC10 reactive monoclonal antibodies, immunization of mice and hybridoma 
generation was performed as described in methods section C4.2 by the monoclonal antibody facility 
(MAF) at the DKFZ, using a 6x histidine-tagged immunization peptide that included HDAC10 amino 
acids 501-617 (HDAC10T2, total length: 133 amino acids, see Table 51) The respective fragment was 
Figure 46: Characterization of the commercial Sigma H3413 polyclonal anti HDAC10 antibody. (a) Specificity 
testing of the H3413 antibody via HDAC10 knockdown in BE(2)-C neuroblastoma cells 6d after siRNA 
transfection. Red arrows indicate off-target bands. (b) Immunofluorescence staining of BE(2)-C cells with the 
H3413 anti HDAC10 antibody 6d after transfection with siRNAs against HDAC10 and control siRNAs, 
respectively. Nuclei were counterstained with DAPI. 
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selected due to its comparably low amino acid sequence homology to other HDACs (Figure 47a). 
Unsurprisingly, the HDAC10T2 fragment was most homologous to the other class IIb HDAC member 
HDAC6, but alignment showed frequent amino acid mismatches, making a cross-reactivity of 
antibodies unlikely (Figure 47b). Cell culture supernatants from initial hybridoma clones which 
produced detectable amounts of IgG antibodies (ELISA performed by the MAF) were tested for 
HDAC10 reactivity on small western blot strips by transfer from preparative PAGE gels as outlined in 
Figure 47c. IMR-32 cells stably transfected with HDAC10 or control plasmid were used as source for 
lysates, because IMR-32 do endogenously express low HDAC10 levels (Figure 47d). Initial western 
blot reactivity of hybridoma supernatants was tested on HDAC10 overexpressing IMR-32 cells only 
and reactive clones were counter-tested against empty vector transfected control cells in a second 
step. 
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Figure 47: Selection of the HDAC10 immunization peptide and pipeline for western blot testing of hybridoma 
supernatants. (a) A 133 amino acid peptide fragment including 117 amino acids of the c-terminal section of 
HDAC10 (amino acids 501-617) was selected for injection into mice due to its low homology to other HDACs (full 
sequence see Table 51). The peptide sequence was BLASTed search against other HDACs. Numbers in brackets 
indicate sequence identity (left) and maximum identity score (right) of the BLAST search. (b) BLAST alignment of 
HDAC6 sequences to the immunization peptide. Red color indicates mismatches. (c) Western blot pipeline for 
testing of hybridoma supernatants. 370 - 450 μg of protein lysate were added onto a preparative PAGE gel, 
transferred onto a pre-labeled PVDF membrane and cut into small membrane strips which were then incubated 
over night with undiluted hybridoma supernatants. Bound primary antibodies were detected with peroxidase-
coupled anti mouse antibody. (d) Western blot showing expression of HDAC10 in IMR-32 cells stably transfected 
with HDAC10 expressing and control vector (e.v.), respectively. 
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3.1.2 Identification of HDAC10 reactive mouse hybridoma clones via western 
blot 
In total, 598 hybridoma parental cultures (numbered according their initial culture number 
regardless of ELISA reactivity) were identified as reactive against the HDAC10T2 peptide in initial 
ELISAs (performed by the MAF) and then tested via western blot using IMR-32 cells that stably 
expressed HDAC10. Of these 598 cultures, exactly 100 showed substantial reactivity against HDAC10 
on western blot level, with a varying degree of reactivity and specificity. For example, the culture 
#477 displayed high reactivity against HDAC10 (Figure 48a blue arrow), but also had significant 
activity against a protein of higher molecular weight (Figure 48a red arrow). As this cross-reactivity 
also occurred in empty vector transfected, HDAC10 low-expressing IMR-32 cells, the second band 
was likely off-target activity or an HDAC10 isoform (example shown in Figure 52). However, as known 
HDAC10 isoforms are smaller than the full-length protein, the latter was unlikely. Its strong reactivity 
made culture #477 interesting for subcloning and potentially antibody purification. Cultures #13, #17 
(Figure 48b) and #50 (Figure 48c) also showed reactivity against HDAC10, which was lower compared 
to #477. However, in case of culture #13 and #17 off-target activity was completely absent. Thus, 
these two parental cultures were also selected for subcloning. The parental culture #1013 was of 
special interest as it showed very high HDAC10 reactivity and negligible off-target activity on western 
blot level, making it the most promising parental clone (Figure 48d). Unfortunately, this hybridoma 
ceased to produce IgGs even before initiation of subcloning, possibly due to overgrowth by non-
producing hybridoma cells. Other cultures selected for subcloning and their fate over the course of 
the project are summarized in Figure 49a (section E3.1.3).  
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3.1.3 Subcloning of hybridoma cultures and selection of hybridoma clones for 
clonal expansion 
Initial hybridoma cultures consist of a mixed population of antibody producing and non-producing 
hybridoma cells, which carries the risk that non-producing cells overgrow the clones of interest, 
leading to an eventual loss of antibody production. Moreover, the initial cultures can contain more 
than one antibody-producing clone, potentially contaminating the antibody of interest and causing 
off-target activity. This problem can be overcome by seeding of individual hybridoma cells into 96-
Figure 48: Testing of initial hybridoma cultures via Western Blot. Undiluted hybridoma supernatants were 
tested on lysates from HDAC10 overexpressing IMR-32 cells. Examples of reactive parental clones 477 (a), 13 
and 17 (b), 50 (c) and 1013 (d) are shown. Sigma H3413 polyclonal rabbit anti HDAC10 antibody (1 μg/ml) was 
used as positive control. Blue arrows indicate on-target activity, red arrows indicate off-target activity. 
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well plates and clonal outgrowth (subcloning), which generates stable hybridoma cultures of identical 
cells that produce antibodies which bind to the same epitope (monoclonal antibodies). 
Of the reactive hybridoma parental cultures described in section E3.1.2, 27 were selected for at least 
one round of subcloning in order to shed non-producing cells or potential off-target activity in case 
that the off-target activity was not inherent to the HDAC10-recognizing antibody itself (summarized 
in Figure 49a). In total, more than 400 supernatants from subclones and sub-subclones were tested. 
Of the 27 selected parental clones, 10 clones and their respective subclones had completely lost their 
reactivity against HDAC10 after subcloning, possibly by overgrowth of non-producing hybridoma cells 
(exemplary shown for clone 17 in Figure 49b). 
 
Supernatants from the most promising subclones were tested on lysates from BE(2)-C neuroblastoma 
cells, which endogenously express HDAC10 at moderate levels, as well as on lysates from BE(2)-C 
cells that had been transfected with siRNAs against HDAC10. Here, many of the supernatants that 
reacted against overexpressed HDAC10 in IMR-32 cells failed to detect or only weakly detected 
endogenously expressed HDAC10 in BE(2)-C cells. These clones were not further considered for 
Figure 49: Subcloning of parental hybridoma cultures. (a) Summary of western blot reactivity of subclones 
derived from parental hybridoma cultures. Undiluted hybridoma supernatants were tested on lysates from IMR-
32 cells overexpressing HDAC10. At the stage of subcloning, several initially reactive clones and their subclones 
had lost reactivity. (b) Example of initially reactive clone 17, which lost HDAC10 reactivity at the stage of 
subcloning (17/15). Sigma H3413 polyclonal rabbit anti HDAC10 antibody (1 μg/ml) was used as positive 
control.  
 RESULTS 155
clonal expansion or antibody purification. Supernatants of subclones from the #477 (Figure 50a) and 
#50 (Figure 50b) family commonly showed good reactivity against endogenously expressed HDAC10, 
although both of the above named clones had considerable reactivity against proteins of higher 
molecular weight, which did not fade in case of HDAC10 depletion. As reported HDAC10 isoforms 
have a smaller molecular weight than the full-length protein and because siRNAs were designed to 
target all HDAC10 isoforms, these bands were likely due to off-target activity (Figure 50 red arrows).  
 
Figure 50: Testing of various subclones for reactivity against endogenously expressed HDAC10 in BE(2)-C cells. 
(a) Undiluted hybridoma supernatant were tested on lysates from BE(2)-C cells transfected with HDAC10 and 
control siRNAs, respectively. Lysates were generated 6d after siRNA transfection. Subclones of the 477 clone (e.g. 
477/16) showed good on-target activity (blue arrow) but also significant off-target activity at a higher molecular 
weight (red arrow). On target activity disappeared upon HDAC10 knockdown. (b) Testing of sub-subclones of the 
50/7 and 477/16 family. Numbers below the subclone name indicate sub-subclone number. Blue and red arrows 
indicate on-target and off-target activity, respectively. Sigma H3413 polyclonal rabbit anti HDAC10 antibody (1 
μg/ml) was used as positive control.  
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3.1.4 Evaluation of the potential suitability of the 477/16/13 and 50/7/1 clones 
for immunofluorescence and immunohistochemistry 
Of the #50 and #477 hybridoma family, subclones 50/7/1 and 477/16/3 were selected for hybridoma 
expansion and antibody purification, as they showed comparably good reactivity and signal-to-noise 
ratio in on endogenously expressed HDAC10 (see section E3.1.3). During expansion, the 50/7/1 clone 
looked particularly promising and repeatedly displayed good reactivity against HDAC10 with limited 
off-target activity (Figure 51a). Undiluted supernatants from both clones were further able to 
specifically detect overexpressed HDAC10 in IMR-32 cells both in confocal immunofluorescence and 
in paraffin-embedded cells, showing their potential suitability for these approaches (Figure 51b, c). 
Immunofluorescence analysis on IMR-32 cells revealed that HDAC10 was not only localized in the 
cytoplasm but also in the nucleus, even though HDAC10 is thought to be a cytoplasmic HDAC due to 
the presence of nuclear export signals (NES) (Tong et al. 2002).  
 
Figure 51: Testing of the 50/7/1 sub-subclone during clonal expansion. (a) Testing of undiluted hybridoma 
supernatant via western blot on lysates from BE(2)-C cells transfected with HDAC10 siRNA and control siRNA, 
respectively. Lysates were generated 6d after siRNA transfection (b) Testing of undiluted 477/16/3 and 50/7/1 
supernatants via confocal immunofluorescence microscopy using HDAC10 overexpressing IMR-32 cells and 
control cells. (c) HDAC10 expressing and control transfected IMR-32 cells were embedded into paraffin in order 
to test undiluted hybridoma supernatants in an immunohistochemistry setting. Embedding and staining of cells 
was performed by Dr. Marcus Renner (Heidelberg University Hospital). 
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Protein G affinity based purification of antibodies from the 477/16/3 clone did not substantially alter 
off-target activity on western blot, suggesting that off-target activity was inherent to the HDAC10-
reactive antibody itself (Figure 52a). Although previous immunofluorescence experiments with 
477/16/3 hybridoma supernatant on HDAC10 overexpressing IMR-32 cells suggested potential 
suitability of this antibody for immunofluorescence approaches, this was not confirmed when 
purified 477/16/3 antibody was used for the staining of endogenous HDAC10 in BE(2)-C cells, as no 
differential staining was observed in siCtrl versus siHDAC10 transfected cells (Figure 52b).  
In marked contrast to antibodies purified from 477/16/3 hybridoma cultures, purified antibodies of 
the 50/7/1 clone unexpectedly displayed strong off-target activity (Figure 52c) . Direct comparison of 
purified antibodies (50/7/1_03_15#1 and 50/7/1_03_15#2) with the respective source hybridoma 
supernatant revealed that off-target activity was strongly enriched in case of purified antibodies, 
suggesting potential enrichment of a secondary, off-target, antibody.  
 
Figure 52: Purification of HDAC10 antibodies from 477/16/3 
and 50/7/1 hybridoma supernatants. (a) Western blot testing 
of purified 477/16/3 antibody (final concentration 1 μg/ml) on 
lysates from HDAC10 overexpressing IMR-32 versus control, as 
well as BE(2)-C cells transfected with HDAC10 and control 
siRNAs (6 days). Purified antibody was compared to undiluted 
hybridoma supernatant. (b) Testing of purified 477/16/3 
antibody on BE(2)-C cells transfected with siRNAs against 
HDAC10 and control siRNAs, respectively. Staining was 
performed 6d after transfection of siRNAs. (c) Western blot 
testing of two different batches of purified 50_7_1 antibody 
(final concentration 1 μg/ml) on BE(2)-C cells transfected with 
siRNAs against HDAC10 and control siRNAs, respectively. 
Antibody reactivity was compared to undiluted supernatant 
used for purification (source supernatant). Sigma H3413 
antibody was used as positive control. Red arrow indicates off-
target activity, which was markedly increased after purification. 
Nuclei were counterstained with DAPI. 
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3.1.5 Different batches of purified 50/7/1 antibody reveal that off-target 
activity of this clone depends on hybridoma batch but is likely not due to 
contamination with a secondary clone 
After initial antibody purifications of the 50/7/1 clone had been unsatisfactory due to a strong 
increase in antibody off-target activity (see section E3.1.4), various batches of 50/7/1 hybridoma cells 
were defrosted and taken into culture. Intriguingly, one of these batches completely lacked off-target 
activity and only detected the HDAC10 band on western blot (Figure 53a). When the respective blot 
was re-probed with previous batches of purified 50/7/1 antibody, the off-target band observed in 
section E3.1.4 was readily detected, excluding that the absence of the off-target band was due to 
poor blotting or due to absence of the respective off-target protein in these lysates (Figure 53a). 
Purified 50/7/1 antibody that was immediately isolated from the above described hybridoma batch 
("50/7/1_05/15") also completely lacked off-target activity, while the on-target HDAC10 band was 
comparable to previous 50/7/1 antibody batches (Figure 53b). Therefore, off-target activity of the 
50/7/1 antibody was probably not inherent to the HDAC10-recognizing antibody itself but more likely 
caused by production of a second, unspecific, antibody, possibly due to contamination with a 
secondary hybridoma clone.  
Purified antibody from the 50/7/1_05_15 batch allowed for the detection of endogenous HDAC10 in 
BE(2)-C via confocal microscopy (Figure 53c). Similar to the results obtained for overexpressed 
HDAC10 in IMR-32 cells, endogenous HDAC10 was preferably localized in the nucleus and cytoplasm 
of BE(2)-C cells. RNAi mediated knockdown confirmed that the detected signal was HDAC10, as it 
slightly but visibly decreased staining intensity. These results demonstrated the full potential of 
antibodies from the 50/7/1 hybridoma clone in case that off-target activity can be durably 
eliminated. 
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In an attempt to exclude re-occurrence of off-target reactivity, the 50/7/1 culture lacking off-target 
activity was subjected to an extra round of subcloning. Paradoxically, subcloning caused the 
recurrence of off-target activity in all tested sub-subclones (Figure 54a). Consequently, antibodies 
purified from these supernatants (termed 50/7/1/7) also displayed off-target activity (Figure 54b).  
In summary, multiple rounds of subcloning failed to isolate 50/7/1 clones with stable on-target and 
no off-target activity. It is unlikely that the 50/7/1 hybridoma clone is contaminated with a secondary 
hybridoma clone. At the same time, it is also unlikely that off-target activity is inherent to the 
Figure 53: Comparison of various batches of purified 50/7/1 antibody. (a) Supernatant from 50/7/1 cells that 
lacked secondary reactivity (05_15) was tested on BE(2)-C cells transfected with HDAC10 siRNA and control 
siRNA, respectively. The blot was re-incubated with 1μg/ml purified 50/7/1 antibody (03_15) which nearly 
exclusively displays off-target reactivity (right panel). (b) 50/7/1 antibody purified from supernatants without 
secondary reactivity (05_15#1) was compared to previous 50/7/1 purifications (03_15#1 and 03_15#2) and 
antibodies from the 477/16/3 hybridoma HDAC10 overexpressing and control transfected IMR-32 cells. Sigma 
H3413 antibody was used as HDAC10 positive control. Antibodies were used at a concentration of 1 μg/ml. (c) 
186 μg/ml of 50/7/1 purified antibody 05_15#1 was used on PFA-fixed cells transfected with HDAC10 siRNA and 
control siRNA, respectively. 
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HDAC10-reactive antibody itself, as distinct antibody batches lacked off-target while retaining on-
target activity (Figure 54b).  
 
3.1.6 The 50/7/1 hybridoma clone is potentially unstable 
Continuous culturing of the 50/7/1 hybridoma clone caused the loss of off-target activity of the 
50/7/1 hybridoma culture. However, clones lacking off-target activity were unstable and gradually 
also lost on-target reactivity (Figure 55a). Attempts to purify antibody from 50/7/1 cultures that had 
residual on-target reactivity and completely lacked off-target reactivity remained unsuccessful 
(Figure 55b). In this case, purified antibodies lacked reactivity even when used at the same or at 
higher concentrations than previously purified antibodies (2 μg/ml).  
Figure 54: Sub-subcloning of 50/7/1 hybridoma batches that initially lacked off-target activity. (a) Western 
blot testing of 12 sub-subclones of the 50/7/1 hybridoma batch that lacked off-target activity after defrosting. 
Sub-subcloning paradoxically caused recurrence of off-target activity in all tested sub-subclones. (b) Direct 
comparison of purified antibodies from sub-subcloned 50/7/1/7 cultures (50/7/1/7_06_15#1) with a purified 
50/7/1 antibody batch that lacked off-target activity (50/7/1_05_15#1) on western blot. Antibodies were tested 
on lysates from BE(2)-C cells transfected with siRNAs against HDAC10 or control siRNAs. Both antibody batches 
were used at a final concentration of 1 μg/ml. Red arrow indicates off-target activity. 
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3.1.7 Purification of antibodies from alternative hybridoma clones and clones 
that should be considered for future re-testing 
Due to the unsatisfactory quality and batch-to-batch variability of HDAC10 antibodies from the 
50/7/1 hybridoma clone, a subset of alternative hybridoma clones was re-taken into culture and re-
tested via western blot on lysates from cells overexpressing HDAC10, as well as on lysates from 
BE(2)-C cells with moderate HDAC10 expression. Empty vector transfected IMR-32 cells and BE(2)-C 
cells with RNAi-mediated HDAC10 knockdown were used as respective controls. In total, 10 clones 
were re-thawed, including parental hybridoma cultures (263, 428, 964, 17, 58, 885), as well as sub or 
sub-subclones (32/1, 13/1/6/1, 885/1/20) (Figure 56). With the exception of clone 17, which had 
been shown to be unstable before (Figure 49b), clones showed good reactivity and relatively good 
specificity on IMR-32 lysates with HDAC10 overexpression (Figure 56 left panel). However, most 
clones did show very limited reactivity against endogenously expressed HDAC10 in BE(2)-C cells, with 
the exception of clone 428, 13/1/6/1 and, to a limited extent, 885/1/20. As clone 428 showed high 
cross-reactivity to non-HDAC10 bands, it was excluded from antibody purification (Figure 56 right 
panel). 
Figure 55: The 50/7/1 hybridoma clone can lose antibody productivity over longer periods of cultivation. (a) 
Antibody productivity of 50/7/1 cells was assessed on western blot level using lysates of BE(2)-C cells. 
Supernatants from 50/7/1 hybridoma clones either cultivated at low (1) or high (2) confluency were collected at 
indicated timepoints after an arbitrarily set time point zero (t0). Sigma H3413 HDAC10 antibody was used as 
positive control (b) Supernatants from around t21d were collected, used for antibody purification (50/7/1_10_15) 
and tested on lysates from IMR-32 cells overexpressing HDAC10, as well as BE(2)-C cells with HDAC10 
knockdown. HDAC10 reactivity was compared to earlier 50/7/1 purifications (in this case 50/7/1_08_15) as well 
as to the Sigma H3413 antibody (positive control). 50/7/1 antibodies were at used at a concentrations of 2 
μg/ml. 
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When used at 1 μg/ml, purified 13/1/6/1 and 885/1/20 antibodies displayed little to no reactivity 
even towards overexpressed HDAC10, let alone towards endogenously expressed HDAC10 (Figure 
57a). This suggested that either affinity of these antibodies towards HDAC10 was low or that 
antibody purifications were contaminated with undesired protein. 
Alternative clones such as 22, 198, 256, 275 and 917 should be considered for re-testing. Here, 
especially clone 917 showed very high reactivity towards overexpressed HDAC10 (Figure 57b). 
Figure 56: Testing of supernatants of defrosted alternative hybridoma clones. (a, b) Suitability of various 
alternative hybridoma clones for antibody purification was assessed on western blot level using lysates from 
IMR-32 overexpressing HDAC10 (left panel) and BE(2)-C cells with HDAC10 knockdown (right panel). Sigma 
H3413 commercial HDAC10 antibody was used as positive control. 
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Although showing significant cross-reactivity towards proteins other than HDAC10, which likely 
makes it unusable for immunofluorescence or immunohistochemistry, this clone could still yield 
antibodies with high sensitivity on western blot level.  
 
3.2 Alternative approaches to generate an HDAC10 antibody 
3.2.1 Generation of a commercial rabbit polyclonal HDAC10 antibody using 
short peptide epitopes 
Since production of a monoclonal HDAC10 antibody could not be successfully completed, an attempt 
was made to generate a polyclonal HDAC10 antibody in rabbits with the help of the "speedy 28-day 
polyclonal protocol" provided by Eurogentec. Although polyclonal antibodies have clear 
Figure 57: Purification of antibodies from 885/1/20 and 13/1/6/1 clones. (a) 885/1/20 and 13/1/6/1 antibodies 
purified from supernatants of the respective hybridoma clones were tested on western blot level using lysates 
from HDAC10 overexpressing IMR-32 cells and BE(2)-C cells with HDAC10 knockdown, respectively. Sigma H3413 
commercial HDAC10 antibody was used as positive control. (b) Alternative clones (exemplary shown for clone 
917) should be considered for future antibody purifications. Although hybridoma culture showed significant off-
target activity, its strong reactivity could make it a useful source for a highly reactive western blot antibody. 
Sigma H3413 commercial HDAC10 antibody was used as positive control. 
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disadvantages like batch-to-batch variability or the presence of non-specific antibodies in sera of 
immunized animals, they can be produced quicker and cheaper than monoclonal antibodies, as 
production of the former bypasses cultivation of hybridoma cells and complex screening procedures. 
Moreover, unspecific antibodies can be in part circumvented by the injection of short peptide 
immunogens that recognize unique epitopes on the protein of interest and by purification of 
antibodies via immobilized injection peptide. 
Of the eleven potential short injection peptide sequences provided by Eurogentec, two 15 amino 
acid peptides (P1610192 and P1610193) with the least amount of cross-reactivity to other human 
proteins in BLAST searches were selected. These were coupled to KLH as carrier protein (5 mg) and 
injected into two rabbits (SY7749 and SY7750). All peptide sequences provided by Eurogentec 
showed at least five sequential amino acids that were identical to other human peptides or proteins 
(Figure 58a). Eurogentec performed the coupling of the immunogens to KLH, animal immunization, 
ELISA-testing of animal sera against the immunogens, as well as purification of the antibodies against 
the respective peptides. Serum from one of the immunized animals (SY7749) that displayed higher 
antibody titers was used for purification. Two batches of purified antibodies were generated by 
affinity binding against either of the injection peptides (Figure 58b). 
Purified antibodies, as well as sera from both immunized animals were tested on western blot using 
lysates from IMR-32 cells overexpressing HDAC10 and the respective empty vector control cells 
(Figure 58b, c). Here, all sera showed lacked reactivity against HDAC10 and showed cross-reactivity 
to other proteins. Only, in case of purified antibodies from rabbit SY7749, slight reactivity against 
HDAC10 was observed when antibodies were used at a concentration of 1 µg/ml (Figure 58b). At 
higher concentrations (5 µg/ml), both purified antibodies showed detectable but weak reactivity 
towards HDAC10, and, in case of antibody 1610192, also considerable cross-reactivity to other 
proteins (Figure 58d).  
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To test whether either purified antibody was useful for IF/IHC approaches, they were tested at 
various concentrations in immunofluorescence using paraformaldehyde-fixed HDAC10 transfected 
IMR-32 cells and empty vector transfected control cells. Here, both antibodies failed to differentially 
stain empty vector versus HDAC10 transfected IMR-32 cells and were thus considered as unspecific 
in an immunofluorescence setting (Figure 59). Moreover, the presence of highly-fluorescent artifacts 
Figure 58: Testing of commercially generated HDAC10 antibodies, as well as immune sera from immunized 
animals. (a) Selection of two 15 amino acid peptides for co-injection into two rabbits. Peptides that showed 
lowest cross-reactivity to other proteins on BLAST search were selected for coupling to KLH and injection into 
animals. Notably, no peptide of choice showed less than five sequential amino acids identical to other human 
proteins. (b) Western blot testing of sera and purified antibodies(P1610192, P1610193) from immunized 
rabbit SY7749 on lysates from IMR-32 cells overexpressing HDAC10 and empty vector transfected cells, 
respectively. Antibodies were purified separately against the immunization peptides P1610192 and P1610193 
and used at a final concentration of 1 μg/ml. Sigma H3413 commercial HDAC10 antibody was used as positive 
control. (c) Western blot testing of sera from immunized rabbit SY7750. Sera from this rabbit did not undergo 
purification. Sigma H3413 commercial HDAC10 antibody was used as positive control (d) Western blot testing 
of purified antibodies from rabbit SY7749 at higher concentrations (5 μg/ml) on IMR-32 cells with HDAC10 
overexpression or empty vector transfected control cells. Abbreviations: p.i.s. - pre-immune serum; m.b.s. - 
medium bleed serum; f.b.s. - final bleed serum. 
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in the stainings hinted at the presence of impurities or aggregated antibodies. Therefore, the attempt 
to generate polyclonal rabbit antibodies against HDAC10 remained unsuccessful.  
 
3.2.2 Testing of potential HDAC10 antibodies generated by antibody phage 
display 
Alternative to the classical way, which involves injection of an antigen into and isolation of B-cells 
from immunized animals, monoclonal antibodies can be generated without the use of animals via so 
called antibody phage display (see methods section C4.3). Two linearized HDAC10 fragments 
(HDAC10T1 and HDAC10T2 in 8M Urea, see Table 51 and methods section C4.1), the latter of which 
was used to generate HDAC10-reactive mouse hybridoma clones (see section E3.1), were used for 
testing against the human antibody phage libraries display libraries HAL9/10 (Kugler et al. 2015) in 
the lab of Dr. Michael Hust (TU Braunschweig). Panning revealed four clones reactive against the 
HDAC10T1 fragment, while no HDAC10T2 reactive clones were identified (data not shown). Titration 
ELISA assays of the four clones (performed by Saskia Helmsing, TU Braunschweig) showed binding of 
Figure 59: Assessing suitability of purified antibodies from immunized rabbit SY7749 for immunofluorescence 
analysis. Various concentrations of antibodies purified from final bleed serum of rabbit SY7749 against the 
immunization peptides P1610192 and P1610193 were used to stain IMR-32 cells overexpressing HDAC10 and 
control transfected cells, respectively. Nuclei were counterstained with DAPI. 
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these clones to HDAC10T1, but not to the negative control (BSA) or the HDAC10T2 fragment (Figure 
60a). Here, especially clone C12 showed promisingly high affinity towards HDAC10T1. After recloning 
of the reactive VH and VL genes into the pCSE2.6-mIgG2a-Fc-XP plasmid, thus generating scFv-Fc 
fusion genes with a murine IgG2a Fc fragment (scFV-Fc antibody), antibody plasmids were ectopically 
expressed in Expi293F™ cells, followed by purification of scFV-Fc antibodies via protein A (performed 
by Saskia Helmsing, TU Braunschweig). Purified antibodies were then tested via western blot on 
lysates from HDAC10 overexpressing IMR-32 cells and the respective control cells (Figure 60b-e). 
Here, only antibodies from the H7 clone showed reactivity towards HDAC10 (Figure 60c), while 
antibodies from other clones were either unreactive (G2), or only recognized off-target proteins (A5 
and C12). However, reactivity of the H7 antibody even against overexpressed HDAC10 in IMR-32 cells 
was low, as high concentrations of antibody and prolonged exposure were necessary. Thus, none of 
the clones was thus further developed. 
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Figure 60: Testing of potentially HDAC10 reactive clones from antibody phage display. (a) Titration ELISA of 
four scFv fragments that had been identified as reactive against the HDAC10T1 fragment in panning assays. 
ScFv fragments were also tested against BSA (negative control) and the HDAC10T2 antigen. Panning and ELISA 
assays were performed by Saskia Helmsing in the lab of Michael Hust (TU Braunschweig). (b-e) Testing of 
murine scFv-Fc fusion antibodies G2 (b), H7 (c), C12 (d) and A5 (e) on western blot level. ScFv fragments, which 
had been cloned onto a mouse IgG2a Fc region and purified from HEK293 cells were used at two different 
concentrations (1 μg/ml and 5 μg/ml). Bound antibodies were detected using peroxidase-conjugated anti 
mouse antibodies. 
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F DISCUSSION 
Neuroblastomas have a fairly good outcome with a five year overall survival rate of almost 80 %. 
Nevertheless overall survival remains below 50 % in neuroblastomas categorized as high-risk tumors 
by the INRG classification system (see section A1.2) (Cohn et al. 2009). Prognosis is even worse in 
patients with relapsed high-risk tumors, which occur in about 50 % of high-risk neuroblastoma cases 
and where five year overall survival is below 10 % in spite of intensification of treatment regimens 
(Basta et al. 2016). Resistance to a wide range of chemotherapeutics due to multidrug resistance 
(MDR) is one of the main factors limiting treatment success in high-risk and relapsed neuroblastoma 
patients, highlighting the need for novel, targeted therapy approaches capable of either 
circumventing or reversing MDR.  
Aberrant HDAC activity is a common observation in cancer, and HDACs are critically involved in 
numerous cancer-relevant pathways (reviewed in (Ropero and Esteller 2007; Witt et al. 2009)). 
Together with their excellent druggability, this makes them an attractive target for cancer therapy. 
The efficacy of pan and broad-spectrum HDACi such as vorinostat (SAHA), romidepsin, belinostat and 
panobinostat has been proven in leukemias and lymphomas, leading to their approval for clinical 
application and further testing in numerous clinical trials in other cancer entities including 
neuroblastoma (Witt et al. 2012; Ceccacci and Minucci 2016)(clinical study: NCT01422499). The use 
of such broad-spectrum inhibitors is, however, hampered by dose limiting off-target toxicities 
including myelosuppression, fatigue and gastrointestinal symptoms like diarrhea, nausea and 
vomiting. It is postulated that such toxicities mainly arise from the inhibition of HDACs 1, 2 and 3, 
which epigenetically regulate the expression of a large number of genes in both neoplastic and non-
neoplastic cells (Lane and Chabner 2009; Witt et al. 2009; Wilting et al. 2010). Thus, the key question 
remains, whether off-target toxicity can be reduced and on-target efficacy retained by a more 
specific inhibition of individual HDAC enzymes that are critical for the respective cancer entity or 
tumor subtype. Moreover, elucidating molecular mechanisms through which individual HDAC 
enzymes exert their tumor promoting function can help identify potential tumor escape mechanisms, 
as well as markers capable of monitoring or predicting the response of the tumor. The advantage of 
targeting individual HDACs in neuroblastoma has been demonstrated in a recent study, where 
specific inhibition of HDAC8 was as effective as vorinostat treatment with significantly lower dose-
limiting side effects (Rettig et al. 2015). 
One other HDAC suggested to be of particular importance in neuroblastoma biology is the class IIb 
member HDAC10, elevated expression of which correlates with poor prognosis specifically in INSS 
stage 4 neuroblastoma patients (Oehme et al. 2013a; Oehme et al. 2013b). Interference with 
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HDAC10 function sensitizes neuroblastoma cell lines to neuroblastoma-relevant chemotherapeutics 
such as doxorubicin and vincristine, suggesting that HDAC10 mediates chemoresistance. In contrast, 
high expression of HDAC6 does not correlate with poor prognosis in neuroblastoma (Oehme et al. 
2009b; Oehme et al. 2013b), suggesting that despite their high homology (Fischer et al. 2002; 
Guardiola and Yao 2002; Kao et al. 2002), class IIb HDACs have partly non-redundant functions. 
1 HDAC10 promotes lysosomal resistance mechanisms 
in neuroblastoma  
1.1 Interference with HDAC10 function causes expansion of the 
lysosomal compartment via lysosomal accumulation 
Both class IIb HDACs have been repeatedly linked to various modes of cellular stress response 
including DNA repair (Namdar et al. 2010; Kotian et al. 2011; Wang et al. 2012; Radhakrishnan et al. 
2015), degradation of proteins and aggregates (Hook et al. 2002; Kawaguchi et al. 2003; Boyault et al. 
2007; Pandey et al. 2007; Lee et al. 2010b; Ouyang et al. 2012), as well as lysosomal trafficking (Lee 
et al. 2010b; Oehme et al. 2013a). With regards to autophagy, HDAC6 appears to be particularly 
important for the induction of aggregate-induced autophagy (aggrephagy), as well as for 
autophagosome maturation during ubiquitin-mediated autophagy (Lee et al. 2010b). Conversely, 
HDAC10 is required for late stage autophagic flux, i.e. the delivery of autophagosomal material to 
lysosomes in a fusion process, in neuroblastoma, where lack of HDAC10 function further appears to 
interfere with lysosomal function (Oehme et al. 2013a). Given their high homology and partly 
overlapping functions, the role of HDAC6 and HDAC10 in lysosomal biology in neuroblastoma were 
dissected in this study using RNAi approaches, as well as HDAC6/10 (tubastatin A) and HDAC6 
(tubacin) inhibitors with differential HDAC10 inhibitory capability (Butler et al. 2010; Bantscheff et al. 
2011; Oehme et al. 2013a). Differential inhibitor specificities of tubacin (HDAC6) versus tubastatin A 
(HDAC6/10) were confirmed this study by NanoBRET tracer displacement assays (performed in the 
group of Dr. Aubry Miller, DKFZ Heidelberg), where tubastatin A but not tubacin showed high binding 
activity towards HDAC10 (Ridinger et al. 2018).  
Several lines of evidence presented in this study demonstrate that HDAC10 but not HDAC6 is critical 
for lysosomal function in neuroblastoma. First, RNAi mediated depletion of HDAC10 but not HDAC6 
increased the number of lysosomes as indicated by western blot analysis of lysosomal marker LAMP-
2 and by fluorescence microscopic as well as flow cytometric analyses of stainings with acidotropic 
dyes such as LysoTracker DND-99 and acridine orange. Second, treatment with HDAC6/10 but not 
HDAC6 specific inhibitors phenocopied the above described expansion of the lysosomal 
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compartment. Third, HDAC6/10 inhibitors with abolished HDAC10- but intact HDAC6 binding capacity 
did not increase the number of lysosomes. Thus, and despite the absence of non HDAC6-
crossreactive HDAC10 inhibitors, these data clearly point towards a distinct role of class IIb member 
HDAC10 in neuroblastoma lysosomal homeostasis. 
The precise mechanism how HDAC10 affects lysosomal physiology in neuroblastoma cells was not 
conclusively identified in this study, and several distinct mechanisms might be contributing to the 
observed expansion of the lysosomal compartment. Transcriptional up-regulation of lysosomal genes 
by changes in histone acetylation seems unlikely, as HDAC10 has only rarely been reported to be a 
direct epigenetic regulator of gene expression (Li et al. 2015). Also, localization of the lysosomal 
master transcriptional regulator TFEB was unchanged after HDAC10 inhibitor treatment, speaking 
against induction of de novo lysosomal biogenesis via the CLEAR gene-regulatory network (Sardiello 
et al. 2009; Palmieri et al. 2011). Although the role of other autophagy-inducing transcription factors 
such as FoxO1 and FoxO3a was not further investigated, preliminary data from a follow-up project 
indicate that HDAC10 inhibition with tubastatin A does not promote induction of lysosomes via 
nuclear translocation of FoxO family transcription factors (Koerholz, unpublished). In line with this 
hypothesis, depletion of HDAC10 increased lysosomal numbers as well as protein levels of the 
lysosomal marker LAMP-2 without increasing LAMP2 transcript levels, indicating that there is no 
global upregulation of lysosomal genes. Moreover, when lysosomal accumulation was induced with a 
lysosomal exocytosis inhibitor, no additional expansion of the lysosomal compartment was observed 
when HDAC10 inhibitors were added. This suggested that HDAC10 inhibition did not promote de 
novo biogenesis of lysosomes, as de novo production would have further increased lysosomal 
numbers.  
Rather, interference with HDAC10 function likely caused an accumulation of dysfunctional 
lysosomes. Dysfunction of lysosomes, in turn, is known to promote lysosomal accumulation by 
various mechanisms. First, lack or malfunction of lysosomal enzymes, as observed in lysosomal 
storage diseases, leads to storage of "non-degraded" material in lysosomes, which in turn causes 
accumulation of lysosomes with impaired function (Sardiello et al. 2009; Durchfort et al. 2012; 
Appelqvist et al. 2013). Second, mutations in genes governing the autophagic lysosome reformation 
(ALR) pathway are known to cause accumulation of enlarged autophagolysosomes after longterm 
starvation probably due to defective degradation of cargo (Rong et al. 2011). ALR is required for the 
reformation of free lysosomes from autophagolysosomes, as the former are rapidly depleted by 
fusion with autophagosomes during periods of autophagy, and this reformation pathway is thus 
crucial for lysosomal homeostasis (Yu et al. 2010). Although ALR has been mainly characterized in 
Drosophila mutants, mouse models of human hereditary spastic paraplegia show defects in ALR, 
accompanied by depletion of free lysosomes and accumulation of autophagolysosomes that contain 
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undegraded material (Chang et al. 2014; Renvoise et al. 2014; Varga et al. 2015). Third, perturbance 
of the lysosome to cytoplasm pH gradient (de-acidification/alkalinization) can cause lysosomal 
accumulation. Although acidification of lysosomes is not absolutely required for fusion of lysosomes 
with cargo-carrying vesicles (Klionsky et al. 2008; Mauvezin et al. 2015; Mauvezin and Neufeld 2015), 
prolonged alkalinization e.g. by lysosomal inhibitors such as chloroquine or bafilomycin A promotes 
the accumulation of endo- and autophagosomal organelles, as well as de-acidified LAMP-positive 
lysosomes, by interfering with lysosomal fusion processes (Jahreiss et al. 2008; Yoon et al. 2010; 
Chen et al. 2011). Data reported in this study, namely the accumulation of acidotropic dyes in 
lysosomes after interference with HDAC10 function, preclude however, that interference with 
HDAC10 function caused de-acidification of lysosomes, as the number of acidic vesicles was clearly 
increased. Last, blocking of proteins or protein complexes required for lysosomal fusion events such 
as the HOPs complex triggers both autophagosome and lysosome accumulation (Jiang et al. 2014). In 
fact, data presented in a previous study show that interference with HDAC10 function causes 
accumulation of both acidic organelles and autophagosomes, as well as accumulation of the 
autophagosome cargo receptor SQSTM1/p62, suggestive of non-productive autophagy (Oehme et al. 
2013a). Corroborating these findings, this study demonstrates that HDAC10 knockdown further 
blocks lysosomal exocytosis, i.e. the fusion of lysosomes with the plasma membrane (further 
discussed in section F1.2). Taken together, the data presented in (Oehme et al. 2013a) and this study 
suggest that HDAC10 is crucial for lysosomal fusion events in neuroblastoma cells, although it 
remained unclear whether blocked fusion was cause or consequence of lysosomal dysfunction. 
Future studies could clarify for example if the degradative capacity of neuroblastoma cell lysosomes 
is impaired after interference with HDAC10 function by analyzing turnover of lysosomal substrates 
such as tagged EGF receptor (endocytic route) (Jiang et al. 2014) or overexpressed tagged 
polyglutamine (polyQ)-expanded huntingtin protein (Renna et al. 2011). Alternatively, lysosomal 
cathepsin activity could also be quantified using Magic Red™ dye (Johnson et al. 2016). 
Although several lines of evidence suggest that interference with HDAC10 function caused the 
expansion of the lysosomal compartment in neuroblastoma cells by perturbing lysosomal function, it 
cannot be excluded that hyperacidification of lysosomes contributed to the above described 
phenotype. Indeed, increased V-ATPase function has been associated with lower lysosomal and 
enhanced acidification of post Golgi vesicles in cancer cells (Altan et al. 1998; Larsen et al. 2000; 
Gong et al. 2003; Hrabeta et al. 2015). The idea that HDAC10 could be involved in lysosomal 
acidification is supported by the identification of two acetylated lysine residues in subunit A of 
lysosomal V-ATPase complex (ATP6V1A) after HDAC6/10 but not after HDAC6 inhibition. This subunit 
of the cytosolic peripheral V1 domain is critical for ATP hydrolysis and provides the energy required 
for pumping protons across the lysosomal membrane via the membrane-inserted V0 domain 
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(reviewed in (Forgac 2007)). Intriguingly, mutational analyses in subunit A of yeast V-ATPase have 
demonstrated that certain amino acid exchanges can increase coupling efficiency, i.e. the amount of 
protons pumped per ATP hydrolyzed, of the V-ATPase. Although the amino acid affected in the 
respective study was not a lysine residue, it is still conceivable that conformational changes induced 
by posttranslational modifications such as lysine acetylation alter ATP hydrolysis rates, V-ATPase 
assembly rates or coupling efficiency (Shao et al. 2003). Thus, HDAC10 potentially acts on the level of 
lysosome acidification by modulating V-ATPase function. Intriguingly, while lysosomal function 
critically depends on acidification of the lysosomal lumen due to the low pH optimum of lysosomal 
enzymes, some reports suggest that hyperacidification can also result in lysosomal dysfunction. Such 
hyperacidic lysosomes have been reported in cells from patients with the lysosomal storage disease 
mucolipidosis type IV (Soyombo et al. 2006). Here, mutations in the MCOLN1/TRPML1 gene, which 
encodes for a lysosomal cation transporter, resulted in over-acidified lysosomes and impaired 
lysosomal lipid hydrolysis. 
The lysosomal role of non class IIb HDACs in neuroblastoma lysosomal homeostasis 
While the contribution of HDAC6 inhibition to the above described lysosomal phenotype in 
neuroblastoma cells was clearly omitted in this study, it remains to be clarified whether other HDACs 
apart from HDAC10 contribute to lysosomal function in the investigated cell lines. The data 
presented show that high concentrations of tubastatin A indeed cross-inhibit class I HDACs, depletion 
of which have been repeatedly associated with autophagy induction in various cancer models (Oh et 
al. 2008; Xie et al. 2012; Schipper et al. 2014; Koeneke et al. 2015). Regardless, results from RNAi 
mediated knockdown of individual HDACs do not support a marked role of class I HDACs in 
neuroblastoma lysosomal homeostasis, even though a small but not statistically significant expansion 
of the lysosomal compartment was observed in case of HDAC1 depletion. A similar phenotype to 
HDAC1 depletion was observed upon knockdown of the class IV member HDAC11, which was 
included in the analysis due to the high homology of its catalytic domain to both class I and class II 
HDACs (Gao et al. 2002; Seto and Yoshida 2014). Notably, class IIa HDACs 4, 5, 7 and 9 were not 
investigated in this study as they have been reported to have low intrinsic HDAC activity and to 
mostly exert they transcriptionally repressive activity via a SMRT/N-Cor corepressor complex that 
contains the class I member HDAC3 (Kao et al. 2000; Fischle et al. 2002; Jones et al. 2008; Gaur et al. 
2016). While the knockdown data clearly dismissed a significant role for individual class I or class IV 
HDACs, it cannot be excluded that simultaneous inhibition of several HDACs cumulatively induces 
lysosomal dysfunction in neuroblastoma cells. Data obtained from two different designated class I 
HDAC inhibitors (valproic acid and entinostat/MS-275) showed conflicting results, as MS-275 induced 
lysosomal accumulation while VPA did not. A potential cross-reactivity of entinostat to HDAC10 was 
ruled out by NanoBRET assay. It remained unclear, whether lysosomal accumulation after entinostat 
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treatment was due to an off-target effect or whether it could be a result of simultaneous co-
inhibition of class I HDACs and HDAC11. The HDAC11 binding capacity of entinostat, which was 
suggested in a recent study (Tian et al. 2017), and other HDAC inhibitors, as well as the effect of 
simultaneous inhibition of multiple individual HDACs on lysosomal homeostasis should thus be 
investigated more closely in consecutive studies.  
1.2 HDAC10 promotes doxorubicin secretion via lysosomal 
exocytosis 
An expansion of the lysosomal compartment often correlates with increased tumor chemoresistance 
e.g. via the sequestration of weakly basic drugs within lysosomes (Willingham et al. ; Zhitomirsky and 
Assaraf 2015; Guo et al. 2016). Therefore, a key question of this study was whether the expansion of 
the lysosomal compartment after interference with HDAC10 function triggered drug resistance by 
promoting lysosomal sequestration of chemotherapeutics. Indeed, lysosomal sequestration of 
chemotherapeutic drugs has been recently proposed as a resistance mechanism in neuroblastoma 
cells (Hrabeta et al. 2015). Doxorubicin, an anthracycline chemotherapeutic widely used for 
neuroblastoma therapy (Louis and Shohet 2015; Tran et al. 2015), has both weakly basic properties 
and - like its structural relative daunorubicin - a marked autofluorescence, which made it an ideal 
tool compound for the study of cellular drug uptake and subcellular drug distribution (Willingham et 
al. 1986). Despite elevated levels of doxorubicin-positive, perinuclear vesicles (likely doxorubicin 
loaded lysosomes) HDAC10 inhibition did not promote complete sequestration into lysosomal 
vesicles, as it also caused substantially elevated nuclear doxorubicin levels. In line with this, 
HDAC6/10 inhibitor tubastatin A increased sensitivity of neuroblastoma cells to doxorubicin rather 
than promoting doxorubicin resistance. Therefore, HDAC10 inhibition did not promote drug 
resistance via lysosomes. Rather, HDAC10 depletion or inhibition promoted globally increased 
intracellular doxorubicin levels in neuroblastoma cells, although this increase was not observed in 
every tested neuroblastoma cell line (further discussed in section F1.3). However, it cannot be denied 
that a substantial fraction of doxorubicin was located in lysosomes, raising the question whether 
additional permeabilization of lysosomes could further increase treatment efficacy (vide infra). 
Not all lysosomes were located perinuclearly under conditions of HDAC10 knockdown or inhibition. 
This, together with the previous finding that HDAC10 was required for lysosomal fusion with 
autophagosomes (Oehme et al. 2013a), prompted the idea that HDAC10 absence or inhibition blocks 
lysosomal fusion processes. In particular, lysosomes are known to fuse with the plasma membrane in 
a process called lysosomal exocytosis. Although the mechanistic details of this process are not fully 
understood, it is known that it involves two basic steps, namely the relocalization of lysosomes from 
the perinuclear cloud to the cell periphery (Jaiswal et al. 2002), which is followed by a Ca2+ 
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dependent fusion with the plasma membrane (Rodriguez et al. 1997; Reddy et al. 2001; Medina et al. 
2011). Cell surface stainings for the lysosomal marker LAMP-1 indicate that both knockdown and 
inhibition of HDAC10 impaired lysosomal exocytosis in neuroblastoma cells. In contrast to a previous 
study, which suggested that HDAC6 was critical for IL-1 secretion via lysosomal exocytosis from 
human monocytes (Carta et al. 2006), HDAC6 was not required for lysosomal exocytosis in 
neuroblastoma cells. Coherently, HDAC10 but not HDAC6 inhibition reduced the rate of doxorubicin 
secretion in washout experiments. HDAC10 inhibition did not alter trafficking of P-glycoprotein, an 
ATP-driven drug efflux pump previously published to promote doxorubicin resistance in 
neuroblastoma (Michaelis et al. 2009), to the plasma membrane. Furthermore, the data presented 
indicate that HDAC10 inhibition promoted doxorubicin accumulation regardless of cellular P-
glycoprotein levels.  
The precise mechanism how HDAC10 promotes lysosomal exocytosis remains to be clarified, which is 
aggravated by the fact that lysosomal exocytosis itself is a poorly understood process (reviewed in 
(Samie and Xu 2014)). Interference with HDAC10 function neither caused clustering of lysosomal 
vesicles near the plasma membrane nor centripetal collapse of the lysosomal compartment near the 
MTOC, which has been observed in case of genetic ablation and overexpression of proteins required 
for binding of lysosomes to kinesin motor proteins, respectively (Pu et al. 2016; Wang et al. 2018). It 
is thus unlikely that HDAC10 is critically involved in antero- or retrograde trafficking of lysosomes 
along microtubules. The observed distribution of lysosomes throughout the cytoplasm after HDAC10 
inhibition could be a consequence of lysosomal expansion, failed lysosomal exocytosis or both. 
Lysosomal exocytosis is regulated on many levels by vesicle tethering factors, SNARE proteins, cation 
channels and Ca2+-sensing proteins (Rao et al. 2004; Verderio et al. 2012; Samie and Xu 2014). Future 
experiments could focus on the identification of HDAC10 binding partners that are involved in 
lysosomal exocytosis via immunoprecipitation and mass spectrometry approaches. However, 
pulldown experiments with endogenously expressed HDAC10 are currently hampered by the absence 
of HDAC10 antibodies of sufficient specificity (see section F3). Intriguingly, dysfunction of the 
lysosomal cation channel MCOLN1 has not only been associated with lysosomal hyperacidification 
(Soyombo et al. 2006) but also with alterations in lysosomal fusion processes including lysosomal 
exocytosis (LaPlante et al. 2006; Dong et al. 2009). A more recent report indicates that MCOLN1 is 
required for the fusion of lysosomes with the plasma membrane by acting as a lysosomal Ca2+ efflux 
channel, providing locally elevated Ca2+ levels necessary for the fusion of lysosomes with the plasma 
membrane (Medina et al. 2011). Thus, the lysosomal expansion or possibly hyperacidification 
phenotype described in section F1.1, and defects in lysosomal exocytosis after HDAC10 inhibition 
might be linked via MCOLN1. In this context, one study even suggests that activity of the MCOLN1 
channel is negatively regulated by a decrease in lysosomal pH (Raychowdhury et al. 2004). It is thus 
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conceivable that HDAC10 is either a direct regulator of MCOLN1 function (e.g. via altering its 
acetylation) and thus lysosomal exocytosis, or that interference with HDAC10 function causes 
secondary dysfunction of MCOLN1 by increased lysosomal acidification.  
Lysosomal exocytosis does not only favor tumor progression by promoting the sequestration and 
secretion of chemotherapeutic drugs, but also by the secretion of lysosomal hydrolases to the 
extracellular space which increases invasiveness of tumor cells by increased degradation of ECM 
components (Vasiljeva and Turk 2008; Liu et al. 2012b; Fonovic and Turk 2014; Machado et al. 2015). 
It is tempting to speculate that interfering with HDAC10 function in vivo could block tumor 
progression via two separate mechanisms, namely the reversal of tumor chemoresistance and the 
reduction of tumor cell invasion and metastasis formation. The data in this study further indicate that  
blockage of HDAC10 function does not sensitize proliferating human fibroblasts to doxorubicin, 
possibly because fibroblasts do not depend on lysosomes for the detoxification of doxorubicin. 
Although these findings suggests that interference with HDAC10 function can be used to specifically 
target tumor cells, this should be further investigated in other non-neoplastic cell models, such as 
cardiomyocytes which are especially sensitive to doxorubicin (Bristow et al. 1978; Doroshow et al. 
1981; Arola et al. 2000).  
Autophagic flux contributes to doxorubicin secretion under 3D conditions 
Three main routes deliver membranes and cargo material to the lysosomal compartment: The 
biosynthetic route via the ER and Golgi, various modes of endocytosis, as well as (macro-)autophagy 
(Luzio et al. 2003). High autophagic flux requires adaptation of the lysosomal compartment. Not 
surprisingly, regulation of autophagy and lysosomal biogenesis under stress conditions are inherently 
linked by coordinated transcriptional programs via TFEB and FoxO family transcription factors (Zhao 
et al. 2007; Settembre et al. 2011). Basal autophagic flux occurs in normal cells, but especially cancer 
cells increase flux rates in order to cope with various stress conditions (reviewed in (White 2012)). 
This raised the question whether the flux of autophagosomes into the lysosomal compartment 
contributed to doxorubicin secretion in neuroblastoma cells. Under two-dimensional cell culture 
conditions, knockdown of ATG5, a central player in autophagosome formation, did not interfere with 
doxorubicin secretion, indicating that the disposal of doxorubicin via lysosomes did not require 
autophagic flux into the lysosomal compartment under these conditions. Also, remaining levels of 
ATG5 protein after knockdown could be sufficient to maintain the required basal autophagic flux 
under 2D conditions, as these conditions do not impose limits to nutrient and oxygen supply. 
Conversely, the limited levels of ATG5 after knockdown could become a restrictive factor for 
autophagic flux under the stress conditions imposed by three-dimensional culture. In line with this, 
autophagic flux contributed to doxorubicin secretion and reduction of ATG5 levels substantially 
increased intracellular doxorubicin accumulation. Neuroblastoma cells are known to increase 
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autophagic flux under 3D culture conditions, and this is mediated by the FoxO family transcription 
factor FoxO3a (Bingel et al. 2017). Under such conditions, autophagic flux becomes a major 
contributing factor to the lysosomal compartment by an increased formation of 
autophagolysosomes. This is supported by a substantially decreased number of autophago-lysosomal 
numbers under 3D conditions. Lastly, autophagosomes can also contribute to protein secretion by 
direct fusion with the plasma membrane in a process termed secretory autophagy (Kimura et al. 
2017a; Kimura et al. 2017b). Although the presence of autophagosomal markers such as LC3-II at the 
plasma membrane under 2D- and 3D conditions was not analyzed in this study, the non-acidic pH of 
autophagosomes prior to their fusion with lysosomes makes it unlikely that doxorubicin substantially 
accumulates in autophagosomes, and thus that secretory autophagy was a major contributing factor 
to doxorubicin secretion.  
Can addition of LMP provoking agents further increase the efficacy of doxorubicin and HDAC10 
inhibitors in neuroblastoma cells? 
HDAC6/10 inhibitor tubastatin A sensitized neuroblastoma cells to doxorubicin partly by increasing 
intracellular accumulation of doxorubicin. Although this, along with the fact that doxorubicin also 
significantly accumulated in nuclei after HDAC10 inhibition, suggests that interference with HDAC10 
function does not actively promote lysosomal sequestration of weakly basic chemotherapeutic drugs, 
a substantial fraction of doxorubicin remained trapped in lysosomal vesicles and was thus biologically 
inactive. While cancer cells use lysosomes to acquire an increased capability to cope with various 
stress stimuli, increased lysosomal numbers make them also particularly vulnerable to lysosomal 
membrane permeabilization (LMP) (Bivik et al. 2006; Turk and Turk 2009; Enzenmuller et al. 2013). 
Induction of LMP would not only cause leakage of remaining drugs from lysosomes but also trigger 
the release of lysosomal cathepsins to the cytosol, where they induce apoptosis, thus further 
increasing the efficacy of treatment (Roberg and Ollinger 1998; Foghsgaard et al. 2001; Yuan et al. 
2002; Bivik et al. 2006). Fluoremetric assays quantifying the cytosolic activity of lysosomal cathepsins 
performed in this study do not support that HDAC10 inhibitors themselves caused lysosomal 
permeabilization. However, the data presented are partly conflicting and have to be interpreted with 
great care due to several reasons. First, an increase cytoplasmic cathepsin activity after HDAC10 
inhibition was occasionally observed in some of the experimental replicates. Second, even low doses 
of digitonin, which were used to selectively permeabilize the plasma membrane while leaving the 
lysosomal membrane intact, caused high basal cytosolic cathepsin activity in some instances, 
suggesting that the assay itself requires optimization, e.g. by lowering digitonin concentrations. 
Finally, the cathepsin release assay is not sensitive to permeabilization of individual lysosomes. While 
LysoTracker data suggest that most lysosomal membranes are indeed intact after HDAC10 inhibition, 
as the dye would otherwise leak to the cytosol, it cannot be excluded that a subset of dysfunctional 
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lysosomes becomes permeable, which in turn would explain the increased amount of nuclear 
doxorubicin after HDAC10 inhibition. More recent experimental tools, that use fluorescently labeled 
dextrans, are not only able to pick up lysosomal permeabilization more sensitively. Via the use of 
dextrans with different molecular weight, they can also be used to estimate the pore size upon 
lysosomal permeabilization (Aits et al. 2015). Small molecules like doxorubicin or other cytostatic 
drugs escape the lysosome at much smaller degrees of LMP than cathepsins, which have a 
considerably higher molecular weight.  
One particularly interesting candidate for the induction of lysosomal permeabilization is the 
lysosomotropic agent chloroquine, prolonged exposure to which can cause lysosomal membrane 
destabilization (Boya et al. 2003; Enzenmuller et al. 2013). Currently ongoing studies demonstrate 
that addition of chloroquine can potentiate the treatment of various neuroblastoma cell lines with 
doxorubicin and HDAC inhibitors, underlining the importance of lysosomal membrane integrity for 
chemoresistance in the respective models (Koeneke, unpublished). Addition of chloroquine would 
also allow for the use of lower doxorubicin concentrations, which is critical for the reduction of 
doxorubicin-induced side effects such as cardiac dysfunction (Shan et al. 1996). 
1.3 Lysosomal accumulation upon HDAC10 inhibition - a marker 
for dependency of tumor cells on lysosomal resistance 
mechanisms? 
As briefly mentioned in section F1.1, not all cell lines analyzed in this study accumulated higher levels 
of doxorubicin after HDAC10 inhibition. These include two neuroblastoma cell lines (NB-1, Kelly), as 
well as proliferating human foreskin fibroblasts. Differential doxorubicin accumulation in 
neuroblastoma cell lines did not correlate with HDAC10 protein expression, raising the question why 
HDAC10 inhibition promoted doxorubicin accumulation in some cell lines but not in others. Although 
the effect of HDAC10 inhibition on lysosomal exocytosis rates was not investigated for Kelly and NB-1 
cells, HDAC10 inhibition did impair lysosomal exocytosis in fibroblasts and thus in a cell line that did 
not display increased doxorubicin accumulation. This suggested that fibroblasts either disposed of 
doxorubicin primarily by other mechanisms (e.g. ATP driven pumps) or that inhibition of lysosomal 
exocytosis was necessary but not sufficient for the intracellular accumulation of doxorubicin. 
Intriguingly, NB-1 and Kelly cells did not display expansion of the lysosomal compartment under 
HDAC10 inhibited conditions in this study, with Kelly cells being known to display increased 
lysosomal accumulation only at high HDAC10 inhibitor concentrations (Oehme et al. 2013a). The 
same study also indicates that HDAC10 inhibition does not induce lysosomal expansion in fibroblasts. 
Taken together, this suggests that HDAC10i-mediated doxorubicin accumulation requires an 
expansion of the lysosomal compartment. Lysosomal expansion causes a substantial fraction of 
 
DISCUSSION 179 
doxorubicin to be located in lysosomal vesicles, which can then be cleared from cells via lysosomal 
exocytosis.  
The fact that some but not all cell lines react to HDAC10 inhibition with an expansion of the 
lysosomal compartment suggests that HDAC10 acts as a bottleneck for lysosomal homeostasis in 
some but not other cell lines (vide infra). Consequently, not all tumor cells or subtypes might be 
equally dependent on lysosomal resistance mechanisms. Such cells or tumor subtypes possibly rely 
on other resistance-promoting mechanisms including ATP-driven efflux pumps. In fact, tumor cells 
might decide on either lysosomal or pump-driven resistance mechanisms, or both, during initial 
treatment (Hu et al. 1995; Hurwitz et al. 1997; Maitra et al. 2001; Gotink et al. 2015; Zhitomirsky and 
Assaraf 2015). Future systematic viability screens, where clinically approved drugs will be combined 
with HDAC10- or other lysosomal inhibitors in the above described lysosomal responsive and non-
responsive cell lines, could not only help identify drugs, resistance to which critically depends on 
lysosomal function. As all neuroblastoma model cell lines used in follow-up studies have been 
genetically fully characterized in the meantime via whole genome sequencing, gene expression 
profiling and 450k DNA methylation analysis, they could also help identify markers that are able 
predict if tumors depend on lysosomal function as a drug resistance mechanism and can thus be 
sensitized with lysosomal inhibitors. Identification of such response prediction markers are 
prerequisite to clinical testing of HDAC10- or pan HDAC inhibitors with high HDAC10 affinity, because 
they help exclude patients whose tumors do not rely on lysosomal resistance mechanisms and who 
will thus likely not benefit from treatment. 
1.4 Additional mechanisms of cell sensitization after HDAC10 
inhibition 
In line with previous studies (Oehme et al. 2013a; Bingel et al. 2017), the data presented in section 
E1.9 demonstrate that inhibition of HDAC6/10 sensitizes neuroblastoma cells to doxorubicin 
treatment. While increased doxorubicin accumulation likely contributes to sensitization, it cannot be 
the only contributing factor, as P-glycoprotein inhibition with verapamil did not sensitize 
neuroblastoma cells as effectively despite promoting stronger intracellular and nuclear accumulation 
of doxorubicin. It is thus likely that several other mechanisms contribute to increased cell death 
induction after chemotherapeutic treatment. 
Inhibition of autophagy and lysosomal exocytosis contribute to cell death induction 
Lysosomes are not only a central organelle of macromolecule degradation. They are also critical for 
various stress resistance mechanisms, and themselves act as sensor of cellular stress which is 
highlighted by their central role in amino acid sensing under starvation conditions (reviewed in 
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(Settembre et al. 2013)). This suggests that impaired lysosomal function itself was a contributing 
factor to sensitization of neuroblastoma cells to doxorubicin. As shown by (Oehme et al. 2013a), 
interference with HDAC10 function blocks autophagic flux at the stage of autophagosome lysosome 
fusion, causing the accumulation of autophagosomes and thus of aged macromolecules and 
damaged organelles like mitochondria that display elevated ROS production. In this context, several 
studies point at the importance of productive autophagic flux under cytotoxic treatment or other 
stress noxae, where blockage of flux can re-sensitize resistant cancer cells to the respective 
treatment (Carew et al. 2007; Wu et al. 2010). This is also highlighted under threedimensional culture 
conditions, where, due to starvation stress, neuroblastoma cells increase their autophagic flux and, 
as a consequence, become highly resistant to chemotherapeutic treatment. This resistance can be 
almost completely reverted by autophagic flux or HDAC10 inhibitors (Bingel et al. 2017).  
The data presented in this study further demonstrate that lysosomal exocytosis itself can have a pro-
survival function under cytotoxic treatment. Similar to HDAC10 inhibition, blockage of lysosomal 
exocytosis sensitized neuroblastoma cells to doxorubicin while having little effect as single 
treatment. This indicates that lysosomal exocytosis itself becomes important under such stress 
conditions. Increased rates of lysosomal exocytosis occur for example in case of plasma membrane 
disruption, where fusion of lysosomes with the plasma membrane promotes initial membrane 
resealing (Reddy et al. 2001). Moreover, lysosomal exocytosis rates are increased under oxidative 
stress, although excessive formation of ROS can also block lysosomal exocytosis (Liu et al. 2012a; Ravi 
et al. 2016). One of the side effects of doxorubicin is the induction of cumulative cardiomyopathy, 
and it is thought that doxorubicin promotes increased ROS generation, which contributes to both 
induction of cardiomyopathy, as well as to anti tumor effects. (Doroshow 1983; Minotti et al. 2004; 
Takemura and Fujiwara 2007). Increased ROS levels do not only cause the accumulation of DNA 
lesions and damaged organelles, but also promote peroxidation of membrane lipids (Barrera 2012), 
and doxorubicin itself has been shown to promote lipid peroxidation via ROS formation (Goodman 
and Hochstein 1977; Myers et al. 1977; Hrelia et al. 2002). Lipid peroxidation can in turn affect 
interfere with the integrity of cellular membranes or alter function of membrane-bound proteins 
(Stark 2005; Barrera 2012). Thus, plasma membrane repair is one possible mechanism how intact 
lysosomal exocytosis could promote cellular resistance to doxorubicin treatment. 
HDAC6/10 inhibition induces DNA double strand breaks in neuroblastoma cells 
Although class IIb HDACs are thought to be largely located in the cytoplasm (Guardiola and Yao 
2002), several studies indicate that both HDAC6 and HDAC10 can be found the nucleus, where they 
have been suggested to be involved in DNA repair (Kao et al. 2002; Liu et al. 2012a; Wang et al. 2012; 
Radhakrishnan et al. 2015). As of yet, no mechanism has been proposed that explains how HDAC6 
contributes to maintaining DNA integrity. In contrast, HDAC10 is involved in both DNA mismatch 
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repair, possibly by deacetylating MutS homolog 2 (MSH2) (Radhakrishnan et al. 2015), and in the 
repair of DNA double strand breaks by promoting homologous recombination (Kotian et al. 2011), 
although no downstream target was proposed in the latter study. These reports suggested that 
HDAC6/10 inhibition could promote increased sensitivity of neuroblastoma cells to genotoxic drugs 
by interfering with DNA repair processes. As doxorubicin induces DNA double strand breaks by 
topoisomerase II poisoning (Lyu et al. 2007; Nitiss 2009; Yang et al. 2014), a special focus in this study 
was laid on the effect of HDAC6/10 inhibition on DSB numbers. Here, HDAC6/10 inhibition did not 
only increase doxorubicin-induced DSBs to a substantially higher level than P-glycoprotein inhibitor 
verapamil, even though the latter promoted stronger nuclear doxorubicin accumulation. It also 
significantly increased DSBs in the absence of chemotherapeutic treatment, indicating that HDAC6 
and/or HDAC10 are important for maintaining DNA integrity in neuroblastoma cells. Although these 
findings suggest that either or both class IIb HDACs are involved in DSB repair, no direct evidence for 
a decreased DNA repair capacity was provided in this study. Thus, it remains to be answered whether 
increased DSB formation was due to decreased DNA repair or due to other effects associated with 
impaired HDAC6/10 function such as increased ROS formation (Lee et al. 2010a; Oehme et al. 2013a; 
Bai et al. 2015) or changes in the expression of DNA repair genes. Moreover, it remained unclear 
whether increased DSB formation was mediated by inhibition of HDAC6 or HDAC10, as control 
experiments with an HDAC6 specific inhibitor (e.g. tubacin) were not performed. The 
immunofluorescence data provided in this study support the idea of a nuclear function of HDAC10, as 
they for the first time demonstrate nuclear localization of endogenously expressed HDAC10. 
Moreover, very preliminary data from mass spectrometry indicate that inhibition of HDAC6/10, but 
not of HDAC6 only, causes hyperacetylation of a lysine residue within the DNA binding region of 
Ku80, which together with its binding partner Ku70 is critical in the recognition of DSBs and the 
initiation of DSB repair via NHEJ, suggesting that HDAC10 could be critically involved in the regulation 
of the NHEJ repair pathway (reviewed in (Davis and Chen 2013) and also discussed in section F2). 
Ku80 has been before reported to be acetylated after the use of pan HDAC inhibitors, which was 
associated with impaired DNA binding of Ku80, suggesting that classical HDACs are indeed involved in 
the regulation of NHEJ (Robert et al. 2016). Interestingly its binding partner Ku70 is deacetylated by 
the non-classical class III HDAC SIRT1, and deacetylation of Ku70 was associated with increased repair 
of DSBs (Jeong et al. 2007). Future experiments that directly assess the efficiency of homologous 
recombination or non-homologous end-joining (NHEJ) repair mechanisms could help clarify whether 
DNA repair is indeed compromised by HDAC6/10 inhibition and, if so, which repair pathway is 
affected (Mao et al. 2008; Seluanov et al. 2010; Kostyrko and Mermod 2016). Performing such assays 
in the absence of HDAC6 and HDAC10 protein, respectively, or in the presence of differential 
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HDAC6/10 inhibitors could show whether one or both class IIb HDACs promote DNA repair in 
neuroblastoma cells.  
1.5 Future development of HDAC10 inhibitors  
All recent studies demonstrating the potential of HDAC10 inhibition in neuroblastoma (Oehme et al. 
2013a; Bingel et al. 2017; Kolbinger et al. 2018; Ridinger et al. 2018) have used HDAC10 inhibitors 
with significant cross-reactivity against HDAC6. Thus, one question that remains is, whether co-
inhibition of HDAC6 contributes to the anti-tumor effects of HDAC6/10 inhibitors in neuroblastoma 
or whether the HDAC6 inhibitory activity should be abolished because it promotes resistance. In 
future studies, this issue can only be addressed by means of specific HDAC10 inhibitors. As such 
compounds have not yet been published, it is questionable whether the specific inhibition of HDAC10 
is possible. The tubastatin A derivatives tested in this study (synthesized in the lab of Dr. Aubry 
Miller) demonstrate for the first time, that a basic amine group nitrogen atom in the cap structure of 
tubastatin A is required for efficient HDAC10 binding. Importantly, some of the tested tubastatin A 
derivatives (DKFZ-00546 and DKFZ-00574) demonstrated increased HDAC10 binding but unchanged 
HDAC6 affinity, indicating that modification of the cap group could at some point yield highly specific 
HDAC10 inhibitors. While these compounds have been generated by random modifications in the cap 
group, recently published crystal structures of zebrafish HDAC10 (zHDAC10) and both catalytic 
domains of human HDAC6 (Hai and Christianson 2016; Miyake et al. 2016; Hai et al. 2017) now allow 
for a targeted, structure-based development of novel HDAC6 and HDAC10 inhibitors, respectively. 
Such targeted approaches could finally enable the generation of HDAC6 non-cross-reactive HDAC10 
inhibitors, which will serve as valuable tool compounds for deciphering anti-tumor effects of class IIb 
HDAC inhibitors. In this context, fitting of tubastatin A to HDAC6 and the human homology model 
derived from zHDAC10 recently demonstrated that the amine group of tubastatin A specifically 
mediates hydrogen bonding to Glu274 (Glu272 in human HDAC10), which is found in HDAC10 but not 
in HDAC6 (Hai et al. 2017). Conversely, the remaining cap group mediates binding to HDAC6 via 
hydrophobic interactions (Geraldy, unpublished). 
Clinical testing and application of tubastatin A is limited by its unfavorable pharmacokinetic profile - a 
two hour plasmatic half-life was reported in a recent study in mice (Wang et al. 2016) -, and by the 
fact that it has not been optimized for oral application (Cosenza and Pozzi 2018). One way to 
circumvent this issue in the short-term would be the use of abexinostat, a pan HDAC inhibitor that 
has proven to be an excellent HDAC10 inhibitor in this study. In phase I/II clinical trials in adult 
patients with lymphoma and chronic lymphocytic leukemia, abexinostat had favorable 
pharmacokinetic properties and manageable toxicities, being readily taken up after oral 
administration with a plasma half-life of about 4h, and displaying promising clinical activity including 
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durable responses (Morschhauser et al. 2015) (Evens et al. 2016). Abexinostat was further tested in 
adult sarcoma patients in combination with doxorubicin, where partial responses were observed 
(Choy et al. 2015). It is currently also tested in renal cell carcinoma (NCT03592472), metastatic solid 
tumors (NCT01543763), relapsed and refractory follicular lymphoma (NCT03600441) and advanced 
cutaneous melanomas (NCT03590054), both as single treatment (NCT03600441) and in combination 
with the tyrosine kinase inhibitor pazopanib (NCT03592472, NCT01543763) or with the immune-
checkpoint inhibitor pembrolizumab (NCT03590054). The highest reported peak plasma 
concentrations in lymphoma patients were 250 nM (Morschhauser et al. 2015) and >300 nM (Evens 
et al. 2016), respectively, at the recommended dose of 45 mg/m2. These concentrations lie well 
within the concentration range where abexinostat treatment caused lysosomal accumulation in 
neuroblastoma cell lines, suggesting that it has the potential to become an HDAC10 inhibiting drug in 
neuroblastoma patients, although pharmacokinetics and maximum tolerated dose would have to be 
re-evaluated in children. As not all neuroblastoma cell lines equally displayed lysosomal expansion 
upon abexinostat treatment (see sections E1.4.3 and F1.1), it is more than likely that not all patients 
will equally benefit from combined treatment abexinostat and genotoxic drugs (e.g. doxorubicin). 
This underlines the need to systematically correlate the abexinostat-induced lysosomal expansion 
phenotype to cell viability after combination of abexinostat with a large number of clinically applied 
anti-cancer drugs. Correlating the hereby generated sensitivity profiles to gene expression data of 
fully characterized neuroblastoma models (including the cell lines in section E1.4.3) can also help 
identify prospective biomarkers that are required for efficient selection of patients that are most 
likely to benefit from treatment. 
Apart from HDAC10, inhibition of HDAC8 has shown promising effects in preclinical neuroblastoma 
models (Oehme et al. 2009a; Rettig et al. 2015), and co-inhibition of both enzymes might thus be 
desirable for the treatment of high-risk neuroblastoma. Co-inhibition would be greatly facilitated by 
a compound co-targeting both enzymes, as this would for example exclude differential 
metabolization of the drugs. However, attempts to create effective HDAC8/10 inhibitors by adding a 
second hydroxamic acid moiety to the cap group of tubastatin A derivatives, thus creating a chimeric 
compound reminiscent of both tubastatin A and the HDAC8 specific inhibitor PCI-34051, remained 
unsuccessful. Such compounds repeatedly displayed reduced inhibitory activity towards HDAC8 and 
HDAC10 in biochemical (HDAC-Glo for HDAC8) and cellular assays (SMC3 acetylation for HDAC8 and 
LysoTracker as well as NanoBRET assay for HDAC10). While it is true that addition of the second 
hydroxamic acid probably reduced affinity to HDAC8 and HDAC10 when compared to the respective 
analog containing only one hydroxamic acid residue, it is also obvious that the activity of the chimeric 
compound was more drastically reduced in BE(2)-C cells when compared to biochemical and 
NanoBRET data, the latter having been obtained in HeLa cells. In fact, HDAC8 (SMC3 acetylation) and 
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HDAC10 (lysosomal phenotype) inhibitory activity were completely abolished in BE(2)-C cells for the 
chimeric DKFZ-00580 analog. While the discrepancy between NanoBRET data in HeLa cells and 
functional assays in BE(2)-C cells, as well as the complete lack of HDAC8 inhibitory activity in BE(2)-C 
cells, cannot be fully explained, it has to be taken into account that addition of a second hydroxamic 
acid moiety increases polarity of the chimeric compounds. It is thus conceivable that reduced 
inhibitory capacity on HDAC8/10 in BE(2)-C cells was in fact related to decreased intracellular drug 
levels. Moreover, addition of a second hydroxamic acid could have also altered the affinity of the 
respective compounds to various drug efflux pumps. This raises the question, whether differential 
expression of such pumps in HeLa versus neuroblastoma cells, in turn, could explain why inhibitory 
activity was more drastically affected in one cell line than the other.  
In a recent proof of concept study, the efficacy of combined HDAC8 and HDAC10 inhibition in 
neuroblastoma was demonstrated with the combined HDAC6/8/10 inhibitor TH34 (3-(N-
benzylamino)-4-methylbenzhydroxamic acid), a non-tubastatin A based compound with strong 
HDAC6/8/10 binding capacity (Kolbinger et al. 2018). Single treatment with TH34 induced caspase-
dependent cell death in a panel of high-risk neuroblastoma cell lines while being well tolerated in 
non-transformed cells. 
2 Potential HDAC10 downstream targets 
HDAC10 as a polyamine deacetylase 
To date, no HDAC10 downstream target has been conclusively identified and it remains questionable 
whether HDAC10 serves as a lysine deacetylase. This debate was fueled by a recent study, in which 
both zebrafish and human HDAC10 demonstrated excellent polyamine deacetylase activity in 
biochemical assays, with high preference for N8-acetylspermidine (PDAC activity) but poor activity on 
acetylated lysine substrates (Hai et al. 2017). Using the crystal structure of zebrafish HDAC10, the 
authors identified two major structural determinants that ensure PDAC activity specifically in 
HDAC10. A negatively charged Glutamine residue (Glu274, numbering according to its position in 
zHDAC10) establishes specificity for cationic substrates such as polyamines. This residue is conserved 
in human HDAC10 (Glu272), but is not found in the catalytic domains (CDs) of other HDACs, which, 
with the exception of a lysine residue in the HDAC6 CD1, display a conserved hydrophobic amino acid 
(leucine or methionine) at the respective site. Secondly, they identified a unique structural element 
in the L1 loop of the zHDAC10 CD (a 310-helix termed A2), that lengthens and constricts the active 
site tunnel, thus making acetylated lysine side chains too short to reach the enzyme's active site. 
While the report by (Hai et al. 2017) clearly demonstrates that HDAC10 is indeed an excellent 
deacetylase for N8-acetylspermidine in biochemical assays, it is questionable whether this is its main 
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function in neuroblastoma cells. N8-acetylated spermidine could neither be detected in BE(2)-C cells 
with full HDAC10 expression or function, nor in cells with HDAC10 knockdown or inhibition, making it 
unlikely that lysosomal expansion after interference with HDAC10 function was related to HDAC10's 
role as a N8-acetylspermidine PDAC. While polyamines have been implicated in multiple cellular 
processes, including protein translation (Park et al. 2010; Mandal et al. 2013), DNA replication (Gallo 
et al. 1986), and also autophagy (Eisenberg et al. 2009), a clear link between polyamine levels and 
lysosomal function remains to be shown (Jonas et al. 1987), although it is conceivable that 
polyamines indirectly influence lysosomal function via the autophagy axis (Eisenberg et al. 2009).  
In fact, literature evidence of N8-acetylspermidine and its cellular function is sparse. Studies, mainly 
performed in HeLa cells or on homogenates from rat liver, suggest that N8-acetylspermidine is 
generated in the nucleus by an enzyme with histone acetyltransferase (HAT) activity, and rapidly 
converted back to spermidine by a cytosolic PDAC without HDAC activity (Blankenship 1978; Libby 
1978; Libby 1980; Marchant et al. 1986; Marchant et al. 1989). Moreover, the study by Marchant et 
al. found that N8-acetylspermidine levels are hardly detectable with the HPLC gradient that is 
commonly used for detection of acetylated polyamines, suggesting that N8-acetylspermidine levels 
are low in cultured cells (Marchant et al. 1989). It is not fully clear which HAT enzyme is responsible 
for N8-acetylation, but a recent study proposed that P/CAF converts spermidine to N8-
acetylspermidine (Burgio et al. 2016). The cellular function of N8-acetylspermidine is even more 
enigmatic and reports are conflicting, as it has been suggested to stimulate growth in a mouse 
lymphatic leukemia cell line (Wang et al. 1999), while promoting differentiation in rat 
pheochromocytoma cell line in another study (Mudumba et al. 2002). Although the  data presented 
in this study, that suggest a subordinate role for N8-acetylated polyamines in the lysosomal biology of 
BE(2)-C cells as they are not present at detectable levels, aberrant polyamine metabolism has been 
repeatedly associated with adverse outcome in neuroblastoma (Hogarty et al. 2008; Gamble et al. 
2012). Therefore, future studies should focus on identifying neuroblastoma cell lines with detectable 
levels of N8-acetylspermidine (currently ongoing). These could serve as valuable models for the 
identification of both physiological and tumor- or neuroblastoma-specific roles of N8-
acetylspermdine, and possibly other polyamines as well. Moreover, recent data from the Casero lab 
suggest that N8-acetylspermidine is rapidly secreted from cells. Thus, cellular supernatants are likely 
more suitable to investigate the role of HDAC10 as PDAC.  
Potential protein downstream targets of HDAC10 
While the zHDAC10 model of (Hai et al. 2017) elegantly explains the preference of HDAC10 for 
polyamine substrates over acetylated lysines in biochemical assays, it also suggests that HDAC6/10 
inhibitor tubastatin A does not fit into the catalytic domain due to the specific structure of the 
HDAC10 L1 loop, which restricts access of the inhibitor to the active site (Geraldy unpublished). 
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However, NanoBRET data generated by Aubry Miller and co-workers, as well as LysoTracker data 
(section E1.2.1), demonstrate that tubastatin A and its derivatives are excellent HDAC10 binders and 
inhibitors in cells, suggesting that the L1 loop of human HDAC10 is flexible. Moreover, biochemical 
testing by Hai and colleagues does not take into accounts that protein conformation can be heavily 
modulated by protein-protein interactions. Therefore, lysine deacetylase activity might be restored 
by movement of the L1 loop in living cells. In this context, Hai and colleagues already demonstrated 
in their study that ablation of the A2 helix in HDAC10 (see previous section) generated a 
bifunctional HDAC-PDAC, while ablation of Glu274 generated a lysine deacetylase. Thus, it is 
reasonable to assume that HDAC10 can possess a lysine deacetylase function of HDAC10 in cells , e.g. 
via a conformational change in the L1 loop.  
Two recent studies by (Lai et al. 2010) and (Oehme et al. 2013a) have proposed HSP70 family 
members HSC70 and HSP70 as HDAC10 interacting partners and potential downstream targets, and 
the latter study demonstrated that interaction of HDAC10 with HSP70/HSC70 is abolished in the 
presence of the broad-spectrum HDACi TSA. A further study by (Yang et al. 2013) suggested that 
HSP70 is deacetylated by HDAC6 at lysine 159 and that K159 acetylation of HSP70 was required for 
efficient autophagosome formation. Given the further involvement of HSP70 family members in 
lysosomal processes, such as chaperone-mediated autophagy (HSC70) (Cuervo and Dice 1996; 
Salvador et al. 2000) and stabilization of the lysosomal membrane (HSP70) (Daugaard et al. 2007a), a 
key question of this study was therefore, whether HDAC10 modulated lysosomal function via HSP70 
family members. LC-MS/MS analyses, however, could not identify specific de novo acetylation sites 
neither after HDAC10 nor HDAC6 inhibition. While it is possible that these HSP70 family members are 
not targets of class IIb HDACs, the quality of data does not allow for a complete dismissal either. 
Since no SILAC based approach was used, quantitative comparison of HSP70 peptides that were 
commonly acetylated in control and treated conditions is difficult. Moreover, similar to other post-
translational modifications such as phosphorylation, acetylation likely occurs at low frequency 
relative to the non-modified peptide, and might thus be missed in a complex mixture of proteins (Fila 
and Honys 2012). This suggests that the herein applied LC-MS/MS-based detection of acetylated 
peptides requires technical optimization, such as enrichment of acetylated proteins or peptides, 
which is routinely done for phosphorylated protein (Fila and Honys 2012). Recent acetylome studies 
have used acetyl-lysine specific antibodies after tryptic digestion to enrich for acetylated peptides 
(Choudhary et al. 2009; Scholz et al. 2015). However, in contrast to the mostly chemical or 
chromatography-based enrichment methods used in phosphoproteomic approaches, IP-based 
methods have several pitfalls. Firstly, acetyl-lysine antibodies tested in our lab have been mostly 
highly reactive towards acetylated histone and tubulin. Secondly, even though the IP-based 
enrichment of acetylated peptides after tryptic digestion allows for the enrichment of low abundance 
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peptides, protein identification via MS becomes more difficult when enrichment is performed with 
peptides rather than full-length protein. This is because protein identification after peptide 
enrichment is based only on a limited number of peptides that were successfully enriched - in some 
occasion potentially only one peptide -, while non-modified peptides are lost during the enrichment 
process. The former problem can be likely solved by separating the protein mixture via SDS-PAGE or 
HPLC prior to digestion and enrichment, as this would allow for the elimination of fractions where 
tubulin and histones are enriched. Still, the fact, that even in recent proteomic studies, a substantial 
number of acetylated peptides cannot be detected reproducibly in two independent runs, 
demonstrates that these IP-based methods require further optimization, possibly by improving 
quality of pan-acetyl reactive antibodies (Scholz et al. 2015). 
More global analysis of lysine acetylation on whole cell lysates (mass range 95 to 50 kDa) revealed 
potential de novo acetylation sites after HDAC10 inhibition in subunit A of the V-ATPase complex 
(ATP6V1A K480 and K506) and in the DNA repair protein Ku80 (K443), respectively (also discussed in 
sections F1.1 and F1.4). While these hits are interesting from a mechanistic point of view as they 
could explain lysosomal expansion and increased DNA double strand breaks after HDAC10 inhibition, 
they have to be interpreted with care as long as they have not been confirmed in a second, 
independent approach. Moreover, the data from the initial run already suggest that a high number of 
identified peptides could be random hits. First, the total number of identified peptides did not 
substantially increase after treatment with HDAC6/10 or HDAC6 inhibitors. Second, the overlap of 
acetylated peptides between HDAC6/10 and HDAC6 inhibitor treated groups was small even though 
both inhibit one common enzyme. As discussed above, enrichment of acetylated peptides, possibly 
combined with quantitative MS approaches such as SILAC, could help to more robustly and 
quantitatively identify acetylated peptides. Intriguingly, both ATP6V1A and Ku80 were found to be 
hyperacetylated after treatment with bufexamac in the study of (Scholz et al. 2015). However, the 
identified peptides did not overlap with the ones found in this study. With the confirmation of 
ATP6V1A and Ku80 peptides still pending, binding of these proteins to HDAC6 and/or HDAC10 could 
be investigated in a yeast two-hybrid screen. If selective binding of either or both proteins to HDAC10 
were observed, the lysine residues of interest could be replaced by arginine or glutamine residues to 
yield acetylation-dead or acetylation-mimicking mutants, respectively. However, it has to be 
considered that overexpression of such mutants would only work in case of an activating effect of 
acetylation (as suggested in case of ATP6V1A) or in case of a dominant negative effect (possibly the 
case for Ku80). 
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3 Development of an HDAC10 antibody - future 
perspectives 
Three independent attempts to generate a highly specific HDAC10 antibody were made in this study. 
Generation of a polyclonal antibody in rabbit and affinity selection over a human antibody library via 
phage display remained largely unsuccessful due to low specificity and reactivity of the produced 
antibodies, respectively. In contrast, production of a monoclonal antibody from mice injected with a 
118 amino acid peptide (termed HDAC10T2) corresponding to amino acids 501-618 of human 
HDAC10 yielded at least two highly specific hybridoma clones. Here, especially the clone termed 
50/7/1 showed low off-target activity and, in contrast to the highly specific but weakly reactive 
13/1/6/1 clone, decent reactivity towards endogenously expressed HDAC10 in both western blot and 
immunofluorescence approaches. Such an antibody could become a valuable tool in the future, as it 
allows for mechanistic studies with endogenously expressed HDAC10 (e.g. via immunofluorescence 
or IP-based approaches). Moreover, the 50/7/1 antibody showed promising results on paraffin-
embedded neuroblastoma cells and is thus suitable for IHC approaches, which is crucial for 
evaluation of HDAC10 expression in human tumor tissues. However, high inter batch variability of 
50/7/1 hybridoma cultures drastically hamper reliable antibody production at this point, as cultures 
of this clone repeatedly re-develop off-target activity which is enriched after antibody purification via 
solid phase binding against Protein G. Off-target activity was most likely not an inherent property of 
the HDAC10 binding antibody itself or due to cross-reactivity of the HDAC10-reactive antibody to a 
similar epitope (mimitope), as highly specific antibody could be purified from hybridoma culture 
batches without signs of cross-reactivity. Moreover, off-target activity randomly re-occurred in 
50/7/1 hybridomas without prior off-target activity and could not be eliminated by repeated 
subcloning, making contamination with a second hybridoma clone unlikely. While this behavior 
seemed enigmatic at first sight, it is important to notice that, owing to the nature of hybridoma 
generation, hybridomas can co-express additional "background" antibody chains and that such 
chains can cause the production of additional combinatorial antibodies. In this context, a recent 
study analyzing sequence data from 185 random hybridomas (including commercial hybridomas), has 
found that additional heavy or light variable chains occur in up to 32 % of hybridomas deemed as 
monoclonal, thus making them non-mono-specific (Bradbury et al. 2018). In some instances, the 
authors reported that the most abundantly expressed chains were not even producing antibodies 
with the specificity of interest. The 50/7/1 clone has been derived from fusion of spleen cells with 
Sp2/0 myeloma cell line. In this myeloma line, background expression of the original productive 
antibody chains has been abolished (Shulman et al. 1978), but Sp2/0 cells are known to express an 
aberrant  light chain transcript (Carroll et al. 1988; Duan and Pomerantz 1994). This transcript 
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normally does not contribute to antibody production due to a frameshift base pair deletion, resulting 
in non-functional rearrangement and a premature stop codon (Carroll et al. 1988). While this 
aberrant  chain rarely causes the production of an additional  chain, additional light and heavy 
chains can however, according to the study by Bradbury, originate via the following mechanisms: 
Fusion of myeloma cells with more than one B cell, additionally re-arranged light chain or heavy 
chain alleles prior to of post fusion with myeloma cells, or mutations acquired due to longterm 
cultivation of hybridomas (Bradbury et al. 2018). It is conceivable that the 50/7/1 hybridoma clone 
indeed produces more than one antibody due to one of the above named mechanism. This is 
supported by the finding that off-target binding antibody is enriched by Protein G-mediated antibody 
purification, which suggests that 50/7/1 cultures with off-target activity mainly produce off-target-
reactive antibodies. Since this antibody has clearly shown a great deal of potential in western blot 
and immunofluorescence approaches, this problem should be remedied by sequencing and cloning 
of variable heavy and light chains, followed by overexpression of all possible chain combinations in 
HEK cells.  
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